Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der...

108
Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München Direktor: Prof. Dr. med. Dr. rer. nat. Michael von Bergwelt Prognostische Faktoren bei Patienten mit Gallengangskarzinomen eine retrospektive Analyse aus einem universitären Zentrum Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München vorgelegt von Anna Preinfalk aus Hutthurm 2018

Transcript of Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der...

Page 1: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

Aus der Medizinischen Klinik und Poliklinik III

der Ludwig-Maximilians-Universität München

Direktor: Prof. Dr. med. Dr. rer. nat. Michael von Bergwelt

Prognostische Faktoren

bei Patienten mit Gallengangskarzinomen – eine

retrospektive Analyse aus einem universitären Zentrum

Dissertation

zum Erwerb des Doktorgrades der Medizin

an der Medizinischen Fakultät der

Ludwig-Maximilians-Universität zu München

vorgelegt von

Anna Preinfalk

aus

Hutthurm

2018

Page 2: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

Mit Genehmigung der Medizinischen Fakultät

der Universität München

Berichterstatter: Prof. Dr. med. Stefan Böck

Mitberichterstatter: Prof. Dr. Andreas Eigler

Mitbetreuung durch den

promovierten Mitarbeiter: Dr. med. Benedikt Westphalen

Dekan: Prof. Dr. med. dent. Reinhard Hickel

Tag der mündlichen Prüfung: 15.11.2018

Page 3: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

Eidesstattliche Versicherung Stand: 31.01.2013

Eidesstattliche Versicherung

Name, Vorname

Ich erkläre hiermit an Eides statt,

dass ich die vorliegende Dissertation mit dem Thema selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe. Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde.

Ort, Datum Unterschrift Doktorandin/Doktorand

Preinfalk, Anna

Landshut, 16.11.2018 Anna Preinfalk

Prognostische Faktoren bei Patienten mit Gallengangskarzinomen - eine retrospektiveAnalyse aus einem universitären Zentrum

Page 4: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!"! #$%&'()*+,-+./%$.)0

!" #$%&'$()%*"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!"

!+!" ,-."/-&&'%*-%*.0-12$%34"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!"

!+!+!" 51.61)%*"7'."893&-%*$32'&&)&:1'%";-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!"

!+!+<" #6$7'4$3&3*$'")%7"=$.$03>-0(31'%"7'."893&-%*$32'&&)&:1'%";-12$%34."++++++++++++++++++++++++++++"<"

!+!+?" ,$-*%3.'"7'."893&-%*$32'&&)&:1'%";-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?"

!+!+?+!" ;&$%$.89'"@1:.'%(-($3%"7'1"@-($'%('%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?"

!+!+?+<" A$&7*'B)%*"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C"

!+!+?+?" D-B316-1-4'('1"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C"

!+!+C" E9'1-6$'"7'."893&-%*$32'&&)&:1'%";-12$%34."++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"F"

!+!+C+!" ;)1-($G'"E9'1-6$'03%2'6('"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"F"

!+!+C+<" H'3-7I)G-%('")%7"-7I)G-%('"E9'1-6$'03%2'6('++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"J"

!+!+C+?" H$89(K0)1-($G'"E9'1-6$'03%2'6('"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"J"

!+!+F" E)4316-(93&3*$'"7'."893&-%*$32'&&)&:1'%";-12$%34."++++++++++++++++++++++++++++++++++++++++++++++++++++++"L"

!+!+J" E)4310&-..$>$0-($3%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"M"

!+!+J+!" N(-*$%*"7'."893&-%*$32'&&)&:1'%";-12$%34."++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"M"

!+!+J+<" #$%('$&)%*"7'1"7$.(-&'%"'O(1-9'6-($.89'%"P93&-%*$30-12$%34'"++++++++++++++++++++++++++++++++++"!!"

!+!+J+?" #$%('$&)%*"7'1"6'1$9$&:1'%"P93&-%*$30-12$%34'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!?"

!+!+J+C" #$%('$&)%*"%-89"A$.4)(9KP31&'(('"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!F"

!+!+J+F" #$%('$&)%*"7'1"$%(1-9'6-($.89'%"P93&-%*$30-12$%34'"++++++++++++++++++++++++++++++++++++++++++++++++"!J"

!+<" @'1$%')1-&'"Q%G-.$3%"B'$4"/-&&'%*-%*.0-12$%34"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!R"

!+<+!" S3&'0)&-1'"S'89-%$.4'%"7'1"6'1$%')1-&'%"Q%G-.$3%"++++++++++++++++++++++++++++++++++++++++++++++++++++"!M"

!+<+<" H')13(1369$%'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<T"

<" U$'&.'(2)%*"7'1"V1B'$("+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<<"

?" S-('1$-&$'%")%7"S'(937'%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<?"

?+!" @-($'%('%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<?"

?+<" @1:(9'1-6')($.89'",$-*%3.($0"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<J"

?+?" W$.(36-(93&3*$.89'"5%('1.)89)%*"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<J"

?+?+!" #1.('&&)%*"'$%'."E$..)'"S$813"V11-X"YESVZ"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<J"

?+?+<" Q44)%9$.(389'4$.89'"[:1B)%*"7'1"ESV."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<J"

?+?+?" V).\'1()%*"7'1"$44)%9$.(389'4$.89'%"[:1B)%*'%"+++++++++++++++++++++++++++++++++++++++++++++++++++++"<L"

?+C" N(-($.($.89'"V).\'1()%*"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<L"

?+C+!" /1)66'%G'1*&'$89'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<L"

?+C+<" ]G'1-&&"N)1G$G-&")%7"@13*1'..$3%"[1''"N)1G$G-&"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<L"

?+C+?" P3OK='*1'..$3%.-%-&X.'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<R"

Page 5: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?+C+C" D-B316-1-4'('1"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<R"

C" #1*'B%$..'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<M"

C+!" ;&$%$.89'",-('%"7'1"@-($'%('%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<M"

C+!+!" ^B'1.$89("+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<M"

C+!+<" A37XKS-..KQ%7'O"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?!"

C+!+?" _31'101-%0)%*'%")%7"N)89(4$(('&-B).)."7'.";3&&'0($G."++++++++++++++++++++++++++++++++++++++++++++++++"?<"

C+!+C" E)431.(-7$)4"%-89"5QPP"YL+"V)>&-*'Z"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"??"

C+!+F" ['1%4'(-.(-.$'1)%*"2)4"U'$(6)%0("7'1"#1.(7$-*%3.'"++++++++++++++++++++++++++++++++++++++++++++++++++++"?C"

C+!+J" D-B316-1-4'('1"B'$"#1.(7$-*%3.'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?J"

C+!+L" E9'1-6$'"7'."893&-%*$32'&&)&:1'%";-12$%34."++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?L"

C+!+L+!" ]6'1-($3%"$%"0)1-($G'1"Q%('%($3%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?L"

C+!+L+<" @-&&$-($G'"#1.(&$%$'%(9'1-6$'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CT"

C+!+L+?" @-&&$-($G'"U\'$(&$%$'%(9'1-6$'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C<"

C+!+L+C" @-&&$-($G'",1$((&$%$'%(9'1-6$'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CC"

C+!+L+F" @-&&$-($G'"_$'1(K"B$."V89(&$%$'%(9'1-6$'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CJ"

C+!+R" ]G'1-&&"N)1G$G-&"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CR"

C+!+R+!" ]G'1-&&"N)1G$G-&"$%"VB9:%*$*0'$("7'1"E)431&30-&$.-($3%"+++++++++++++++++++++++++++++++++++++++++++++"CM"

C+!+R+<" ]G'1-&&"N)1G$G-&"$%"VB9:%*$*0'$("7'."5QPPKN(-7$)4."++++++++++++++++++++++++++++++++++++++++++++++++++"CM"

C+!+R+?" ]G'1-&&"N)1G$G-&"$%"VB9:%*$*0'$("'$%'1"36'1-($G'%"E9'1-6$'"+++++++++++++++++++++++++++++++++++++++"F!"

C+!+R+C" ]G'1-&&"N)1G$G-&"$%"VB9:%*$*0'$("7'."-%*'\-%7('%"6-&&$-($G'%"E9'1-6$'03%2'6('."+++"F<"

C+!+M" @13*1'..$3%"[1''"N)1G$G-&"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"FC"

C+<" V%-&X.'"613*%3.($.89'1"[-0(31'%"2)4"U'$(6)%0("7'1"#1.(7$-*%3.'"$%"A'2)*"-)>"]G'1-&&"N)1G$G-&")%7"@13*1'..$3%"[1''"N)1G$G-&"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"FF"

C+<+!" 5%$G-1$-('"P3OK='*1'..$3%.-%-&X.'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"FF"

C+<+<" S)&($G-1$-('"P3OK='*1'..$3%.-%-&X.'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JR"

C+<+<+!" S)&($G-1$-('"P3OK='*1'..$3%"$%"A'2)*"-)>"7-."]N"+++++++++++++++++++++++++++++++++++++++++++++++++++++++"JR"

C+<+<+<" S)&($G-1$-('"P3OK='*1'..$3%"$%"A'2)*"-)>"7-."@[N"+++++++++++++++++++++++++++++++++++++++++++++++++++++"LT"

C+?" V).\'1()%*"7'1"$44)%9$.(389'4$.89'%"[:1B)%*'%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"L<"

F" ,$.0)..$3%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"L?"

F+!" ;&$%$.89'",-('%"7'1"@-($'%('%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LC"

F+!+!" @-($'%('%89-1-0('1$.($0-"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LC"

F+!+<" E)431&30-&$.-($3%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LF"

F+!+?" =$.$03>-0(31'%++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LJ"

F+!+C" DX4690%3('%K")%7"['1%4'(-.(-.$'1)%*"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LL"

F+!+F" D-B31\'1('"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LR"

F+!+J" E9'1-6$'+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LM"

F+!+J+!" ;)1-($G'"E9'1-6$'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LM"

Page 6: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

F+!+J+<" @-&&$-($G'"E9'1-6$'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"R!"

F+<" #O61'..$3%"G3%"H/[K!"#$%"&'$()*"++++++++++++++++++++++++++++++++++++++++++++++++++ ++++++++++++++++++++++++++++++++++++++++"RC"

J" U).-44'%>-..)%*"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"RJ"

L" D$('1-()1G'12'$89%$."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"RL"

R" ,-%0.-*)%*"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"MJ"

M" V%9-%*"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"ML"

"

Page 7: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

1&2+''+$*+,-+./%$.)0

E-B'&&'"!`"EHSK;&-..$>$0-($3%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!T"E-B'&&'"<`"EKN(-7$)4"7'."7$.(-&'%"'O(1-9'6-($.89'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++++"!!"E-B'&&'"?`"HKN(-7$)4"7'."7$.(-&'%"'O(1-9'6-($.89'%"P93&-%*$30-12$%34."++++++++++++++++++++++++++++++++++++++++++++"!!"E-B'&&'"C`"SKN(-7$)4"7'."7$.(-&'%"'O(1-9'6-($.89'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++"!!"E-B'&&'"F`"5QPPKN(-7$)4"7'."7$.(-&'%"'O(1-9'6-($.89'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++"!<"E-B'&&'"J`"EKN(-7$)4"7'."6'1$9$&:1'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!?"E-B'&&'"L`"HKN(-7$)4"7'."6'1$9$&:1'%"P93&-%*$30-12$%34."++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!?"E-B'&&'"R`"SKN(-7$)4"7'."6'1$9$&:1'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!?"E-B'&&'"M`"5QPPKN(-7$)4"7'."6'1$9$&:1'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!C"E-B'&&'"!T`"#$%('$&)%*"%-89"A$.4)(9KP31&'(('"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!F"E-B'&&'"!!`"EKN(-7$)4"7'."$%(1-9'6-($.89'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!J"E-B'&&'"!<`"HKN(-7$)4"7'."$%(1-9'6-($.89'%"P93&-%*$30-12$%34.+++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!J"E-B'&&'"!?`"SKN(-7$)4"7'."$%(1-9'6-($.89'%"P93&-%*$30-12$%34."++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!J"E-B'&&'"!C`"5QPPKN(-7$)4"7'."$%(1-9'6-($.89'%"P93&-%*$30-12$%34."+++++++++++++++++++++++++++++++++++++++++++++++++++"!L"E-B'&&'"!F`"A$%7)%*..('&&'%"7'1"H')13(1369$%'"-%"7$'".6'2$>$.89'%"E10K='2'6(31'%"++++++++++++++++++++++++++++"<T"E-B'&&'"!J`"U)4"U'$(6)%0("7'1"#1.(7$-*%3.'"'193B'%'"@-($'%('%89-1-0('1$.($0-"+++++++++++++++++++++++++++++++++"<C"E-B'&&'"!L`"^B'1.$89("aB'1"7$'"0&$%$.89'%",-('%"7'."@-($'%('%03&&'0($G."++++++++++++++++++++++++++++++++++++++++++++++"<M"E-B'&&'"!R`"V7$63.$(-.K;&-..$>$0-($3%"7'1"b'&(K/'.)%79'$(.K]1*-%$.-($3%"YbW]Z"++++++++++++++++++++++++++++++++"?!"E-B'&&'"!M`"_'1('$&)%*"G3%"_31'101-%0)%*'%")%7"=$.$03>-0(31'%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?<"E-B'&&'"<T`"V%2-9&"7'1"['1%4'(-.(-.$'1)%*'%"I'"%-89"E)431.(-7$)4"YEHSZ"B'$4"$PPV"+++++++++++++++++++++"?F"E-B'&&'"<!`"V%2-9&"7'1"['1%4'(-.(-.$'1)%*'%"I'"%-89"E)431.(-7$)4"YEHSZ"B'$4"6PPV"++++++++++++++++++++"?F"E-B'&&'"<<`"D-B316-1-4'('1"B'$"#1.(7$-*%3.'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?J"E-B'&&'"<?`"V%*'\-%7('"%'3-7I)G-%('"E9'1-6$'03%2'6('"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?R"E-B'&&'"<C`"V%*'\-%7('"-7I)G-%('"E9'1-6$'03%2'6('"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?R"E-B'&&'"<F`"_'1('$&)%*"7)189*'>a91('1"E9'1-6$'%"G31"#$%(1$(("$%"7-."6-&&$-($G'"#101-%0)%*..(-7$)4"++++"CT"E-B'&&'"<J`"E9'1-6$'>314'%"!+"6-&&$-($G'"E9'1-6$'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C!"E-B'&&'"<L`"N3%.($*'"#1.(&$%$'%KE9'1-6$'>314'%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C!"E-B'&&'"<R`"E9'1-6$'>314'%"<+"6-&&$-($G'"E9'1-6$'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C?"E-B'&&'"<M`"N3%.($*'"U\'$(&$%$'%KE9'1-6$'>314'%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"C?"E-B'&&'"?T`"E9'1-6$'>314'%"?+"6-&&$-($G'"E9'1-6$'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CC"E-B'&&'"?!`"E9'1-6$'>314'%"C+"6-&&$-($G'"E9'1-6$'"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CJ"E-B'&&'"?<`"_'1('$&)%*"7'1"F+KR+"D$%$'%(9'1-6$'"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CL"E-B'&&'"??`",$'"G$'1"-4"9:)>$*.('%"-%*'\-%7('%"E9'1-6$'03%2'6('"B'$"7'1"U\'$(&$%$'%(9'1-6$'"++++++++"F<"E-B'&&'"?C`"5%$G-1$-('"V%-&X.'"613*%3.($.89'1"[-0(31'%"2)4"U'$(6)%0("7'1"#1.(7$-*%3.'"$%"A'2)*"-)>"7-."]Nc".31($'1("%-89"6Kb'1("+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"FF"E-B'&&'"?F`"5%$G-1$-('"V%-&X.'"613*%3.($.89'1"[-0(31'%"$%"A'2)*"-)>"7-."@[Nc".31($'1("%-89"6Kb'1("+++"FL"('+,--,"./0"123$242*'$5,"6)3,+$277,"%,)"8#-529')2'5,$":$'-;7,"<=,5>?%,"@ABC*DE)57"7C>)255D,27,FG"613*%3.($.89'1"[-0(31'%"2)4"U'$(6)%0("7'1"#1.(7$-*%3.'"$%"A'2)*"-)>"7-."]N"+++++++++++++++++++++++++++++++++++++"JR"('+,--,".H0"=#-529')2'5,":$'-;7,"&)?3$?7527C>,)"I'*5?),$"+,2"(>,)'&2,+,32$$"<=,5>?%,"@62$7C>-#77FG"$%"A'2)*"-)>"7-."]N"4$("-&&'%"@-1-4'('1%"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JR"('+,--,".J0"123$242*'$5,"6)3,+$277,"%,)"8#-529')2'5,$":$'-;7,"<=,5>?%,"@ABC*DE)57"7C>)255D,27,FG"613*%3.($.89'1"[-0(31'%"2)4"U'$(6)%0("7'1"#1.(7$-*%3.'"$%"A'2)*"-)>"7-."@[N"+++++++++++++++++++++++++++++++++++"LT"('+,--,".K0"=#-529')2'5,":$'-;7,"&)?3$?7527C>,)"I'*5?),$"+,2"(>,)'&2,+,32$$"<=,5>?%,"@62$7C>-#77FG"$%"A'2)*"-)>"7-."@[N"4$("-&&'%"@-1-4'('1%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"LT"E-B'&&'"CT`"^B'1.$89("aB'1"7$'"/'\'B'613B'%"7'.";3&&'0($G."+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"L<"

Page 8: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

322.'45$6)*+,-+./%$.)0

VBB$&7)%*"!`"#$%('$&)%*"7'."893&-%*$32'&&)&:1'%";-12$%34."%-89"D30-&$.-($3%"++++++++++++++++++++++++++++++++++++++++"!"VBB$&7)%*"<`",$.(1$B)($3%"3>"(9'".()7X"636)&-($3%"$%"(9'"F+".(-*$%*".X.('4."$.".93\%"++++++++++++++++++++++++++++"M"VBB$&7)%*"?`"#$%('$&)%*"%-89"A$.4)(9KP31&'(('"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"!F"VBB$&7)%*"C`"/13d'1"6'1$69'1'1"H'1G"$4"e)'1.89%$((+"f+++g"[:1B)%*`"G-%"/$'.3%h"_'1*1+"!FK>-89"++++++++++"!R"VBB$&7)%*"F`"N'&'0($3%"7'1"N()7$'%636)&-($3%"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"<?"VBB$&7)%*"J`"/'\$89(.0&-..$>$0-($3%")%7"_'1('$&)%*"%-89"ASQ"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?!"VBB$&7)%*"L`"5QPPKN(-7$)4"7'."$PPV"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"??"VBB$&7)%*"R`"5QPPKN(-7$)4"7'."6PPV"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"??"VBB$&7)%*"M`"5QPPKN(-7$)4"7'."7PPV"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"?C"VBB$&7)%*"!T`"D30-&$.-($3%"7'1"S'(-.(-.'%"2)4"U'$(6)%0("7'."A'*$%%."7'1"!+"6-&&$-($G'%"E9'1-6$'"++++"?C"VBB$&7)%*"!!`"^B'1.$89("aB'1"7$'"-4";3&&'0($G"-%*'\-%7('%"E9'1-6$'03%2'6('"+++++++++++++++++++++++++++++++++"?L"VBB$&7)%*"!<`"='.'0($3%..(-()."%-89"'$%'1"]6'1-($3%"$%"0)1-($G'1"VB.$89("++++++++++++++++++++++++++++++++++++++++++"?M"VBB$&7)%*"!?`"^B'1.$89("aB'1"7$'"B'$"7'1"!+"6-&&$-($G'%"E9'1-6$'"-%*'\-%7('%"E9'1-6$'03%2'6('"+++++"CT"VBB$&7)%*"!C`"^B'1.$89("aB'1"7$'"B'$"7'1"<+"6-&&$-($G'%"E9'1-6$'"-%*'\-%7('%"E9'1-6$'03%2'6('"+++++"C<"VBB$&7)%*"!F`"^B'1.$89("aB'1"7$'"B'$"7'1"?+"6-&&$-($G'%"E9'1-6$'"-%*'\-%7('%"E9'1-6$'03%2'6('"+++++"CC"VBB$&7)%*"!J`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"7'."*'.-4('%";3&&'0($G."Y$%"S3%-('%Z"+++++++++++++++++++++"CR"VBB$&7)%*"!L`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"-B9:%*$*"G34"5QPPKN(-7$)4">a1"7-."$PPV"Y5QPPKN(-7$)4"Qc"QQc"QQQc"Q_-"G.+"5QPPKN(-7$)4"Q_BZ"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"CM"VBB$&7)%*"!R`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"-B9:%*$*"G34"5QPPKN(-7$)4">a1"7-."6PPV"Y5QPPKN(-7$)4"Tc"Qc"QQc"QQQ-"G.+"5QPPKN(-7$)4"QQQBc"Q_-c"Q_BZ"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"FT"VBB$&7)%*"!M`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"-B9:%*$*"G34"5QPPKN(-7$)4">a1"7-."7PPV"Y5QPPKN(-7$)4"Tc"Q-c"QB"G.+"5QPPKN(-7$)4"QQ-c"QQBc"QQQc"Q_Z"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"FT"VBB$&7)%*"<T`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7$'",)189>a91)%*"'$%'1"]6'1-($3%"$%"0)1-($G'1"VB.$89("Y%"i"!TFh"]N`"!M"S3%-('"G.+"M"S3%-('h"6"i"TcTT!Z"++++++++++++++++++++++++++++++++"F!"VBB$&7)%*"<!`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"-B9:%*$*"G3%"7'1"!+"6-&&$-($G'%"E9'1-6$'"Y9$'1"/'48$(-B$%"'%(9-&('%7'"E9'1-6$'03%2'6('"G.+"NQ=EZ"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"F<"VBB$&7)%*"<<`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7$'"<+"6-&&$-($G'"E9'1-6$'"Y/'48$(-B$%"G.+"/'48$(-B$%"j"@&-($%7'1$G-("G.+"[]D[Q=Q"G.+"NQ=EZ"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"F?"VBB$&7)%*"<?`";-6&-%KS'$'1KN89:(2'1">a1"7-."@[N"$%"A'2)*"-)>"7$'"D30-&$.-($3%"+++++++++++++++++++++++++++++++++++"FC"VBB$&7)%*"<C`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7-."E)431.(-7$)4"2)"A'*$%%"7'1"6-&&$-($G'%"E9'1-6$'"Y&30-&">31(*'.891$(('%"G.+"4'(-.(-.$'1(Z"++++++++++++++++++++++++++++++++++++++++++++++++"FM"VBB$&7)%*"<F`";-6&-%KS'$'1KN89:(2'1">a1"7-."@[N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7-."E)431.(-7$)4"2)"A'*$%%"'$%'1"6-&&$-($G'%"E9'1-6$'"Y>31(*'.891$(('%"G.+"4'(-.(-.$'1(Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++"FM"VBB$&7)%*"<J`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7-."E)431KN(-7$)4"%-89"EHS"YE!"j"E<"G.+"E?"j"ECZ"++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JT"VBB$&7)%*"<L`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7-."['1%4'(-.(-.$'1)%*..(-7$)4"Y0'$%'"['1%4'(-.(-.$'1)%*"G.+"['1%4'(-.(-.$'1)%*"'$%*'(1'('%Z"++++++++++"J!"VBB$&7)%*"<R`";-6&-%KS'$'1KN89:(2'1">a1"7-."@[N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7-."['1%4'(-.(-.$'1)%*..(-7$)4"Y0'$%'"['1%4'(-.(-.$'1)%*"G.+"['1%4'(-.(-.$'1)%*"'$%*'(1'('%Z"++++++++++"J!"VBB$&7)%*"<M`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"PV!MKMKb'1("YPV!MKM"k"!TTT"5l4&"G.+"PV!MKM"L"!TTT"5l4&Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"J<"VBB$&7)%*"?T`";-6&-%KS'$'1KN89:(2'1">a1"7-."@[N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"PV!MKMKb'1("YPV!MKM"k"!TTT"5l4&"G.+"PV!MKM"L"!TTT"5l4&Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"J<"VBB$&7)%*"?!`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"PV!MKMKb'1("YPV!MKM"k"!TTT"5l4&"G.+"PV!MKM"L"!TTT"5l4&Z+"@-($'%('%"4$("'$%'4"A$&$1)B$%Kb'1("L"!cF"4*l7&"\)17'%"-).*'.89&3..'%+"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"J?"

Page 9: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

VBB$&7)%*"?<`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"P#VKb'1("YP#V"k"CcF"%*l4&"G.+"P#V"L"CcF"%*l4&Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JC"VBB$&7)%*"??`";-6&-%KS'$'1KN89:(2'1">a1"7-."@[N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"P#VKb'1("YP#V"k"CcF"%*l4&"G.+"P#V"L"CcF"%*l4&Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JC"VBB$&7)%*"?C`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"P#VKb'1("YP#V"k"CcF"%*l4&"G.+"P#V"L"CcF"%*l4&Z+"@-($'%('%"4$("'$%'4"A$&$1)B$%Kb'1("L"!cF"*l7&"\)17'%"-).*'.89&3..'%+"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JF"VBB$&7)%*"?F`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7'%"W:43*&3B$%Kb'1("YWB"k"!?"*l7&"G.+"WB"L"!?"*l7&Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JJ"VBB$&7)%*"?J`";-6&-%KS'$'1KN89:(2'1">a1"7-."]N"Y$%"S3%-('%Z"$%"A'2)*"-)>"7-."V&('1"2)4"U'$(6)%0("7'1"#1.(7$-*%3.'"Yk"JJ"m-91'"G.+"L"JJ"m-91'Z++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"JL"VBB$&7)%*"?L`"Q44)%9$.(389'4$.89'1"H-89\'$."G3%"H/[K!"<:++M".H":G"#$%"&'$()*"<:++M".H"NG"7?D2,"W:4-(3OX&$%K#3.$%K[:1B)%*"YW#c"VBB+"?L"AZ"'O'46&-1$.89'1"893&-%*$32'&&)&:1'1";-12$%34'"Y-&&'"VBB$&7)%*'%"$%"<TTK>-89'1"_'1*1nd'1)%*Z"+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++"L<"

Page 10: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!"#$%&'()*+,%&,-./(-*0

0

FK[5" FK[&)313)1-8$&"FKm^=" FKm-91'.K^B'1&'B'%.1-('"VmPP" V4'1$8-%"m3$%("P344$(''"3%"P-%8'1"V;E" @13('$%";$%-.'"A"A,H[" A1-$%K7'1$G'7"%')13(1369$8">-8(31"ASQ" A37XKS-..KQ%7'O"PV"!<F" P-1B39X71-('."V%($*'%"!<F"PV!MKM" P-1B39X71-('."V%($*'%"!MKM"PPP" P93&-%*$32'&&)&:1'.";-12$%34"P#V" P-18$%3'4B1X3%-&'."V%($*'%"P#," P913%$.89"'%(2a%7&$89'",-14'101-%0)%*"P]o" PX8&33OX*'%-.'"P=@" PK1'-0($G'."@13('$%"PE" P346)('1(343*1-69$'"Pp[=V"<!K!" UX(30'1-($%>1-*4'%("<!K!"7PPV" ,$.(-&'."893&-%*$32'&&)&:1'.";-12$%34"#/[" #6$7'14-&"/13\(9"[-8(31"#/[=" #6$7'14-&"/13\(9"[-8(31"='8'6(31"#=P@" #%73.036$.89"1'(13*1-7'"P93&-%*$36-%01'-($03*1-69$'"[]D[Q=Q" FK[&)313)1-8$&"j"[3&$%.:)1'"j"Q1$%3('8-%"[]D[]o" FK[&)313)1-8$&"j"[3&$%.:)1'"j"]O-&$6&-($%"WB" W:43*&3B$%"WPP" W'6-(32'&&)&:1'.";-12$%34"W#" W:4-(3OX&$%K#3.$%"W=" W-2-17"=-($3"$PPV" Q%(1-9'6-($.89'."893&-%*$32'&&)&:1'.";-12$%34"QDKJ" Q%('1&')0$%"J";=VN" ;$1.('%"1-(".-1834-"G$1-&"3%83*'%'"D,W" D-0(-(7'9X713*'%-.'"DEo" D'B'1(1-%.6&-%(-($3%"SV@;" S$(3*'%"-8($G-('7"613('$%"0$%-.'"S#E" EX13.$%K@13('$%0$%-.'"S#E"S=P@" S-*%'(1'.3%-%2893&-%*$36-%01'-($03*1-69$'"S=E" S-*%'(1'.3%-%2(343*1-69$'"OIPQ" H)8&'-1">-8(31"q0-66-K&$*9(K89-$%K'%9-%8'1q"3>"-8($G-('7"

AK8'&&."H/[" H'1G'"/13\(9"[-8(31"H=VN" H')13B&-.(34-"G$1-&"3%83*'%'"9343&3*"HE[" H')13(1369$%"]N" ]G'1-&&"N)1G$G-&"6LFHE=" 6LF"H')13(1369$%K='2'6(31"6-%E10" E10"Vc"A")%7"P"6PPV" @'1$9$&:1'."893&-%*$32'&&)&:1'.";-12$%34"@,E" @93(37X%-4$.89'"E9'1-6$'"@#EKPE" @3.$(13%'%'4$..$3%.(343*1-69$'KP346)('1(343*1-69$'"@[N" @13*1'..$3%"[1''"N)1G$G-&"@Q?;" @93.693$%3.$($7K?K;$%-.'"@;P" @13('$%0$%-.'"P"

Page 11: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

@DP" @93.693&$6-.'"P"@HQ" @'1$%')1-&'"Q%G-.$3%"@NP" @1$4:1".0&'13.$'1'%7'"P93&-%*$($."=VN" =-(".-1834-"Y/E@-.'Z"=#PQNE" ='.63%.'"#G-&)-($3%"P1$('1$-"$%"N3&$7"E)431."N," N(-%7-17-B\'$89)%*"NQ=E" N'&'0($G'"$%('1%'"=-7$3(9'1-6$'"EVP#" E1-%.-1('1$'&&'"P9'43'4B3&$.-($3%"(RIS" ()'$74?)82$3"R)?D5>"I'C5?)"S"ESV" E$..)'"S$813"V11-X"E@F?" E)431"@13('$%"F?"E10"" E13634X3.$%"='2'6(310$%-.'"5QPP" 5%$3%"$%('1%-($3%-&'"83%(1'"&'"8-%8'1"bW]" b'&(K/'.)%79'$(.K]1*-%$.-($3%"

Page 12: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!""

!F 7.$'+.(5$60

!"!F 8&)09&''+$6&$6):&,-.$;<0

!"!"!F =,)>,5$604+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0"

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`'-$ 0'($ 'X8+"2':"8-#92'($%"&&'()"()#*"+,-(./'($ 3(8'+#92'-0'8$/"($ ,<-#92'($ 0'($ :'+-2-&4+'($ 6111$ 0'+$ :+.X-/"&'($%"&&'()4()'7$ 3(0$ 0'($ 0-#8"&'($ 111#A$!-'$ 0-#8"&'($%"&&'()"()#*"+,-(./'$<'+0'($-/$a'#'(8&-92'($<-'$b"&-)(./'$0'#$S"(*+'"#*.:='#$@'2"(0'&8$3(0$@'=-(0'($#-92$,<-#92'($0'+$b](03()$0'#$!3983#$9c#8-93#$3(0$0'+$O/:3&&"$P"8'+-$6I",3/-&"P"$U$%.+'#B$CDE\7A$!"#$:'+-2-&4+'$%"&&'()"()#*"+,-(./$-#8$,<-#92'($0'+$Q-(/](03()$0'#$!3983#$9c#8-93#$3(0$0'+$;':"8-*3#)"@'&$&.*"&-#-'+8$3(0$<-+0$("92$`-#/382$3(0$1.+&'88'$*&"##-=-,-'+8$6`'9*'+$'8$"&AB$CDDL7A$

$

$

!""#$%&'()*+),#'-.#$&'()%./)012$3'(#24.$$&$56.')7364#'28/)'301)92:3$#/3-#2');<2(.$).-)3$=>)?@*AB)

"

!-'#'$ 0+'-$Q(8-848'($ 3(8'+#92'-0'($ #-92$ 2-(#-928&-92$ -2+'+$>3/.+@-.&.)-'B$ 0'+$ >2'+":-'$ 3(0$ -2+'+$5&-(-*B$=.&)&-92$-#8$'-('$)'("3'$!-=='+'(,-'+3()$P.($)+.R'+$`'0'383()$6%2.3+-$'8$"&AB$CDEJ7A$b"*+.#*.:-#92$<'+0'($0-'$0+'-$a"92#83/#8c:'($-(=-&8+"8-PB$(.03&4+$3(0$-(8+"03*8"&$3(8'+#92-'0'($6?-/$U$S"+*B$CDD\7A$_("@24()-)$P.($0'+$?.*"&-#"8-.($2"(0'&8$'#$#-92$@'-$VD$G$0'+$%"&&'()"()#*"+,-(./'$2-#8.&.)-#92$3/$O0'(.*"+,-(./'$6%2.3+-$'8$"&AB$CDEJW$52"(B$>2./"#B$!"P-0#.(B$'8$"&AB$CDDJ7A$

$

Page 13: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<""

!"!"AF 7>.4+<.;';6.+05$40B.).:;C&:(;,+$04+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0"

JD$G$ 0'+$ %"&&'()"()#83/.+'$ #-(0$ :'+-2-&4+B$ \D$G$ 'X8+"2':"8-#92$ 3(0$ ED$G$ -(8+"2':"8-#92$ &.*"&-#-'+8$6!'Y&-P'-+"$'8$"&AB$CDD^7A$b'-#8'(#$8+'8'($0-'$12.&"()-.*"+,-(./'$("92$0'/$JDA$?'@'(#d"2+$"3=$6e.)'&$'8$"&AB$CDE\7A$b4(('+$'+*+"(*'($EBJF/"&$243=-)'+$"&#$f+"3'($6O&8'*+3#'$'8$"&AB$CDEJ7A$K($0'($&'8,8'($N"2+,'2(8'($-#8$'-($#8"+*'+$O(#8-')$0'+$K(,-0'(,$0'+$-(8+"2':"8-#92'($111#$-($0'($<'#8&-92'($?4(0'+($,3$@'.@"928'(A$K/$g'-8+"3/$P.($EV^D$@-#$ EVVD$ #8-')$0-'$ K(,-0'(,$0'+$ -11O#$ -($0'($_hO$3/$E[J$G$P.($DBLCMEDDDDD$ "3=$DBiJMEDDDDD$ 6%2.3+-$ '8$ "&AB$ CDEJW$ h2"-@$ '8$ "&AB$ CDD\7A$ K/$ %')'(#"8,$ 0",3$ @&-'@$ 0-'$ K(,-0'(,+"8'$ 0'+$'X8+"2':"8-#92'($%"&&'()"()#*"+,-(./'$-($0'($&'8,8'($N"2+,'2(8'($*.(#8"(8$6f"+)'#$'8$"&AB$CDEE7$.0'+$,'-)8'$'-('$ &'-928$ +]9*&43=-)'$ >'(0'(,$ 6S"8'&B$ CDDE7A$ !-'$ %+](0'$ =]+$ 0'($ O(#8-')$ 0'+$ K(,-0'(,$ @'-$ 0'($-(8+"2':"8-#92'($ %"&&'()"()#*"+,-(./'($ #-(0$ (.92$ 3(*&"+A$ e'+#92-'0'('$ Q+*&4+3()#"(#48,'$ <-'$ @'##'+'$!-")(.#'/H)&-92*'-8'($3(0$<'92#'&(0'$5&"##-=-*"8-.('($&-'R'($#-92$&'8,8&-92$(-928$2"&8'(B$0"$#-92$0'+$O(#8-')$0'+$K(,-0'(,+"8'$(-928$-($"&&'($'82(-#92'($%+3::'($0'/.(#8+-'+'($&-'R$6S"8'&B$CDDEW$h2"-@$'8$"&AB$CDD\7A$O392$'-('$g3("2/'$0'+$K(,-0'(,$0'+$:+-/4+$#*&'+.#-'+'(0'($12.&"()-8-#$6Sh17B$'-('+$Q+*+"(*3()B$0-'$/-8$'-('/$0'38&-92$ '+2H28'($ I-#-*.$ =]+$ 0-'$ Q(8<-9*&3()$ '-('#$ %"&&'()"()#*"+,-(./#$ "##.,--'+8$ -#8B$ #92'-(8$ *'-('$_+#"92'$ =]+$ 0-'$ "(#8'-)'(0'$ K(,-0'(,$ 0'#$ -11O#$ ,3$ #'-($ 6h2"-@$ '8$ "&AB$ CDD\7A$ Q-('$ #8'-)'(0'$Q+*+"(*3()#243=-)*'-8$P.($;':"8-8-#F1FK(='*8-.('(B$(-928$"&*.2.&-#92'+$?'@'+,-++2.#'($#.<-'$0-'$0'38&-92'$g3("2/'$P.($O0-:.#-8"#$3(0$0'+$0"/-8$P'+)'#'&&#92"=8'8'($f'88&'@'+$*H((8'($0-'$g3("2/'$0'+$K(,-0'(,$0'#$-(8+"2':"8-#92'($%"&&'()"()#*"+,-(./#$'+*&4+'(B$0"$0-'$"3=)',42&8'($5+"(*2'-8'($"&#$I-#-*.="*8.+'($=]+$0"#$-11O$)'&8'($6Q(0.$'8$"&AB$CDDi7A$$!-'$2.2'$K(,-0'(,$-($0'($"#-"8-#92'($?4(0'+($<-+0$P.+$"&&'/$03+92$'(0'/-#92'$S"+"#-8'(-(='*8-.('($/-8$?'@'+')'&($6Y:2-#8.+92-#$P-P'++-(-B$1&.(.+92-#$#-('(#-#7$'+*&4+8$65"'<:-8..($'8$"&AB$CDDiW$h2-($'8$"&AB$EVV[7A$$`'-$ (3+$ \D$G$ 0'+$ Q+*+"(*3()'($ *"(($ '-($ g3#"//'(2"()$ /-8$ 0'($ -($ 0'+$ <'#8&-92'($ a'&8$ @'*"((8'($I-#-*.="*8.+'($2'+)'#8'&&8$<'+0'($6h2"-@$'8$"&AB$CDDJ7A$b'-#8$#92'-('($0-'#'$/-8$'-('+$92+.(-#92'($Q(8,](03()$0'#$%"&&'()"()':-82'&#$-($e'+@-(03()$,3$#8'2'(A$h.$<'+0'($:+.-(=&"//"8.+-#92'$gc8.*-('$<-'$K(8'+&'3*-($[$6K?F[7$/-8$0'+$Q(8#8'23()$0'#$%"&&'()"()#*"+,-(./#$"##.,--'+8$6h3)"<"+"$'8$"&AB$EVVi7A$;-'+$-#8$"($'+#8'+$h8'&&'$ 0-'$ @'+'-8#$ .@'($ '+<42(8'$ :+-/4+$ #*&'+.#-'+'(0'$ 12.&"()-8-#$ ,3$ ('(('(B$ '-('$ #'&8'('$ 92+.(-#92'$Q(8,](03()$ 0'+$ %"&&'(<')'B$ 0-'$ -/$ <'-8'+'($ e'+&"3=$ ,3$ '-('+$ @-&-4+'($ g-++2.#'$ =]2+'($ *"((A$ !"#$?'@'(#,'-8+-#-*.$'-($111$,3$'(8<-9*'&($@'8+4)8$=]+$0-'$"($Sh1$'+*+"(*8'($S"8-'(8'($EDFEJ$G$652"0'+-$U$h3##/"(B$CDEJ7B$<.@'-$="#8$"&&'$('3$"3=)'8+'8'('($111#$-(('+2"&@$0'+$'+#8'($0+'-$N"2+'$("92$!-")(.#'$0'+$Sh1$0-")(.#8-,-'+8$<'+0'($61&"'##'($'8$"&AB$CDDV7A$K(#)'#"/8$#-(0$<'(-)'+$"&#$ED$$G$0'+$12.&"()-.*"+,-(./'$"3=$'-('$Sh1$,3+]9*,3=]2+'($6>c#.($U$Q&Fh'+")B$CDEE7A$!"#$/-88&'+'$Q+*+"(*3()#"&8'+$0'+$S"8-'(8'(B$0-'$-/$I"2/'($'-('+$Sh1$'-($111$'(8<-9*'&(B$@'<')8$#-92$-/$`'+'-92$0'#$\A$?'@'(#d"2+,'2(8'#$6`'+)j3-#8$'8$"&AB$CDD[W$12"&"#"(-$'8$"&AB$CDDD7A$$a'-8'+'$Q+*+"(*3()'(B$0-'$/-8$'-('+$!-")(.#'$0'#$111$-($d]()'+'($N"2+'($'-(2'+)'2'(B$#-(0$"()'@.+'('$f'2&@-&03()'($0'+$%"&&'()4()'$<-'$@'-#:-'&#<'-#'$%"&&'()"()#,c#8'($.0'+$0-'$1"+.&-F5+"(*2'-8$6%"88.$'8$"&AB$CDED7A$$O392$P-+"&'$ K(='*8-.('($0'+$?'@'+$@')](#8-)'($0-'$Q(8<-9*&3()$'-('#$111#A$ K($,<'-$_hF"/'+-*"(-#92'($h830-'($<"+$0-'$S+4P"&'(,$P.($;':"8-8-#$1$@'-$"($-(8+"2':"8-#92'/$12.&"()-.*"+,-(./$'+*+"(*8'($S"8-'(8'($P-'+/"&$ 2H2'+$ "&#$ -($ 0'+$ Z.+/"&@'PH&*'+3()A$ Q-('$ K(='*8-.($ /-8$ ;':"8-8-#$`$ *.((8'$ 2-'+$ (-928$ "&#$#-)(-=-*"(8'+$I-#-*.="*8.+$@'#848-)8$<'+0'($6Q&Fh'+")$'8$"&AB$CDDVW$h2"-@$'8$"&AB$CDDJ7A$K/$%')'(#"8,$0",3$#"2'($?''$'8$"&A$ 6?''$'8$"&AB$CDEJ7$ -($'-('+$*.+'"(-#92'($h830-'()+3::'$/-8$"($ -(8+"2':"8-#92'/$111$'+*+"(*8'($S'+#.('($'-('$0'38&-92$2H2'+'$S+4P"&'(,$"($;':"8-8-#F`FK(='*8-.('(W$'-('$Q+*+"(*3()$"($;':"8-8-#$1$,'-)8'$#-92$2-'+$(-928$"&#$I-#-*.="*8.+A$K($'-('+$b'8""("&c#'$*.((8'($?-$'8$"&A$'@'(="&&#$;':"8-8-#$`$"&#$I-#-*.="*8.+$@'#848-)'($6?-$'8$"&AB$CDEC7A$$12.&'0.92.&-82-"#-#B$12.&'&-82-"#-#$6a'&,'&$'8$"&AB$CDD^7$3(0$;':"8.&-82-"#-#$F$'-('$-/$a'#8'($#'&8'('B$'2'+$-($O#-'($P.+*.//'(0'$Q+*+"(*3()$F$)'&8'($"3=)+3(0$0'+$92+.(-#92'($Q(8,](03()$3(0$Q:-82'&:+.&-='+"8-.($"&#$I-#-*.="*8.+'($653@.$'8$"&AB$EVVJ7A$$

Page 14: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?""

Q-($<'-8'+'+$I-#-*.="*8.+$=]+$0-'$Q(8#8'23()$'-('#$111#$-#8$0"#$e.+&-')'($'-('+$92+.(-#92$'(8,](0&-92'($!"+/'+*+"(*3()$ 61Q!7$ 6a'&,'&$ '8$ "&AB$ CDD^7A$ !"$ 0-'$ :+-/4+$ #*&'+.#-'+'(0'$ 12.&"()-8-#$ /-8$ 92+.(-#92$'(8,](0&-92'($ !"+/'+*+"(*3()'($ "##.,--'+8$ -#8B$ #8'&&8$ #-92$ 0-'$ f+")'B$ .@$ 0-'$ Q+*+"(*3()$ "($ 1Q!#$ "&#$3("@24()-)'+$I-#-*.="*8.+$"()'#'2'($<'+0'($*"(($.0'+$.@$0-'$Sh1$0'($8"8#492&-92'($I-#-*.="*8.+$0"+#8'&&8A$LB[$G$0'+$b.+@3#F1+.2(FS"8-'(8'($3(0$J$G$0'+$1.&-8-#F3&9'+.#"FS"8-'(8'($'(8<-9*'&($'-('$Sh1$6;3"-$'8$"&AB$CDE\7A$ K($ '-('+$ O+@'-8$ P.($ Q+-92#'($'8$"&A$ <"+$ @'-$ JD$G$ 0'+$ 1Q!FS"8-'(8'(B$ 0-'$ "($ '-('/$%"&&'()"()#*"+,-(./$'+*+"(*8$<"+'(B$"392$'-('$Sh1$@'*"((8$6Q+-92#'($'8$"&AB$CDDV7A$!-'#$'+#92<'+8$'#B$0'($g3#"//'(2"()$P.($0'+$Sh1B$0'($1Q!#$3(0$0'/$%"&&'()"()#*"+,-(./$,3$'+*'(('(A$;3"-$'8$"&A$*.((8'($-($'-('+$b'8""("&c#'$#.<.2&$0"#$e.+&-')'($'-('+$1.&-8-#$3&9'+.#"$"&#$"392$'-('#$b.+@3#$1+.2($"&#$I-#-*.="*8.+$@'#848-)'(A$ K($ 0-'#'+$ O+@'-8$ <3+0'$ P'+#3928B$ '@'($ '+<42(8'#$ S+.@&'/$ ,3$ 3/)'2'(B$ -(0'/$ h830-'($"3#)'#92&.##'($<3+0'(B$ 0-'$5.&&'*8-P'$ P.($ S"8-'(8'($/-8$ 1Q!$ 3(0$ )&'-92,'-8-)'/$e.+&-')'($ '-('+$ Sh1$'-(#92&.##'($6;3"-$'8$"&AB$CDE\7A$$T@'+)'<-928$ 6Y2$ '8$ "&AB$ CDDJ7B$ Z-*.8-("@3#3#B$ !-"@'8'#$ /'&&-83#$ 612"-8''+"*-d$ '8$ "&AB$ CDEL7$ 3(0$ 0"#$/'8"@.&-#92'$hc(0+./$)'&8'($"&#$<'-8'+'$I-#-*.="*8.+'($6a'&,'&$'8$"&AB$CDEE7A$!-'#$-#8$@'#.(0'+#$-(8'+'##"(8B$0"$'#$#-92$3/$/.0-=-,-'+@"+'$I-#-*.="*8.+'($2"(0'&8A$e'+#92-'0'('$h830-'($2"@'($@'+'-8#$3(8'+$"(0'+'/$=]+$0"#$2':"8.,'&&3&4+'$5"+,-(./$)','-)8B$0"##$0-'$Q-(("2/'$P.($b'8=.+/-($/-8$'-('/$+'03,-'+8'($I-#-*.$=]+$'-('$ >3/.+'(8<-9*&3()$ '-(2'+)'28$ 6!.("0.($ '8$ "&AB$ CDEDW$ ?''$ '8$ "&AB$ CDEE7A$ Q@'(="&&#$ *.((8'($12"-8''+"*-d$'8$"&A$@'-$S"8-'(8'(B$0-'$b'8=.+/-($'-(("2/'(B$'-($ #-)(-=-*"(8$(-'0+-)'+'#$I-#-*.$'+*'(('($"($'-('/$92.&"()-.,'&&3&4+'($5"+,-(./$,3$'+*+"(*'($612"-8''+"*-d$'8$"&AB$CDEL7A$Q-($Q=='*8$"3=$0"#$T@'+&'@'($("92$!-")(.#'#8'&&3()$,'-)8'$#-92$(-928$6k"()$'8$"&AB$CDEJ7A$

$

!"!"DF 8.&6$;)+04+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0

!"!"D"!F @'.$.)/%+0E,?)+$(&(.;$04+,0E&(.+$(+$0"

!-'$!-")(.#'$0'#$92.&"()-.,'&&3&4+'($5"+,-(./#$<-+0$/'-#8$'+#8$#:48$)'#8'&&8B$0"$#-92$0-'$Q+*+"(*3()$*&-(-#92$.=8$ P'+)&'-92#<'-#'$ 3("3==4&&-)$ P'+24&8$ 6b"&2-$U$%.+'#B$ CDD[W$I-,P-$U$%.+'#B$ CDELW$g'()$U$>".B$ CDEJ7A$S"8-'(8'($/-8$ "#c/:8./"8-#92'($Q+*+"(*3()'($ ="&&'($ )')'@'('(="&&#$ 03+92$ '+2H28'$12.&'#8"#':"+"/'8'+$"3=A$!"#$-(8+"2':"8-#92'$%"&&'()"()#*"+,-(./$:+4#'(8-'+8$#-92$'2'+$/-8$3(#:',-=-#92'($O&&)'/'-(#c/:8./'($<-'$"@0./-('&&'($h92/'+,'($3(0$O::'8-8&.#-)*'-8B$ -/$#:48'($5+"(*2'-8##8"0-3/$"392$Z"928#92<'-R$3(0$%'<-928#P'+&3#8$ 6%2.3+-$ '8$ "&AB$ CDEJ7B$ .0'+$ /-8$ hc/:8./'(B$ 0-'$ 03+92$ P.+2"(0'('$ f'+(/'8"#8"#'($P'+3+#"928$<'+0'($6e.)'&$'8$"&AB$CDE\7A$S"8-'(8'($/-8$0-#8"&'/$.0'+$:'+-2-&4+'/$12.&"()-.*"+,-(./$#8'&&'($#-92$ .=8$ /-8$ :'+#-#8-'+'(0'/$ K*8'+3#$ 3(0$ 12.&'#8"#'$ /-8$ S+3+-83#$ 3(0$ 03(*&'/$ _+-($ P.+$ 6S"8'&B$ CDD[7A$O3=)+3(0$0'+$?.*"&-#"8-.($0'#$:'+-2-&4+'($3(0$'X8+"2':"8-#92'($111#$8+'8'($12.&'#8"#'#c/:8./'$+'&"8-P$=+]2$-/$5+"(*2'-8#P'+&"3=$"3=A$h./-8$<'+0'($0-'#'$12.&"()-.*"+,-(./'$/'-#8$-($'-('/$=+]2'+'($h8"0-3/$0-")(.#8-,-'+8$ "&#$0-'$ -(8+"2':"8-#92'($111#A$!-'$Q(8<-9*&3()$'-('#$ K*8'+3#$ -#8$@'-$Q+*+"(*3()$"($'-('/$-(8+"2':"8-#92'($%"&&'()"()#*"+,-(./$(-928$8c:-#92$6Z"*''@$'8$"&AB$EVV[7A$$

Page 15: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

C""

!"!"D"AF F.'46+25$60"

O392$@'-$0'+$O3#<"2&$0'+$`-&0)'@3()$-#8$'#$<-928-)B$,<-#92'($-(8+"F$3(0$'X8+"2':"8-#92$6:'+-2-&4+$3(0$0-#8"&7$&.*"&-#-'+8'($%"&&'()"()#*"+,-(./'($,3$3(8'+#92'-0'(A$Q+#8'+$!-")(.#'#92+-88B$P.+$"&&'/$@'-$e.+&-')'($'-('+$12.&'#8"#'B$-#8$'-('$_&8+"#92"&&3(8'+#3923()A$O&&'+0-()#$-#8$0'+'($O3##")'*+"=8$@')+'(,8$3(0$24()8$#'2+$P.($0'+$Q+="2+3()$0'#$_(8'+#392'+#$"@B$#.0"##$"(0'+'$`-&0)'@3()#/'82.0'($=.&)'($#.&&8'($6%2.3+-$'8$"&AB$CDEJ7A$h.<.2&$1./:38'+8./.)+":2-'$61>7$"&#$"392$b")('8+'#.("(,8./.)+":2-'$6bI>7$#-(0$=]+$0-'$h392'$("92$0'/$S+-/"+-3#$3(0$("92$h"8'&&-8'(&4#-.('($#.<-'$@'-$0'+$`'3+8'-&3()$0'+$%+HR'$0'#$>3/.+#$)''-)('8$6I-,P-$U$ %.+'#B$ CDEL7A$ f]+$ 0"#$ :'+-2-&4+'$ 92.&"()-.,'&&3&4+'$ 5"+,-(./$ -#8$ 0-'$ (-928F-(P"#-P'$b")('8+'#.("(,92.&"()-.:"(*+'"8-*.)+":2-'$ 6bI1S7$ 0-'$ `-&0)'@3()$ 0'+$ a"2&A$ !-'$ %'("3-)*'-8$ 0'+$_(8'+#3923()$-($`',3)$"3=$&.*"&'$O3#@+'-83()$3(0$I'#'*8"@-&-848$@'8+4)8$@-#$,3$VJ$G$6`&'92"9,$'8$"&AB$CDEE7$3(0$ -#8$ #./-8$ P'+)&'-92@"+$/-8$ 0'+$ '(0.#*.:-#92$ +'8+.)+"0'($12.&"()-.:"(*+'"8-*.)+":2-'$ 6QI1S7A$!'+$e.+8'-&$ 0'+$ bI1S$ )')'(]@'+$ 0'+$ QI1S$ -#8$ 0-'$ !"+#8'&&3()$ 0'#$ :+.X-/"&'($ %"&&'()"()#$ d'(#'-8#$ 0'+$Y@#8+3*8-.($65-/$'8$"&AB$CDDD7A$!'#$a'-8'+'($2"(0'&8$'#$#-92$@'-$0'+$bI1S$3/$'-('$(-928F-(P"#-P'$3(0$0"/-8$:"8-'(8'(#92.('(0'$0-")(.#8-#92'$b'82.0'A$e.+8'-&$0'+$QI1S$-#8$'-('$#.=.+8-)'$K(8'+P'(8-.(#/H)&-92*'-8A$h.$ *H(('($ @'-$ Y@#8+3*8-.($ 03+92$ '-($%"&&'()"()#*"+,-(./$%"&&'()"()#8'(8#$ '-()'&')8$ <'+0'(A$ g30'/$@'#8'28$ 0-'$ bH)&-92*'-8$ '-('$ `]+#8'(,c8.&.)-'$ ,3$ )'<-(('(B$ 3/$ '-('$ ,c8.&.)-#92'$ O@*&4+3()$ 0'+$I"3/=.+0'+3()$ ,3$ '++'-92'(A$ 5.//8$ *'-('$ 92-+3+)-#92'M*3+"8-P'$ >2'+":-'$ -($ f+")'B$ #.&&8'$ @'-$+"0-.&.)-#92'/$e'+0"928$ "3=$ '-($/"&-)('#$%'#92'2'($ -($ 0'+$?'@'+$ :+-(,-:-'&&$ P.+$`')-(($ 0'+$ :"&&-"8-P'($>2'+":-'$ '-('$S3(*8-.($ '+=.&)'($ 6>"((":='&$ '8$ "&AB$ CDEC7B$ 3/$ ,<-#92'($ 2':"8-#92'+$b'8"#8"#-'+3()$ '-('+$"(0'+'($>3/.+'+*+"(*3()$3(0$'-('/$:+-/4+'($b"&-)(./$0'+$?'@'+$6;11M1117$,3$3(8'+#92'-0'(A$Q-('$S.#-8+.('('/-##-.(#8./.)+":2-'F1>$6SQ>F1>7$<-+0$@-#<'-&'($@'-$0'+$h392'$("92$b'8"#8"#'($"()'<"(08B$"&&'+0-()#$#-(0$P-'&'$111#$SQ>F(')"8-PB$#.0"##$SQ>F1>#$'-('$3(8'+)'.+0('8'B$(-928$'8"@&-'+8'$I.&&'$-($0'+$!-")(.#8-*$0'#$111#$#:-'&'($6O(0'+#.($'8$"&AB$CDD\7A$$

!"!"D"DF G&2;,>&,&<+(+,0"

!-'$ h392'$ ("92$`-./"+*'+($ -/$`&38$ .0'+$ "(0'+'($5H+:'+=&]##-)*'-8'(B$ 0-'$ '-($ h9+''(-()$ -($ 0'+$ @+'-8'($`'PH&*'+3()$ .0'+$ -($ ;.92+-#-*.)+3::'($ '+/H)&-92'(B$ P'+&-'=$ @-#&"()$ .2('$ ,3=+-'0'(#8'&&'(0'#$ Q+)'@(-#$6g'()$U$>".B$CDEJ7A$!-'$e'+<'(03()$P.($h'+3/F>3/.+/"+*'+($-($0'+$5+'@#0-")(.#8-*$@-'8'8$d'0.92$P-'&'$e.+8'-&'A$!-'#'$*H(('($/-8$'-('/$)'+-()'($O3=<"(0$3(0$3(8'+$<'(-)$`'&"#83()$=]+$0'($S"8-'(8'($)'<.(('($<'+0'($ 3(0$ #-(0$ ,30'/$ /-8$ P'+)&'-92#<'-#'$ (-'0+-)'($ 5.#8'($ P'+@3(0'(A$ e'+<'(0'8$ <'+0'($ -($ 0'+$!-")(.#8-*$ 0'#$ 111#$ 0'+,'-8$ P.+$ "&&'/$ 0"#$ 1"[email protected]+"8'$ O(8-)'($ EVFV$ 61OEVFV7B$ 1"+9-(.'/@+c.("&'#$O(8-)'($ 61QO7$3(0$0"#$1"[email protected]+"8'$O(8-)'($ECJ$ 61O$ECJ7A$1OEVFV$<'-#8$ 8+.8,$)+.R'+$_(8'+#92-'0'$ -($P'+#92-'0'('($h830-'($0-'$@'#8'$h'(#-8-P-848$6Li$GFiV$G7$3(0$h:',-=-848$6JD$GFVi$G7$3(8'+$0'($@'*"((8'($>3/.+/"+*'+($"3=$6Z'2&#$'8$"&AB$CDD\7A$O&&'+0-()#$)-&8$,3$@'"928'(B$0"##$1OEVFV$#.<.2&$@'-$@'(-)('($6:+-/4+$#*&'+.#-'+'(0'$12.&"()-8-#B$:+-/4+$@-&-4+'$g-++2.#'B$ 92+.(-#92'$;':"8-8-#B$S"(*+'"8-8-#B$12.&'0.92.&-82-"#-#$3(0$12.&"()-8-#7$"&#$"392$@'-$/"&-)('($6*.&.+'*8"&'B$2':"8.,'&&3&4+'$3(0$.P"+-'&&'$>3/.+'(7$Q+*+"(*3()'($'+2H28$ #'-($ *"(($ 6K(9'$ '8$ "&AB$ CDE\W$ b"++'&&-$ '8$ "&AB$ CDDV7A$ !"2'+$ *"(($ 0-'#'+$ >3/.+/"+*'+$ (3+$ -($g3#"//'(#92"3$/-8$<'-8'+'($`'=3(0'($6,A$`A$`-&0)'@3()B$`-.:#-'(7$,3+$!-")(.#'#8'&&3()$@'-8+")'($3(0$0-'(8$P.+$"&&'/$,3+$e'+&"3=#@'3+8'-&3()$3(8'+$>2'+":-'$6?3/"92-$'8$"&AB$CDE\7A$$O3=)+3(0$)+.R'+$e"+-"@-&-848$ 0'+$O3##")'($]@'+$h'(#-8-P-848$3(0$h:',-=-848$ P.($1OEVFV$ -($P'+#92-'0'('($h830-'($-#8$0-'$h392'$("92$"(0'+'(B$,3P'+&4##-)'+'($>3/.+/"+*'+($("2'&-')'(0A$$gc8.*'+"8-('$#-(0$S+.8'-('B$0-'$"($0'+$-(8'+,'&&3&4+'($f-&"/'(8@-&03()$@'8'-&-)8$#-(0A$!"$0-'$Q:-82'&-'($'-('#$@'#8-//8'($ Y+)"(#$ '-('$ #:',-=-#92'$ g3#"//'(#'8,3()$ "($ gc8.*'+"8-('($ "3=<'-#'(B$ 2-&=8$ '-('$-//3(2-#8.92'/-#92'$ O("&c#'$ @'-$ 0'+$ g3.+0(3()$ P.($ >3/.+'($ .0'+$ P.($ b'8"#8"#'($ ,3$ -2+'/$S+-/4+83/.+$ 6N"-($ '8$ "&AB$ CDED7A$ gc8.*'+"8-($EV$ <-+0$ -/$ Q:-82'&$ P-'&'+$ Y+)"('$ 'X:+-/-'+8B$ "392$ -($ 0'($%"&&'<')'($6b.&&$'8$"&AB$EViC7A$$

Page 16: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

F""

gc8.*'+"8-(=+")/'(8$CEFE$61kfIO$CEFE7$-#8$'-($-/$`&38$&H#&-92'+$`'#8"(08'-&$P.($gc8.*'+"8-($EV$6;3"()$'8$"&AB$CDE\7$3(0$*.//8$#'&8'($ -/$`&38*+'-#&"3=$)'#3(0'+$K(0-P-03'($P.+$ 612":/"($'8$"&AB$CDEE7A$f]+$'-(-)'$/"&-)('$Q+*+"(*3()'(B$@'-#:-'&#<'-#'$=]+$0"#$S"(*+'"#*"+,-(./B$<3+0'$0'+$0-")(.#8-#92'$3(0$:+.)(.#8-#92'$a'+8$ P.($ 1kfIO$CEFE$ "&#$ `-./"+*'+$ @'+'-8#$ )','-)8$ 6`.'9*$ '8$ "&AB$ CDEL7A$ O392$ @'-$ 0'+$ !-")(.#'$ 0'#$*&'-(,'&&-)'($ `+.(92-"&*"+,-(./#$ #:-'&8$ 1kfIO$CEFE$ '-('$ <-928-)'$ I.&&'$ 6>"*"0"$ '8$ "&AB$ EVVJ7A$ f]+$ 0-'$!-")(.#8-*$0'#$%"&&'()"()#*"+,-(./#$,'-)8'$#-92$1kfIO$CEFE$"&#$P'+&4##&-92'+$`-./"+*'+A$6?3/"92-$'8$"&AB$CDE\W$_'(-#2-$'8$"&AB$CDDi7A$K($5./@-("8-.($/-8$'+2H28'/$1OEVFV$<3+0'$'-('$#'2+$2.2'$h:',-=-848$=]+$0-'$!-")(.#'$ '-('#$ 111#$ @'.@"928'8B$ d'0.92$ '-('$ )'+-()'+'$ h'(#-8-P-848$ "&#$ =]+$ 1OEVFV$ "&&'-('A$ g30'/$ )-&8$1kfIO$CEFE$"&#$#8"+*'+$3("@24()-)'+$:+.)(.#8-#92'+$b"+*'+$ 612":/"($'8$"&AB$CDEE7A$ K/$%')'(#"8,$,3/$1OEVFVFa'+8$-#8$/-8$0'+$`'#8-//3()$P.($1kfIO$CEFE$'-('$)38'$_(8'+#92'-03()$,<-#92'($@'(-)('($3(0$/"&-)('($%"&&'(<')#'+*+"(*3()'($/H)&-92$6;3"()$'8$"&AB$CDE\7A$>+.8,0'/$*.((8'$#-92$0-'$`'#8-//3()$P.($1kfIO$CEFE$@-#$d'8,8$(-928$-($0'+$*&-(-#92'($I.38-('$03+92#'8,'(A$$

!"!"HF 1%+,&>.+04+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0

!"!"H"!F @5,&(.*+01%+,&>.+:;$-+>(+0"

Y@<.2&$ 0-'$ 92-+3+)-#92'$ I'#'*8-.($ 0-'$ '-(,-)'$ *3+"8-P'$ >2'+":-'/H)&-92*'-8$ @'-/$ 92.&"()-.,'&&3&4+'($5"+,-(./$0"+#8'&&8B$-#8$#-'$(3+$@'-$EDFCD$G$0'+$S"8-'(8'($/H)&-92$6?-$'8$"&AB$CDE\7B$0"$#-92$0-'$Q+*+"(*3()$,3/$g'-8:3(*8$0'+$!-")(.#'#8'&&3()$]@'+<-')'(0$#92.($-($'-('/$&.*"&$.0'+$#c#8'/-#92$=.+8)'#92+-88'('($h8"0-3/$@'=-(0'8A$;"8$0'+$>3/.+$(.92$*'-('$f'+(/'8"#8"#'($)'@-&0'8B$@'#8'28$:+-(,-:-'&&$0-'$bH)&-92*'-8$0'+$I'#'*8-.(A$ !-'#$ -#8$ d'0.92$ "@24()-)$ P.($ #'-('+$ &.*"&'($ O3#@+'-83()B$ 0'+$ `'8'-&-)3()$ )+.R'+$ 2':"8-#92'+$`&38)'=4R'$ 6@'-#:-'&#<'-#'$ 0'+$ S.+8"&P'('7$ 3(0$ P./$ O&&)'/'-(,3#8"(0$ 0'#$ S"8-'(8'(A$ Q-($ <'-8'+'#$O3##92&3##*+-8'+-3/$ -#8$ '-('$ =.+8)'#92+-88'('$?'@'+,-++2.#'$ 6N"+(")-($U$h2.3:B$CDD\7A$>+.8,$3/="##'(0'+$:+4.:'+"8-P'+$ !-")(.#8-*$ #8'&&'($ #-92$ P-'&'$ 12.&"()-.*"+,-(./'$ '+#8$ -/$ I"2/'($ 0'+$ 92-+3+)-#92'($QX:&.+"8-.($"&#$(-928$+'#'*8"@'&$0"+A$K($'-('+$@+-8-#92'($h830-'$&")$@'-$\J$G$0'+$S"8-'(8'(B$0'+'($Q+*+"(*3()$+"0-.&.)-#92$"&#$+'#'*8"@'&$'-()'#83=8$<.+0'($<"+B$-(8+".:'+"8-P$'-('$(-928$+'#'*8"@&'$h-83"8-.($P.+$6`"+&.<$'8$"&AB$CDEL7A$$!"#$g-'&$0'+$Y:'+"8-.($#.&&8'$'-('$P.&&#84(0-)'$I'#'*8-.($0'#$>3/.+#$/-8$83/.+=+'-'($O@#'8,3()#+4(0'+($#'-(A$!-'#$*"(($d'0.92$@'-$<'(-)'+$"&#$LD$G$0'+$.:'+-'+8'($S"8-'(8'($'++'-928$<'+0'($6I",3/-&"P"$U$%.+'#B$CDE\7A$!-'$JFNTI$@'8+4)8$("92$'-('+$Y:'+"8-.($/-8$*3+"8-P'/$O(#"8,$LDF\D$G$=]+$:'+-2-&4+'B$CCFL[$G$=]+$-(8+"2':"8-#92'B$3(0$CDFLD$G$=]+$'X8+"2':"8-#92'$111#$652"($'8$"&AB$CDDCW$S"8'&B$CDD[7A$S+.)(.#'="*8.+'($=]+$'-($I',-0-P$#-(0$P"#*3&4+'$K(P"#-.(B$?c/:2*(.8'(/'8"#8"#'(B$h"8'&&-8'(&4#-.('($3(0$g-++2.#'$6I-,P-$U$%.+'#B$ CDEL7A$!"#$/-88&'+'$T@'+&'@'($ P.($S"8-'(8'($/-8$ (-928$ +'#'*8"@&'/$`'=3(0$ @'8+4)8$ [FEC$b.("8'$65.(0.$'8$"&AB$CDDi7A$$!-'$ 92-+3+)-#92'$>2'+":-'$ 0'#$ -(8+"2':"8-#92'($ 12.&"()-.*"+,-(./#$ -#8$ 42(&-92$ 0'+$ 0'#$ 2':"8.,'&&3&4+'($5"+,-(./#$3(0$@'-(2"&8'8$/'-#8$'-('$?.@'*8./-'$.0'+$"392$h')/'(8'*8./-'$/-8$)&'-92,'-8-)'+$I'#'*8-.($0'#$ 0"+-($ &-')'(0'($ %"&&'()"()#$ 6?-'#'+$ '8$ "&AB$ EVVi7A$ I"0-*"&'+$ -#8$ "3=)+3(0$ 0'#$ 0-==3#F-(=-&8+-'+'(0'($a"92#83/#$0-'$*3+"8-P'$>2'+":-'$0'#$:'+-2-&4+'($%"&&'()"()#*"+,-(./#A$;-'+$*.//8$d'$("92$?.*"&-#"8-.($'-('$ '+<'-8'+8'$ ;'/-2':"8'*8./-'$ +'928#$ .0'+$ &-(*#$ /-8$ ?c/:2"0'('*8./-'$ -($ f+")'B$ .=8$ -#8$ '-('$>'-&+'#'*8-.($0'+$S=.+8"0'+$.0'+$0'+$O+8'+-"$2':"8-9"$(.8<'(0-)$6h''2.='+$'8$"&AB$CDEC7A$$!-'$ *3+"8-P'$ >2'+":-'$ 0'#$ 'X8+"2':"8-#92'($ %"&&'()"()#*"+,-(./#$ '+=.&)8$ ,3/'-#8$ -/$ h-(('$ '-('+$S"(*+'"8-*.03.0'('*8./-'$6a2-::&'FY:'+"8-.(7$/-8$'+<'-8'+8'+$?c/:2"0'('*8./-'B$="*3&8"8-P$)'=.&)8$P.($'-('+$"0d3P"(8'($12'/.82'+":-'$6k.#2-0"$'8$"&AB$CDDC7A$$K($ 0'+$ *3+"8-P'($ >2'+":-'$ 0'#$ 'X8+"2':"8-#92'($ 3(0$ :'+-2-&4+'($ %"&&'()"()#*"+,-(./#$ )'<-((8$ 0-'$?'@'+8+"(#:&"(8"8-.($,3('2/'(0$"($`'0'383()A$Z"92$"(=4()&-92$'(8843#92'(0'($Q+)'@(-##'($-/$;-(@&-9*$"3=$ 0"#$ Q-(8+'8'($ P.($ I',-0-P'($ 6JE$G7$ 3(0$ 0-'$ JFNTI$ 6CL$G7$ 6b'c'+$ '8$ "&AB$ CDDD7$ *.((8'($ -($ '-('+$"/'+-*"(-#92'($ h830-'$ @'-$ #.+)=4&8-)'+$ S"8-'(8'(#'&'*8-.($ P-'&P'+#:+'92'(0'$ Q+)'@(-##'$ /-8$ '-('+$+',-0-P=+'-'($JFNTI$P.($[J$G$'++'-928$<'+0'($6!"+<-#2$b3+"0$'8$"&AB$CDEC7A$$

Page 17: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

J""

!"!"H"AF I+;&4J5*&$(+05$40&4J5*&$(+01%+,&>.+:;$-+>(+0"

O392$@'-$0'+$I'#'*8-.($P.($!"#$%&%$'(8#8"(0'('($12.&"()-.*"+,-(./'($-#8$0-'$I',-0-P+"8'$/-8$@-#$,3$iD$G$-/$JFN"2+'#Ff.&&.<F_:$'+2'@&-92$6>"*"0"$'8$"&AB$CDDC7A$!-'$O(<'(03()$P.($('."0d3P"(8'($3(0$"0d3P"(8'($>2'+":-'*.(,':8'($<-'$I"0-.82'+":-'B$12'/.82'+":-'$.0'+$'-('+$*./@-(-'+8'($I"0-.92'/.82'+":-'$@"#-'+8$0'+,'-8$(.92$"3=$P'+)&'-92#<'-#'$(-'0+-)'+$h830-'('P-0'(,A$K($'-('+$d":"(-#92'($h830-'$,'-)8'$0-'$`'2"(0&3()$/-8$ '-('+$ "0d3P"(8'($ 12'/.82'+":-'$ /-8$ JFf&3.+.3+"9-&$ 6JFf_7$ 3(0$ b-8./c9-($ *'-('($ #-)(-=-*"(8'($_(8'+#92-'0$-/$e'+)&'-92$,3+$5.(8+.&&)+3::'$6>"*"0"$'8$"&AB$CDDC7A$O392$0-'$!3+92=]2+3()$'-('+$"0d3P"(8'($I"0-.82'+":-'$*.((8'$0"#$/-88&'+'$YP'+"&&$h3+P-P"&$ 6Yh7$.0'+$0-'$JFNTI$(-928$P'+@'##'+($ 6Z"*''@$'8$ "&AB$EVV[7B$ <.2-()')'($ -($ '-('+$ "(0'+'($ h830-'$ '-('$ e'+@'##'+3()$ 0'#$ Yh$ ("92$ '-('+$ "0d3P"(8'($I"0-.92'/.82'+":-'$)'#'2'($<3+0'$6h'+"=-(-$'8$"&AB$CDDE7A$K($'-('+$b'8""("&c#'$]@'+$0-'$"0d3P"(8'$>2'+":-'$0'#$111$/-8$ -(#)'#"/8$[^EC$S"8-'(8'($*.((8'$'@'(="&&#$*'-('$#-)(-=-*"(8'$e'+@'##'+3()$0'#$Yh$)'#'2'($<'+0'(A$O&&'+0-()#$:+.=-8-'+8'($'2'+$S"8-'(8'($/-8$&c/:2.)'('+$b'8"#8"#-'+3()$.0'+$("92$IEFI'#'*8-.($P.($'-('+$ "0d3P"(8'($ >2'+":-'A$ K($ 0-'#'+$ h830-'$ <3+0'$ (-928$ ,<-#92'($ 0'($ P'+#92-'0'('($ 82'+":'38-#92'($b.0"&-848'($612'/.82'+":-'B$I"0-.92'/.82'+":-'$3(0$I"0-.82'+":-'7$3(8'+#92-'0'(B$#.0"##$0'+$h8'&&'(<'+8$0'#$'-(,'&('($>2'+":-'"(#"8,'#$2-'+$ &'8,8&-92$3(*&"+$@&'-@8$ 6;.+)"($'8$"&AB$CDECW$h3+$'8$"&AB$CDE\7A$ K($'-('+$'-("+/-)'($ S2"#'$ KKFh830-'$ 6haY%$DiDV7$ *.((8'$ 03+92$ 0-'$ 5./@-("8-.(#82'+":-'$ /-8$%'/9-8"@-(M1":'9-8"@-($)'=.&)8$P.($0'+$`'2"(0&3()$/-8$1":'9-8"@-($3(0$'-('+$,3#48,&-92'($I"0-.82'+":-'$'-($ #-)(-=-*"(8$ &4()'+'#$Yh$'++'-928$<'+0'($ 6`'(FN.#'=$'8$ "&AB$ CDEJ7A$5]+,&-92$<3+0'($0-'$Q+)'@(-##'$0'+$`K?1OSFh830-'$ :+4#'(8-'+8A$ ;-'+$ ,'-)8'$ #-92$ 0-'$ "0d3P"(8'$ >2'+":-'$ /-8$ 1":'9-8"@-($ '-('+$ "&&'-(-)'($`'.@"9283()$ ("92$ '-('+$ *3+"8-PF-(8'(0-'+8'($Y:'+"8-.($ ]@'+&')'(B$ #.0"##$ (3($ '+#8/"&#$ QP-0'(,$ =]+$ 0-'$!3+92=]2+3()$'-('+$"0d3P"(8'($>2'+":-'$"3=$`"#-#$P.($+"(0./-#-'+8'($S2"#'FKKKF!"8'($@'#8'28$6S+-/+.#'$'8$"&AB$CDE^7A$$O392$=]+$0-'$O(<'(03()$'-('+$('."0d3P"(8'($>2'+":-'$='2&8$@-#$d'8,8$0-'$QP-0'(,$03+92$)+.R'$h830-'(A$!-'$Q(8#92'-03()$=]+$0-'$!3+92=]2+3()$'-('+$('."0d3P"(8'($>2'+":-'$=4&&8$,3/'-#8$-/$I"2/'($P.($#.)'("((8'($>3/.+@."+0#$-/$h-(('$'-('#$-(0-P-03"&-#-'+8'($>2'+":-'*.(,':8'#A$$

!"!"H"DF I./%(K:5,&(.*+01%+,&>.+:;$-+>(+0"

O3=)+3(0$0'+$ #:48'($!-")(.#'#8'&&3()$3(0$0'($*./:&'X'($ "("8./-#92'($%')'@'(2'-8'($@'#8'28$ =]+$0-'$%+.R,"2&$0'+$S"8-'(8'($/-8$%"&&'()"()#*"+,-(./$*'-($*3+"8-P'+$>2'+":-'"(#"8,A$h./-8$@&'-@8$=]+$0-'$/'-#8'($S"8-'(8'($(3+$0-'$bH)&-92*'-8$'-('+$:"&&-"8-P'($>2'+":-'$/-8$0'/$P.++"()-)'($g-'&$'-('+$e'+@'##'+3()$0'+$?'@'(#j3"&-848A$

Q-('$ <-928-)'$ 5./:.('(8'$ -($ 0'+$ :"&&-"8-P'($ `'2"(0&3()$ 0'#$ 111$ -#8$ 0-'$ #c#8'/-#92'$ 12'/.82'+":-'A$a')'($0'+$P'+)&'-92#<'-#'$(-'0+-)'($K(,-0'(,$3(0$0'+$0"+"3#$+'#3&8-'+'(0'($)'+-()'($f"&&,"2&'($#8'&&8$#-92$0-'$ I'*+38-'+3()$ P.($ h830-'(:"8-'(8'($ ,3+$ Q8"@&-'+3()$ 'P-0'(,@"#-'+8'+$ >2'+":-'#8"(0"+0#$ <'-8'+2-($#92<-'+-)$0"+A$Q-(-)'$12'/.82'+":'38-*"$6JFf&3.+.3+"9-&B$b'82"(#3&=.(B$1-#:&"8-(B$I-="/:-9-(B$b-8./c9-(B$S"9&-8"X'&B$ %'/9-8"@-(7$ <3+0'($ -($ S2"#'FKKFh830-'($ )'8'#8'8A$ !-'$ S"8-'(8'($ ,'-)8'($ 0"@'-$ '-('$03+92#92(-88&-92'$T@'+&'@'(#,'-8$ ,<-#92'($C$3(0$EC$b.("8'($3(0$ '-($:"+8-'&&'#$>2'+":-'"(#:+'92'($P.($DFV$G$ 6%"88.$ '8$ "&AB$ CDED7A$ K($ '-('+$ b'8""("&c#'$ P.($ ED\$ h830-'($ /-8$ CiED$S"8-'(8'(B$ 0-'$ "($ '-('/$%"&&'()"()#*"+,-(./$'+*+"(*8$<"+'(B$@+"928'$'-('$5./@-("8-.($"3#$%'/9-8"@-($3(0$'-('/$S&"8-(F!'+-P"8$0'($)+HR8'($T@'+&'@'(#P.+8'-&$6Q9*'&$U$h92/-0B$CDD^7A$$Z"92$0'+$e'+H=='(8&-923()$0'+$Q+)'@(-##'$0'+$_5FO`1FDCFh830-'$)-&8$0-'$5./@-("8-.($"3#$%'/9-8"@-($3(0$1-#:&"8-($ "&#$ h8"(0"+0$ -($ 0'+$ `'2"(0&3()$ 0'#$ 12.&"()-.*"+,-(./#A$ K/$ I"2/'($ 0-'#'+$ h830-'B$ 0-'$ \ED$S"8-'(8'($'-(#92&.##B$<3+0'$0-'$5./@-("8-.($"3#$%'/9-8"@-(M1-#:&"8-($/-8$'-('+$%'/9-8"@-(Fb.(.82'+":-'$P'+)&-92'(A$K($0'+$5./@-("8-.(#)+3::'$,'-)8'$#-92$-/$e'+)&'-92$,3$0'+$/-8$'-('+$%'/9-8"@-(Fb.(.82'+":-'$@'2"(0'&8'($%+3::'$ '-($ #-)(-=-*"(8$ P'+@'##'+8'#$/'0-"('#$Yh$ 6EEB^$b.("8'$P#A$iBE$b.("8'7$ 6e"&&'$ '8$ "&AB$CDED7A$$

Page 18: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

L""

K/$ I"2/'($ 0'+$ `KZ%YFh830-'$ <3+0'$ 0-'$ ;-(,3("2/'$ P.($ 1'83X-/"@$ ,3+$ 5./@-("8-.($ "3#$%'/9-8"@-(MYX"&-:&"8-($)'8'#8'8A$!-'$h830-'$'+)"@$*'-('($e.+8'-&$03+92$0-'$,3#48,&-92'$%"@'$P.($1'83X-/"@B$#.0"##$0-'$5./@-("8-.($"3#$%'/9-8"@-(MS&"8-(0'+-P"8$<'-8'+2-($"&#$h8"(0"+082'+":-'$)'&8'($/3##$6b"&*"$'8$"&AB$CDE\7A$$O*83'&&$'X-#8-'+'($,3+$O(<'(03()$'-('+$g<'-8&-(-'(82'+":-'$@'-/$92.&"()-.,'&&3&4+'($5"+,-(./$(3+$<'(-)'$h830-'($/-8$)'+-()'($f"&&,"2&'(B$#.0"##$0-'$QP-0'(,$2-(#-928&-92$0-'#'+$f+")'#8'&&3()$#'2+$)'+-()$-#8A$K($'-('+$"/'+-*"(-#92'($ h830-'$ <3+0'($ -(#)'#"/8$ JJ$S"8-'(8'($ /-8$ '-('+$ g<'-8&-(-'(82'+":-'$6%'/9-8"@-(MS&"8-(0'+-P"8B$%'/9-8"@-(Mf&3.+.:c+-/-0-(B$P'+#92-'0'('$f&3.+.:c+-/-0-('$-($5./@-("8-.(7$@'2"(0'&8A$_("@24()-)$P.($0'+$ "()'<'(0'8'($>2'+":-'$ *.((8'$ '-($S+.)+'##-.($f+''$h3+P-P"&$ 6Sfh7$ P.($03+92#92(-88&-92$CB^$b.("8'($@'.@"928'8$<'+0'(A$S.#-8-P$ #92'-(8$ #-92$ d'0.92$'-($a'92#'&$ "3=$ '-('$,3P.+$(-928$P'+<'(0'8'$>2'+":-'$"3#,3<-+*'($6I.)'+#$'8$"&AB$CDE\7A$$Z'@'($0'+$#c#8'/-#92'($12'/.82'+":-'$)-@8$'#$(.92$'-(-)'$"(0'+'$>2'+":-'P'+="2+'(B$0-'$-($0'+$:"&&-"8-P'($>2'+":-'$0'#$111$)38'$Q+)'@(-##'$,'-)'(A$$!-'$'(0.#*.:-#92'$!'*./:+'##-.($P.($)'#8"38'($%"&&'(<')'($03+92$0"#$Q-(@+-()'($P.($h8'(8#$ -#8$'-('$#'2+$'=='*8-P'$b'82.0'$,3+$e'+@'##'+3()$0'+$?'@'(#j3"&-848$0'+$S"8-'(8'($6O(0'+#'($'8$"&AB$EViV7A$$K($'-('+$*.+'"(-#92'($h830-'$*.((8'$03+92$'-('$5./@-("8-.($"3#$'-('+$S2.8.0c("/-#92'($>2'+":-'$6S!>7$3(0$ '-('+$ )&'-92,'-8-)'($ #c#8'/-#92'($ 12'/.82'+":-'$ 6%'/9-8"@-($ .0'+$ %'/9-8"@-($l$1-#:&"8-(7$ -/$e'+)&'-92$,3+$(3+$/-8$'-('+$S!>$@'2"(0'&8'($S"8-'(8'()+3::'$'-($#-)(-=-*"(8$ &4()'+'#$T@'+&'@'($'++'-928$<'+0'($6JLi$P#A$LL\$>")'7$6;.()$'8$"&AB$CDE\7A$`'-$0'+$S!>$<-+0$("92$K(d'*8-.($'-('#$S2.8.#'(#-@-&-#"8.+#$'-('$?"#'+&-928$"@)'@'(0'$h.(0'$:'+$'(0.#*.:-#92$+'8+.)+"0'+$12.&"()-.)+":2-'$-/:&"(8-'+8A$!'+$03+92$0"#$?"#'+&-928$"*8-P-'+8'$S2.8.#'(#-@-&-#"8.+$,'+#8H+8$(3($0"#$3/&-')'(0'$>3/.+)'<'@'$6?'))'88$'8$"&AB$CDEC7A$$Q-('$<'-8'+'$&.*"&$"()'<"(08'$>2'+":-'$-#8$0-'$8+"(#"+8'+-'&&'$12'/.'/@.&-#"8-.($6>O1Q7A$?'@'+83/.+'($<'+0'($="#8$P.&&#84(0-)$"3#$0'+$O+8'+-"$2':"8-9"$/-8$`&38$P'+#.+)8A$!-'#'$'-)('8$#-92$"&#.$2'+P.++")'(0$=]+$0-'$O::&-*"8-.($ P.($ 12'/.82'+":'38-*"$ <-'$ b-8./c9-($ 1A$ _/$ '-('$ &4()'+'$ a-+*3()#,'-8$ "/$ >3/.+$ ,3$)'<42+&'-#8'(B$<'+0'($Q/@.&-#"8-.(#/-88'&$<-'$?-:-0-.&m$,3)')'@'(A$!-'#'$>2'+":-'$#.&&8'$ d'0.92$(3+$"($'-('/$ #.+)#"/$ "3#)'<42&8'($ S"8-'(8'()38$ 03+92)'=]2+8$ <'+0'(A$ Q-('$ 92-('#-#92'$ h830-'$ ,'-)8'B$ 0"##$S"8-'(8'(B$ 0'+'($ >3/.+$ #-92$ -/$ >ZbFh8"0-3/$ KKFKe$ @'="(0B$ 03+92"3#$ P.($ 0'+$ >2'+":-'$ :+.=-8-'+8'(B$<.)')'($#-'$@'-$S"8-'(8'($/-8$>ZbFh8"0-3/$K$,3$'-('+$2H2'+'($I',-0-P+"8'$=]2+8'$6?-$'8$"&AB$CDE\7A$$K($'-(-)'($-(0-P-03'&&'($f4&&'($<-+0$0-'$#'&'*8-P'$-(8'+('$I"0-.82'+":-'$6hKI>7$"()'<"(08A$;-'+$<-+0$]@'+$'-('($?'-#8'(*"82'8'+$k88+-3/$VD$P'+"@+'-928B$0"#$#-92$0"(($-/$>3/.+)'<'@'$"(#"//'&8$3(0$]@'+$/'2+'+'$>")'$6;"&@<'+8#,'-8n$"#$%&$'Fh8+"2&3()$"@)-@8A$!-'$hKI>$'+,-'&8$-($0'+$:"&&-"8-P'($̀ '2"(0&3()$)38'$Q+)'@(-##'$/-8$'-('/$/H)&-92'+<'-#'$P'+@'##'+8'/$Yh$6/'0-"('#$Yhn$\LB^$b.("8'7$6;.==/"(($'8$"&AB$CDEC7A$

"

!"!"LF 15<;,>&(%;';6.+04+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0"

O3=)+3(0$0'+$#92&'928'($S+.)(.#'$P.($S"8-'(8'($/-8$=.+8)'#92+-88'('($%"&&'()"()#*"+,-(./'(B$0-'$/-8$'-('+$:"&&-"8-P'($ 12'/.82'+":-'$ @'2"(0'&8$ <'+0'(B$ -#8$ 0-'$ h392'$ ("92$ ('3'($ >2'+":-'"(#48,'($ 3(@'0-()8$(.8<'(0-)A$K($0'+$(42'+'($e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g'&&'($#8"88B$,30'/$-#8$0"#$b-&-'3$+'-92$"($gc8.*-('($3(0$a"92#83/#="*8.+'(A$!-'#$=H+0'+8$0-'$,'&&3&4+'$S+.&-='+"8-.($3(0$@')](#8-)8$0"#$O3=8+'8'($P.($b38"8-.('($6g"@+.($'8$"&AB$CDEL7A$$

Page 19: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

R""

`'-$0'($12.&"()-.*"+,-(./'($*.((8'$@'+'-8#$'-('$2.2'$K(03*8-.($P.($h-)("&<')'(B$0-'$-($0'+$S+.)+'##-.($3(0$S+.&-='+"8-.($P.($>3/.+,'&&'($'-('$@'0'38'(0'$f3(*8-.($2"@'($6,A`A$Q%f$!$Q:-0'+/"&$%+.<82$f"98.+B$IOh$!$I"8$#"+9./"$6%>S"#'7B$O5>$!$S+.8'-(*-("#'$`B$bQ>$!$>c+.#-(FS+.8'-(*-("#'$bQ>7$("92)'<-'#'($<'+0'($6h-"$'8$"&AB$CDEL7A$!-'$T@'+'X:+'##-.($P.($Q:-0'+/"&$%+.<82$f"98.+$I'9':8.+$6Q%fI7$=]2+8$,3+$Q(8<-9*&3()$ P.($ 12.&"()-.*"+,-(./'($ 3(0$ 0'+'($ S+.)+'##-.(A$ b38"8-.('($ P.($ Q%fI$ #-(0$ #'&8'('$Q+'-)(-##'A$$!"#$5IOhFS+.8'-($65-+#8'($+"8$#"+9./"$P-+"&$.(9.)'('7$-#8$'-($@'0'38'(0'+$b'0-"8.+$-($'-('+$h-)("&*"#*"0'B$0-'$ 03+92$ Q%fI$ +')3&-'+8$ <-+0A$ %&'-92,'-8-)$ -#8$ '#$ 0"#$ "/$ 243=-)#8'($ /38-'+8'$ S+.8'-($ 6iFJ\$G7$ @'-/$-(8+"2':"8-#92'($92.&"()-.,'&&3&4+'($5"+,-(./$6O(0'+#'($U$>2.+)'-+##.(B$CDEC7A$!-'$%"&&'(=&]##-)*'-8$P.($"($Sh1$'+*+"(*8'($S"8-'(8'($<-'#$,3$LD$G$5IOhFb38"8-.('($"3=A$!-'#$=]2+8'$,3$0'+$e'+/383()B$0"##$0-'$Q+*+"(*3()$ "($ '-('+$ Sh1$ '-($ =+]2,'-8-)'+$ I-#-*.="*8.+$ =]+$ 0-'$ @"&0-)'$ Q(8<-9*&3()$ '-('#$%"&&'()"()#*"+,-(./#$#'-($*H((8'$653@-9*"$'8$"&AB$CDDE7A$g30'/$)'&8'($"*8-P-'+8'$5IOhFb38"8-.('($@'-/$5.&.(*"+,-(./$ "&#$ b"+*'+$ =]+$ '-('$ I'#-#8'(,$ )')'($ '-('$ >2'+":-'$ /-8$ "(8-FQ%fI$ O(8-*H+:'+($ <-'$1'83X-/"@$.0'+$S"(-83/3/"@$6h8-(8,-()$'8$"&AB$CDDV7A$$12+.(-#92'$12.&'#8"#'B$ 3("@24()-)$ P.($ 0'+$ ,3)+3(0'&-')'(0'($Q+*+"(*3()B$ @')](#8-)8$ 0-'$Q(8<-9*&3()$'-('#$92.&"()-.,'&&3&4+'($5"+,-(./#A$%"&&'(#43+'($2"@'($'-('$<-928-)'$f3(*8-.($-($0-'#'/$S+.,'##B$0"$#-'$0'($Q%fFI',':8.+$"*8-P-'+'($3(0$0"/-8$]@'+$'-('$bOS5F5"#*"0'$6b-8.)'($"98-P"8'0$:+.8'-($*-("#'7$0-'$QX:+'##-.($0'+$1c9&..Xc)'("#'FC$61YoFC7$'+2H2'(A$!-'$1YoFC$T@'+'X:+'##-.($<-+0$,3#48,&-92$(.92$03+92$YX-#8'+.&'$ 3(0$ h8-9*#8.==/.(.X-0#c(82"#'($ -(03,-'+8$ 6I-,P-$ U$ %.+'#B$ CDEL7A$ !-'$ 1YoFC$ -(2-@-'+8$ 0-'$O:.:8.#'$3(0$=H+0'+8$0"#$a"92#83/$0'+$>3/.+,'&&'($6;"($'8$"&AB$CDD\W$Z,'"*.$'8$"&AB$CDDC7A$$!-'$ K("*8-P-'+3()$ P.($ >SJL$ 6>3/.+$ S+.8'-($ JL7B$ '-('/$ g'&&,c*&3#+')3&"8.+B$ -#8$ '-('$ 0'+$ @'*"((8'#8'($h8H+3()'($-($0'+$5"+,-(.)'('#'A$Q-($I'P-'<$]@'+$ED$h830-'($"3#$Q3+.:"B$O#-'($3(0$0'($_hO$/-8$-(#)'#"/8$CCV$S"8-'(8'(B$ 0-'$ "($ '-('/$ 111$ '+*+"(*8$ <"+'(B$ ,'-)8'$ '-('$ >SJLFb38"8-.($ -($ CE$G$ 0'+$ f4&&'$ 652"(B$>2./"#B$>.&'0"(.B$'8$"&AB$CDDJ7A$b38"8-.('($-($"(0'+'($%'('(B$@'-#:-'&#<'-#'$Q%fIB$('3+.@&"#8./"$IOh$P-+"&$.(9.)'($2./.&.)$6ZIOh7$.0'+$S2.#:2.-(.#-8-0FLF5-("#'$6SKL57$<3+0'($#'&8'('+$@'#92+-'@'($6I-,P-$U$%.+'#B$CDEL7A$$g3#"//'(="##'(0$ *"(($ ='#8)'2"&8'($ <'+0'(B$ 0"##$ @'-$ 0'+$ 12.&"()-.*"+,-(.)'('#'$ '8&-92'$ /.&'*3&"+'$h-)("&<')'$'-('$I.&&'$#:-'&'(B$0'+'($h-)(-=-*"(,$@-#$0"8.$(-928$P.&&#84(0-)$P'+#8"(0'($-#8A$$

Page 20: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

M""

!"!"MF 15<;,:'&)).C.:&(.;$0

!"!"M"!F N(&6.$604+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0"

b'2+'+'$ O+@'-8'($ ,'-)'(B$ 0"##$ #-92$ 03+92$ 0-'$ O(<'(03()$ 0'+$ P'+#92-'0'('($ O3=&")'($ 0'+$ON11F5&"##-=-*"8-.($ 6O/'+-9"($ N.-(8$ 1.//-8''$ .($ 1"(9'+$ F$ "392$ @'*"((8$ "&#$ >ZbFhc#8'/7$ 0'38&-92'$_(8'+#92-'0'$ -($ 0'+$ Q-(8'-&3()$ 0'+$ >3/.+#8"0-'($ @'-$ -(8+"2':"8-#92'($ %"&&'()"()#*"+,-(./'($ '+)'@'($6f"+)'#$'8$"&AB$CDEEW$Y*"@"c"#2-$'8$"&AB$CDDEW$k"/"#"*-B$CDDL7A$$$

$

!""#$%&'()?+)C#/-6#"&-#2')2D)-1.)/-&%E)F2F&$3-#2')#')-1.)G=)/-3(#'()/E/-.8/)#/)/12H'=);!B)I)/-3(./)2D)*@*)J@K@)F3-#.'-/)36.)/12H'=);LB)IJK)/-3(./)2D)*MN)F3-#.'-/)36.)/12H');O36(./).-)3$=>)?@**B)

$`-#$ ,3+$ ^A$O3=&")'$ 0'+$ _K11F5&"##-=-*"8-.($ <3+0'($ 0-'$ -(8+"2':"8-#92'($ 111#$ <-'$ 0"#$ 2':"8.,'&&3&4+'$5"+,-(./$'-()'8'-&8A$!-'#'$b'82.0'$<"+$ =]+$0"#$ -11O$(3+$@'0-()8$)''-)('8$ 6O&d-==+c$'8$ "&AB$ CDDV7B$0"$0-'$ON11F5&"##-=-*"8-.($0-'$>3/.+'($2-(#-928&-92$ -2+'+$%+HR'$'-(8'-&8'B$0-'#'$ -#8$"@'+$(-928$/-8$0'+$S+.)(.#'$"##.,--'+8$6Z"82"($'8$"&AB$CDDVW$Y*"@"c"#2-$'8$"&AB$CDDE7A$O392$-/$;-(@&-9*$"3=$0"#$'X8+"2':"8-#92'$111$)"@$'#$@'-$Q-(=]2+3()$0'+$̂ A$O3=&")'$0'+$_K11F5&"##-=-*"8-.($'-('$0'38&-92'$e'+4(0'+3()A$h.$<3+0'$(3($'+#8/"&#$,<-#92'($:'+-2-&4+'($3(0$0-#8"&'($%"&&'()"()#*"+,-(./'($3(8'+#92-'0'(A$$f]+$0"#$:'+-2-&4+'$%"&&'()"()#*"+,-(./$#8'28$,3#48,&-92$(.92$0"#$/.0-=-,-'+8'$hc#8'/$("92$̀ -#/382F1.+&'88'$,3+$e'+=])3()A$!-'#'#$hc#8'/$-#8$=]+$0-'$?.*"&-#"8-.($0'#$>3/.+#$#'2+$"3##")'*+4=8-)B$&-'='+8$d'0.92$*'-('$)38'($K(=.+/"8-.('($]@'+$0-'$I'#'*8"@-&-848B$0"$'#$<'0'+$0'($?c/:2*(.8'(#8"83#$(.92$'P'(83'&&$P.+2"(0'('$b'8"#8"#'($@'+]9*#-928-)8$6`-#/382$'8$"&AB$EVVC7A$K($0'+$P.+&-')'(0'($O+@'-8$<3+0'$=]+$0-'$5&"##-=-*"8-.($"&&'+$%"&&'()"()#83/.+'($ 0-'$ ^A$O3=&")'$ 0'+$ _K11F5&"##-=-*"8-.($ P'+<'(0'8B$ 0-'$ :'+-2-&4+$ &.*"&-#-'+8'($ 111#$<3+0'($,3#48,&-92$("92$0'+$5&"##-=-*"8-.($P.($`-#/382F1.+&'88'$'-()'8'-&8A$$

Page 21: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!T""

!-'$>ZbF5&"##-=-*"8-.($@'3+8'-&8$=.&)'(0'$S"+"/'8'+n$

I3".$$.)*+)IJKP7$3//#D#:3-#2')

!"#$ %&'()*&+,-./$

>n$ `'#92+'-@8$0-'$%+HR'$3(0$O3#0'2(3()$0'#$S+-/4+83/.+#$

Zn$ `'#92+'-@8$0-'$O(,"2&$0'+$@'="&&'('($?c/:2*(.8'($

bn$ `'#92+'-@8$0"#$O3=8+'8'($3(0$0-'$?.*"&-#"8-.($P.($f'+(/'8"#8"#'($$

Page 22: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!!""

!"!"M"AF 7.$(+.'5$604+,04.)(&'+$0+O(,&%+>&(.)/%+$0P%;'&$6.;:&,-.$;<+0Q@;;>R0AS!DT0"

I3".$$.)?+)IPQ-3%#&8)%./)%#/-3$.').R-631.F3-#/01.')S12$3'(#2:364#'28/)

!01234+-5$ %&'()*&+,-./$

>o$ S+-/4+83/.+$*"(($(-928$@'3+8'-&8$<'+0'($

>D$ 5'-($O(2"&8$=]+$S+-/4+83/.+$

>-#$ 1"+9-(./"$-($h-83$

>E$ >3/.+$-#8$"3=$0'($%"&&'()"()$@'#92+4(*8$

>C"$ >3/.+$03+92@+-928$0'($%"&&'()"()$

>C@$ >3/.+$-(=-&8+-'+8$@'("92@"+8'#$?'@'+)'<'@'$

>L$ >3/.+$-(=-&8+-'+8$@'("92@"+8'$Y+)"('$

>\$ >3/.+$-(=-&8+-'+8$>+3(93#$9.'&-"93#$.0'+$OA$/'#'(8'+-9"$#3:'+-.+$

"

I3".$$.)N+)JPQ-3%#&8)%./)%#/-3$.').R-631.F3-#/01.')S12$3'(#2:364#'28/)

"01234+-5$ %&'()*&+,-./$

Zo$ I')-.(4+'$?c/:2*(.8'($(-928$@'3+8'-&@"+$

ZD$ 5'-('$+')-.(4+'($?c/:2*(.8'(/'8"#8"#'($

ZE$ I')-.(4+'$?c/:2*(.8'(/'8"#8"#'($P.+2"(0'($

"

I3".$$.)A+)KPQ-3%#&8)%./)%#/-3$.').R-631.F3-#/01.')S12$3'(#2:364#'28/)

#01234+-5$ %&'()*&+,-./$

bo$ f'+(/'8"#8"#'($(-928$@'3+8'-&@"+$

bD$ 5'-('$f'+(/'8"#8"#'($

bE$ f'+(/'8"#8"#'($P.+2"(0'($

"

Page 23: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!<""

h8"0-3/$("92$_K11B$^A$Q0-8-.($6a-88'*-(0$U$Y@'+#92/-0B$CDED7$

I3".$$.)G+)TUSSPQ-3%#&8)%./)%#/-3$.').R-631.F3-#/01.')S12$3'(#2:364#'28/)

1234+-5$ 6*+2&*+&.$

h8"0-3/$D$ >-#$ZD$bD$

h8"0-3/$KO$ >E$ZD$bD$

h8"0-3/$K`$ >C$ZD$bD$

h8"0-3/$KKO$ >L$ZD$bD$

h8"0-3/$KK`$ >EFL$ZE$bD$

h8"0-3/$KKK$ >\$d'0'#$Z$bD$

h8"0-3/$Ke$ N'0'#$>$d'0'#$Z$bE$

"

Page 24: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!?""

!"!"M"DF 7.$(+.'5$604+,0>+,.%.'?,+$0P%;'&$6.;:&,-.$;<+0Q@;;>R0AS!DTU0"

I3".$$.)M+)IPQ-3%#&8)%./)F.6#1#$56.')S12$3'(#2:364#'28/)

!01234+-5$ %&'()*&+,-./$

>o$ S+-/4+83/.+$*"(($(-928$@'3+8'-&8$<'+0'($

>D$ 5'-($O(2"&8$=]+$S+-/4+83/.+$

>-#$ 1"+9-(./"$-($h-83$

>E$ >3/.+$-#8$"3=$0'($%"&&'()"()$@'#92+4(*8$

>C"$ >3/.+$03+92@+-928$0'($%"&&'()"()$

>C@$ >3/.+$-(=-&8+-'+8$@'("92@"+8'#$?'@'+)'<'@'$

>L$ >3/.+$-(=-&8+-'+8$3(-&"8'+"&'$p#8'$0'+$eA$:.+8"'$.0'+$0'+$OA$2':"8-9"$9.//3(-#$

>\$>3/.+$-(=-&8+-'+8$;"3:8#8"//$0'+$eA$:.+8"'$.0'+$@-&"8'+"&'$p#8'B$OA$2':"8-9"$9.//3(-#B$@-&"8'+"&'$%"&&'()4()'$CA$Y+0(3()$.0'+$3(-&"8'+"&'$%"&&'()4()'$CA$Y+0(3()$/-8$`'="&&$P.($*.(8+"&"8'+"&'($p#8'($0'+$eA$:.+8"'$

"

I3".$$.)V+)JPQ-3%#&8)%./)F.6#1#$56.')S12$3'(#2:364#'28/)

"01234+-5$ %&'()*&+,-./$

Zo$ I')-.(4+'$?c/:2*(.8'($(-928$@'3+8'-&@"+$

ZD$ 5'-('$+')-.(4+'($?c/:2*(.8'(/'8"#8"#'($

ZE$ I')-.(4+'$?c/:2*(.8'(/'8"#8"#'($P.+2"(0'($

"

I3".$$.)W+)KPQ-3%#&8)%./)F.6#1#$56.')S12$3'(#2:364#'28/)

#01234+-5$ %&'()*&+,-./$

bo$ f'+(/'8"#8"#'($(-928$@'3+8'-&@"+$

bD$ 5'-('$f'+(/'8"#8"#'($

bE$ f'+(/'8"#8"#'($P.+2"(0'($

"

Page 25: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!C""

h8"0-3/$("92$_K11B$^A$Q0-8-.($6a-88'*-(0$U$Y@'+#92/-0B$CDED7$

I3".$$.)X+)TUSSPQ-3%#&8)%./)F.6#1#$56.')S12$3'(#2:364#'28/)

1234+-5$ 6*+2&*+&.$

h8"0-3/$D$ >-#$ZD$bD$

h8"0-3/$K$ >E$ZD$bD$

h8"0-3/$KK$ >C"F@$ZD$bD$

h8"0-3/$KKKO$ >L$ZD$bD$

h8"0-3/$KKK`$ >EFL$ZE$bD$

h8"0-3/$KeO$ >\$d'0'#$Z$bD$

h8"0-3/$Ke`$ N'0'#$>$d'0'#$Z$bE$

"

Page 26: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!F""

!"!"M"HF 7.$(+.'5$60$&/%0F.)<5(%KP;,'+((+0"

"

!""#$%&'()N+),#'-.#$&'()'301)L#/8&-1PS26$.--.);Q&36.4PK&'24).-)3$=>)?@*NB)

$

I3".$$.)*@+),#'-.#$&'()'301)L#/8&-1PS26$.--.)

!78$ %&'()*&+,-./$

K$ !3983#$ 2':"8-93#$ 9.//3(-#$ @'8+'=='(0B$ 5.//3(-*"8-.($ ,<-#92'($ @'-0'($ !3983#$2':"8-9-$P.+2"(0'($

KK$ a"92#83/$@-#$-($0-'$;':"8-*3#)"@'&$

KKKO$ K(=-&8+-'+'(0'#$a"92#83/$-($0'($+'928'($;':"8-*3#"#8$

KKK`$ K(=-&8+-'+'(0'#$a"92#83/$-($0'($&-(*'($;':"8-*3#"#8$

Ke$ K(=-&8+-'+'(0'#$ a"92#83/$ -($ @'-0'$ !3983#$ 2':"8-9-$ /-8$ e.+<"92#'($ -($ 0-'$h')/'(8)"&&'()4()'$

"

Page 27: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!J""

!"!"M"LF 7.$(+.'5$604+,0.$(,&%+>&(.)/%+$0P%;'&$6.;:&,-.$;<+0Q@;;>R0AS!DT0"

I3".$$.)**+)IPQ-3%#&8)%./)#'-631.F3-#/01.')S12$3'(#2:364#'28/)

!01234+-5$ %&'()*&+,-./$

>E$ h.&-84+'+$>3/.+$.2('$%'=4R-(P"#-.($

>C"$ h.&-84+'+$>3/.+$/-8$%'=4R-(P"#-.($

>C@$ b3&8-:&'$>3/.+'($

>L$ S'+=.+"8-.($0'#$P-#,'+"&'($S'+-8.('3/#$.0'+$'X8+"2':"8-#92'+$Z"92@"+#8+3*83+'($

>\$ S'+-03*8"&'$K(P"#-.($

$

I3".$$.)*?+)JPQ-3%#&8)%./)#'-631.F3-#/01.')S12$3'(#2:364#'28/)

"01234+-5$ %&'()*&+,-./$

Zo$ I')-.(4+'$?c/:2*(.8'($(-928$@'3+8'-&@"+$

ZD$ 5'-('$+')-.(4+'($?c/:2*(.8'(/'8"#8"#'($

ZE$ I')-.(4+'$?c/:2*(.8'(/'8"#8"#'($P.+2"(0'($

$

I3".$$.)*N+)KPQ-3%#&8)%./)#'-631.F3-#/01.')S12$3'(#2:364#'28/)

#01234+-5$ %&'()*&+,-./$

bo$ f'+(/'8"#8"#'($(-928$@'3+8'-&@"+$

bD$ 5'-('$f'+(/'8"#8"#'($

bE$ f'+(/'8"#8"#'($P.+2"(0'($

$

Page 28: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!L""

N(-7$)4"%-89"5QPPc"L+"#7$($3%"Yb$(('0$%7"r"]B'1.894$7c"<T!TZ"

I3".$$.)*A+)TUSSPQ-3%#&8)%./)#'-631.F3-#/01.')S12$3'(#2:364#'28/)

1234+-5$ 6*+2&*+&.$

h8"0-3/$D$ >-#$ZD$bD$

h8"0-3/$K$ >E$ZD$bD$

h8"0-3/$KK$ >C$ZD$bD$

h8"0-3/$KKK$ >L$ZD$bD$

h8"0-3/$KeO$ >\$ZD$bD$N'0'#$>$ZE$bD$

h8"0-3/$Ke`$ N'0'#$>$d'0'#$Z$bE$

"

Page 29: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!R""

!"AF E+,.$+5,&'+0#$*&).;$02+.<09&''+$6&$6):&,-.$;<0"

"

!""#$%&'()A+)Y62Z.6)F.6#F1.6.6)J.6[)#8)\&.6/01'#--=)]===^)O56"&'(+)[3')Y#./2'_)<.6(6=)*GPD301=);`.$/01)a)C.$$.6>)?@*@B)

"

Q-('$@'#.(0'+'$Q-)'(#92"=8$P.($/"&-)('($g'&&'($-#8$-2+'$f42-)*'-8$,3$/'8"#8"#-'+'(B$-(0'/$#-'$#-92$"3#$-2+'/$3+#:+]()&-92'($g'&&P'+@"(0$&H#'($3(0$]@'+$`&38F$.0'+$?c/:2@"2('($,3$"(0'+'($%'<'@'($.0'+$Y+)"('($)'&"()'(A$!-'$b'8"#8"#-'+3()#<')'$]@'+$`&38$.0'+$?c/:2'$#-(0$@'+'-8#$3/="##'(0$3(8'+#3928$3(0$0'8"-&&-'+8$@'#92+-'@'(A$h92.($#'-8$?"()'/$-#8$@'*"((8B$0"##$'-(-)'$>3/.+'$"392$-($3(0$'(8&"()$P.($Z'+P'(@"2('($<"92#'(A$!-'#$<3+0'$,3'+#8$=]+$5.:=F$3(0$;"&#83/.+'($@'#92+-'@'($61+3P'-&2-'+B$EiLJW$Z'3/"((B$Ei[C7A$K(,<-#92'($ -#8$ @'*"((8B$ 0"##$ 0-'$ :'+-('3+"&'$ K(P"#-.($ 6SZK7$ @'-$ 0'+$ S+.)+'##-.($ P-'&'+$ >3/.+'($ '-('$@'0'38'(0'$ I.&&'$ #:-'&8B$ #.$ @'-#:-'&#<'-#'$ @'-$5"+,-(./'($ 0'#$ S"(*+'"#B$ 0'#$5.&.(#B$ 0'#$I'*83/#B$ 0'+$S+.#8"8"$3(0$0'#$b")'(#$"@'+$"392$@'-/$12.&"()-.*"+,-(./A$f]+$'-(-)'$0-'#'+$/"&-)('($>3/.+'($)-&8$0-'$SZK$"&#$:+.)(.#8-#92'+$b"+*'+$ =]+$'-($+'03,-'+8'#$YP'+"&&$h3+P-P"&$ 6Oc"&"$'8$"&AB$CDDEW$`":"8$'8$"&AB$CDEEW$S.'#92&$'8$"&AB$CDEDW$h2'($'8$"&AB$CDEDW$g2.3$'8$"&AB$CDEJ7A$`'+'-8#$EVDJ$<3+0'$P'+#3928$0-'$,3)+3(0'&-')'(0'($:"82.:2c#-.&.)-#92'($b'92"(-#/'($,3$'+*&4+'($6Q+(#8B$EVDJ7B$0'((.92$)'&"()8'$0-'#'+$b'8"#8"#-'+3()#<')$'+#8$-($0'($&'8,8'($N"2+'($-($0'($f.*3#$0'+$"*83'&&'($f.+#923()A$$Q-($ :'+-:2'+'+$ Z'+P$ @'#8'28$ "3#$ 0+'-$ h92-928'(n$ Q:-('3+-3/B$ S'+-('3+-3/$ 3(0$ Q(0.('3+-3/A$ O&#$Q(0.('3+-3/$@','-92('8$/"($0"#$&.9*'+'$`-(0')'<'@'B$0"##$0-'$h92<"((,'&&'($0'+$'-(,'&('($Z'+P'(="#'+$3/)-@8A$!"#$S'+-('3/$="##8$/'2+'+'$Z'+P'(="#'+($,3$f"#,-*'&($,3#"//'(B$0-'#'$<'+0'($<-'0'+3/$03+92$0"#$Q:-('3+-3/$,3$'-('/$Z'+P$)'@](0'&8$!$#-'2'$O@@-&03()$\$6O3/]&&'+$'8$"&AB$CDE\W$a'&#92$U$!'&&'+B$CDED7A$$

Page 30: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

!M""

`.9*/"(($'8$"&A$*.((8'($,'-)'(B$0"##$#-92$0-'$K(P"#-.($P.($:"(*+'"8-#92'($>3/.+,'&&'($(-928$(3+$"3=$0"#$S'+-('3+-3/$@'#92+4(*8B$#.(0'+($0"##$0-'#'$"392$-($0"#$Q(0.('3+-3/$0'#$Z'+P'($'-(0+-()'($3(0$0.+8$-($'()'/$5.(8"*8$/-8$0'($h92<"((,'&&'($3(0$0'/$OX.($0'#$Z'+P'($#8'2'($6`.9*/"($'8$"&AB$EVV\7A$O*83'&&$#:+-928$/"($P.($'-('+$:'+-('3+"&'($K(P"#-.(B$<'(($-($'-('+$0'+$0+'-$`-(0')'<'@##92-928'(B$0-'$0'($Z'+P$3/)'@'($6Q:-FB$S'+-FB$3(0$Q(0.('3+-3/7B$>3/.+,'&&'($,3$=-(0'($#-(0B$.0'+$<'(($'-($/"&-)('+$;'+0$'-('($:'+-:2'+'($ Z'+P$ ,3$ /-(0'#8'(#$ LL$G$ 3//"3'+8$ 6?-'@-)$ '8$ "&AB$ CDDV7A$ !-'$ K(,-0'(,$ 0'+$ SZK$ @'-/$S"(*+'"#*"+,-(./$ &-')8$ @'-$ iDFEDD$G$ 3(0$ -#8$ "##.,--'+8$ /-8$ 82'+":-'+'=+"*84+'($ h92/'+,'($ 3(0$ '-('+$#92&'928'($S+.)(.#'$ 6`":"8$ '8$ "&AB$ CDEE7A$O392$@'-/$%"&&'()"()#*"+,-(./$,'-)8'$ #-92$ '-('$ 42(&-92$2.2'$K(,-0'(,$/-8$^\Fi\$G$6b3+"*"/-$'8$"&AB$CDE\W$h2-+"-$'8$"&AB$CDDi7A$K($'-('+$h830-'$/-8$JV$"($-11O$'+*+"(*8'($S"8-'(8'($,'-)8'$#-92$@'-$0'+$%+3::'$/-8$SZK$'-('$JFNTI$P.($E^$GB$@'-$S"8-'(8'($.2('$SZK$@'&-'=$#-92$0-'$JFNTI$"3=$^D$G$6h2-+"-$'8$"&AB$CDDi7A$!"+]@'+$2-("3#$-#8$0-'$SZK$@'-/$12.&"()-.*"+,-(./$/-8$'-('+$2.2'($:.#8.:'+"8-P'($I',-0-P+"8'$3(0$'-('+$ #92&'928'($S+.)(.#'$"##.,--'+8$ 6Z"*").2+-$ '8$ "&AB$ CDDL7A$h./-8$<-+0$0'38&-92B$0"##$0"#$e'+#84(0(-#$0'+$S"82.)'('#'$0'+$:'+-('3+"&'($K(P"#-.($'-($<-928-)'+$h92+-88$"3=$0'/$a')$,3$('3'($h8")-()Fh8+"8')-'($3(0$/H)&-92'+<'-#'$"392$,3$('3'($`'2"(0&3()#/'82.0'($0"+#8'&&'($*H((8'A$$!-'$2.2'$K(,-0'(,$0'+$SZK$@'-/$12.&"()-.*"+,-(./$'+*&4+8$#-92$"3#$0'($"("8./-#92'($%')'@'(2'-8'(A$!-'$?'@'+$'(824&8$'-($<'-8$P'+,<'-)8'#$Z'8,<'+*$P.($#c/:"82-#92'($3(0$:"+"#c/:"82-#92'($Z'+P'(="#'+(B$0-'$3(8'+$ "(0'+'/$ "392$ 0-'$ %"&&'()4()'$ -(('+P-'+'(A$ O/$ ?'@'+2-&3#$ @-&0'($ 0-'$ f"#'+($ 0'#$ "38.(./'($Z'+P'(#c#8'/#$'-('($S&'X3#$3(0$P'+&"3='($/-8$p#8'($0'+$O+8'+-"$2':"8-9"$3(0$0'($%"&&'()4()'($@-#$,3$0'+'($*&'-(#8'($e'+,<'-)3()'($-($0'($S.+8"&='&0'+($3(0$@-&0'($#.$'-('($.:8-/"&'($b'8"#8"#-'+3()#<')$6!"(9c)-'+B$CDDL7A$

"

!"A"!F V;'+:5'&,+0V+/%&$.)<+$04+,0>+,.$+5,&'+$0#$*&).;$0"

K(-8-"&$ <3+0'$ :.#83&-'+8B$ 0"##$ 0"#$ a"92#83/#P'+2"&8'($ 0'#$ >3/.+#$ '(8&"()$ P.($ Z'+P'($ "3=$ 0-'$ 0"/-8$'+&'-928'+8'$b-)+"8-.($,3+]9*,3=]2+'($#'-($)*+$,-./+$012%3*4$536/$7*8$09*:$7*6$:*+;8:6<*8$9;7*+6<587*64$6`"8#"*-#B$ EViJW$ ?-'@-)$ '8$ "&AB$ CDDV7A$ !-'#'$ O(("2/'$ )-&8$ -(,<-#92'($ "&#$ ]@'+2.&8A$ `.9*/"(($ '8$"&A$'(8<-9*'&8'($0-'$>2'.+-'=$7566$7*.$,+586>/+.;8:$?+/1<%$@5A</+$B$C,?@B&$*;8*$*8<6A%*;7*87*$D/33*$E*;$7*+$K(P"#-.($0'+$>3/.+,'&&'($,3*.//8A$K($'-('+$h830-'$,'-)8'($@'="&&'('$Z'+P'($'-('$2.2'$K//3(+'"*8-P-848$F/8$,?@B=$G-:3*;A%$*.((8'$'-('$T@'+'X:+'##-.($0'#$Q%fFI',':8.+#=$7*.$85<H+3;A%*8$D*G*I</+$F/8$,?@B=$@'-$0'($g'&&'($0'#$S"(*+'"#*"+,-(./#$='#8)'#8'&&8$<'+0'($6`.9*/"($'8$"&AB$EVV\7A$!-'#'$>2'.+-'$`.9*/"((#$<"+$ 0'+$ '(8#92'-0'(0'$;-(<'-#B$ 0"##$ 0-'$ >3/.+,'&&'($ (-928$ (3+$ 0'($Z'+P$ @'="&&'(B$ #.(0'+($ "392$ ]@'+$/.&'*3&"+'$h-)("&<')'$/-8$-2/$-(8'+")-'+'($3(0$-2($"*8-P$@''-(=&3##'($6?-'@-)$'8$"&AB$CDDV7A$K($'-('/$'$#&'()%$b.0'&&$<3+0'($b"3#Fh:-("&)"()&-'($/-8$:+.#8"8-#92'($>3/.+,'&&'($-($'-('+$b"8+-)'&Fb"8+-X$*.F*3&8-P-'+8A$Q#$,'-)8'$ #-92B$ 0"##$ 0-'$ Z'3+-8'($ 0'+$Z'3+.('$ P.($b"3#Fh:-("&)"()&-'($ "3=$ 0-'$ :+.#8"8-#92'($ >3/.+,'&&'($,3<392#'($3(0$0-'#'$#-92$<-'0'+3/$'(8&"()$0'+$Z'3+-8'($P'+@+'-8'8'($6Oc"&"$'8$"&AB$CDDE7A$O392$-($'-('/$'$#&'()%$b.0'&&$/-8$:"(*+'"8-#92'($>3/.+,'&&'($*.((8'$0-'#'#$a"92#83/#P'+2"&8'($@'.@"928'8$<'+0'($6!"-$'8$"&AB$CDD^7A$!-'$Q+)'@(-##'$0-'#'+$h830-'($0'38'($"3=$'-('$K(8'+"*8-.($P.($>3/.+,'&&'($3(0$Z'+P'($2-(B$0-'$#.<.2&$,3$'-('+$'+=.&)+'-92'($S+.)+'##-.($0'#$>3/.+#$"&#$"392$,3$'-('/$P'+#84+*8'($a"92#83/$0'+$Z'+P'($=]2+8A$!-'$,3)+3(0'&-')'(0'($b'92"(-#/'($0-'#'+$>3/.+,'&&FMZ'+P'(,'&&-(8'+"*8-.($2"@'($-($0'($&'8,8'($N"2+'($ P'+#84+*8$ <-##'(#92"=8&-92'$ O3=/'+*#"/*'-8$ "3=$ #-92$ )',.)'(A$ h.$ <'-R$ /"($ -(,<-#92'(B$ 0"##$Z'3+.8+.:2-('$3(0$-2+'$I',':8.+'($6g23$'8$"&AB$EVVV7B$12'/.*-('$6b"+92'#-$'8$"&AB$CDDi7B$"@'+$"392$gc8.*-('$6`.9*/"($'8$"&AB$EVV\7$'-('$<-928-)'$I.&&'$-/$/.&'*3&"+'($b'92"(-#/3#$0'+$SZK$#:-'&'(A$$

Page 31: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<T""

!"A"AF I+5,;(,;>%.$+0"

Z'3+.8+.:2-('$#-(0$S':8-0'B$0-'$0"#$a"92#83/B$0-'$!-=='+'(,-'+3()$3(0$0"#$T@'+&'@'($d3()'+$Z'+P'(,'&&'($*.(8+.&&-'+'($6;3"()$U$I'-92"+08B$CDDE7A$h-'$<'+0'($#.<.2&$P.($Z'+P'(,'&&'($"&#$"392$P.($>3/.+,'&&'($"3#)'#92]88'8$6`":"8$'8$"&AB$CDEE7A$O/$@'*"((8'#8'($-#8$0-'$f"/-&-'$0'+$Z'+P'(<"92#83/#="*8.+'(B$0-'$"3#$0'/$ Z'+P'$ %+.<82$ f"98.+$ 6Z%f7B$ 0'/$ `+"-(F0'+-P'0$ ('3+.8+.:2-9$ ="98.+$ 6`!Zf7B$ Z'3+.8+.:2-($ L$6Z>fL7B$Z'3+.8+.:2-($\$6Z>f\7$3(0$Z'3+.8+.:2-($J$6Z>fJ7$@'#8'28$6b"+92'#-$'8$"&AB$CDED7A$!-'$b-8)&-'0'+$0'+$Z%fFf"/-&-'$ @-(0'($ "($ ,<'-$ P'+#92-'0'('$I',':8.+'(B$<.03+92$ d'<'-&#$ "(0'+'$ h-)("&<')'$ "*8-P-'+8$<'+0'(A$ N'0'#$ Z'3+.8+.:2-($ @-(0'8$ /-8$ 2.2'+$ O==-(-848$ "($ '-('($ I',':8.+$ 0'+$ f"/-&-'$ 0'+$>+.:./c.#-(FI',':8.+*-("#'($6>+*7$3(0$/-8$)'+-()'+$O==-(-848$"($0'($:^J$Z'3+.8+.:2-(FI',':8.+$6:^JZ>I7B$b-8)&-'0$0'+$>3/.+('*+.#'="*8.+Fh3:'+="/-&-'$ 6O+'P"&.$U$a3B$CDD[7A$!-'$P'+#92-'0'('($Z'3+.8+.:2-('$6Z%fB$`!ZfB$Z>fLB$Z>f\7$@-(0'($d'<'-&#$#:',-=-#92$"($'-('($@'#8-//8'($>+*FI',':8.+n$

)

I3".$$.)*G+)L#'%&'(//-.$$.')%.6)J.&62-62F1#'.)3')%#.)/F.4#D#/01.')I6:Pb.4.F-26.');b.#0136%->)?@@MB)

"&-2*98)+.$ :&;&829*$

"<=$ >+*O$

%>"=?"!=@$ >+*`$

"!=A$ >+*1$

$$!-'$/'-#8'($h830-'($,3/$>2'/"$SZK$<3+0'($"($:"(*+'"8-#92'($g'&&+'-2'($03+92)'=]2+8A$Z%f$3(0$"392$#'-('$@'-0'($I',':8.+'($ 6:^JZ>I$3(0$>+*O7$<'+0'($P.($0'($:"(*+'"8-#92'($>3/.+,'&&'($3(0$"392$0'($&.*"&'($Z'+P'($P'+#84+*8$'X:+-/-'+8$6`":"8$'8$"&AB$CDEE7B$Z%f$/'2+$P.($0'($>3/.+,'&&'(B$>+*O$P'+/'2+8$-/$S'+-('3+-3/$0'+$:"(*+'"8-#92'($Z'+P'($6g23$'8$"&AB$EVVV7A$%-)&-.,,-$'8$"&A$*.((8'($,'-)'(B$0"##$)'#3(0'$12.&"()-.,c8'($ Z%f$ 3(0$ >+*O$ 'X:+-/-'+'(A$ K/$ g3)'$ '-('+$ %"&&'()"()##8'(.#'$ <'+0'($ 0-'#'$]@'+'X:+-/-'+8$6%-)&-.,,-$'8$"&AB$CDD\7A$k"()$'8$"&A$*.((8'($-($'-('+$*&-(-#92'($h830-'B$0-'$iL$S"8-'(8'($/-8$'-('/$ -(8+"2':"8-#92'($ 92.&"()-.,'&&3&4+'($ 5"+,-(./$ '-(#92&.##B$ '-('($ #-)(-=-*"(8'($ g3#"//'(2"()$,<-#92'($0'+$QX:+'##-.($P.($>+*O$3(0$Z%f$3(0$0'+$!-=='+'(,-'+3()$0'#$>3/.+#$='#8#8'&&'($6k"()$'8$"&AB$CDE\7A$$O392$Z>fLM\$3(0$>+*1$*.//'($@'-$0'($12.&"()-.,c8'($P.+$6%-)&-.,,-$'8$"&AB$CDD\7A$̀ -(0'($Z'3+.8+.:2-('$"($ >+*FI',':8.+'(B$ <'+0'($ P'+#92-'0'('$ h-)("&<')'$ "*8-P-'+8B$ 0"+3(8'+$ 0'+$ IOhMI":FbOS5Fa')B$ 0'+$SKL5FO*8FB$ 3(0$ 0'+$ S?JKFS51Fh-)("&<')$ 6O+'P"&.$ U$ a3B$ CDD[7A$ !3+92$ 0-'$ O*8-P-'+3()$ 0'#$IOhFbOS5Fh-)("&<')#$<'+0'($-/$K(('+'($0'+$g'&&'$e.+)4()'$"3#)'&H#8B$0-'$=]+$ -2+$T@'+&'@'($3(0$-2+'$!-=='+'(,-'+3()$P.($̀ '0'383()$#-(0$6O+'P"&.$U$a3B$CDD[7A$!'+$I":FbOS5Fh-)("&<')$#.+)8$=]+$0'($Q-(@"3$0'+$>+*FI',':8.+'($-($0-'$'(0.#./"&'($5./:"+8-/'(8'$0'+$g'&&'$6a3$'8$"&AB$CDDE7A$`-(0'8$`Z!f$"($>+*`B$1;+7$7*+$LMJKFS51Fh-)("&<')$"*8-P-'+8B$0'/$'-('$<-928-)'$f3(*8-.($-($0'+$#c(":8-#92'($S&"#8-,-848$,3*.//8$6?'"&$'8$"&AB$CDE\7A$$!-'$O(<'#'(2'-8$P.($:^JZ>I$'+2H28$0-'$O==-(-848$P.($Z%f$3(0$`Z!f$,3$>+*OM`$6O+'P"&.$U$a3B$CDD[W$`":"8$'8$"&AB$CDEE7B$<.@'-$#-92$0-'$f3(*8-.('($P.($:^JZ>I$(-928$(3+$0"+"3=$@'#92+4(*'($&"##'(A$N'$("920'/B$<'&92'$Z'3+.8+.:2-('$"($0"#$:^JZ>I$S+.8'-($@-(0'(B$*"(($'#$#.<.2&$:+.":.:8.8-#92'$h-)("&<')'$"*8-P-'+'(B$"@'+$ "392$ #.&92'B$ 0-'$ ,3$ '-('/$ T@'+&'@'(#P.+8'-&$ 0'+$ g'&&'($ =]2+'(A$ Q-($ `'-#:-'&$ =]+$ ?'8,8'+'#$ -#8$ 0-'$O*8-P-'+3()$0'#$Zf!`Fh-)("&<')'#$6(39&'"+$="98.+$q*"::"F&-)28F92"-(F'(2"(9'+q$.=$"98-P"8'0$`F9'&&#7$03+92$0-'$`-(03()$P.($Z%fB$(-928$"@'+$`!Zf$.0'+$Z>fLB$"($:^JZ>I$61"+8'+$'8$"&AB$EVV[7A$!'#$a'-8'+'($<'+0'($03+92$ 0"#$ :^JZ>I$ S+.8'-($ h-)("&<')'$ "*8-P-'+8B$ 0-'$ '-('$ <-928-)'$ I.&&'$ @'-/$ "X.("&'($ a"92#83/B$ 0'+$g'&&0-=='+'(,-'+3()$3(0$0'+$g'&&:+.&-='+"8-.($#:-'&'($6O+'P"&.$U$a3B$CDD[7A$$

Page 32: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<!""

Q-('$ !'"*8-P-'+3()$ 0'#$ >+*FI',':8.+#$ =]2+8$ ,3$ '-('/$ P'+&4()'+8'($ ('3+.("&'($ T@'+&'@'(B$ <.2-()')'($)','-)8$ <3+0'B$ 0"##$ 0"#$ `-(0'($ P.($Z'3+.8+.:2-('($ "&&'-('$ "($ 0'($ :^JZ>IFI',':8.+$ ,3$ '-('+$ '+2H28'($O:.:8.#'FI"8'$=]2+'($*"(($6`":"8$'8$"&AB$CDEEW$!'f+'-8"#$'8$"&AB$CDDE7A$!"+]@'+$2-("3#$*.//8$'#$03+92$0-'$h8-/3&-$92.&-('+)'+$Z'+P'($,3$'-('+$K(03*8-.($P.($Z%f$60"$S'(2"$`'+,")2-$'8$"&AB$EVVLW$b"2/.30$'8$"&AB$CDEJ7B$0-'#'+$#'&@#8$<-'0'+3/$#8-/3&-'+8$"*8-P$0"#$a"92#83/$P.($92.&-('+)'($Z'+P'(="#'+($6;"c"*"<"$'8$"&AB$CDE^7A$K($0'($)'("((8'($O+@'-8'($*.((8'$)','-)8$<'+0'(B$0"##$'#$#-92$3/$'-('$"*8-P'$K(8'+"*8-.($-/$h-(('$'-('+$0@**7E5AN6A%3*;>*4$F/8$O*+F$-87$,-./+G*33*$%587*3<=$7;*$HE*+$*;8*$I*+;8*-+53*$P8F56;/8$%;85-6:*%<($$

Page 33: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<<""

AF W.+')+(-5$604+,03,2+.(0%"&&'()"()#*"+,-(./'$#-(0$#'&8'($3(0$,'-)'($("92$<-'$P.+$'-('$43R'+#8$#92&'928'$S+.)(.#'A$Q-('$*3+"8-P'$>2'+":-'$-#8$@'-$'-('/$%+.R8'-&$0'+$S"8-'(8'($,3/$g'-8:3(*8$0'+$!-")(.#'#8'&&3()$(-928$/'2+$/H)&-92B$0"$#-92$0"#$111$#92.($ -($'-('/$,3$<'-8$ =.+8)'#92+-88'('($h8"0-3/$@'=-(0'8A$!-'$:"&&-"8-P'$>2'+":-':&"(3()$)'#8"&8'8$#-92$.=8$*./:&'XB$0-'$!"8'(&")'$-#8$"3=)+3(0$0'+$)'+-()'($K(,-0'(,$0'+$Q+*+"(*3()$/"()'&2"=8A$g-'&$0-'#'+$ O+@'-8$ -#8$ '#$ 0"2'+B$ 0-'$ `'2"(0&3()#+'"&-848$ "($ '-('/$ 3(-P'+#-84+'($ g'(8+3/$ /-8$ 2.2'/$h:',-"&-#-'+3()#)+"0$0"+,3#8'&&'(A$

K($'-('/$'+#8'($h92+-88$#.&&'($-($0'+$P.+&-')'(0'($O+@'-8$0-")(.#8-#92'B$':-0'/-.&.)-#92'$3(0$82'+":'38-#92'$!"8'($0'+$ED[$S"8-'(8'($0'+$h830-'(:.:3&"8-.($+'8+.#:'*8-P$"("&c#-'+8$3(0$@',])&-92$Q-(=&3##="*8.+'($"3=$0"#$T@'+&'@'($.0'+$"3=$0-'$g'-8$@-#$,3+$>3/.+:+.)+'##-.($"3#)'<'+8'8$<'+0'(A$$K($0-'#'/$g3#"//'(2"()$'+)"@'($#-92$=.&)'(0'($f+")'#8'&&3()'(n$$

EAF a'&92'$*&-(-#92'($12"+"*8'+-#8-*"$,'-)8'($0-'$S"8-'(8'(r$CAF K($ <'&92'/$ >3/.+#8"0-3/$ <3+0'($ 0-'$ >3/.+'$ '+#80-")(.#8-,-'+8r$ g'-)8'($ #-92$ 0-'#@',])&-92$

_(8'+#92-'0'$-/$;-(@&-9*$"3=$0-'$?.*"&-#"8-.(r$LAF a'&92'$&"@.+92'/-#92'($e'+4(0'+3()'($,'-)8'($0-'$S"8-'(8'(r$\AF a'&92'$>2'+":-'$<3+0'$@'-$0'($S"8-'(8'($03+92)'=]2+8r$g'-)8'($#-92$2-'+$_(8'+#92-'0'$-/$;-(@&-9*$

"3=$0"#$T@'+&'@'(r$JAF a-'$&"()'$<"+'($0"#$Yh$3(0$0"#$Sfhr$5H(('($_(8'+#92-'0'$@',])&-92$*&-(-#92'+$12"+"*8'+-#8-*"B$

0'+$>3/.+&.*"&-#"8-.($.0'+$P'+#92-'0'('($?"@.+:"+"/'8'+($='#8)'#8'&&8$<'+0'(r$[AF a'&92'$f"*8.+'($<-+*'($#-92$#-)(-=-*"(8$"3=$0"#$Yh$3(0$"3=$0"#$Sfh$0'+$S"8-'(8'($"3#$3(0$*H((8'($

#./-8$"&#$S+.)(.#'="*8.+'($0-'('(r$$O3=)+3(0$ 0'+$ #92&'928'($ S+.)(.#'$ 0'#$ 92.&"()-.,'&&3&4+'($ 5"+,-(./#$ -#8$ '#$ 3(@'0-()8$ '+=.+0'+&-92$O()+-==#:3(*8'$ =]+$ '-('$ ,-'&)'+-928'8'$ >2'+":-'$ ,3$ =-(0'(A$ f]+$ P-'&'$ >3/.+'(8-848'($ -#8$ '-($ (')"8-P'+$g3#"//'(2"()$,<-#92'($0'+$QX:+'##-.($P.($Z%f$3(0$>+*O$3(0$0'/$Yh$@'*"((8B$=]+$0"#$111$*.((8'$0-'#$ @-#2'+$ (3+$ "($ '-('/$ d":"(-#92'($5.&&'*8-P$/-8$Q+*+"(*3()$ "($ '-('/$ -(8+"2':"8-#92'($111$ )','-)8$<'+0'($6k"()$'8$"&AB$CDE\7A$h.$#.&&$-($'-('/$,<'-8'($h92+-88$3(8'+#3928$<'+0'(B$.@$@'-$0'($>3/.+:+.@'($0'#$5.&&'*8-P#$'-('$P'+/'2+8'$QX:+'##-.($P.($Z%f$.0'+$>+*O$("92)'<-'#'($<'+0'($*"(($3(0$.@$#-92$'-('$5.++'&"8-.($/-8$0'/$Yh$.0'+$/-8$0'/$Sfh$,'-)'($&4##8A$$

Page 34: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<?""

DFV&(+,.&'.+$05$40V+(%;4+$0

D"!F E&(.+$(+$0"

K($'-('/$'+#8'($h92+-88$<3+0'($+'8+.#:'*8-P$E[[$S"8-'(8'($-0'(8-=-,-'+8B$0-'$,<-#92'($CDD[$3(0$CDEC$"3=)+3(0$'-('#$ >3/.+#$ 0'#$ @-&-4+'($>+"*8#$ -/$I"2/'($ 0'+$%"#8+.-(8'#8-("&'($>3/.+*.(='+'(,$ "/$5&-(-*3/$ 0'+$_(-P'+#-848$b](92'($!$1"/:3#$%+.R2"0'+($P.+)'#8'&&8$<3+0'(A$!"P.($"3#)'#92&.##'($<3+0'($[D$S"8-'(8'($"3#$P'+#92-'0'('($%+](0'($!$6#-'2'$O@@-&03()$J7A$h./-8$*.((8'($ED[$S"8-'(8'($-($0-'$P.+&-')'(0'$h830-'$"3=)'(.//'($<'+0'(B$@'-$0'('($0-'$!-")(.#'$'-('#$92.&"()-.,'&&3&4+'($5"+,-(./#$/-88'&#$'-('+$`-.:#-'$.0'+$'-('#$Y:'+"8-.(#:+4:"+"8'#$3(0$'-('+$2-#8.&.)-#92'($_(8'+#3923()$)'#-92'+8$<'+0'($*.((8'A$g3#"//'(="##'(0$)"&8'($=.&)'(0'$Q-(#92&3##*+-8'+-'(n$$

!F ;-#8.&.)-#92$)'#-92'+8'$Q+#80-")(.#'$'-('#$92.&"()-.,'&&3&4+'($5"+,-(./#$!F O3#+'-92'(0'$!"8'(&")'$]@'+$0'($<'-8'+'($5+"(*2'-8#P'+&"3=$!F O3##92&3##$P.($S"8-'(8'($/-8$b-#9283/.+'($#.<-'$>3/.+'($"(0'+'+$?.*"&-#"8-.('($

"

"

!""#$%&'()G+)Q.$.:-#2')%.6)Q-&%#.'F2F&$3-#2')

"

Page 35: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<C""

K($'-('/$,<'-8'($h92+-88$<3+0'$0'+$*&-(-#92'$e'+&"3=$"(2"(0$P.($'&'*8+.(-#92'($O*8'($0'+$b'0-,-(-#92'($5&-(-*$ KKK$ "/$ 5&-(-*3/$ %+.R2"0'+($ 3(0$ S":-'+"*8'($ 0'#$ g'(8+"&"+92-P#$ "/$ 5&-(-*3/$ %+.R2"0'+($("92P.&&,.)'(A$ S"8-'(8'(@',.)'('$ !"8'($ <3+0'($ 03+92$ 0-'$ e'+)"@'$ P.($ =.+8&"3='(0'($ Z3//'+($"(.(c/-#-'+8A$ Q-($ )]&8-)'#$ Q82-*P.83/$ 6Q82-**.//-##-.($ 0'+$ ?b_$ b](92'(W$ O(8+")$ CiJFEJ7$ =]+$ 0-'$e'+<'(03()$0'+$!"8'($@'+'-8#$P'+#8.+@'('+$S"8-'(8'($&")$P.+A$e.($0'($@'-$O@#92&3##$0'+$!"8'('+2'@3()$(.92$&'@'(0'($S"8-'(8'($<3+0'$'-('$#92+-=8&-92'$Q-(P'+#84(0(-#'+*&4+3()$'-()'2.&8A$$`'-$ "&&'($ S"8-'(8'($ <3+0'($ 0-'$ -($ >"@'&&'$ E[$ "3=)'&-#8'8'($ b'+*/"&'$ '+="##8A$ !-'$ h8"0-'('-(8'-&3()$ 0'+$>3/.+'($ '+=.&)8'$ "(2"(0$ 0'+$ >ZbF5&"##-=-*"8-.($ 6_K11B$ ^A$ O3=&")'$ CDED7A$ !-'$ :.#8.:'+"8-P$2-#8.:"82.&.)-#92$ )'#-92'+8'($ >3/.+#8"0-'($ <3+0'($ 0'($ S"8-'(8'("*8'($ @,<A$ 0'($ S"82.&.)-'@'=3(0'($'(8(.//'(A$!"$'-(-)'$f4&&'$(.92$("92$0'+$[A$O3=&")'$0'+$_K11F5&"##-=-*"8-.($@'=3(0'8$<.+0'($<"+'(B$<3+0'($ 0-'#'$ (.92$ '-(/"&$ ('3$ ("92$ 0'+$ ^A$O3=&")'$ *&"##-=-,-'+8B$ 3/$ '-('$e'+)&'-92@"+*'-8$ 0'+$!"8'($ ,3$)'<42+&'-#8'(A$`'-$0'($+'#8&-92'($S"8-'(8'($'+=.&)8'$0-'$h8"0-'('-(8'-&3()$*&-(-#92F+"0-.&.)-#92$"(2"(0$0'+$^A$O3=&")'$0'+$_K11F5&"##-=-*"8-.(A$

I3".$$.)*M+)c&8)c.#-F&':-)%.6),6/-%#3('2/.).612".'.)d3-#.'-.'01363:-.6#/-#:3)

B+/&.'()3C2$ D.2&*2&+E-./$

<&,-*2'432-5$ 00M//Mcccc$

<*FG&$ 9/$

<&H+()2$ *)$

I&+28-.J2$4&*$B*'24+3/.9'&$ 00M//Mcccc$

B*J*3.J-./''234+-5$,&+$B*'24+3/.9'&$

&.*"&$=.+8)'#92+-88'($/'8"#8"#-'+8$+'#'*8"@'&$

K9J3E+'32+9.$4&'$!-59*'$

-(8+"2':"8-#92$'X8+"2':"8-#92$:'+-2-&4+$

6E3''+C+;+&*-./$.3()$%+'5-2)0L9*E&22&$ #-'2'$EAEA[A\$

6E3''+C+;+&*-./$.3()$!"#?DMLL$ #-'2'$EAEA[ACB$EAEA[AL$3(0$EAEA[AJ$

N+'29E9/+&$4&'$!-59*'$O0'(.*"+,-(./$S":-&&4+F/3,-(H#$

<*34+./$

)38$0-=='+'(,-'+8$/4R-)$0-=='+'(,-'+8$)'+-()$0-=='+'(,-'+8$3(0-=='+'(,-'+8$

B*J*3.J-./''234+-5$,&+$123*2$&+.&*$83EE+32+O&.$

!)&*38+&$

&.*"&$=.+8)'#92+-88'($/'8"#8"#-'+8$

P9*E+&/&.$-.4$K9J3E+'32+9.$O9.$#&23'23'&.$5'-('$f'+(/'8"#8"#-'+3()$f'+(/'8"#8"#-'+3()$'-()'8+'8'($

Q8&*32+9.$+.$J-*32+O&*$R,'+()2$ g'-8:3(*8B$I'#'*8-.(#)+"0B$O@@+392$0'+$Y:'+"8-.($

>3-&*S$ R*2S$ I7JE&.$ &+.&*$ '7'2&5+'()&.$

!)&*38+&$"0d3P"(8M('."0d3P"(8M:"&&-"8-P$

>3-&*$&+.&*$&2H3+/&.$%&'2*3)E-./$ -($b.("8'($

Page 36: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<F""

,&+$B+.2*+22$&+.&'$:&;+4+O'$g'-8:3(*8$0'#$O3=8+'8'(#B$?.*"&-#"8-.(B$>2'+":-'$0'#$I',-0-P#$

,&+$R-C2*&2&.$&+.&'$6*3.J)&+2'8*9/*&''&'$ g'-8:3(*8$0'#$O3=8+'8'(#$$

B.4432-5$4&*$R.3E7'&$$

g'-8:3(*8$ 0'#$ >.0'#M&'8,8'$ e.+#8'&&3()$ -($%+.R2"0'+(M@'-$ (.92$ &'@'(0'($ S"8-'(8'(n$EJADLACDE[$

K3,9*432&.$ TB*C3''-./$ ;-5$ I&+28-.J2$ 4&*$

B*'24+3/.9'&U$

1OEVFVB$1QOB$`-&-+3@-(B$1F+'"*8-P'#$S+.8'-($61IS7B$?"*8"80'2c0+.)'("#'$ 6?!;7B$ ;4/.)&.@-($ 6;@7B$?'3*.,c8'(B$ >2+./@.,c8'(B$ !-=='+'(8-"&@&38@-&0$6#.<'-8$3(8'+#39287$

P9*&*J*3.J-./&.$

S+-/4+$ #*&'+.#-'+'(0'$ 12.&"()-8-#B$ ;':"8-8-#$ OF!B$92+.(-#92$ '(8,](0&-92'$ !"+/'+*+"(*3()'(B$!-"@'8'#$ /'&&-83#$ >c:$ K$l$KKB$ ?'@'+,-++2.#'B$12.&'0.92.&-82-"#-#B$ gA(A$ /"&-)('+$>3/.+'+*+"(*3()$

1-()25+22&E3,-'-'$ Z-*.8-("@3#3#B$O&*.2.&"@3#3#$

Page 37: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<J""$

D"AF E,?(%+,&>+5(.)/%+08.&6$;)(.:0"

g3/$ g<'9*'$ 0'#$ :+482'+":'38-#92'($ h8")-()#$ <3+0'($ @'-$ 0'($ S"8-'(8'($ 0'#$ h830-'(*.&&'*8-P#$ '-('$h.(.)+":2-'B$'-('$1>F$.0'+$bI>F_(8'+#3923()B$'-('$Q(0.#.(.)+":2-'$3(0$/'-#8$'-('$QI1S$.0'+$'-('$bI1S$03+92)'=]2+8B$3/$0-'$&.*"&'$3(0$0-##'/-(-'+8'$O3#@+'-83()$0'#$S+-/4+83/.+#$,3$@'3+8'-&'(A$a"+$@'-$0'($S"8-'(8'($,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$ #92.($'-($ K*8'+3#$"3=)'8+'8'(B$ '+=.&)8'$0-'$'(0.#*.:-#92'$!'*./:+'##-.($0'+$)'#8"38'($%"&&'(<')'$03+92$0"#$Q-(@+-()'($P.($h8'(8#$3/$h9240'($"($0'+$?'@'+$03+92$0-'$12.&'#8"#'$,3$P'++-()'+(A$`'-$S"8-'(8'(B$@'-$0'('($'-('$*3+"8-P'$>2'+":-'$-/$I"2/'($'-('+$Y:'+"8-.($)':&"(8$<"+B$<3+0'$ -($/"(92'($f4&&'($'-('$S.+8"&P'('('/@.&-#"8-.($03+92)'=]2+8B$3/$0"#$:.#8.:'+"8-P'$?'@'+P.&3/'($,3$'+2H2'(A$$

D"DF X.)(;>&(%;';6.)/%+0=$(+,)5/%5$60"

O(2"(0$ 0'+$ :"82.&.)-#92'($ `'=3(0@'+-928'$ <3+0'($ 0-'$ Q-()"()#(3//'+($ P.($ +':+4#'(8"8-P'($2-#8.&.)-#92'($ h92(-88:+4:"+"8'($ 3(0$ *.++'#:.(0-'+'(0'($ 83/.+8+")'(0'($ S"+"==-(@&H9*'($ 0'+$92.&"()-.,'&&3&4+'($ 5"+,-(./'$ -0'(8-=-,-'+8A$ a"+$ 0-'$ %'<'@''(8("2/'$ "/$ 5&-(-*3/$ 0'+$ _(-P'+#-848$b](92'($ '+=.&)8B$ <3+0'($ 0-'#'$ "3#$ 0'/$ O+92-P$ 0'#$ S"82.&.)-#92'($ K(#8-838#$ 0'+$ _(-P'+#-848$ b](92'($"*j3-+-'+8A$ `'-$ "3#<4+8-)$ '+=.&)8'+$ 2-#8.&.)-#92'+$ Q+#80-")(.#'$ <3+0'($ 0-'$ %'<'@'@&H9*'$ "3#$ 0'($@'8+'=='(0'($5&-(-*'($@,<A$S"82.&.)-'($"()'=.+0'+8A$!-'$h92(-88:+4:"+"8'$<3+0'($03+92$'-('($S"82.&.)'($6!+A$/'0A$hA$Y+/"((#B$S"82.&.)-#92'#$K(#8-838$0'+$_(-P'+#-848$b](92'(7$("92@'=3(0'8A$K/$#'&@'($h92+-88$<3+0'($"392$)''-)('8'$>3/.+"+'"&'$"3=$0'/$Y@d'*88+4)'+$/"+*-'+8A$$

D"D"!F 7,)(+''5$60+.$+)01.))5+0V./,;03,,&Y0Q1V3T0"

b-88'&#$0'+$"()','-92('8'($Y@d'*88+4)'+$<3+0'($"3=$0'($,3)'2H+-)'($S"+"==-(@&H9*'($)''-)('8'$O+'"&'$/-8$>3/.+)'<'@'$-0'(8-=-,-'+8A$O3#$0-'#'($/"+*-'+8'($O+'"&'($<3+0'($/-82-&='$'-('#$2"&@"38./"8-#92'($>-##3'$O++"c'+#$ 6`''92'+$ K(#8+3/'(8#B$ h3($S+"-+-'B$aKB$_hO7$0+'-$%'<'@',c&-(0'+$ P.($ E$//$!3+92/'##'+$ "($P'+#92-'0'('($ ?.*"&-#"8-.('($ "3#)'#8"(,8A$ O(#92&-'R'(0$ <3+0'($ 0-'$ %'<'@',c&-(0'+$ -($ '-('($ &''+'($S"+"==-(@&.9*$ 6Q/:=4()'+@&.9*7$ ]@'+8+")'($ 3(0$ 03+92$Q+<4+/3()$ =-X-'+8A$ !-'$ -($ S"+"==-($ '-()'@'88'8'($>bO#$ <3+0'($ 0"(($ -($ ]@&-92'+$a'-#'$ -($ \$ s/$ 0-9*'$ %'<'@'#92(-88'$ )'#92(-88'($ 6b-9+.8./7$ 3(0$ "3=$Y@d'*88+4)'+($ =-X-'+8A$ Q-($ h92(-88:+4:"+"8$ d'0'#$ >bO$ <3+0'$ ,3+$ `'3+8'-&3()$ 0'+$ t3"&-848$ 3(0$ 0'#$>3/.+)'2"&8#$d'0'+$h8"(,'$-/$I.38-('0-")(.#8-*&"@.+$0'#$S"82.&.)-#92'($K(#8-838#$0'+$_(-P'+#-848$b](92'($;4/"8.Xc&-(FQ.#-($ 6;Q7$ )'=4+@8$ 3(0$ /-88'&#$ '-('#$ ?-928/-*+.#*.:#$ 6g'-##$ OX-.#*.:B$ g'-##B$ a'8,&"+B$!'38#92&"(07$@')38"928'8A$$

D"D"AF #<<5$%.)(;/%+<.)/%+0Z?,25$604+,01V3)0"

b-88'&#$-//3(2-#8.92'/-#92'+$f4+@3()'($<3+0'$3(8'+#3928B$.@$0-'$O(8-)'('$Z%fF'$-87$,+NOB$`$3(0$1$-/$ >3/.+)'<'@'$ .0'+$ :'+-83/.+"&'($ %'<'@'$ 0'+$ 3(8'+#3928'($ %'<'@':+.@'($ 0'#$ S"8-'(8'(*.&&'*8-P#$'X:+-/-'+8$<'+0'(A$$_/$ '-('$ QX:+'##-.($ P.($Z%fF'$ 85A%G-1*;6*8B$ '+=.&)8'$ -($ '-('/$ '+#8'($ h92+-88$ 0-'$ !'/"#*-'+3()$ 0'+$O(8-)'('$03+92$0-'$`'2"(0&3()$/-8$>"+)'8$_(/"#*-()$f&3-0$ 6f"A$S"(S"82B$`30'&B$Z-'0'+&"(0'7A$!"("92$<3+0'($0-'$h92(-88'$@'-$I"3/8'/:'+"83+$[D$b-(38'($/-8$'-('/$:.&c*&.("&'($5"(-(92'(FO(8-*H+:'+$6O9+-#$O([email protected]'#B$;'+=.+0B$%'+/"(c7$-($0'+$e'+0]((3()$En\DD$-(*3@-'+8A$$

Page 38: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<L""

!-'$!'8'*8-.($0'+$QX:+'##-.($P.($>+*OB$`$3(0$1$6:"(>+*7$'+=.&)8'$-($42(&-92'+$a'-#'A$!-'$!'/"#*-'+3()$0'+$ O(8-)'('$ '+=.&)8'$ 2-'+$ 03+92$ 0-'$ ;-8,'P.+@'2"(0&3()$ /-8$ Q:-8.:'$ I'8+-'P"&$ h.&38-.($ :;i$ 6f"A$Z.P.9"#8+"B$Z'<9"#8&'$ 3:.($>c('B$_57A$!-'$ K(*3@"8-.($ 0'+$h92(-88'$ '+=.&)8'$ 0"(($ =]+$ [D$b-(38'($ @'-$I"3/8'/:'+"83+$/-8$'-('/$/.(.*&.("&'($O(8-F:"(>+*FO(8-*H+:'+$69&.('n$QSIE^L\EB$O@9"/B$1"/@+-0)'B$_57$-($'-('+$e'+0]((3()$P.($EnEDDA$$!'+$Z"92<'-#$0'+$S+-/4+"(8-*H+:'+$'+=.&)8'$3(8'+$O(<'(03()$P.($K//S+'##$I'")'(8$5-8$O(8-FI"@@-8$K)%$6f"A$ e'98.+$ &"@.+"8.+-'#B$ `3+&-()"/'B$ 1OB$ _hO7A$ _/$ #-'$ #-928@"+$ ,3$ /"92'(B$ <3+0'($ 0-'$ h92(-88'$ 0+'-$b-(38'($/-8$!-"/-(.@'(,-0-($6!O`lB$!"*.B$%&.#8+3B$!4('/"+*7$@'2"(0'&8A$!-'$%')'(=4+@3()$<3+0'$/-8$;4/"8.Xc&-($%-&&u#$f.+/3&"$6f"A$e'98.+$&"@.+"8.+-'#B$`3+&-()"/'B$1OB$_hO7$03+92)'=]2+8A$$K($0-'$f4+@3()'($<3+0'($:"##'(0'$S.#-8-PF5.(8+.&&'($'-()'#92&.##'($6)'#3(0'$:"(*+'"8-#92'$K(#'&,'&&'($=]+$Z%fF'$-87$(.+/"&'#$Z'@'((-'+'()'<'@'$=]+$:"(>+*7A$$

D"D"DF 35)[+,(5$604+,0.<<5$%.)(;/%+<.)/%+$0Z?,25$6+$0"

N'0'$>3/.+#8"(,'$0'+$>bO#$<3+0'$'-(,'&($-/$?-928/-*+.#*.:$@'8+"928'8$3(0$2-(#-928&-92$-2+'+$f4+@3()$"3#)'<'+8'8A$!-'$=.8.)+"=-#92'$!.*3/'(8"8-.($0'+$ -//3(2-#8.92'/-#92'($f4+@3()'($'+=.&)8'$/-8$'-('/$?'-9"$!b!EDi$f.8./-*+.#*.:$6?'-9"$b-*+.#c#8'/'B$a'8,&"+B$!'38#92&"(07A$$

D"HF N(&(.)(.)/%+035)[+,(5$60"

!-'$ O3#<'+83()$ 0'+$ 0'#*+-:8-P'($ h8"8-#8-*'($ 3(0$ 0'+$ T@'+&'@'(#,'-8"("&c#'($ #.<-'$ 0-'$ Q+#8'&&3()$ 0'+$!-")+"//'$'+=.&)8'$/-8$0'/$h8"8-#8-*$S+.)+"//$hShhB$e'+#-.($CDAD$@,<A$b-9+.#.=8$QX9'&B$e'+#-.($CDE[A$SFa'+8'$v$DBDJ$<3+0'($"&#$#8"8-#8-#92$#-)(-=-*"(8$@'8+"928'8A$$$

D"H"!F 9,5>>+$*+,6'+./%+0"

b-8$0'/$5.&/.).+.PFh/-+(.PF>'#8$<3+0'$"3=$Z.+/"&P'+8'-&3()$)':+]=8A$?")$2-'+$0"#$h-)(-=-*"(,(-P'"3$]@'+$J$G$<3+0'$*'-('$Z.+/"&P'+8'-&3()$"()'(.//'($3(0$0'+$b"((Fa2-8('cF_F>'#8$"()'<'(0'8A$?")$'-('$Z.+/"&P'+8'-&3()$P.+B$<3+0'$0'+$>F>'#8$=]+$3("@24()-)'$h8-92:+.@'($@'(38,8A$$

D"H"AF \*+,&''0N5,*.*&'05$40E,;6,+)).;$0Z,++0N5,*.*&'0"

!"#$Yh$<3+0'$0'=-(-'+8$"&#$,'-8&-92'#$K(8'+P"&&$,<-#92'($0'/$!"83/$0'+$Q+#80-")(.#'$3(0$'(8<'0'+$0'/$O@&'@'($0'+$S"8-'(8'(B$0'/$Q(00"83/$0'+$!"8'('+2'@3()$@'-$(.92$&'@'(0'($S"8-'(8'($6"&#$h8-928")$<3+0'$0'+$EJADLACDE[$='#8)'#'8,87$.0'+$0'/$&'8,8'($>'+/-($-($0'+$'&'*8+.(-#92'($O*8'$0'+$b'0-,-(-#92'($5&-(-*$KKK$"/$5&-(-*3/$%+.R2"0'+(A$?'8,8'+'#$<3+0'$@'-$S"8-'(8'($@'(38,8B$@'-$0'('($"392$03+92$8'&'=.(-#92'$O(=+")'$@'-$ 0'($ @'8+'3'(0'($ ;"3#4+,8'($ *'-('$ <'-8'+'($ K(=.+/"8-.('($ ]@'+$ 0'($ 5+"(*2'-8#P'+&"3=$ )'<.(('($<'+0'($*.((8'(A$$!"#$ Sfh$ )-&8$ "&#$ S"+"/'8'+$ =]+$ 0"#$ O(#:+'92'($ '-('+$ >2'+":-'A$ f]+$ 0-'$ `'+'92(3()$ 0'+$ g'-8$ @-#$ ,3+$>3/.+:+.)+'##-.($ /3##8'$ /-88'&#$ @-&0)'@'(0'+$ e'+="2+'($ '-($ S+.)+'##$ 0'#$ >3/.+#$ ("92$ 0'($IQ1Kh>F5+-8'+-'($ 6I'#:.(#'$QP"&3"8-.($1+-8'+-"$ -($h.&-0$>3/.+#7$ F$ #-'2'$O(2"()$ F$ '+="##8$<.+0'($#'-($6Q-#'(2"3'+$'8$"&AB$CDDV7A$$

Page 39: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<R""

!-'$O("&c#'$P.($T@'+&'@'(#,'-80"8'($'+=.&)8'$/-8$;-&='$0'#$5":&"(Fb'-'+Fh9248,'+#$6g-')&'+$'8$"&AB$CDD^7A$_/$0-'$T@'+&'@'(#,'-8'($P.($,<'-$.0'+$/'2+$%+3::'($,3$P'+)&'-92'(B$<3+0'$0'+$?.)F+"(*F>'#8$"()'<"(08A$O&#$h-)(-=-*"(,(-P'"3$<3+0'$"392$2-'+$'-($:Fa'+8$v$DBDJ$='#8)'&')8A$$

D"H"DF P;OKB+6,+)).;$)&$&'Y)+0"

!-'$1.XFI')+'##-.(B$"392$"&#$:+.:.+8-.("&'#$;","+0Fb.0'&&$@','-92('8B$-#8$'-($#'/-F:"+"/'8+-#92'+$O(#"8,$,3+$O("&c#'$P.($T@'+&'@'(#,'-8'($6-($0'+$P.+&-')'(0'($O+@'-8$Yh$3(0$Sfh7A$!"@'-$<-+0$0-'$;","+0+"8'$"&#$S+.03*8$ 0'#$ (-928F:"+"/'8+-#92'($ `"#'&-('F;","+0#$ 3(0$ '-('+M/'2+'+'($ 3("@24()-)'($ e"+-"@&'($6:"+"/'8+-#927$0'=-(-'+8A$h./-8$@'<-+*8$0'+$Q=='*8$0'+$3("@24()-)'($e"+-"@&'M($'-('$:+.:.+8-.("&'$p(0'+3()$0'+$;","+0+"8'A$!"@'-$<-+0$@'-$0'+$O(<'(03()$0'+$1.XFI')+'##-.($0-'$O(("2/'$)'8+.=='(B$0"##$0-'$;","+0$I"8-.$6;I$w$P'+'-(="928$0"#$Q+'-)(-#+-#-*.$,<-#92'($'-('+$I-#-*.)+3::'$3(0$'-('+$I'='+'(,)+3::'7$]@'+$0-'$g'-8$*.(#8"(8$-#8$6g<-'('+$'8$"&AB$CDEE7A$$K($0'+$P.+&-')'(0'($O+@'-8$<3+0'($/'2+'+'$:.8'(8-'&&'$Q-(=&3##="*8.+'(B$0-'$'(8<'0'+$-($@-(4+'+$O3#:+4)3()$P.+&")'($.0'+$ -($,<'-$5"8').+-'($'-()'8'-&8$<3+0'(B$/-88'&#$0'+$3(-P"+-"8'($1.XFI')+'##-.($'P"&3-'+8A$O&#$I'='+'(,)+3::'$ <3+0'$ -($ 0'+$ O+@'-8$ d'<'-&#$ 0-'$ ,<'-8)'("((8'$ P'+<'(0'8A$ Q-('$ ;I$x$E$ @'0'38'8$ '-('$Q+2H23()$0'#$I-#-*.#$)')'(]@'+$0'+$I'='+'(,)+3::'A$a4+'$@'-#:-'&#<'-#'$0-'$;I$EBJ$<]+0'$0"#$@'0'38'(B$0"##$ 0"#$I-#-*.$ '-('#$Q+'-)(-#'-(8+-88#$ 6-($0'+$ P.+&-')'(0'($O+@'-8$ '(8<'0'+$S+.)+'##$ .0'+$>.07$ =]+$ '-('$S"8-'(8'()+3::'$ -/$e'+)&'-92$ ,3+$ I'='+'(,)+3::'$ 3/$ JD$G$ '+2H28$ -#8$ 6g<-'('+$ '8$ "&AB$ CDEE7A$ f.&)'(0'$e"+-"@&'($<3+0'($-($0'+$3(-P"+-"8'($1.XFI')+'##-.(#"("&c#'$@'8+"928'8n$%'#92&'928B$O&8'+$@'-$Q+#80-")(.#'$6@-#$ [[$ N"2+'$P#A$4&8'+7B$ `.0cFb"##FK(0'X$ 6`bK7$ 6@-#$LD$*)M/y$P#A$2H2'+7B$ >3/.+#8"0-3/$ 6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+87B$ >Fh8"0-3/$ ("92$ >Zb$ 6>E$l$>C$P#A$>L$l$>\7B$ ?c/:2*(.8'(@'="&&B$f'+(/'8"#8"#-'+3()B$ %+"0-()$ 6%E$l$%C$P#A$%L$l$%\7B$ 1OEVFVB$ 1QOB$ `-&-+3@-(B$ 1ISB$ ?!;B$ ;@B$?'3*.,c8'(B$>2+./@.,c8'(A$e.($ "&&'($?"@.+:"+"/'8'+($<3+0'$ ,30'/$(.92$0'+$("8]+&-92'$?.)"+-82/3#$)'@-&0'8A$O392$2-'+$@'#92+'-@8$0-'$;I$'-('$I-#-*.,3("2/'$)')'(]@'+$'-('/$3/$'-('$&.)"+-82/-#92'$Q-(2'-8$0"+3(8'+&-')'(0'($a'+8A$$K($0"#$/3&8-P"+-"8'$1.XFb.0'&&$/-8$0'/$Q(0:3(*8$Yh$<3+0'($"&&'$.@'($)'("((8'($e"+-"@&'($"3=)'(.//'(A$!"(($<3+0'($/-8$0'+$Q*<%/7*$0DHAN12+<#$#92+-88<'-#'$6?-*'&-2..0Ft3.8-'(874$6A%+;<<1*;6*$533*$R5+;5E3*8$'(8='+(8B$0-'$'-($h-)(-=-*"(,(-P'"3$S$DBED$"3=<-'#'($6`]2&B$CDE\7A$K/$f.&)'(0'($<3+0'($0-'$P'+@&-'@'('($#-)(-=-*"(8'($e"+-"@&'($6%+"0-()B$O&8'+B$>Fh8"0-3/B$;4/.)&.@-(Fa'+8B$?'3*.,c8'("(,"2&B$&.)$z1OEVFV{7$-($'-($/3&8-P"+-"8'#$1.XFI')+'##-.(#/.0'&&$/-8$0'/$Q(0:3(*8$Yh$'-()'#92&.##'($3(0$"&&'$.@'($)'("((8'($R5+;5E3*8$ ;8$7;*6*.$Q/7*33$ *;8G*38$.;<$7*+$Q*<%/7*$0T;86A%3-664$85A%*;8"(0'+$"3=$h-)(-=-*"(,$)'8'#8'8A$h'&@-)'#$ e'+="2+'($ <3+0'$ "($ '-('/$ /3&8-P"+-"8'($ 1.XFI')+'##-.(#/.0'&&$ /-8$ 0'/$ Q(0:3(*8$ Sfh$"()'<'(0'8A$ Q-()'#92&.##'($ <3+0'($ "392$ 2-'+$ 0-'$ #-)(-=-*"(8'($ Q+)'@(-##'$ 0'+$ /3&8-P"+-"8'($ O("&c#'$CQ*<%/7*$ 0DHAN12+<6$ 6A%+;<<1*;6*47n$ f'+(/'8"#8"#-'+3()B$ `-&-+3@-(Fa'+8B$ 1ISFa'+8$ 3(0$ &.)$z1IS{A$ O&&'$e"+-"@&'($ "3#$ >"@'&&'$ LJ$ <3+0'($ "($ 0-'#'/$ b.0'&&$ ("92'-("(0'+$ "3=$ h-)(-=-*"(,$ )'8'#8'8A$ !3+92$ 0-'$#-/3&8"('$ h9248,3()$ 0'+$ I')+'##-.(#*.'==-,-'(8'($ 0'+$ 3("@24()-)'($ e"+-"@&'($ #-(0$ 0-'$ Q+'-)(-#+-#-*'($d'<'-&#$<'92#'&#'-8-)$"0d3#8-'+8A$$Q@'(="&&#$"()')'@'($<3+0'$0"#$VJ$GF5.(=-0'(,-(8'+P"&&A$!-'#'#$)-@8$0'($̀ '+'-92$"(B$-($0'/$0'+$<"2+'$a'+8$0'+$;I$/-8$'-('+$a"2+#92'-(&-92*'-8$P.($VJ$G$&-')8A$$

D"H"HF G&2;,>&,&<+(+,0"

!"$ "3#$ 0'+$ ?-8'+"83+$ 2'+P.+)'28B$ 0"##$ 0"#$ e.+&-')'($ '-('+$ 12.&'#8"#'$ '-('$ Q+2H23()$ 0'+$ >3/.+/"+*'+$1OEVFV$ 3(0$ 1QO$ P'+3+#"92'($ *"((B$ <3+0'($ S"8-'(8'($ /-8$ '-('/$ `-&-+3@-(<'+8$x$EBJ$/)M0&$6EBJF/"&$I'='+'(,<'+87$ -($ '-('/$ ,<'-8'($ `'+'92(3()#03+92)"()$ "3#)'#92&.##'(B$ 3/$ '-('$ 'P'(83'&&'$`''-(=&3##3()$0'+$Q+)'@(-##'$"3=,3,'-)'($ 6h92&-'/"($'8$"&AB$CDDL7A$a3+0'$0-'#'#$e'+="2+'($ -($0'+$O+@'-8$"()'<'(0'8B$<-+0$'X:&-,-8$0"+"3=$2-()'<-'#'(A$

" $

Page 40: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

<M""

HF 7,6+2$.))+0

H"!F @'.$.)/%+08&(+$04+,0E&(.+$(+$0

H"!"!F ]2+,)./%(0"

I3".$$.)*V+)e".6/#01-)f".6)%#.):$#'#/01.')C3-.')%./)d3-#.'-.':2$$.:-#[/)

P3*+3,E&$ R.;3)E$T.U$ V*9;&.2$

<&'()E&()2$

$<'-@&-92$/4((&-92$$-(#)'#"/8$

$

$

\J$[E$ED[$

$

$

\CBJ$G$J^B\$G$$

RE2&*$T+.$W3)*&.U$

$I"()'$b'0-"($

$$CVFi^$[L$

$

B*J*3.J-./''234+-5$,&+$

!)&*38+&,&/+..$

$&.*"&$=.+8)'#92+-88'($/'8"#8"#-'+8$+'#'*8"@'&$$

$$$C[$LJ$\J$

$$$C\BJ$G$LL$G$\CBJ$G$

K9J3E+'32+9.$4&'$V*+5X*2-59*'$

$-(8+"2':"8-#92$:'+-2-&4+$'X8+"2':"8-#92$60-#8"&7$

$$[D$LJ$EE$

$$J[B[$G$LL$G$EDB\$G$

B*J*3.J-./''234+-5$,&+$

!)&*38+&,&/+..$+.$R,)X./+/J&+2$O9.$

4&*$!-59*E9J3E+'32+9.$$

-(8+"2':"8-#92$&.*"&$=.+8)'#92+-88'($/'8"#8"#-'+8$+'#'*8"@'&$

$

:'+-2-&4+$&.*"&$=.+8)'#92+-88'($/'8"#8"#-'+8$+'#'*8"@'&$

$

'X8+"2':"8-#92$&.*"&$=.+8)'#92+-88'($+'#'*8"@'&$

$$$$$E\$C\$CC$$$ED$EE$E\$$$C$V$

$$$$$CLBL$G$\D$G$L[B^$G$$$CiB[$G$LEB\$G$\D$G$$$EiBC$G$iEBi$G$

0 "

Page 41: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?T""

V&*+)+EX*&'$LLL$!$6E32'J+.06E3''+C+J32+9.$

$

`-#/382$K$`-#/382$KK$`-#/382$KKK"$`-#/382$KKK@$`-#/382$Ke$='2&'(0$

$$$[$C$L$E$CD$L$

$$$E^BE$G$JB^$G$iB[$G$CBV$G$J^BE$G$iB[$G$

N+'29E9/+'()&*$!-59*278$

$O0'(.*"+,-(./$S":-&&4+F/3,-(H#$

$$EDJ$E$

$$VVBE$G$DBV$G$

<*34+./$+.$R,)X./+/J&+2$O9.$4&*$

!-59*E9J3E+'32+9.$

$-(8+"2':"8-#92$

%E$%C$%L$O()"@'$='2&8$

$'X8+"2':"8-#92$6:11O$l$011O7$

%E$%C$%L$%\$O()"@'$='2&8$

$$$$J$CD$LE$\$$$E$E^$CC$C$\$

$$$$iBL$G$LLBL$G$JEB^$G$$$$CBC$G$L[BV$G$\^Bi$G$\B\$G$$

!-59*'234+-5$

$>E$l$>C$>L$l$>\$

$$^L$LL$

$$[iBi$G$LEBE$G$

1232-'$4&*$V32+&.2&.$35$12+()23/$

TYZ[\A[]\Y^U$

$P'+#8.+@'($&'@'(0$(-928$,3$'+2'@'($

$$$iE$J$CD$

$$$^[B\$G$\B^$G$EiBV$G$

"

a-'$ @'+'-8#$ <'-8'+$ .@'($ @'#92+-'@'($ *.((8'($ ("92$ `'+]9*#-928-)3()$ 0'+$ Q-(F$ 3(0$ O3##92&3##*+-8'+-'($ED[$S"8-'(8'($-($0-'$+'8+.#:'*8-P'$!"8'("("&c#'$'-(@',.)'($<'+0'(A$$J^B\$G$0'+$S"8-'(8'($<"+'($/4((&-92'($%'#92&'928#B$0"#$/'0-"('$O&8'+$@'-$Q+#80-")(.#'$@'8+3)$[L$N"2+'A$`'-$\CBJ$G$0'+$S"8-'(8'($,'-)8'$#-92$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$(.92$'-($*3+"8-P$82'+":-'+@"+'#$h8"0-3/B$@'-$LL$G$0'+$S"8-'(8'($&")'($@'-$Q+#80-")(.#'$@'+'-8#$f'+(/'8"#8"#'($P.+$!$#-'2'$O@@-&03()$EDA$$`'-$9"A$\D$G$0'+$S"8-'(8'($2"88'$0'+$>3/.+$@'-$Q+#80-")(.#'$@'+'-8#$0-'$Y+)"()+'(,'($]@'+#92+-88'(A$b'2+$"&#$ 0-'$ ;4&=8'$ 0'+$ S"8-'(8'($ <"+$ "($ '-('/$ -(8+"2':"8-#92'($ 92.&"()-.,'&&3&4+'($ 5"+,-(./$ '+*+"(*8B$ @'-$3()'=42+$'-('/$!+-88'&$0'+$S"8-'(8'($&.*"&-#-'+8'$#-92$0'+$>3/.+$:'+-2-&4+A$5&"##-=-,-'+8'$/"($0-'$:'+-2-&4+'($%"&&'()"()#*"+,-(./'$("92$`-#/382F1.+&'88'$,'-)8'$#-92B$0"##$@'-$]@'+$0'+$;4&=8'$0-'$>3/.+"3#0'2(3()$@'+'-8#$0-'$h')/'(8)"&&'()4()'$@'-0'+$?'@'+&"::'($6`-#/382$eK7$'++'-928'A$$!-'$2-#8.&.)-#92'$_(8'+#3923()$0'+$>3/.+:+.@'($'+)"@$@'-$'-('/$P.($ED[$f4&&'($'-($:":-&&4+F/3,-(H#'#$5"+,-(./B$@'-$0'($+'#8&-92'($f4&&'($,'-)8'$#-92$'-($O0'(.*"+,-(./A$$`'-$O@#92&3##$0'+$!"8'('+2'@3()$<"+'($@'+'-8#$^[B\$G$0'+$S"8-'(8'($P'+#8.+@'(A$

Page 42: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?!""

H"!"AF F;4YKV&))K#$4+O00"

!'+$̀ .0cFb"##FK(0'X$0-'(8$0'+$̀ '<'+83()$0'#$5H+:'+)'<-928#$-($I'&"8-.($,3+$5H+:'+)+HR'$3(0$<-+0$)'/4R$=.&)'(0'+$f.+/'&$@'+'92('8n$

0

"

"

I3".$$.)*W+)!%#F2/#-3/P7$3//#D#:3-#2')%.6)`.$-PY./&'%1.#-/Pg6(3'#/3-#2');`hgB)

%#M$TJ/?5_U$ 6E3''+C+J32+9.$

Y`SZ$0$a$]Z$ Z.+/"&)'<-928$

]Z$0$a$A\$ S+4"0-:.#-8"#$

A\$0$a$AZ$ O0-:.#-8"#$%+"0$E$

AZ$0$a$@\$ O0-:.#-8"#$%+"0$C$

$b$@\$ O0-:.#-8"#$%+"0$L$

"

a-'$ ("92=.&)'(0'/$ !-")+"//$ ,3$ '(8('2/'($ :+4#'(8-'+8'$ #-92$ '-($ %+.R8'-&$ 0'+$ h830-'()+3::'$ /-8$Z.+/"&)'<-928$.0'+$&'0-)&-92$&'-928'/$T@'+)'<-928n$$

"!""#$%&'()M+)Y.H#01-/:$3//#D#:3-#2')&'%)<.6-.#$&'()'301)LKU!

TcTsFcTs!TcTs!FcTs<TcTs<FcTs?TcTs?FcTsCTcTsCFcTsFTcTs

CJc<s?JcFs

!CcCs !cTs !cMs

@132'%(

/'\$89(.0&-..$>$0-($3%

ASQ"i";n16'1*'\$89("Y0*Z"l";n16'1*1nd't"Y4tZ"

Page 43: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?<""

H"!"DF ^;,+,:,&$:5$6+$05$40N5/%(<.((+'&25)5)04+)0@;''+:(.*)0"

`'-$VEBJ$G$0'+$S"8-'(8'($<"+'($,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$e.+'+*+"(*3()'($@'*"((8A$O/$243=-)#8'($*.((8'$0-'$Q+*+"(*3()$"($!-"@'8'#$/'&&-83#$6E^BD$G7$'+2.@'($<'+0'(A$JB^$G$0'+$S"8-'(8'($<"+'($"($'-('+$/H)&-92'+<'-#'$/-8$ 0'/$ 92.&"()-.,'&&3&4+'($5"+,-(./$ "##.,--'+8'($O38.-//3('+*+"(*3()$ 61Q!B$ Sh17$'+*+"(*8A$12+.(-#92'$S+.,'##'$-($0'+$?'@'+$*.((8'($@'-$\B^$G$0'+$S"8-'(8'($='#8)'#8'&&8$<'+0'(A$`'-$^B[$G$<"+$0-'$!-")(.#'$0'#$111$@'+'-8#$'-($g<'-8F$.0'+$"392$!+-88/"&-)(./A$$`'-$VB\$G$0'+$S"8-'(8'($*.((8'$"(2"(0$0'+$O*8'(+'92'+92'$'-('$12.&'0.92.&-82-"#-#$'+2.@'($<'+0'(A$JD$G$0"P.($'+2-'&8'($'-('$12.&',c#8'*8./-'A$K(#)'#"/8$'+2-'&8'($LVB[$G$0'+$S"8-'(8'($'-('$12.&',c#8'*8./-'B$.=8$-/$I"2/'($0'+$>3/.+.:'+"8-.(A$

I3".$$.)*X+)<.6-.#$&'()[2')<26.6:63':&'(.')&'%)b#/#:2D3:-26.')

P3*+3,E&$ R.;3)E$T.U$ V*9;&.2$

>+3,&2&'$5&EE+2-'$

$>c:$K$>c:$KK$

$$E$E^$

$$DBV$G$E[$G$

L)*9.+'()0&.2;c.4E+()&$>3*5&*J*3.J-./&.$

$b.+@3#$1+.2($1.&-8-#$3&9'+.#"$

$$E$L$

$$DBV$G$CBi$G$

V*+5X*$'JE&*9'+&*&.4&$L)9E3./+2+'$ L$ CBi$G$

L)*9.+'()&$K&,&*&*J*3.J-./&.$

$;':"8-8-#$`$;':"8-8-#$1$?'@'+,-++2.#'$

$$C$E$C$

$$EBV$G$DBV$G$EBV$G$

I[$.[$53E+/.&*$!-59*&*J*3.J-./$ i$ ^BJ$G$

REJ9)9E3,-'-'$ \$ LBi$G$

"+J92+.3,-'-'$ L$ CBi$G$

!

Page 44: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

??""

H"!"HF 15<;,)(&4.5<0$&/%0=#PP0Q_"035C'&6+T0"

K(#)'#"/8$ *.((8'$ 0"#$>3/.+#8"0-3/$ @'-$ ED\$ 0'+$ ED[$S"8-'(8'($ @'#8-//8$<'+0'(A$a-'$ #92.($ 3(8'+$ LAE$@'#92+-'@'($ '+=.&)8'$ 0-'$ h8"0-'('-(8'-&3()$ @'-$ JJ$S"8-'(8'($ 6JEBV$G7$ "(2"(0$ 0'+$ :.#8.:'+"8-P$ '+#8'&&8'($:"82.&.)-#92'($`'=3(0'$ "3#$ 0'($ S"8-'(8'("*8'(B$ @'-$ JE$S"8-'(8'($ 6\iBE$G7$<3+0'$ 0-'$Q-(8'-&3()$ "(2"(0$*&-(-#92F+"0-.&.)-#92'+$`'=3(0'$03+92)'=]2+8A$$$

$

!""#$%&'()V+)TUSSPQ-3%#&8)%./)#SS!)

"

$

!""#$%&'()W+)TUSSPQ-3%#&8)%./)FSS!)

T

F

!T

!F

<T

<F

N(-7$)4"Q N(-7$)4"QQ N(-7$)4"QQQ N(-7$)4"Q_V N(-7$)4"Q_A

M !T!

!J

<C

W:)

>$*0'$(

5QPPKN(-7$)4"$PPV

T

<

C

J

R

!T

!<

N(-7$)4"QQ N(-7$)4"QQQV N(-7$)4"QQQA N(-7$)4"Q_V N(-7$)4"Q_A

!!

<

!T

<

!T

W:)

>$*0'$(

5QPPKN(-7$)4"6PPV

Page 45: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?C""

$

!""#$%&'()X+)TUSSPQ-3%#&8)%./)%SS!)

`'-$[[$G$0'+$[D$S"8-'(8'($/-8$'-('/$-(8+"2':"8-#92'($92.&"()-.,'&&3&4+'($5"+,-(./$<3+0'$0-'$Q+#80-")(.#'$-/$h8"0-3/$Ke$("92$_K11$0-")(.#8-,-'+8A$`'-$0'($LJ$S"8-'(8'($/-8$'-('/$:'+-2-&4+'($111$@'="(0'($#-92$LEB\$G$0'+$S"8-'(8'($@'-$Q+#80-")(.#'$-/$h8"0-3/$KKB$L\BL$G$-/$h8"0-3/$KKK$3(0$<'-8'+'$L\BL$G$0'+$S"8-'(8'($-/$h8"0-3/$KeA$!-'$Q+#80-")(.#'$@'-$0'($EE$S"8-'(8'($/-8$'-('/$'X8+"2':"8-#92'($111$'+=.&)8'$@'-$\JB\$G$0'+$S"8-'(8'($-/$h8"0-3/$KB$@'-$J\BJ$G$-/$h8"0-3/$KKA$$

H"!"LF Z+,$<+(&)(&).+,5$60-5<0W+.(>5$:(04+,07,)(4.&6$;)+0

"

!!""#$%&'()*@+)92:3$#/3-#2')%.6)K.-3/-3/.')4&8)c.#-F&':-)%./)L.(#''/)%.6)*=)F3$$#3-#[.')I1.63F#.)

`'-$LL$G$0'+$S"8-'(8'($<"+'($,3$`')-(($0'+$:"&&-"8-P'($12'/.82'+":-'$@'+'-8#$f'+(/'8"#8"#'($='#8)'#8'&&8$<.+0'(A$`'-$CCBV$G$0'+$S"8-'(8'($/-8$f'+(/'8"#8"#-'+3()$<"+'($@'+'-8#$,<'-$.0'+$/'2+$Y+)"('$@'8+.=='(A$O/$243=-)#8'($8+"8'($?'@'+/'8"#8"#'($"3=$6[D$G$0'+$b'8"#8"#-'+3()'(7B$)'=.&)8$P.($>3/.+"@#-'0&3()'($-($0"#$S'+-8.('3/$6CCBV$G7$.0'+$-($0-'$?3()'$6E\BL$G7A$

" $

T

TcF

!

!cF

<

<cF

?

?cF

C

CcF

F

N(-7$)4"QV N(-7$)4"QA N(-7$)4"QQV N(-7$)4"QQA

!

C

!

F

W:)

>$*0'$(

5QPPKN(-7$)4"7PPV

TF!T!F<T<F

F

<!

R <C <

JW:)

>$*0'$(

D30-&$.-($3%"7'1"S'(-.(-.'%"2)4"U'$(6)%0("7'."A'*$%%."7'1"'1.('%"6-&&$-($G'%"E9'1-6$'

Page 46: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?F""

_(8'+#3928$<3+0'$"392B$.@$@'-/$P.+&-')'(0'($5.&&'*8-P$>3/.+'$-($'-('/$(-'0+-)'+'($>Fh8"0-3/$#'&8'('+$f'+(/'8"#8"#'($'(8<-9*'&8'($"&#$>3/.+'$ -($'-('/$2H2'+'($>Fh8"0-3/A$!-'$ =.&)'(0'($>"@'&&'($,'-)'($ -($O@24()-)*'-8$0'#$>Fh8"0-3/#$0-'$O(,"2&$0'+$S"8-'(8'(B$@'-$0'('($@'+'-8#$'-('$f'+(/'8"#8"#-'+3()$'-()'8+'8'($<"+A$Q-('$f'+(/'8"#8"#-'+3()$8+"8$03+92<')$@'-$"&&'($>Fh8"0-'($"3=$6#-'2'$>"@'&&'$CD$3(0$>"@'&&'$CE7A$$$

I3".$$.)?@+)!'431$)%.6)O.6'8.-3/-3/#.6&'(.')i.)'301)I&826/-3%#&8);IJKB)".#8)#SS!)

!-59*'234+-5$ .$

!Y$ C$

!]3$ J$

!],$ ^$

!A$ \$

!@$ J$

$$

I3".$$.)?*+)!'431$)%.6)O.6'8.-3/-3/#.6&'(.')i.)'301)I&826/-3%#&8);IJKB)".#8)FSS!)

!-59*'234+-5$ .$

!Y$ \$

!],$ E$

!A$ L$

!@$ \$

$

" $

Page 47: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?J""

H"!"MF G&2;,>&,&<+(+,02+.07,)(4.&6$;)+0"

`'-$VVBE$G$0'+$S"8-'(8'($<"+'($0-'$?"@.+:"+"/'8'+$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$@'*"((8A$`'-$'-('/$S"8-'(8'($*.((8'$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$*'-($`&38@-&0$'+2.@'($<'+0'(B$0"$0-'$!-")(.#'$'-($N"2+$P.+$0'+$Q+#8P.+#8'&&3()$"/$5&-(-*3/$%+.R2"0'+($'+=.&)8'A$g30'/$<3+0'($@'-$Q+#80-")(.#'$(-928$@'-$"&&'($S"8-'(8'($ '-(2'-8&-92$ 0-'#'&@'($ ?"@.+:"+"/'8'+$ '+2.@'(B$ #.0"##$ '#$ 8'-&<'-#'$ ,3$ O@<'-923()'($ P.($ 0'+$%'#"/8,"2&$*.//8A$$

I3".$$.)??+)93"26F3638.-.6)".#),6/-%#3('2/.)

L.#)%.6)L.H.6-&'()%.6)I&826836:.6')S!*XPX)&'%)S,!)H&6%.')#').#'.8).6/-.')Q016#--)3$$.)d3-#.'-.')".6f0:/#01-#(-=)U').#'.8)4H.#-.')Q016#--)H&6%.')%#.i.'#(.')3&/(./01$2//.'>)%.6.')L#$#6&"#')j)*>GP83$)b.D.6.'4H.6-)".-6&(=)

K3,9*83*35&2&*$ "9*5H&*2$ V32)9E9/+'()&$d&*2&$$ #&4+3.$ P&*2&+E-./$

1OEVFV$.2('$O3##92&3##$ U$L^$_M/&$ ^^MVi$6^iB[$G7$ E\^BJ$ CBJFL\VDDD$

1OEVFV$ U$L^$_M/&$ \VM[[$6^\BC$G7$ EC\$ JB[FL\VDDD$

1QO$.2('$O3##92&3##$ U$\B^$()M/&$ CJMVL$6C[BV$G7$ CBJ$ DBCF\[^$

1QO$ U$\B^$()M/&$ E[M[L$6CJB\$G7$ CBC$ DBCF\[^$

`-&-+3@-($ U$E$/)M0&$ JDMEDJ$6\^B[$G7$ E$ LFL[BV$

1IS$ U$DBJ$/)M0&$ iEMEDJ$6^^BE$G7$ EB\$ DBEFJV$

?!;$ U$CJD$_M&$ LiMED\$6L[BJ$G7$ CCE$ CBJF[Ci$

;@$"$#$

$EEBJFE^BJ$)M0&$ELBJFEJB\$)M0&$

$ECM\\$6C^BL$G7$LDM[E$6\VBC$G7$

$ECB[J$E[BC$

$VFEJBi$[BiFE[BC$

"

e.($0'($Vi$S"8-'(8'($/-8$:"82.&.)-#92$'+2H28'($1OEVFVFa'+8'($,'-)8'($LC$,3)&'-92$'-('($:'+$0'=-(-8-.('/$6EBJF/"&$I'='+'(,<'+87$'+2H28'($`-&-+3@-(Fa'+8$3(0$<3+0'($#./-8$-($'-('/$,<'-8'($h92+-88$"3#$0'+$O("&c#'$"3#)'#92&.##'(A$O3#$0'/#'&@'($%+3(0$<3+0'($LD$S"8-'(8'($/-8$:"82.&.)-#92$'+2H28'($1QOFa'+8'($(-928$@'+]9*#-928-)8A$$

Page 48: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?L""

H"!"_F 1%+,&>.+04+)0/%;'&$6.;-+''5'?,+$0@&,-.$;<)0

H"!"_"!F \>+,&(.;$0.$0:5,&(.*+,0#$(+$(.;$0"

"

!""#$%&'()**+)e".6/#01-)f".6)%#.)38)72$$.:-#[)3'(.H3'%-.')I1.63F#.:2'4.F-.)

"

Y@<.2&$-($'-('/$'+#8'($h92+-88$@'-$\CBJ$G$"&&'+$S"8-'(8'($0'#$5.&&'*8-P#$0"#$>3/.+#8"0-3/$"&#$+'#'*8"@'&$'-()'#83=8$<3+0'B$<3+0'($-(#)'#"/8$JDBV$G$0'+$S"8-'(8'($-($*3+"8-P'+$K(8'(8-.($.:'+-'+8A$!"+3(8'+$@'="(0'($#-92$ 0+'-$S"8-'(8'(B$ @'-$ 0'('($ '#$ ("92$ '-('+$ :"&&-"8-P'($ >2'+":-'$ /-8$ %'/9-8"@-($ 3(0$ 1-#:&"8-($65./@-("8-.(#82'+":-'7B$S2.8.82'+":-'$.0'+$12'/.'/@.&-#"8-.($,3$'-('/$I')+'##$0'#$>3/.+#$*"/B$#.0"##$0-'#'+$ "(#92&-'R'(0$.:'+"8-P$ P'+#.+)8$<'+0'($ *.((8'A$ `'-$ E[B[$G$ 0'+$ J\$S"8-'(8'($<3+0'$ 0-'$Y:'+"8-.($d'0.92$"&#$'X:&.+"8-P'$?":"+.8./-'$"@)'@+.92'(B$0"$#-92$-(8+".:'+"8-P$'-($(-928$+'#'*8"@&'#$>3/.+#8"0-3/$,'-)8'A$h./-8$<3+0'$'-('$Y:'+"8-.($-($*3+"8-P'+$O@#-928$@'-$iLBL$G$S"8-'(8'($6\JMJ\7$0'+$:+-/4+$.:'+-'+8'($S"8-'(8'($P.&&'(0'8A$$

Page 49: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?R""

^$ 0'+$ J\$ :+-/4+$ .:'+-'+8'($ S"8-'(8'($ 6ELBD$G7$ '+2-'&8'($ '-('$ ('."0d3P"(8'$ 12'/.82'+":-'A$ Q#$ <3+0'($3(8'+#92-'0&-92'$>2'+":-'#92'/"8"$"()'<"(08$!$ #-'2'$>"@'&&'$CLA$`'-$'-('/$S"8-'(8'($<3+0'($EC$gc*&'($12'/.82'+":-'$/-8$ P'+#92-'0'('($b'0-*"/'(8'($ 03+92)'=]2+8$ 61":'9-8"@-(B$ JFf&3.+.3+"9-&B$YX"&-:&"8-(B$%'/9-8"@-($3(0$1'83X-/"@7A$!"$'#$#-92$3/$'-('($S"8-'(8'($"3#$0'/$O3#&"(0$2"(0'&8'B$<"+'($3(#$0-'$%+](0'$=]+$0'($243=-)'($a'92#'&$3(@'*"((8A$a-+$<'+8'8'($0-'$"()'<"(08'($>2'+":-'($0'((.92$"&#$('."0d3P"(8B$0"$@'-$0'/$S"8-'(8'($0"(($@'-$3(#$'-('$Y:'+"8-.($-($*3+"8-P'+$K(8'(8-.($03+92)'=]2+8$<3+0'A$$

I3".$$.)?N+)!'(.H3'%-.)'.23%i&[3'-.)I1.63F#.:2'4.F-.)

!)&*38+&'()&53$ R.;3)E$T.U$

L38&(+23,+.S$Z0=E-9*9-*3(+ES$Qe3E+8E32+.S$<&5(+23,+.$

-.4$L&2-e+53,$$E$

<&5(+23,+.$$ E$

Z0=E-9*9-*3(+E$f$%&'2*3)E-./$ C$

L)&59&5,9E+'32+9.$ E$

V)9292)&*38+&$ E$

<&5(+23,+.$f$Qe3E+8E32+.$ E$

$

e.($0'($8"8#492&-92$*3+"8-P$.:'+-'+8'($\J$S"8-'(8'($'+2-'&8'($C\$G$'-('$"0d3P"(8'$12'/.82'+":-'A$O392$2-'+$&-'R$#-92$*'-($'-(2'-8&-92'#$>2'+":-'#92'/"$'+*'(('(B$=.&)'(0'$>2'+":-'"(#48,'$<3+0'($"()'<'(0'8$F$#-'2'$>"@'&&'$C\n$

I3".$$.)?A+)!'(.H3'%-.)3%i&[3'-.)I1.63F#.:2'4.F-.)

!)&*38+&'()&53$ R.;3)E$T.U$

<&5(+23,+.$ \$

L38&(+23,+.$Tg&E943U$ C$

Z0=E-9*9-*3(+E$f$%&'2*3)E-./$ L$

Z0=E-9*9-*3(+E$f$%&'2*3)E-./$f$<&5(+23,+.$ C$

$

$ $

Page 50: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

?M""

`'-$[[B^$G$0'+$*3+"8-P$.:'+-'+8'($S"8-'(8'($*.((8'$0'+$>3/.+$-/$)'#3(0'($%'<'@'$'(8='+(8$<'+0'($6ID7A$`'-$LEBL$G$*.((8'$&'0-)&-92$'-('$IEFI'#'*8-.($03+92)'=]2+8$<'+0'(A$`'-$'-('/$S"8-'(8'($6CBC$G7$*.((8'($-/$I"2/'($0'+$O*8'(+'92'+92'$*'-('$O()"@'($,3/$I'#'*8-.(##8"83#$)'=3(0'($<'+0'(A$$

$

!""#$%&'()*?+)b./.:-#2'//-3-&/)'301).#'.6)gF.63-#2')#'):&63-#[.6)!"/#01-)

$[CBC$G$0'+$.:'+-'+8'($S"8-'(8'($'(8<-9*'&8'($'-($I',-0-PB$'(8<'0'+$ -($f.+/$'-('#$?.*"&+',-0-P#$6LJB^$G7B$'-('+$f'+(/'8"#8"#-'+3()$6LJB^$G7$.0'+$0'+$5./@-("8-.($"3#$&.*"&'/$I',-0-P$3(0$f'+(/'8"#8"#'($6CJ$G7A$!-'#$ @'8+"=$ ^EB\$G$0'+$S"8-'(8'(B$ @'-$ 0'('($ '-('$IDFI'#'*8-.(B$ 3(0$ CJ$G$0'+$S"8-'(8'(B$ @'-$ 0'('($ '-('$IEFI'#'*8-.($'++'-928$<3+0'A$`'-$'-('/$S"8-'(8'($<"+$0'+$:.#8.:'+"8-P'$I'#'*8-.(##8"83#$(-928$@'*"((8A$$E^BV$G$0'+$Ci$S"8-'(8'(B$0-'$'-($I',-0-P$'(8<-9*'&8$2"88'(B$<3+0'($.:'+-'+8A$!"#$/'0-"('$T@'+&'@'($("92$0'+$ *3+"8-P'($ Y:'+"8-.($ 0'#$ I',-0-P#$ @'8+3)$ ^$b.("8'$ 6b-88'&<'+8$ ^B[$b.("8'B$ b-(-/3/$ L$ a.92'(B$b"X-/3/$EJ$b.("8'7A$Z"92$0'+$I',-0-PFY:'+"8-.($'(8<-9*'&8'($C$S"8-'(8'($'-($,<'-8'#$I',-0-PA$Q#$="(0$*'-('$<'-8'+'$>2'+":-'$/'2+$#8"88A$$!"#$/'0-"('$*+"(*2'-8#=+'-'$K(8'+P"&&$("92$'-('+$IDFI'#'*8-.($@'8+3)$^$b.("8'$6b-88'&<'+8n$E\BDJ$b.("8'B$h8"(0"+0"@<'-923()$6h!7n$EJBi$b.("8'7B$("92$'-('+$IEFI'#'*8-.($CD$b.("8'$6b-88'&<'+8n$CDBi$b.("8'B$h!n$ELBi$b.("8'7A$ED$G$0'+$LD$S"8-'(8'(B$@'-$0'('($'-('$IDFI'#'*8-.($'++'-928$<'+0'($*.((8'B$'+2-'&8'($'-('$"0d3P"(8'$>2'+":-'B$<.2-()')'($@'-$0'+$%+3::'$/-8$IEFI'#'*8-.($@'-$JD$G$0'+$S"8-'(8'($'-('$"0d3P"(8'$>2'+":-'$03+92)'=]2+8$<3+0'A$$

JJcLs

?!c?s

<c<s

='.'0($3%..(-().

=T

=!

['9&'%7

Page 51: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CT""

H"!"_"AF E&''.&(.*+07,)('.$.+$(%+,&>.+0"

I3".$$.)?G+)<.6-.#$&'()%&601(.Df16-.6)I1.63F#.')[26),#'-6#--)#')%3/)F3$$#3-#[.),6:63':&'(//-3%#&8)

!)&*38+&C9*5$ R.2&+E$

"&934h-O3.2&$!)&*38+&$ LM^[$6LBV$G7$

R4h-O3.2&$!)&*38+&$ [M^[$6^Bi$G7$

Q8&*32+9.$+.$J-*32+O&*$R,'+()2$ C^M^[$6LJBJ$G7$

Q8&*32+9.$+.$J-*32+O&*$R,'+()2$3E'$&e8E9*32+O&$

K383*9'J98+&$3,/&,*9()&.$^M^[$6VBC$G7$

:&;+4+O$.3()$Q8&*32+9.$ CDM^[$6C[BL$G7$

"

^EB^$G$ 0'+$ -(#)'#"/8$ ED[$S"8-'(8'($ '+2-'&8'($ -/$ 5+"(*2'-8#P'+&"3=$ '-('$ :"&&-"8-P'$ >2'+":-'A$ a-'$ "3#$O@@-&03()$EE$'+#-928&-92B$<"+$0-'$:"&&-"8-P'$>2'+":-'$(3+$@'-$[\B\$G$0'+$#-92$-/$:"&&-"8-P'($5+"(*2'-8##8"0-3/$@'=-(0&-92'($ S"8-'(8'($ 0-'$ :+-/4+'$ >2'+":-'B$ LJBJ$G$ 0-'#'+$ S"8-'(8'()+3::'$ 2"88'($ #-92$ @'+'-8#$ '-('+$.:'+"8-P'($>2'+":-'$/-8$'P'(83'&&$@')&'-8'(0'+$"0d3P"(8'+$3(0M.0'+$('."0d3P"(8'+$>2'+":-'$3(8'+,.)'(A$$^[$ 0'+$ ED[$S"8-'(8'($ '+2-'&8'($ '-('$ :"&&-"8-P'$Q+#8&-(-'(82'+":-'B$<.@'-$ 0-'#'$ @'-$/'2+$ "&#$ 0'+$;4&=8'$0'+$S"8-'(8'($ 6JEBL$G7$ %'/9-8"@-($ @'-(2"&8'8'B$ #.<.2&$ "&#$ b.(.F$ "&#$ "392$ "&#$ 5./@-("8-.(#82'+":-'A$ O&#$5./@-("8-.(#:"+8('+$P.($%'/9-8"@-($<3+0'($YX"&-:&"8-($3(0$1-#:&"8-($P'+<'(0'8A$EiB\$G$'+2-'&8'($'-('$S2.8.82'+":-'B$E\BJ$G$<3+0'($/-8$'-('+$hKI>$@'2"(0'&8A$$

"!""#$%&'()*N+)e".6/#01-)f".6)%#.)".#)%.6)*=)F3$$#3-#[.')I1.63F#.)3'(.H3'%-.')I1.63F#.:2'4.F-.!

$

"

12345

16375

14315

17385

17385

11365

9325

!+"6-&&$-($G'"E9'1-6$'

/'48$(-B$%"j"]O-&$6&-($%

@93(3(9'1-6$'

/'48$(-B$%"j"P$.6&-($%

NQ=E

/'48$(-B$%"S3%3(9'1-6$'

.3%.($*'"E9'1-6$'%

FK[&)313)1-8$&"j"D')83G31$%

Page 52: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

C!""

I3".$$.)?M+)I1.63F#.D268.')*=)F3$$#3-#[.)I1.63F#.)

!)&*38+&C9*5$ R.;3)E$T.U$ I7JE&.$T#&4+3.U$

<&5(+23,+.$ ($w$EE$ L$

<&5(+23,+.$f$L+'8E32+.$ ($w$EL$ \$$

<&5(+23,+.$f$Qe3E+8E32+.$ ($w$EJ$ L$$

Z0=E-9*9-*3(+E$f$K&-(9O9*+.$ ($w$L$ i$

V)9292)&*38+&$ ($w$E\$ $

1M:!$ ($w$EE$ $

$

V8<*+$7*.$W+*;66*:.*8<$06/86<;:*$,%*+5I;*84$1-+7*8$7;*X*8;:*8$,%*+5I;*8$G-65..*8:*>566<=$7;*$X*1*;36$(3+$"($'-('/$.0'+$,<'-$S"8-'(8'($03+92)'=]2+8$<3+0'($F$#-'2'$>"@'&&'$C^A$$

I3".$$.)?V+)Q2'/-#(.),6/-$#'#.'PI1.63F#.D268.')

!)&*38+&C9*5$ R.;3)E$T.U$ I7JE&.$T#&4+3.U$

L7,&*J.+C&2)&*38+&$ ($w$E$ $

L)&59&5,9E+'32+9.$ ($w$C$ $

:34+32+9$ ($w$E$ $

Z0=E-9*9-*3(+E$f$:34+32+9$ ($w$E$ 3(@'*"((8$

=QK=Qgi$K&-(9O9*+.S$Z0=E-9*9-*3(+ES$Qe3E+8E32+.$ ($w$C$ C$

<&5(+23,+.$f$L38&(+23,+.$ ($w$E$ C$

B8+*-,+(+.$f$Qe3E+8E32+.$ ($w$E$ [$

"" "

Page 53: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

C<""

H"!"_"DF E&''.&(.*+0W[+.('.$.+$(%+,&>.+0"

J^BV$G$ 0'+$ #-92$ -/$ :"&&-"8-P'($ 5+"(*2'-8##8"0-3/$ @'=-(0&-92'($ ^[$S"8-'(8'($ '+2-'&8'($ '-('$ :"&&-"8-P'$g<'-8&-(-'(82'+":-'A$`'-$,<'-$S"8-'(8'($<3+0'$0"#$>2'+":-'#92'/"$0'+$EA$:"&&-"8-P'($>2'+":-'$<-'0'+2.&8A$O3#$ =.&)'(0'($ %+](0'($ <3+0'$ @'-$ 0-'#'($ S"8-'(8'($ 0"##'&@'$ >2'+":-'#92'/"$ "&#$ CA$:"&&-"8-P'$ >2'+":-'$)'<'+8'8n$$f"&&$in$`'-$0-'#'/$S"8-'(8'($*"/$'#$03+92$0-'$>2'+":-'$/-8$%'/9-8"@-($3(0$1-#:&"8-($,3$'-('/$I')+'##$0'#$>3/.+#B$ #.0"##$0-'#'+$#'*3(04+$ +'#'*8"@'&$<3+0'A$Z"92$0'+$Y:'+"8-.($*"/$'#$ d'0.92$,3$'-('/$I',-0-PB$<.+"3=$0'+$S"8-'(8$<-'0'+$'-('$:"&&-"8-P'$12'/.82'+":-'$/-8$%'/9-8"@-($3(0$1-#:&"8-($'+2-'&8A$!-'#'$<3+0'$"&#$,<'-8'$:"&&-"8-P'$>2'+":-'$)'<'+8'8A$$f"&&$Ein$g<-#92'($'+#8'+$3(0$,<'-8'+$:2.8.82'+":'38-#92'+$̀ '2"(0&3()$P'+)-()$'-($g'-8+"3/$P.($EB^J$N"2+'(B$"&&'+0-()#$<"+$,<-#92'(,'-8&-92$*'-($S+.)+'##$'+="##@"+A$$Q-($ S"8-'(8$ '+2-'&8$ '-('$ 3(@'*"((8'$ :"&&-"8-P'$ g<'-8&-(-'(82'+":-'$ 3(0$ <3+0'$ @'-$ 0'+$ O("&c#'$ 0'+$>2'+":-'#92'/"8"$(-928$@'"928'8A$$

!"

!""#$%&'()*A+)e".6/#01-)f".6)%#.)".#)%.6)?=)F3$$#3-#[.')I1.63F#.)3'(.H3'%-.')I1.63F#.:2'4.F-.)

" "

123:5

11325

7365

173952385

7365

7365

7365

11325

17395

<+"6-&&$-($G'"E9'1-6$'

/'48$(-B$%"S3%3(9'1-6$'

/'48$(-B$%"j"P$.6&-($%

P-6'8$(-B$%"Yo'&37-Z

/'48$(-B$%"j"]O-&$6&-($%

NQ=E

PXB'10%$>'

@93(3(9'1-6$'

[]D[]o`"D')83G31$%c"FK[&)313)1-8$&"j"]O-&$6&-($%

[]D[Q=Q "̀FK[&)313)1-8$&c"D')83G31$%c"Q1$%3('8-%

-%7'1'

Page 54: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

C?""

a-'$#92.($@'-$0'+$EA$:"&&-"8-P'($>2'+":-'$@"#-'+8'$'-($%+.R8'-&$0'+$>2'+":-'#92'/"8"$"3=$%'/9-8"@-(B$#.<.2&$"&#$b.(.F$"&#$"392$"&#$5./@-("8-.(#82'+":-'$6\JBC$G7A$Q#$<3+0'($<-'0'+3/$1-#:&"8-($3(0$YX"&-:&"8-($"&#$5./@-("8-.(#:"+8('+$P'+<'(0'8A$a'-8'+'$"()'<"(08'$>2'+":-'(n$#-'2'$>"@'&&'$CiA$

I3".$$.)?W+)I1.63F#.D268.')?=)F3$$#3-#[.)I1.63F#.)

!)&*38+&C9*5$ R.;3)E$T.U$ I7JE&.$T#&4+3.U$

<&5(+23,+.$$ ($w$i$ ^$

<&5(+23,+.$f$Qe3E+8E32+.$ ($w$[$$ E$

<&5(+23,+.$f$L+'8E32+.$ ($w$J$$ E$

=QK=M:M$TZ0=DS$=9E+.'X-*&S$M*+.92&(3.U$ ($w$J$$ \$

1M:!$ ($w$\$$ $

$$K/$f.&)'(0'($ #-(0$0-'$>2'+":-'($ "3=)',42&8B$ 0-'$ "($EFC$S"8-'(8'($ "()'<"(08$<3+0'($!$#-'2'$>"@'&&'$ CVA$9;*7*+-.$1-+7*8$-8<*+$7*.$W+*;66*:.*8<$06/86<;:*$,%*+5I;*84$7;*X*8;:*8$,3#"//'()'="##8B$0-'$(3+$@'-$'-('/$S"8-'(8'($"()'<"(08$<3+0'(A$

I3".$$.)?X+)Q2'/-#(.)cH.#-$#'#.'PI1.63F#.D268.')

!)&*38+&$ R.;3)E$T.U$ I7JE&.$T#&4+3.U$

L38&(+23,+.$ ($w$C$$ _(@'*"((8$

L7,&*J.+C&$ ($w$C$$ $

V)9292)&*38+&$ ($w$C$ $

L+'8E32+.$f$>9e9*-,+(+.$ ($w$E$$ \$

Z0=E-9*9-*3(+E$f$%&O3(+;-53,$ ($w$E$$ J$

Z0=E-9*9-*3(+E$f$%&'2*3)E-./$ ($w$E$$ C$

=QK=Qg$TZ0=E-9*9-*3(+ES$K&-(9O9*+.S$

Qe3E+8E32+.U$($w$C$$ E$

Z0=E-9*9-*3(+E$ ($w$E$ C^$

<&5(+23,+.$f$L3*,98E32+.$ ($w$E$$ L$

%&O3(+;-53,$f$=QK=M:M$ ($w$E$$ EE$

"

Page 55: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CC""

H"!"_"HF E&''.&(.*+08,.(('.$.+$(%+,&>.+0"

!!""#$%&'()*G+)e".6/#01-)f".6)%#.)".#)%.6)N=)F3$$#3-#[.')I1.63F#.)3'(.H3'%-.')I1.63F#.:2'4.F-.))

$$C^B[$G$ 0'+$ #-92$ -/$ :"&&-"8-P'($ 5+"(*2'-8##8"0-3/$ @'=-(0&-92'($ S"8-'(8'($ '+2-'&8'($ '-('$ :"&&-"8-P'$!+-88&-(-'(82'+":-'A$Q-($%+.R8'-&$0'+$S"8-'(8'($6\CBV$G7$<3+0'$<-'0'+$/-8$'-('+$"3=$%'/9-8"@-($@"#-'+'(0'($>2'+":-'$@'2"(0'&8B$#.<.2&$"&#$b.(.82'+":-'$ 6CLBi$G7$"&#$"392$ -($5./@-("8-.($/-8$YX"&-:&"8-($ 6EVBE$G7$.0'+$h.+"='(-@$6\Bi$G7A$N'<'-&#$,<'-$S"8-'(8'($6VBJ$G7$'+2-'&8'($'-('$>2'+":-'$/-8$YX"&-:&"8-(B$JFf&3.+.3+"9-&$.0'+$0-'$5./@-("8-.($"3#$JFf&3.+.3+"9-&B$%'/9-8"@-($3(0$`'#8+"2&3()A$hKI>B$S2.8.82'+":-'B$1c@'+*(-='$3(0$ 0-'$ >2'+":-'$ ("92$ 0'/$ fY?fYoF$ .0'+$ fY?fKIKFh92'/"$<3+0'($ d'<'-&#$ "($ (3+$ '-('/$ S"8-'(8'($"()'<"(08$!$#-'2'$>"@'&&'$LDA$

I3".$$.)N@+)I1.63F#.D268.')N=)F3$$#3-#[.)I1.63F#.)

!)&*38+&C9*5$ R.;3)E$T.U$ I7JE&.$T#&4+3.U$

<&5(+23,+.$$ ($w$J$ EBJ$

<&5(+23,+.$f$Qe3E+8E32+.$ ($w$\$ ECBJ$

<&5(+23,+.$f$19*3C&.+,$ ($w$E$ 3(@'*"((8$

Qe3E+8E32+.$ ($w$C$ CBJ$

Z0=E-9*9-*3(+E$ ($w$C$ CBJ$

Z0=D$f$<&5(+23,+.$f$%&'2*3)E-./$ ($w$C$ 3(@'*"((8$

0 "

;9365

123:5

736573657365

7365

7365

7365

2385

2385

2385

?+"6-&&$-($G'"E9'1-6$'

/'48$(-B$%"S3%3(9'1-6$'

/'48$(-B$%"j"]O-&$6&-($%

NQ=E

PXB'10%$>'

@93(3(9'1-6$'

/'48$(-B$%"j"N31->'%$B

[]D[]o`"D')83G31$%c"FK[&)313)1-8$&"j"]O-&$6&-($%

[]D[Q=Q "̀FK[&)313)1-8$&c"D')83G31$%c"Q1$%3('8-%

FK[&)313)1-8$&

]O-&$6&-($%

FK[&)313)1-8$&"j"/'48$(-B$%"j"A'.(1-9&)%*

Page 56: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CF""

1M:!$ ($w$E$ $

V)9292)&*38+&$ ($w$E$ $

L7,&*J.+C&$ ($w$E$ $

=QK=Qg$TZ0=E-9*9-*3(+ES$K&-(9O9*+.S$Qe3E+8E32+.U$ ($w$E$ ^$

=QK=M:M$TZ0=E-9*9-*3(+ES$K&-(9O9*+.S$M*+.92&(3.U$ ($w$E$ 3(@'*"((8$

$

$ $

Page 57: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CJ""

H"!"_"LF E&''.&(.*+0^.+,(K02.)03/%('.$.+$(%+,&>.+0"

EiB\$G$ 0'+$ S"8-'(8'(B$ 0-'$ -($ '-($ :"&&-"8-P'#$ Q+*+"(*3()##8"0-3/$ '-(8+"8'(B$ '+2-'&8'($ '-('$ :"&&-"8-P'$e-'+8&-(-'(82'+":-'A$ !"P.($ '+2-'&8'($ 0+'-$S"8-'(8'($ 6CEB\$G7$ d'<'-&#$ '-('($ gc*&3#$ '-('+$ >2'+":-'$ /-8$%'/9-8"@-(A$ a'-8'+'$ 0+'-$S"8-'(8'($ '+2-'&8'($ o'&.0"$ 61":'9-8"@-(7A$ N'<'-&#$ ,<'-$S"8-'(8'($ 6E\BL$G7$3(8'+,.)'($ #-92$ '-('+$>2'+":-'$/-8$%'/9-8"@-($ 3(0$YX"&-:&"8-($ 6/'0-"('$gc*&3#"(,"2&n$ JW$b-(-/3/n$ LW$b"X-/3/n$ ^7$ .0'+$ '-('+$>2'+":-'$/-8$ 0'/$fY?fYoFh92'/"$ 6/'0-"('$gc*&3#"(,"2&$ EBJW$b-(-/3/n$ EW$b"X-/3/n$ C7A$a'-8'+'$ d'<'-&#$ (3+$ @'-$ '-('/$ S"8-'(8'($ 6^BE$G7$ "()'<"(08'$>2'+":-'*.(,':8'$<"+'($ 0-'$5./@-("8-.($%'/9-8"@-($l$1-#:&"8-($.0'+$K+-(.8'9"($l$1'83X-/"@B$'-('$hKI>$.0'+$'-('$`'2"(0&3()$/-8$0'/$fY?fKIKFh92'/"$!$#-'2'$>"@'&&'$LEA$$

I3".$$.)N*+)I1.63F#.D268.')A=)F3$$#3-#[.)I1.63F#.)

!)&*38+&C9*5$ R.;3)E$T.U$ I7JE&.$T#&4+3.U$

<&5(+23,+.$$ ($w$L$ E$

L38&(+23,+.$Tg&E943U$ ($w$L$ L$

<&5(+23,+.$f$Qe3E+8E32+.$ ($w$C$ J$

=QK=Qg$ ($w$C$ EBJ$

<&5(+23,+.$f$L+'8E32+.$ ($w$E$ C$

1M:!$ ($w$E$ $

M*+.92&(3.$f$L&2-e+53,$ ($w$E$ _(@'*"((8$

=QK=M:M$ ($w$E$ E$

$

Page 58: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CL""

h'92#$6^BV$G7$S"8-'(8'($'+2-'&8'($'-('$f](=8&-(-'(82'+":-'B$P-'+$6JBL$G7$'-('$h'92#8&-(-'(82'+":-'B$,<'-$6CB[$G7$'-('$h-'@8&-(-'(82'+":-'$3(0$'-($S"8-'(8$#92&-'R&-92$'-('$O928&-(-'(82'+":-'$6EBL$G7A$$!'+$ T@'+#-928$ 2"&@'+$ <3+0'($ 0-'$ =]+$ 0-'$ JAFiA$ :"&&-"8-P'$ >2'+":-'$ "()'<"(08'($ >2'+":-'+')-/'$ -($ '-('+$>"@'&&'$0"+)'#8'&&8$!$#-'2'$>"@'&&'$LCA$$

I3".$$.)N?+)<.6-.#$&'()%.6)G=PW=)9#'#.'-1.63F#.)

!)&*38+&$ R.;3)E$ I7JE&.$T#&4+3.U$

Z[$83EE+32+O&$!)&*38+&$

$

%'/9-8"@-($l$1'83X-/"@$I"0-.92'/.82'+":-'$/-8$%'/9-8"@-($l$1-#:&"8-($1":'9-8"@-($JFf&3.+.3+"9-&$1'83X-/"@$1c@'+*(-='$

($w$[$$$($w$E$$($w$E$$($w$E$$($w$E$$($w$E$$($w$E$$

$$[$3(@'*"((8$3(@'*"((8$EC$_(@'*"((8$$

^[83EE+32+O&$!)&*38+&$

$%'/9-8"@-($l$1-#:&"8-($%'/9-8"@-($l$`'P"9-,3/"@$S2.8.82'+":-'$

($w$L$$$($w$E$$($w$E$$($w$E$$

$$\$L$$

j[$83EE+32+O&$!)&*38+&$

$%'/9-8"@-($$`'P"9-,3/"@$

($w$C$$$($w$E$$($w$E$$

$$\$E$

`[83EE+32+O&$!)&*38+&$

$fY?fKIK$l$1'83X-/"@$

($w$E$$$($w$E$

$$\$

"

Page 59: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CR""

H"!"`F \*+,&''0N5,*.*&'0"

`-#$,3/$O@#92&3##$0'+$!"8'('+2'@3()$6EJADLACDE[7$<"+'($^[B\$G$0'+$ED[$S"8-'(8'($P'+#8.+@'(B$@'-$EiBV$G$0'+$S"8-'(8'($<"+$0'+$5+"(*2'-8#P'+&"3=$(-928$"@#92&-'R'(0$("92P.&&,-'2@"+B$\B^$G$0'+$S"8-'(8'($<"+'($(.92$"/$?'@'(A$$

"!""#$%&'()*M+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ)%./)(./38-.')72$$.:-#[/);#')K2'3-.'B!

$`'-$'-('/$S"8-'(8'($*.((8'$0"#$!"83/$0'+$Q+#80-")(.#'$(-928$)'*&4+8$<'+0'(B$<./-8$"392$0-'$Q+/-88&3()$0'+$!"3'+$0'#$`'.@"9283()#,'-8+"3/#$(-928$/H)&-92$<"+A$!"#$/'0-"('$YP'+"&&$h3+P-P"&$0'+$+'#8&-92'($EDJ$S"8-'(8'($"@$0'/$g'-8:3(*8$0'+$Q+#80-")(.#'$@'8+3)$EJ$b.("8'A$

" $

Page 60: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

CM""

H"!"`"!F \*+,&''0N5,*.*&'0.$032%?$6.6:+.(04+,015<;,';:&'.)&(.;$0"

!"#$/'0-"('$YP'+"&&$ h3+P-P"&$ @'8+3)$ @'-$ S"8-'(8'(B$ 0-'$ "($ '-('/$ -(8+"2':"8-#92'($111$ '+*+"(*8$ <"+'(B$EJ$b.("8'B$@'-$0'($"($'-('/$:11O$'+*+"(*8'($S"8-'(8'(B$V$b.("8'B$3(0$@'-$0'($S"8-'(8'(B$@'-$0'('($'-($011O$ 0-")(.#8-,-'+8$ <.+0'($ <"+B$ E^$b.("8'A$ !-'#'+$ _(8'+#92-'0$ ,'-)8'$ #-92$ d'0.92$ #8"8-#8-#92$ (-928$#-)(-=-*"(8$6:$w$DBLCE7A$$

H"!"`"AF \*+,&''0N5,*.*&'0.$032%?$6.6:+.(04+)0=#PPKN(&4.5<)0"

_(8'+#3928$<3+0'$"392B$.@$#-92$d'$("92$_K11Fh8"0-3/$0'#$>3/.+#$_(8'+#92-'0'$-/$Yh$,'-)'(A$O3=)+3(0$0'+$)'+-()'($S"8-'(8'(,"2&'($<3+0'($d'<'-&#$,<'-$P'+)&'-92@"+$)+.R'$%+3::'($)'@-&0'8A$K/$;-(@&-9*$"3=$0"#$-(8+"2':"8-#92'$%"&&'()"()#*"+,-(./$ ,'-)8'$ #-92$ '-($ #-)(-=-*"(8$ *]+,'+'#$/'0-"('#$YhB$<'(($ 0'+$>3/.+$@'+'-8#$0"#$h8"0-3/$Ke@$("92$_K11$'++'-928$2"88'$6[$b.("8'$P#A$CE$b.("8'W$:$w$DBDD\7$!$#-'2'$O@@-&03()$E^A$`'8+"928'8'$/"($0-'$@'-0'($"(0'+'($?.*"&-#"8-.('($6'X8+"2':"8-#92$.0'+$:'+-2-&4+7B$<"+$0'+$_(8'+#92-'0$(-928$#-)(-=-*"(8$!$#-'2'$O@@-&03()$Ei$3(0$O@@-&03()$EVA$

$

"!""#$%&'()*V+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)3"15'(#()[28)TUSSPQ-3%#&8)Df6)%3/)#SS!);TUSSPQ-3%#&8)U>)UU>)UUU>)

U<3)[/=)TUSSPQ-3%#&8)U<"B!

!

Page 61: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FT""

""

"!""#$%&'()*W+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)3"15'(#()[28)TUSSPQ-3%#&8)Df6)%3/)FSS!);TUSSPQ-3%#&8)@>)U>)

UU>)UUU3)[/=)TUSSPQ-3%#&8)UUU">)U<3>)U<"B!

!

"!""#$%&'()*X+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)3"15'(#()[28)TUSSPQ-3%#&8)Df6)%3/)%SS!);TUSSPQ-3%#&8)@>)U3>)

U")[/=)TUSSPQ-3%#&8)UU3>)UU">)UUU>)U<B!

!

$

Page 62: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

F!""

H"!"`"DF \*+,&''0N5,*.*&'0.$032%?$6.6:+.(0+.$+,0;>+,&(.*+$01%+,&>.+0"

a3+0'$@'-$0'($S"8-'(8'($'-('$Y:'+"8-.($-($*3+"8-P'+$O@#-928$03+92)'=]2+8$6($w$\J7$,'-)8'$#-92$'-($#-)(-=-*"(8$&4()'+'#$/'0-"('#$YP'+"&&$h3+P-P"&$6:$w$DBDDE7$P.($EV$b.("8'($-/$e'+)&'-92$,3$0'+$h3@)+3::'B$0-'$*'-('$Y:'+"8-.($-($*3+"8-P'+$O@#-928$'+2"&8'($2"88'$6($w$[DW$/'0-"('#$Yhn$V$b.("8'7A$`'-$'-('/$S"8-'(8'($*.((8'$0"#$Yh$(-928$@'+'92('8$<'+0'(B$0"$0'+$g'-8:3(*8$0'+$Q+#80-")(.#'$3(@'*"((8$<"+A$Z"92$O3=8+'8'($'-('#$I',-0-P#$ &'@8'($0-'$S"8-'(8'($ -/$b'0-"($(.92$^$b.("8'A$S"8-'(8'(B$0-'$'-('$('."0d3P"(8'$>2'+":-'$.0'+$"0d3P"(8'$>2'+":-'$'+2"&8'($2"88'(B$,'-)8'($*'-($#-)(-=-*"(8$&4()'+'#$YP'+"&&$h3+P-P"&$"&#$0-'$S"8-'(8'(B$0-'$(3+$ '-('$ *3+"8-P'$ Y:'+"8-.($ '+2"&8'($ 2"88'($ 6/'0-"('#$ Yhn$ CL$b.("8'$ @'-$ ('."0d3P"(8'+$ >2'+":-'B$CJ$b.("8'$ @'-$ "0d3P"(8'+$ >2'+":-'B$ E[$b.("8'$ @'-$ S"8-'(8'(B$ 0-'$ <'0'+$ '-('$ "0d3P"(8'$ (.92$ '-('$('."0d3P"(8'$>2'+":-'$'+2"&8'($2"88'(7A$

"!""#$%&'()?@+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%#.)C&601Df16&'().#'.6)gF.63-#2')#'):&63-#[.6)

!"/#01-);')k)*@G_)gQ+)*X)K2'3-.)[/=)X)K2'3-._)F)k)@>@@*B!

!O($0-'#'+$h8'&&'$<3+0'$0'+$Q-(=&3##$'-('+$('."0d3P"(8'($.0'+$"0d3P"(8'($>2'+":-'$3(8'+#3928A$S"8-'(8'(B$0-'$'-('$ ('."0d3P"(8'$ >2'+":-'$ '+2"&8'($ 2"88'($ 6($w$^7B$ ,'-)8'($ '-($ &4()'+'#$ /'0-"('#$ YP'+"&&$ h3+P-P"&$ -/$e'+)&'-92$/-8$Y:'+-'+8'($.2('$('."0d3P"(8'$>2'+":-'$6($w$Li7$6LD$b.("8'$P#A$Ei$b.("8'7A$!-'#'$>'(0'(,$,'-)8'$#-92$#8"8-#8-#92$(-928$#-)(-=-*"(8$6:$w$DBC[V7A$$O392$ 0-'$`'2"(0&3()$/-8$ '-('+$ "0d3P"(8'($>2'+":-'$ ("92$ '-('+$Y:'+"8-.($ -($ *3+"8-P'+$O@#-928$ 6($w$EE7$#92-'($ #-92$:.#-8-P$ "3=$0"#$/'0-"('$Yh$ "3#,3<-+*'(B$ "&&'+0-()#$ ,'-)8'$ #-92$ "392$2-'+$0'+$_(8'+#92-'0$ -/$;-(@&-9*$"3=$0-'$e'+)&'-92#)+3::'$6($w$L\7$(-928$#-)(-=-*"(8$6C^$b.("8'$P#A$E[BJ$b.("8'W$:$w$DBLL7A$$

Page 63: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

F<""

H"!"`"HF \*+,&''0N5,*.*&'0.$032%?$6.6:+.(04+)0&$6+[&$4(+$0>&''.&(.*+$01%+,&>.+:;$-+>(+)0"

`'-$^J$0'+$^[$S"8-'(8'(B$0-'$#-92$-/$5+"(*2'-8#P'+&"3=$'-('+$:"&&-"8-P'($`'2"(0&3()$3(8'+,.)'($2"88'(B$<"+$0"#$ EA$ :"&&-"8-P'$ >2'+":-'+')-/'$ @'*"((8A$ EE$S"8-'(8'($ <3+0'($ /-8$ %'/9-8"@-(B$ C^$ /-8$ %'/9-8"@-($ -($5./@-("8-.($ /-8$ '-('/$ S&"8-(0'+-P"8$ @'2"(0'&8A$ g<-#92'($ 0-'#'($ @'-0'($ %+3::'($ ,'-)8'$ #-92$ '-($_(8'+#92-'0$ -/$h9248,'+$0'#$/'0-"('($YhB$0-'#'+$<"+$"&&'+0-()#$#8"8-#8-#92$(-928$#-)(-=-*"(8$6%'/9-8"@-(n$E^$b.("8'$P#A$%'/9-8"@-($l$S&"8-(0'+-P"8n$ i$b.("8'W$ :$w$DB\EV7A$ K($ '-('/$ (492#8'($ h92+-88$ <3+0'($ "&&'$S"8-'(8'(B$ 0-'$ /-8$ '-('+$ >2'+":-'$ @'2"(0'&8$ <3+0'($ 0-'$ %'/9-8"@-($ '(82-'&8B$ -($ '-('+$ %+3::'$,3#"//'()'="##8$ 6($w$Li7$ 3(0$/-8$ 0'($S"8-'(8'($ P'+)&-92'(B$ 0'+'($ EA$ :"&&-"8-P'$>2'+":-'$ '-('$ hKI>$<"+$6($w$EE7A$!"#$Q+)'@(-#$'+)"@$'-($#-)(-=-*"(8$&4()'+'#$YP'+"&&$h3+P-P"&$@'-$0'+$S"8-'(8'()+3::'B$0-'$'-('$hKI>$'+2"&8'($2"88'$6CV$P#A$EE$b.("8'W$:$w$DBDEi7A$

!

"!""#$%&'()?*+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)3"15'(#()[2')%.6)*=)F3$$#3-#[.')I1.63F#.);1#.6)Y.80#-3"#')

.'-13$-.'%.)I1.63F#.:2'4.F-.)[/=)QUbIB!

$\\$0'+$^[$#-92$-/$:"&&-"8-P'($Q+*+"(*3()##8"0-3/$@'=-(0&-92'($S"8-'(8'($'+2-'&8'($'-('$g<'-8&-(-'(82'+":-'A$O3=)+3(0$0'+$O(<'(03()$P.($EJ$P'+#92-'0'('($>2'+":-'#92'/"8"$<3+0'($(3+$0-'d'(-)'($@'"928'8B$0-'$"/$243=-)#8'($"()'<"(08$<3+0'($!$#-'2'$>"@'&&'$LLA$$

I3".$$.)NN+)C#.)[#.6)38)15&D#(/-.')3'(.H3'%-.')I1.63F#.:2'4.F-.)".#)%.6)cH.#-$#'#.'-1.63F#.))

!)&*38+&$ R.;3)E$T.U$ #&4+3.&'$Q1$T+.$#9.32&.U$

<&5(+23,+.$ ($w$i$6EiBC$G7$ \DBJ$$

<&5(+23,+.$f$L+'8E32+.?Qe3E+8E32+.$ ($w$EE$6CJ$G7$ Ci$

1M:!$ ($w$C$6\Bi$G7$ LV$

=QK=M:M$ ($w$J$6EEB\$G7$ i$

$

Page 64: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

F?""

K($ 0'+$ 5":&"(Fb'-'+FO("&c#'$ ,'-)8'$ #-92$ (3+$ ,<-#92'($ 0'+$ S"8-'(8'()+3::'B$ 0-'$ /-8$ 0'+$ 5./@-("8-.($%'/9-8"@-($l$S&"8-(0'+-P"8$ 3(0$ d'('+B$ 0-'$ /-8$ 0'/$ fY?fKIKFh92'/"$ @'2"(0'&8$ <.+0'($ <"+B$ '-($#-)(-=-*"(8'+$_(8'+#92-'0$-/$Yh$6:$w$DBDD\7A$`'-/$e'+)&'-92$0'+$"(0'+'($`'2"(0&3()#)+3::'($'+)"@$#-92$*'-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ -/$ /'0-"('($ Yh$ 6%'/9-8"@-($l$S&"8-(0'+-P"8$P#A$hKI>W$%'/9-8"@-($P#A$fY?fKIKW$hKI>$P#A$fY?fKIK7$!$#-'2'$O@@-&03()$CCA$$

"!""#$%&'()??+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%#.)?=)F3$$#3-#[.)I1.63F#.);Y.80#-3"#')[/=)

Y.80#-3"#')l)d$3-#'%.6#[3-)[/=)Og9OUbU)[/=)QUbIB!

" "

Page 65: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FC""

H"!"aF E,;6,+)).;$0Z,++0N5,*.*&'0"

`'-$\[BC$G$0'+$S"8-'(8'($0'#$5.&&'*8-P#$*.((8'$'-($S+.)+'##$)'/4R$0'($IQ1Kh>F5+-8'+-'($6#-'2'$O(2"()7$='#8)'#8'&&8$<'+0'($ 6Q-#'(2"3'+$ '8$ "&AB$ CDDV7A$`'-$ VJBV$G$0'+$S"8-'(8'($/-8$ '-('/$S+.)+'##$<"+$ "392$ 0'+$g'-8:3(*8$ @'*"((8A$ Q#$ '+)"@$ #-92$ '-($ /'0-"('#$ Sfh$ P.($ ^$b.("8'($ 6b-(-/3/n$ D$b.("8'W$ b"X-/3/n$\i$b.("8'7A$ K($ `',3)$ "3=$ 0"#$ Sfh$ *.((8'$ '-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ ,<-#92'($ 0'($ '-(,'&('($?.*"&-#"8-.('($='#8)'#8'&&8$<'+0'($6:$w$DBDD\7A$!"#$/'0-"('$Sfh$*.((8'$/-8$i$b.("8'($=]+$0"#$-11OB$/-8$LBJ$b.("8'($=]+$0"#$:11O$3(0$/-8$ECBJ$b.("8'($=]+$0"#$011O$@'+'92('8$<'+0'(A$$

"!""#$%&'()?N+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)dOQ)#')L.4&()3&D)%#.)92:3$#/3-#2')

"

Page 66: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FF""

H"AF 3$&'Y)+0>,;6$;)(.)/%+,0Z&:(;,+$0-5<0W+.(>5$:(04+,07,)(4.&6$;)+0.$0F+-560&5C0\*+,&''0N5,*.*&'05$40E,;6,+)).;$0Z,++0N5,*.*&'0

H"A"!F =$.*&,.&(+0P;OKB+6,+)).;$)&$&'Y)+0"

I3".$$.)NA+)T'#[36#3-.)!'3$E/.)F62('2/-#/01.6)O3:-26.')4&8)c.#-F&':-)%.6),6/-%#3('2/.)#')L.4&()3&D)%3/)gQ>)/26-#.6-)'301)FP`.6-)

P3*+3,E&$ .$Q1$

T#&4+3.US$#9.32&$8$ N3;3*4$*32+9$

>3/.+#8"0-3/$$E9J3E$C9*2/&'()*+22&.$

5&23'23'+&*2$

$\^$\V$

$CE$^$

$\S\\Y$

$DB\\V$6DBC^i$!$DB^CL7$E$

1QO$a$@SZ$./?5E$

$$@SZ$./?5E$$

E9/$kLBRl$$

$[^$Li$$EDJ$

Ei$[$$

$\S\\Y$

$

$

a$\S\\Y$

$DB\Ji$6DBCi[$!$DB^L\7$E$$EB\^J$6EBCC[$!$EB^^J7$

1QO$6S"8-'(8'($/-8$'-('/$`-&-+3@-(Fa'+8$P.($$$x$EBJ$/)M0&$"3#)'#92&.##'(7$a$@SZ$./?5E$

$$@SZ$./?5E$

$$$\[$CC$

$$$Ei$JBJ$

$$$a$\S\\Y$

$$$DBLEC$6DBE[C$!$DB[DE7$E$

1OEVFV$a$Y\\\$D?5E$

$$Y\\\$D?5E$$

E9/$kLRYm0ml$

$iL$CC$$EDJ$

$E^$JBJ$$$

$\S\\Y$

$

$

a$\S\\Y$

$DBLi\$6DBCCC$!$DB[[\7$E$$EBCJC$6EBEEi$!$EB\DE7$

1OEVFV$6S"8-'(8'($/-8$'-('/$`-&-+3@-(Fa'+8$P.($$$x$EBJ$/)M0&$"3#)'#92&.##'(7$a$Y\\\$D?5E$

$$Y\\\$D?5E$

$$$JE$EL$

$$$E[$J$

$$$\S\\A$

$$$DBLJE$6DBE^[$!$DB[VV7$E$

f'+(/'8"#8"#-'+3()$$J&+.&$=&*.5&23'23'+&*-./$

=&*.5&23'23'+&*-./$

$^D$LJ$

$E^$J$

$\S\\@$

$DBJ$6DBLEE$!$DBiDJ7$E$

;@$a$YA$/?4E$

$$YA$/?4E$$

E9/$kN,l$

$JE$J\$$EDJ$

i$EVBJ$$

$\S\\@$

$

$

\S\\@$

$EBV[L$6EBC\L$!$LBDVi7$E$$DBDVV$6DBDCE$!$DB\^[7$

>Fh8"0-3/$("92$>Zb$!Y$f$!]$

!A$f$!@$

$^L$LL$

$E[BJ$V$

$\S\]A$

$DBJ^J$6DBLJ^$!$DBVC^7$E$

1IS$a$Y$5/?4E$$$Y$5/?4E$$

E9/$kL:Vl$

$\J$[D$$EDJ$

E^$V$$

$DBDJV$$$DBLJE$

$DB[\V$6DB\E\$!$EBDE^7$E$$EBD^E$6DBVC^$!$EBCL^7$

0 "

Page 67: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FJ""

O&8'+$a$^^$

$$^^$

$J\$JE$

$EJBJ$EE$

$DBD[$

$DB[JL$6DB\EV$!$EBDEi7$E$

%+"0-()$<Y$f$<]$

<A$f$<@$

$\L$JJ$

$E[$i$

$DBE\C$

$DB^DL$6DB\\$!$EBECJ7$E$

?'3*.,c8'($a$YY$<?E$

$$YY$<?E$$

E9/$kK&-J9;72&.l$

$iE$C\$$EDJ$

E[$EC$$

$DBJDV$$$DBL^E$

$DBi\J$E$$EBEVi$6DBiD[$!$EB^iD7$

>2+./@.,c8'($a$]ZA$<?E$

$$]ZA$<?E$$

E9/$k!)*95,9;72&.l$

$JC$JL$$EDJ$

EE$E[$$

$DB\LL$$$DB[iC$

$EBEVC$E$$DBVDL$6DBJJ\$!$EB\^C7$

?c/:2*(.8'(@'="&&$6&+.$K758)J.92&.,&C3EE$

K758)J.92&.,&C3EE$

$\i$JD$

$E\$E[$

$DB\J^$$

$DBi\C$6DBJLJ$!$EBLCJ7$E$

%'#92&'928$5X..E+()$

H&+,E+()$

$[D$\J$

$ED$EJ$

$DB\VD$

$EBE^C$6DB^\^$!$EBiLV7$E$

?!;$a$]Z\$D?E$

$$]Z\$D?E$$

E9/$kK>Nl$

$[J$\D$$EDJ$

V$E[BJ$$

$DB^Ei$$$DB\VL$

$DBVCE$6DBJVE$!$EB\L^7$E$$EBELD$6DB^V[$!$EB[D[7$

`-&-+3@-($a$Y$5/?4E$

$$Y$5/?4E$$

E9/$k%+E+*-,+.l$

$J\$JE$$EDJ$

$EC$E[$$$

$DB^CL$$$DB[C^$

$DBVCL$6DBJV\$!$EB\LJ7$E$$EBD\[$6DBi^L$!$EBCJC7$

`bK$%#M$a$A\$J/?5_$

%#M$$$A\$J/?5_$

$i[$Ei$

$EC$Ei$

$DBVLJ$

$EBDCJ$6DBJ[\$!$EBi[\7$E$

!!" "

Page 68: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FL""

I3".$$.)NG+)T'#[36#3-.)!'3$E/.)F62('2/-#/01.6)O3:-26.')#')L.4&()3&D)%3/)dOQ>)/26-#.6-)'301)FP`.6-)

P3*+3,E&$ .$V=1$

T#&4+3.US$#9.32&$8$ N3;3*4$*32+9$

1OEVFV$a$Y\\\$D?5E$

$$Y\\\$D?5E$$

E9/$kLRYm0ml$

$iL$CC$$EDJ$

V$\$$ $

$\S\\Y$

$

$

\S\\Z$

$DBLEJ$6DBE[E$!$DB[E^7$E$$EBCCE$6EBD[\$!$EB\DC7$

f'+(/'8"#8"#-'+3()$$J&+.&$=&*.5&23'23'+&*-./$

=&*.5&23'23'+&*-./$

$^D$LJ$

$VBJ$L$

$$a$\S\\Y$

$DBCJ^$6DBEL^$!$DB\iC7$E$

1QO$a$@SZ$./?5E$

$$@SZ$./?5E$$

E9/$kLBRl$

$[^$Li$$EDJ$

\$\$$

$\S\]A$

$

$

DBE[^$

$DB\VL$6DBC[i$!$DBVDV7$E$$EBEiE$6DBVLL$!$EB\V\7$

>3/.+#8"0-3/$E9J3E$C9*2/&'()*+22&.$

5&23'23'+&*2$$

$\^$\V$

$V$\$

$\S\]m$

$DBJEi$6DBCi^$!$DBVLJ7$E$

?!;$a$]Z\$D?E$

$$]Z\$D?E$$

E9/$kK>Nl$

$[J$\D$$EDJ$

\BJ$^$$

$DB\i[$$$DBDiD$

$DBiE[$6DB\[E$!$EB\\J7$E$$EB^JC$6DBVL[$!$LBC^V7$

1QO$TV32+&.2&.$5+2$&+.&5$%+E+*-,+.0d&*2$b$YSZ$5/?4E$

3-'/&'()E9''&.U$

a$@SZ$./?5E$

$$@SZ$./?5E$

$$$$\[$CC$

$$$$VBJ$L$

$$$$DBEE\$

$$$$DBJEL$6DBCC\$!$EBE^\7$E$

1OEVFV$TV32+&.2&.$5+2$&+.&5$%+E+*-,+.0d&*2$

O9.$$$b$YSZ$5/?4E$

3-'/&'()E9''&.U$

a$Y\\\$D?5E$

$$Y\\\$D?5E$

$$$$JL$EJ$

$$$$i$\$

$$$$DBDi[$

$$$$DB\[\$6DBEVL$!$EBEEJ7$E$

>2+./@.,c8'($a$]ZA$<?E$

$$]ZA$<?E$$

E9/$k!)*95,9;72&.l$

$JC$JL$$EDJ$

^$^$$

$DBiiL$$$DBCEL$

$EBD\\$6DBJVE$!$EBi\\7$E$$DB[V[$6DBLVL$!$EBCLC7$

1IS$a$Y$5/?4E$

$$Y$5/?4E$$

E9/$kL:Vl$

$\J$[D$$EDJ$

V$\BJ$$

$DBC^V$$$DBV^^$

$DB^CV$6DB\EE$!$EBCVC7$E$$EBDDL$6DBiLL$!$EBCD^7$

0 "

Page 69: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FR""

;@$a$YA$/?4E$

$$YA$/?4E$$

E9/$kN,l$

$JE$J\$$EDJ$

^$V$$

$DBLLV$$$DB[\\$

$EBLCC$6DB^\[$!$CBL\E7$E$$DB[EC$6DBD^[$!$\BVED7$

`-&-+3@-($a$Y$5/?4E$

$$Y$5/?4E$$

E9/$k%+E+*-,+.l$

$J\$JE$$EDJ$

^$^$$

$DB\E[$$$DBJJD$

$DB^VD$6DB\\i$!$EBLV\7$E$$EBD^D$6DBiJ^$!$EBLL[7$

?'3*.,c8'($a$YY$<?E$

$$YY$<?E$$

E9/$kK&-J9;72&.l$

$iE$C\$$EDJ$

^$^$$

$DB\LJ$$$DB[^V$

$EBLL[$6DB[\[$!$CB^[\7$E$$DBiiE$6DB\iC$!$EB[DV7$

%+"0-()$<Y$f$<]$

<A$f$<@$

$\L$JJ$

$i$[$

$DB\J[$

$DB^VD$6DB\CJ$!$EB\[i7$E$

%'#92&'928$5X..E+()$

H&+,E+()$

$[D$\J$

$^$^$ $

$DB[\E$

$DBi^L$6DB\VC$!$EBJ\i7$E$

O&8'+$a$^^$

$$^^$

$J\$JE$

$^$^$

$DB^JJ$

$EBDV^$6DB[E\$!$EBVJV7$E$

>$!$h8"0-3/$("92$>Zb$!Y$f$!]$

!A$f$!@$

$^C$LL$

$[$^$

$DBi$

$DBVC\$6DB\VV$!$EB^ED7$E$

`bK$%#M$a$A\$J/?5_$

%#M$$$A\$J/?5_$

$i[$Ei$

$^$^$

$DBiVC$

$EBDJ\$6DB\VD$!$CBC^D7$E$

?c/:2*(.8'(@'="&&$6&+.$K758)J.92&.,&C3EE$

K758)J.92&.,&C3EE$

$\i$JD$

$i$^$

$DBVD$

$DBJVL$6DBLC\$!$EBDi\7$E$

!N'<'-&#$E^$P'+#92-'0'('$b'+*/"&'$<3+0'($2-(#-928&-92$-2+'+$:.8'(8-'&&'($>"3)&-92*'-8$"&#$S+.)(.#'="*8.+'($-($`',3)$"3=$0"#$YP'+"&&$h3+P-P"&$6#-'2'$>"@'&&'$L\7$3(0$0-'$g'-8$@-#$,3+$>3/.+:+.)+'##-.($6#-'2'$>"@'&&'$LJ7$3(8'+#3928A$O&#$#8"8-#8-#92$#-)(-=-*"(8$'+<-'#'($#-92$-($0'+$3(-P"+-"8'($1.XFI')+'##-.($-($`',3)$"3=$0"#$Yh$0-'$ @'-0'($ >3/.+/"+*'+$ 1QO$ 3(0$ 1OEVFV$ #.<-'$ 0'+'($ ("8]+&-92'+$ ?.)"+-82/3#$ &.)$z1QO{$ 3(0$&.)$z1OEVFV{B$0"#$>3/.+#8"0-3/$6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+87B$0"#$>3/.+#8"0-3/$("92$0'+$>ZbF5&"##-=-*"8-.(B$ '-('$ '-()'8+'8'('$ f'+(/'8"#8"#-'+3()$ 3(0$ 0'+$;4/.)&.@-(Fa'+8$ #.<-'$ 0'##'($ ("8]+&-92'+$?.)"+-82/3#$ &.)$z;@{A$ K($ 0'+$ 3(-P"+-"8'($ 1.XFI')+'##-.($ /-8$ 0'/$ Q(0:3(*8$ Sfh$ ,'-)8'($ #-92$ 0"#$>3/.+#8"0-3/$6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+87B$0-'$@'-0'($>3/.+/"+*'+$1QO$3(0$1OEVFV$#.<-'$0'+$("8]+&-92'$?.)"+-82/3#$&.)$z1OEVFV{$3(0$'-('$'-()'8+'8'('$f'+(/'8"#8"#-'+3()$#-)(-=-*"(8A$$

" $

Page 70: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

FM""

!"#$>3/.+#8"0-3/$,3$`')-(($0'+$:"&&-"8-P'($>2'+":-'$6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+87$,'-)8'$#-92$"&#$#-)(-=-*"(8'+$ S+.)(.#'/"+*'+$ #.<.2&$ -($ `',3)$ "3=$ 0"#$ YP'+"&&$ h3+P-P"&$ 6CE$P#A$^$b.("8'W$ ;I$DB\\VW$:$w$DBDDE7$!$#-'2'$O@@-&03()$C\$!$"&#$"392$-($`',3)$"3=$0"#$Sfh$6V$P#A$\$b.("8'W$;I$DBJEiW$:$w$DBDCV7$!$#-'2'$O@@-&03()$CJA$$

$

!""#$%&'()?A+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%3/)I&826/-3%#&8)4&)L.(#'')%.6)F3$$#3-#[.')I1.63F#.);$2:3$)D26-(./016#--.')[/=)8.-3/-3/#.6-B)

!

"!""#$%&'()?G+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)dOQ);#')K2'3-.'B)#')L.4&()3&D)%3/)I&826/-3%#&8)4&)L.(#'').#'.6)F3$$#3-#[.')

I1.63F#.);D26-(./016#--.')[/=)8.-3/-3/#.6-B!

!$

Page 71: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JT""

`'="(0$#-92$0'+$>3/.+$@'-$Q+#80-")(.#'$-/$h8"0-3/$>E$.0'+$>C$6>ZbF5&"##-=-*"8-.(7$*.((8'$-/$e'+)&'-92$,3$0'($S"8-'(8'(B$@'-$0'('($#-92$0'+$>3/.+$@'+'-8#$-/$h8"0-3/$>L$.0'+$>\$@'="(0B$'-($#-)(-=-*"(8$&4()'+'#$YP'+"&&$h3+P-P"&$='#8)'#8'&&8$<'+0'($6E[BJ$P#A$V$b.("8'W$;I$DBJ^JW$:$w$DBDCL7$!$#-'2'$O@@-&03()$C[A$$

"!""#$%&'()?M+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%3/)I&826PQ-3%#&8)'301)IJK);I*)l)I?)[/=)IN)l)IAB)

$

Page 72: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

J!""

`'#8"(0$ @'-$ Q+#80-")(.#'$ (.92$ *'-('$ f'+(/'8"#8"#-'+3()B$ *.((8'$ '-($ #-)(-=-*"(8$ &4()'+'#$ Yh$6E^$P#A$J$b.("8'W$;I$DBJW$:$w$DBDD\7$!$#-'2'$O@@-&03()$C^B$"&#$"392$'-('$#-)(-=-*"(8$&4()'+'#$Sfh$='#8)'#8'&&8$<'+0'($6VBJ$P#A$L$b.("8'W$;I$DBCJ^W$:$v$DBDDE7$F$#-'2'$O@@-&03()$CiA$

!

"!""#$%&'()?V+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%3/)O.6'8.-3/-3/#.6&'(//-3%#&8);:.#'.)

O.6'8.-3/-3/#.6&'()[/=)O.6'8.-3/-3/#.6&'().#'(.-6.-.'B!

"

"!""#$%&'()?W+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)dOQ);#')K2'3-.'B)#')L.4&()3&D)%3/)O.6'8.-3/-3/#.6&'(//-3%#&8);:.#'.)

O.6'8.-3/-3/#.6&'()[/=)O.6'8.-3/-3/#.6&'().#'(.-6.-.'B)

"

Page 73: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

J<""

Q-($ 1OEVFVFa'+8$ -/$ `'+'-92$v$EDDD$ _M&$ '+<-'#$ #-92$ "&#$ :.#-8-P'+$ S+.)(.#'="*8.+$ =]+$ 0"#$ Yh$6E^$P#A$JBJ$b.("8'W$ ;I$DBLi\W$ :$w$DBDDE7$F$#-'2'$ O@@-&03()$ CV$F$"&#$ "392$ =]+$ 0"#$ Sfh$ 6V$P#A$\$b.("8'W$;I$DBLEJW$:$w$DBDDE7$F$#-'2'$O@@-&03()$LDA$_(8'+$e'+<'(03()$0'#$("8]+&-92'($?.)"+-82/3#$6&.)$z1OEVFV{7$<3+0'$1OEVFV$"&#$#8'8-)'$e"+-"@&'$-($0-'$I')+'##-.(#"("&c#'$("92$1.X$'-(@',.)'(A$O392$2-'+$'+)"@'($#-92$#.<.2&$=]+$0"#$Yh$6;I$EBCJCW$:$v$DBDDE7$"&#$"392$=]+$0"#$Sfh$6;I$EBCCEW$:$w$DBDDJ7$#-)(-=-*"(8'$a'+8'A$$

"!""#$%&'()?X+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%.')S!*XPXP`.6-);S!*XPX)m)*@@@)Tn8$)[/=)

S!*XPX)!)*@@@)Tn8$B!

$

!""#$%&'()N@+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)dOQ);#')K2'3-.'B)#')L.4&()3&D)%.')S!*XPXP`.6-);S!*XPX)m)*@@@)Tn8$)[/=)S!*XPX)!)*@@@)Tn8$B!

"

Page 74: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

J?""

K($ '-('/$ ,<'-8'($ `'+'92(3()##92+-88$ <3+0'($ (3+$ S"8-'(8'($ '-()'#92&.##'(B$ 0'+'($ `-&-+3@-(Fa'+8$@'-$v$EBJ$/)M0&$&")$6#-'2'$LA\A\7A$a-'$-($O@@-&03()$LE$0"+)'#8'&&8B$,'-)8'$#-92$'-($#-)(-=-*"(8$&4()'+'#$Yh$=]+$0-'$S"8-'(8'()+3::'B$0'+'($1OEVFVFa'+8$@'-$Q+#80-")(.#'$v$EDDD$_M/&$@'8+3)$6E[$P#A$J$b.("8'W$;I$DBC^JW$:$w$DBDDL7A$;-(#-928&-92$0'#$Sfh$*.((8'$(3($*'-($#-)(-=-*"(8'+$_(8'+#92-'0$='#8)'#8'&&8$<'+0'(A$$

"!""#$%&'()N*+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%.')S!*XPXP`.6-);S!*XPX)m)*@@@)Tn8$)[/=)

S!*XPX)!)*@@@)Tn8$B=)d3-#.'-.')8#-).#'.8)L#$#6&"#'P`.6-)!)*>G)8(n%$)H&6%.')3&/(./01$2//.'=!

$

Page 75: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JC""

!'+$@'-$Q+#80-")(.#'$)'/'##'('$1QOFa'+8$'+<-'#$#-92$"&#$#-)(-=-*"(8'+$S+.)(.#'="*8.+$-($`',3)$"3=$0"#$Yh$6Ei$P#A$[$b.("8'W$;I$DB\JiW$:$w$DBDDE7$!$#-'2'$O@@-&03()$LCB$"@'+$"392$-/$;-(@&-9*$"3=$0"#$Sfh$6\$b.("8'B$b'0-"($ =]+$ @'-0'$ %+3::'($ )&'-92W$ ;I$DB\VLW$ :$w$DBDCL7$ !$ #-'2'$ O@@-&03()$ LLA$ O(2"(0$ 0'#$?"@.+FI'='+'(,<'+8'#$\BJ$()M/&$<3+0'$0"#$5.&&'*8-P$ -($,<'-$%+3::'($'-()'8'-&8A$_(8'+$`'8+"9283()$P.($1QO$"&#$*.(8-(3-'+&-92'$e"+-"@&'$6&.)$z1QO{7$,'-)8'$#-92$-/$;-(@&-9*$"3=$0"#$Yh$'-($#-)(-=-*"(8'#$Q+)'@(-#$6;I$EB\^JW$:$v$DBDDE7A$$

"!""#$%&'()N?+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%.')S,!P`.6-);S,!)m)A>G)'(n8$)[/=)

S,!)!)A>G)'(n8$B!

$

!""#$%&'()NN+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)dOQ);#')K2'3-.'B)#')L.4&()3&D)%.')S,!P`.6-);S,!)m)A>G)'(n8$)[/=)S,!)!)A>G)'(n8$B)

Page 76: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JF""

O392$ 2-'+$ <3+0'($ -($ '-('/$ ,<'-8'($ `'+'92(3()##92+-88$ "&&'$ S"8-'(8'($ "3#)'#92&.##'(B$ 0'+'($`-&-+3@-(<'+8$S$EBJ$ /)M0&$ @'8+3)A$ !'+$ _(8'+#92-'0$ -/$ YP'+"&&$ h3+P-P"&$ 6Ei$P#A$JBJ$b.("8'7$ ,'-)8'$ #-92$#-)(-=-*"(8$!$#-'2'$O@@-&03()$L\$B$2-(#-928&-92$0'#$Sfh$*.((8'$*'-('$h-)(-=-*"(,$='#8)'#8'&&8$<'+0'(A$$

"!""#$%&'()NA+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%.')S,!P`.6-);S,!)m)A>G)'(n8$)[/=)

S,!)!)A>G)'(n8$B=)d3-#.'-.')8#-).#'.8)L#$#6&"#'P`.6-)!)*>G)(n%$)H&6%.')3&/(./01$2//.'=)

$

Page 77: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JJ""

g3/$g'-8:3(*8$0'+$Q+#80-")(.#'$<3+0'$"392$0'+$;4/.)&.@-(Fa'+8$@'#8-//8A$O(2"(0$0'#$b'0-"(#$P.($EL$)M0&$ *.((8'$ '-('$ #-((P.&&'$ _(8'+8'-&3()$ -($ ,<'-$ S"8-'(8'()+3::'($ '+=.&)'(A$ Q-($;4/.)&.@-(Fa'+8$v$EL$)M0&$ ,'-)8'$ #-92$ -($ 0'+$ 3(-P"+-"8'($ I')+'##-.(#"("&c#'$ "&#$ #8"8-#8-#92$ #-)(-=-*"(8'+$(')"8-P'+$S+.)(.#'="*8.+$-($`',3)$"3=$0"#$YP'+"&&$h3+P-P"&$6i$P#A$EVBJ$b.("8'W$;I$EBV[LW$:$w$DBDD\7$!#-'2'$O@@-&03()$LJA$N'0.92$,'-)8'$#-92$2-'+$ -/$;-(@&-9*$"3=$0"#$Sfh$*'-('$h-)(-=-*"(,A$_(8'+$e'+<'(03()$0'#$("8]+&-92'($ ?.)"+-82/3#$ <3+0'$ "392$ 0'+$ ;4/.)&.@-(<'+8$ 6&.)$z;@{7$ -($ 0-'$ 3(-P"+-"8'$ 1.Xu#92'$I')+'##-.(#"("&c#'$/-8'-(@',.)'($3(0$,'-)8'$ -($`',3)$ "3=$0"#$Yh$'-($ #-)(-=-*"(8'#$Q+)'@(-#$ 6;I$DBDVVW$:$w$DBDD\7A$

"!""#$%&'()NG+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%.')h582($2"#'P`.6-);h")m)*N)(n%$)[/=)

h")!)*N)(n%$B!

" $

Page 78: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JL""

O(2"(0$0'#$b'0-"(#$P.($[[$N"2+'($<3+0'$0"#$5.&&'*8-P$-($,<'-$#-((P.&&'$S+.)(.#')+3::'($@',])&-92$0'#$Yh$ '-()'8'-&8A$ S"8-'(8'(B$ 0-'$ @'-$ Q+#80-")(.#'$ d]()'+$ "&#$ [[$N"2+'$<"+'(B$ ,'-)8'($ '-('$>'(0'(,$ ,3$ '-('/$&4()'+'($Yh$ -/$ e'+)&'-92$ ,3+$ 4&8'+'($ S"8-'(8'()+3::'$ 6EJBJ$P#A$EE$b.("8'W$ ;I$EBJLEW$ :$w$DBD[7$!$ #-'2'$O@@-&03()$L[A$!-'#'+$>+'(0$<"+$-($0'+$3(-P"+-"8'($I')+'##-.(#"("&c#'$("92$1.X$(-928$#-)(-=-*"(8$6:$w$DBDJC7A$$

$

!""#$%&'()NM+)73F$3'PK.#.6PQ015-4.6)Df6)%3/)gQ);#')K2'3-.'B)#')L.4&()3&D)%3/)!$-.6)4&8)c.#-F&':-)%.6),6/-%#3('2/.);m)MM)o316.)[/=)!)MM)o316.B)

!`'-$`'8+"9283()$0'#$1ISFa'+8'#$"&#$S+.)(.#'="*8.+$,'-)8'$#-92$*'-('$h-)(-=-*"(,$-($`',3)$"3=$0"#$Yh$$6E^$P#A$V$b.("8'W$;I$DB[\VW$ :$w$DBDJV7A$O&#$ 938F.==$<3+0'$ 0'+$ ?"@.+FI'='+'(,<'+8$ P'+<'(0'8A$O392$ 0-'$O(<'(03()$0'#$b'0-"(#$P.($EB\$/)M0&$"&#$>+'((&-(-'$'+)"@$*'-('$<'#'(8&-92'$e'+4(0'+3()$0'+$Q+)'@(-##'A$K($'-(-)'($O+@'-8'($<3+0'$'-('$>+'((&-(-'$P.($J$/)M0&$"()'<'(0'8$6>"("*"$'8$"&AB$CDDiW$_'(.$'8$"&AB$CDDD7A$O/$P.+&-')'(0'($5.&&'*8-P$'+)"@'($#-92$3(8'+$0'+$O(<'(03()$'-('+$>+'((&-(-'$P.($J$/)M0&$.0'+$ED$/)M0&$*'-('$ #-)(-=-*"(8'($ _(8'+#92-'0'$ @',])&-92$ 0'#$ YhA$ O392$ @',])&-92$ 0'#$ Sfh$ *.((8'$ *'-($ #-)(-=-*"(8'+$_(8'+#92-'0$,<-#92'($0'($%+3::'($='#8)'#8'&&8$<'+0'(A$$

Page 79: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JR""

H"A"AF V5'(.*&,.&(+0P;OKB+6,+)).;$)&$&'Y)+0

H"A"A"!F V5'(.*&,.&(+0P;OKB+6,+)).;$0.$0F+-560&5C04&)0\N0"

I3".$$.)NM+)Q#('#D#:3'-.),6(."'#//.)%.6)"#$%&'()&(%*+,-+($./*,01*%234*,56789:;)%/,/82)&%%:*&/*<=,>)3?+3/%&/82*),@(9%3)*+,4&8)c.#-F&':-)%.6),6/-%#3('2/.)#')L.4&()3&D)%3/)gQ)

P3*+3,E&$ N:$TmZ$n$LMU$ 8$

<*34+./$T<Y$f$<]$O'[$<A$f$<@U$ DB\CV$6DBCE[$!$DBiJL7$ \S\Y^$

RE2&*$T,+'$^^$W3)*&$O'[$XE2&*U$ DBJD[$6DBCi\$!$DBVDD7$ \S\]\$

!01234+-5$T!Y$f$!]$O'[$!A$f$!@U$ DBJE[$6DBC^^$!$DBV[D7$ \S\Aj$

NX59/E9,+.$Ta$YA$/?4E$O'[$$%YA$/?4EU$

EBi^D$6EBDED$!$LB\[C7$ \S\@^$

K&-J9;72&.$Ta$YY$<?E$O'[$$&&'()$ DBJCV$6DBCJ^$!$EBDi^7$ \S\`A$

E9/$kLRYm0ml$$ EBLVD$6EBE[[$!$EB[Ji7$ $a$\S\\Y$

"

K($'-('/$'+#8'($h92+-88$<3+0'($0-'$-($0'+$3(-P"+-"8'($1.XFI')+'##-.(#"("&c#'$@'8+"928'8'($:+.)(.#8-#92'($f"*8.+'($ 6#-'2'$>"@'&&'$ L\7$ -($ '-($/3&8-P"+-"8'#$b.0'&&$/-8$ 0'/$Q(0:3(*8$Yh$ '-(@',.)'(A$!-'$/-8$ 0'+$Q*<%/7*$0DHAN12+<6$6A%+;<<1*;6*$CM;N*3;%//7$Y-/<;*8<&4$:*1/88*8*8$#-)(-=-*"(8'($Q+)'@(-##'$6:$v$DBE7$-($`',3)$"3=$0"#$Yh$,'-)8$>"@'&&'$L[A$O&#$#-)(-=-*"(8$'+<-'#'($#-92$3(8'+$O(("2/'$'-('#$h-)(-=-*"(,(-P'"3#$P.($ED$G$%+"0-()B$O&8'+B$>3/.+#8"0-3/$("92$>ZbB$;4/.)&.@-(Fa'+8B$?'3*.,c8'(FO(,"2&$3(0$&.)$z1OEVFV{A$$$K($'-('/$,<'-8'($h92+-88$<3+0'($0-'#'$e"+-"@&'($-($'-($/3&8-P"+-"8'#$1.XFb.0'&&$/-8'-(@',.)'(B$"($0'/$(3($"($d'<'-&#$)'8+'((8'($b.0'&&'($d'0'$e"+-"@&'$"3#$>"@'&&'$L\$2-(#-928&-92$-2+'#$:+.)(.#8-#92'($h8'&&'(<'+8'#$"3=$h-)(-=-*"(,$)'8'#8'8$<3+0'$6O(("2/'$'-('#$h-)(-=-*"(,(-P'"3#$P.($J$GZ$Q*<%/7*$0T;86A%3-6647$!$#-'2'$>"@'&&'$L^A$$

I3".$$.)NV+)K&$-#[36#3-.)!'3$E/.)F62('2/-#/01.6)O3:-26.')".#)I1.63F#.".(#'')01*%234*,5A&+/82$#//<=,#')L.4&()3&D)%3/)gQ)8#-)3$$.')d3638.-.6')

P3*+3,E&$ N:$TmZ$n$LMU$ 8$

E9/$kLRYm0ml$$ EBLVD$6EBE[[FEB[Ji7$ $a$\S\\Y$

<*34+./$T<Y$f$<]$O'[$<A$f$<@U$ DB\CV$6DBCE[FDBiJL7$ \S\Y^$

RE2&*$T,+'$^^$W3)*&$O'[$XE2&*U$ DBJD[$6DBCi\FDBVDD7$ \S\]\$

E9/$kN,l$ DBJE$6DBDDLFDB^V[7$ \S\A@$

!01234+-5$T!Y$f$!]$O'[$!A$f$!@U$ DBJE[$6DBC^^FDBV[D7$ \S\Aj$

=&*.5&23'23'+&*-./$T&+./&2*&2&.$O'[$

.+()2$&+./&2*&2&.U$DBJ[\$6DBLCEFDBV^V7$ \S\@]$

0 "

Page 80: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

JM""

!-59*'234+-5$TE9J3E$C9*2/&'()*+22&.$

O'[$5&23'23'+&*2U$DBJ\^$6DBLD[FDBViD7$ \S\@]$

NX59/E9,+.$Ta$YA$/?4E$O'[$$%YA$/?4EU$

EBi^D$6EBDEDFLB\[C7$ \S\@^$

K&-J9;72&.$Ta$YY$<?E$O'[$$&&'()U$ DBJCV$6DBCJ^FEBDi^7$ DBDiL$

E9/$kK>Nl$ DB^^^$6DBJ\EFEBEE^7$ DBE^L$

<&'()E&()2$T5X..E+()$O'[$H&+,E+()U$ EB\E^$6DBiC[FCB\CV7$ DBCDJ$

LBR$Ta$*+,%-.(/)%012%$%*+,%-.(/)3$ DB[^\$6DBLJ[FEBC^J7$ DBCCJ$

E9/$kLBRl$ EBELi$6DBiiVFEB\J^7$ DBLDJ$

%+E+*-,+.$Ta$Y$5/?4E$O'[$$%&%/.(4)3$ DB^iJ$6DB\[iFEBLEV7$ DBL[E$

E9/$k%+E+*-,+.l$ EBDii$6DBiiDFEBL\\7$ DB\L^$

E9/$kK&-J9;72&.l$ DBi[i$6DBJLCFEB\E[7$ DBJ^E$

%#M$Ta$A\$J/?$5_$012%$%56%7.($5_U$ EBE^L$6DB[DVFCBCJV7$ DB[LL$

E9/$k!)*95,9;72&.l$ DBii^$6DBJD[FEBJJ[7$ DB[^[$

K>N$Ta$8,6%9()%012%$%]Z\$D?EU$ EBEE\$6DB[JJFEBiVJ7$ DB[VD$

E9/$kL:Vl$ DBV[L$6DB^iiFEBE^^7$ DB^ED$

LRYm0m$Ta$&666%9(/)%012%$%&666%D?5EU$

DBi^E$6DBL\DFCBCCV7$ DB^^L$

K758)J.92&.,&C3EE$T&+./&2*&2&.$O'[$

.+()2$&+./&2*&2&.U$DBVL[$6DBJE\FEB^DL7$ DBiCi$

!)*95,9;72&.$Ta$8,5%'()%012%$%8,5%<?EU$

DBV^\$6DBJV\FEBJV[7$ DBVEJ$

L:V$Ta$&%/.(4)%012%$%&%/.(4)3$ DBVi[$6DBJJiFEB^\C7$ DBV[D$

)

Q-('($T@'+@&-9*$]@'+$0-'$Q+)'@(-##'$0'+$/3&8-P"+-"8'($O("&c#'$/-8$0'/$Q(0:3(*8$Yh$&-'='+8$>"@'&&'$L^A$Q-($(-'0+-)'+'#$O&8'+$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$,'-)8'$#-92$"&#$3("@24()-)'+$:.#-8-P'+$S+.)(.#'="*8.+$-($`',3)$"3=$0"#$Yh$6;I$DBJD[W$:$w$DBDCD7A$Q@'(#.$'+<-'#'($#-92$'-($2-#8.&.)-#92$)38$@-#$/4R-)$0-=='+'(,-'+8'+$>3/.+$ 6;I$DB\CVW$ :$w$DBDE[7B$ '-($ (.92$ &.*"&$ @')+'(,8'+$ >3/.+$ 6;I$ DBJ\^W$ :$w$DBD\C7B$ *'-('$f'+(/'8"#8"#-'+3()$@'-$Q+#80-")(.#'$ 6;I$DBJ[\W$:$w$DBD\C7$3(0$'-($>3/.+#8"0-3/$>E$.0'+$>C$("92$0'+$>ZbF5&"##-=-*"8-.($"&#$3("@24()-)'$:.#-8-P'$S+.)(.#'="*8.+'($-/$;-(@&-9*$"3=$0"#$YhA$Q-($;4/.)&.@-(Fa'+8$v$EL$ )M0&$ ,'-)8'$ #-92$ "&#$ (')"8-P'+$ f"*8.+$ ,3+$ I-#-*.#8+"8-=-,-'+3()$ 6;I$ EBiW$ :$w$DBD\[7A$ O392$ 0'+$("8]+&-92'$?.)"+-82/3#$&.)$z;@{$6;I$DBJEW$:$w$DBDL\7$#.<-'$&.)$z1OEVFV{$6;I$EBLVW$:$v$DBDDE7$,'-)8'($#-92$"&#$3("@24()-)'$#-)(-=-*"(8'$S+.)(.#'="*8.+'(A$

a'-8'+'$ f"*8.+'(B$ 0-'$ -($ 0-'$ /3&8-P"+-"8'$ 1.XFI')+'##-.($ /-8'-()'#92&.##'($ <3+0'(B$ <"+'($ 0-'$ ,3/$g'-8:3(*8$ 0'+$Q+#80-")(.#'$ '+2.@'('($ ?"@.+:"+"/'8'+$ 6?'3*.,c8'(B$ &.)$z?'3*.,c8'({B$ 1QOB$ &.)$z1QO{B$1OEVFVB$1ISB$&.)$z1IS{B$?!;B$&.)$z?!;{B$>2+./@.,c8'(B$&.)$z>2+./@.,c8'({7B$0'+$`bKB$0"#$%'#92&'928$#.<-'$ 0'+$?c/:2*(.8'(@'="&&A$!-'#'$S"+"/'8'+$ ,'-)8'($ #-92$ -($ 0'+$/3&8-P"+-"8'($1.XFI')+'##-.(#"("&c#'$(-928$#-)(-=-*"(8A$

Page 81: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LT""

H"A"A"AF V5'(.*&,.&(+0P;OKB+6,+)).;$0.$0F+-560&5C04&)0EZN0"

!"#$3(8'+$\ACACAE$@'#92+-'@'('$e'+="2+'($<3+0'$"392$-($̀ ',3)$"3=$0"#$Sfh$"()'<"(08A$!-'$/-8$0'+$b'82.0'$0DHAN12+<6$6A%+;<<1*;6*$CM;N*3;%//7$Y-/<;*8<&4$:*1/88*8*8$6;:8;>;N58<*8$T+:*E8;66*$;8$[',3)$"3=$0"#$Sfh$,'-)8$ >"@'&&'$ LiA$ _(8'+$ O(("2/'$ '-('#$ h-)(-=-*"(,(-P'"3#$ P.($ ED$G$ '+<-'#'($ #-92$ 0-'$ e"+-"@&'($f'+(/'8"#8"#-'+3()$6'-()'8+'8'($P#A$(-928$'-()'8+'8'(7B$0'+$`-&-+3@-(Fa'+8B$0'+$1ISFa'+8$3(0$0'+$("8]+&-92'$?.)"+-82/3#$0'#$1ISFa'+8'#$6&.)$z1IS{7$"&#$#-)(-=-*"(8A$$!-'#'$ #-)(-=-*"(8'($ S+.)(.#'="*8.+'($ <3+0'($ -($ '-($ /3&8-P"+-"8'#$ 1.XFb.0'&&$ /-8$ 0'/$ Q(0:3(*8$ Sfh$'-(@',.)'(A$ O($ d'<'-&#$ )'8+'((8'($b.0'&&'($ <3+0'$ (3($ d'0'$ e"+-"@&'$ "3#$ >"@'&&'$ LJ$ 2-(#-928&-92$ -2+'#$:+.)(.#8-#92'($h8'&&'(<'+8'#$"3=$h-)(-=-*"(,$)'8'#8'8$6O(("2/'$'-('#$h-)(-=-*"(,(-P'"3#$P.($J$G7A$$

I3".$$.)NW+)Q#('#D#:3'-.),6(."'#//.)%.6)8&$-#[36#3-.')-+($./*,01*%234*,56789:;)%/,/82)&%%:*&/*<=,>)3?+3/%&/82*),@(9%3)*+,4&8)c.#-F&':-)%.6),6/-%#3('2/.)#')L.4&()3&D)%3/)dOQ)

P3*+3,E&$ N:$TmZ$n$LMU$ 8$

=&*.5&23'23'+&*-./$T&+./&2*&2&.$O'[$.+()2$

&+./&2*&2&.U$DBDV^$6DBDLV$!$DBC\C7$ $a$\S\\Y$

%+E+*-,+.$Ta$Y$5/?4E$O'[$$%&$5/?4EU$ DBL[V$6DBE^C$!$DB^VL7$ \S\YY$

E9/$kL:Vl$ DBJVV$6DBL^\$!$DBVJi7$ \S\A]$

L:V$Ta$Y$5/?4E$O'[$$%&$5/?4EU$ DBCV[$6DBDVJ$!$DBVCJ7$ \S\A^$

"

"

I3".$$.)NX+)K&$-#[36#3-.)!'3$E/.)F62('2/-#/01.6)O3:-26.')".#)I1.63F#.".(#'')01*%234*,5A&+/82$#//<=,#')L.4&()3&D)%3/)dOQ)8#-)3$$.')d3638.-.6')

P3*+3,E&$ N:$TmZ$n$LMU$ 8$

=&*.5&23'23'+&*-./$T&+./&2*&2&.$O'[$.+()2$

&+./&2*&2&.U$DBDV^$6DBDLVFDBC\C7$ $a$\S\\Y$

%+E+*-,+.$Ta$Y$5/?4E$O'[$$%&$5/?4EU$ DBL[V$6DBE^CFDB^VL7$ \S\YY$

LRYm0m$Ta$&666%9(/)%012%$%&666%9(/)3$ DBL[V$6DBE[iFDBiDV7$ \S\YA$

E9/$kLRYm0ml$ EBCDC$6EBDEiFEB\EV7$ \S\A\$

E9/$kL:Vl$ DBJVV$6DBL^\FDBVJi7$ \S\A]$

L:V$Ta$Y$5/?4E$O'[$$%&$5/?4EU$ DBCV[$6DBDVJFDBVCJ7$ \S\A^$

E9/$kK>Nl$ EB[\C$6DBiL\FLBCLE7$ DBEJE$

K758)J.92&.,&C3EE$T&+./&2*&2&.$O'[$.+()2$

&+./&2*&2&.U$DB[iL$6DBL[EFEBCVC7$ DBC\E$

LBR$Ta$*+,%-.(/)%012%$%*+,%-.(/)3$ DB[[[$6DBLLiFEBLEJ7$ DBC\C$

0 "

Page 82: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

L!""

K&-J9;72&.$Ta$YY$<?E$O'[$$&&$<?EU$ EB\i[$6DB[iCFLBCL[7$ DBLEV$

E9/$kK&-J9;72&.l$ DB^^D$6DB\\LFEBLLV7$ DBLJ\$

<*34+./$T<Y$f$<]$O'[$<A$f$<@U$ DB^\L$6DBLVEFEB\EC7$ DBL[J$

K>N$Ta$8,6%9()%012%$%8,6%9()3$ DB^[^$6DB\CDFEB\DD7$ DBLii$

<&'()E&()2$$ DB^i\$6DB\C^FEB\Li7$ DB\LC$

!01234+-5$T!Y$f$!]$O'[$!A$f$!@U$ EBC[J$6DB[[\FCB\DV7$ DB\^J$

NX59/E9,+.$Ta$YA$/?4E$O'[$$%&5$/?4EU$ EBCJC$6DB[\DFCB\JD7$ DBJEC$

%#M$Ta$A\$J/?$5_$012%$%56%7.($5_U$ EBCVE$6DBJi\FCBiJi7$ DBJCi$

RE2&*$T,+'$^^$W3)*&$O'[$XE2&*U$ EBCEL$6DB[[JFCBCEE7$ DBJCV$

!)*95,9;72&.$Ta$8,5%'()%012%$%8,5%'()3$ DBiLE6DB\[CFEB\V\7$ DBJL[$

E9/$k!)*95,9;72&.l$ DBi^E$6DB\ViFEBJCC7$ DB[C^$

!-59*'234+-5$TE9J3E$C9*2/&'()*+22&.$O'[$

5&23'23'+&*2U$EBC^C$6DB\^CFLB\C[7$ DB[L\$

E9/$kLBRl$ EBD[V$6DBiDLFEB\CL7$ DB[\^$

E9/$k%+E+*-,+.l$ EBDC^$6DB^EJFEB\^[7$ DBiiJ$

E9/$kN,l$ DBViJ$6DBDVDFEDBi\E7$ DBVVD$

"

Q-('($T@'+@&-9*$0'+$Q+)'@(-##'$0'+$/3&8-P"+-"8'($O("&c#'$/-8$0'/$Q(0:3(*8$Sfh$&-'='+8$>"@'&&'$LVA$Q-('$(.92$(-928$'-()'8+'8'('$f'+(/'8"#8"#-'+3()$,'-)8'$#-92$"&#$3("@24()-)'+$:.#-8-P'+$S+.)(.#'="*8.+$-($`',3)$"3=$ 0"#$ Sfh$ 6;I$ DBDV^W$ :$v$DBDDE7A$ Q-($ `-&-+3@-($v$E$/)M0&$ 2"88'$ -($ 0'+$ /3&8-P"+-"8'($ 1.XFI')+'##-.(#"("&c#'$'-('($:.#-8-P'($Q-(=&3##$"3=$0"#$Sfh$6;I$DBL[VW$:$w$DBDEE7A$!-'$?"@.+:"+"/'8'+$1IS$6;I$DBCV[W$:$w$DBDL[7$3(0$1OEVFV$6;I$DBL[VW$:$w$DBDEL7$#.<-'$0'+'($("8]+&-92'+$?.)"+-82/3#$&.)$z1IS{$6;I$ DBJVVW$ :$w$DBDLC7$ 3(0$ &.)$z1OEVFV{$ 6;I$ EBCDCW$ :$w$DBLDL7$ '+<-'#'($ #-92$ '@'(#.$ "&#$ )''-)('8'$3("@24()-)'$S+.)(.#'="*8.+'(A$

a'-8'+'$ f"*8.+'(B$ 0-'$ -($ 0-'$ /3&8-P"+-"8'$ 1.XFI')+'##-.($ /-8'-()'#92&.##'($ <3+0'(B$ <"+'($ 0-'$ ,3/$g'-8:3(*8$ 0'+$ Q+#80-")(.#'$ '+2.@'('($ ?"@.+:"+"/'8'+$ 6;4/.)&.@-(B$ &.)$z;@{B$ ?'3*.,c8'(B$&.)$z?'3*.,c8'({B$1QOB$&.)$z1QO{B$?!;B$&.)$z?!;{B$>2+./@.,c8'(B$&.)$z>2+./@.,c8'({B$&.)$z`-&-+3@-({7B$0'+$̀ bKB$0"#$%'#92&'928B$0"#$O&8'+$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'B$0"#$>3/.+#8"0-3/$6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+8B$0"#$>Fh8"0-3/$("92$0'+$>ZbF5&"##-=-*"8-.(B$0"#$2-#8.&.)-#92'$%+"0-()$0'#$>3/.+#$#.<-'$0'+$ ?c/:2*(.8'(@'="&&A$ !-'#'$ S"+"/'8'+$ ,'-)8'($ #-92$ -($ 0'+$ /3&8-P"+-"8'($ 1.XFI')+'##-.(#"("&c#'$ -($;-(@&-9*$"3=$0"#$Sfh$(-928$#-)(-=-*"(8A$

$ $

Page 83: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

L<""

H"DF 35)[+,(5$604+,0.<<5$%.)(;/%+<.)/%+$0Z?,25$6+$0"

K(#)'#"/8$<"+$@'-$VDB[$G$0'+$S"8-'(8'($6V[MED[7$0'#$5.&&'*8-P#$'-('$%'<'@':+.@'$P.+2"(0'(A$`'-$JD$G$6JLMED[7$0'+$S"8-'(8'($0'#$5.&&'*8-P#$<"+$0"#$>3/.+)'<'@'$,3+$;'+#8'&&3()$'-('#$>bO$)''-)('8A$h./-8$*.((8'$@'-$0-'#'($S"8-'(8'($3(8'+#3928$<'+0'(B$.@$03+92$0'($>3/.+$P'+/'2+8$Z%fF'$/7*+$,+NOB$`$.0'+$1$ 'X:+-/-'+8$ <3+0'A$ JCBi$G$ 0'+$ S"8-'(8'($ <"+'($ "($ '-('/$ -(8+"2':"8-#92'($ 6CiMJL7B$ CiBL$G$ "($ '-('/$:'+-2-&4+'($6EJMJL7$3(0$EiBV$G$"($'-('/$0-#8"&'($6EDMJL7$%"&&'()"()#*"+,-(./$'+*+"(*8A$Q-($#-)(-=-*"(8'+$_(8'+#92-'0$-/$YP'+"&&$h3+P-P"&$&-'R$#-92$-($`',3)$"3=$0-'$?.*"&-#"8-.($0'#$>3/.+#$(-928$='#8#8'&&'(A$$

I3".$$.)A@+)e".6/#01-)f".6)%#.)Y.H.".F62".')%./)72$$.:-#[/)

#32&*+3E$ R.;3)E$ 83.!*J$ "<=0:$

!#R$$

+.2*3)&832+'()$

8&*+)+EX*$

4+'23E$

($w$JL$6JLMED[W$JD$G7$($w$Ci$6CiMJLW$JCBi$G7$($w$EJ$6EJMJLW$CiBL$G7$($w$ED$6EDMJLW$EiBV$G7$

(')"8-P$ (')"8-P$

%+98'+&$

+.2*3)&832+'()$

8&*+)+EX*$

4+'23E$

($w$\\$6\\MED[W$\DBJ$G7$($w$C[$6C[M\\W$JVBE$G7$($w$E^$6E^M\\W$LiB[$G7$($w$E$6EM\\W$CBL$G7$

Z-928$3(8'+#3928$ Z-928$3(8'+#3928$

$$O($ *'-('+$ 0'+$ JL$ -/$ >bO$ '+="##8'($ >3/.+:+.@'($ *.((8'$ '-('$ QX:+'##-.($ P.($ Z%fF'$ /7*+$ I58,+N$("92)'<-'#'($<'+0'(A$!-'#'$b"+*'+$<"+'($-($0-'#'+$%+3::'$#./-8$,3$EDD$G$(')"8-PA$$$

$

!""#$%&'() NV+) U88&'1#/-201.8#/01.6) J301H.#/) [2')JYOPB, 0-CCD, EF) !B) &'%) F3'I6:) ;!""=) NV) SB) /2H#.) h583-2RE$#'P,2/#'PO56"&'();h,>)!""=)NV)LB).R.8F$36#/01.6)012$3'(#24.$$&$56.6)7364#'28.);3$$.)!""#$%&'(.')#')?@@PD301.6)<.6(6pZ.6&'(B)

"

!-'$ 92.&"()-.,'&&3&4+'($ 5"+,-(./'$ 3(#'+'#$ 5.&&'*8-P#$ <'-#'($ *'-('$ QX:+'##-.($ 0'+$ ('3+.("&'($b"+*'+$Z%fF'$ 3(0$ :"(>+*$ "3=A$ Q-('$ Z%fF'FQX:+'##-.($ ,'-)8'$ #-92$ &'0-)&-92$ "&#$ ('8,"+8-)'$ QX:+'##-.($ -/$:'+-83/.+"&'($h8+/.5$*;8G*38*+$,-./+*8$ C\=$]EE($^_$O7B$<42+'(0$ -($0'+$':-82'&-"&'($5./:.('(8'$0'+$>3/.+'($ *'-('$ QX:+'##-.($ ("92<'-#@"+$ <"+$ 6|B$ O@@A$ L^$ O7A$ Q-('$ *+4=8-)'$ :"(>+*FQX:+'##-.($ <"+$ -($)'&')'(8&-92$/-8'+="##8'($Z'+F*8>56*+8$85A%1*;6E5+$C\=$]EE($^_$17$3(0$0-'(8'$"&#$-(8'+('$S.#-8-P*.(8+.&&'A$Q@'(#.$@'#8"(0$*'-('$:"(>+*$QX:+'##-.($ -($0'+$ ':-82'&-"&'($5./:.('(8'$0'+$>3/.+'($ 6|W$O@@A$L^$17A$QX'/:&"+-#92'$!"+#8'&&3()$'-('#$/4R-))+"0-)$0-=='+'(,-'+8'($92.&"()-.,'&&3&4+'($5"+,-(./#$6|B$O@@A$L^$`7A$

"

Page 84: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

L?""

LF 8.):5)).;$0"

!"#$ %"&&'()"()#*"+,-(./$ ,42&8$ /-8$ '-('+$ K(,-0'(,$ P.($ LMEDDDDDMN"2+$ ,3$ 0'($ #.)'("((8'($ #'&8'('($5+'@#'+*+"(*3()'($6;'+.&0B$CDEC7B$0'/'(8#:+'92'(0$'X-#8-'+'($@-#$d'8,8$(3+$<'(-)'$"3##")'*+4=8-)'$h830-'(A$O3=)+3(0$0'+$#92&'928'($S+.)(.#'$0'#$%"&&'()"()#*"+,-(./#$-#8$'#$(.8<'(0-)B$)',-'&8'+'$3(0$'=='*8-P'+'$>2'+":-'"(#48,'$ ,3$ '(8<-9*'&(A$ !-'$ `'2"(0&3()$ 0'#$ 92.&"()-.,'&&3&4+'($ 5"+,-(./#$ -#8$ @-#$ 0"8.$ #'2+$3('-(2'-8&-92A$ h'-8$ e'+H=='(8&-923()$ 0'+$ Q+)'@(-##'$ 0'+$ _5FO`1FDCFh830-'$ )-&8$ 0-'$ 5./@-("8-.($ P.($%'/9-8"@-($3(0$1-#:&"8-($"&#$>2'+":-'#8"(0"+0$@'-$0'+$O(<'(03()$'-('+$EA$:"&&-"8-P'($>2'+":-'$6e"&&'$'8$"&AB$CDED7A$b3##$ 0-'#'$ >2'+":-'$ d'0.92$ "@)'@+.92'($<'+0'(B$ )-@8$ '#$ =]+$ 0"#$ <'-8'+'$e.+)'2'($ *'-('$ *&"+'($I-928&-(-'(A$g-'&$0-'#'+$O+@'-8$<"+$'#B$0-'$̀ '2"(0&3()#+'"&-848$"($'-('/$)+.R'($g'(8+3/$"@,3@-&0'(B$3/$('3'B$,-'&)'+-928'8'$>2'+":-'*.(,':8'$,3$0'=-(-'+'(A$$O3=)+3(0$ 0'+$ #92&'928'($ S+.)(.#'$ 0'#$ %"&&'()"()#*"+,-(./#$ -#8$ 0-'$ Q8"@&-'+3()$ :+482'+":'38-#92'+$f"*8.+'($,3+$I-#-*.#8+"8-=-,-'+3()$2-&=+'-92$@'-$0'+$Q-(#9248,3()$0'+$-(0-P-03'&&'($S+.)(.#'$0'+$Q+*+"(*3()A$K($'-('+$+'8+.#:'*8-P'($O("&c#'$/-8$EC^$"($'-('/$%"&&'()"()#*"+,-(./$'+*+"(*8'($S"8-'(8'(B$0-'$#-92$"&&'$'-('+$*3+"8-P'($Y:'+"8-.($3(8'+,.)'(B$,'-)8'($#-92$0"#$>3/.+#8"0-3/$("92$0'+$_K11F5&"##-=-*"8-.(B$0-'$O(<'(03()$'-('+$"0d3P"(8'($12'/.82'+":-'B$0'+$?c/:2*(.8'(#8"83#$3(0$'-('$IDFI'#'*8-.($"&#$#-)(-=-*"(8'$S+.)(.#'="*8.+'($ -/$;-(@&-9*$ "3=$ 0"#$Yh$ 6b3+"*"/-$ '8$ "&AB$ CDEE7A$Q-('+$<'-8'+'($ +'8+.#:'*8-P'($ h830-'$,3=.&)'B$0-'$J[\$"($'-('/$%"&&'()"()#*"+,-(./$'+*+"(*8'$S"8-'(8'($'-(#92&.##B$<"+'($"392$2-'+$83/.+=+'-'$I'#'*8-.(#+4(0'+$3(0$0'+$?c/:2*(.8'(#8"83#$#-)(-=-*"(8'$S+.)(.#'="*8.+'($6!'Y&-P'-+"$'8$"&AB$CDD^7A$f]+$0"#$S"(*+'"#*"+,-(./$*.((8'$0-'$`'0'383()$P.($:+.)(.#8-#92'($f"*8.+'($#92.($)','-)8$<'+0'(A$K($'-('/$h830-'(*.&&'*8-P$P.($[D^$S"8-'(8'($/-8$'-('/$/'8"#8"#-'+8'($S"(*+'"#*"+,-(./$,'-)8'$#-92$-($'-('+$S2"#'FKKKFh830-'$,3+$Q+#8&-(-'(82'+":-'$/-8$%'/9-8"@-(B$Q+&.8-(-@$3(0$`'P"9-,3/"@$P#A$%'/9-8"@-($3(0$Q+&.8-(-@$(3+$ =]+$ '-('$ ("92$S+.)(.#'="*8.+'($ #8+"8-=-,-'+8'($ h3@)+3::'("("&c#'$ '-($ #-)(-=-*"(8$ &4()'+'#$Yh$ =]+$ 0-'$,3#48,&-92'$`'2"(0&3()$/-8$`'P"9-,3/"@$6e"($138#'/$'8$"&AB$CDDV7A$f.&)&-92$*H((8'$0-'$h8+"8-=-,-'+3()$("92$S+.)(.#'="*8.+'($ =]+$ 0"#$ 92.&"()-.,'&&3&4+'$ 5"+,-(./$ 'P'(83'&&$ 0'($ O3#)"()#:3(*8$ =]+$ '-('$ )',-'&8'+'$>2'+":-'$ 0"+#8'&&'(A$ _(#'+'#$ a-##'(#$ ("92$ 'X-#8-'+'($ (3+$ <'(-)'$ O+@'-8'($ ,3+$ !'8'*8-.($ P.($S+.)(.#'="*8.+'($ =]+$0"#$111$ 6`+-0)'<"8'+$ '8$ "&AB$ CDE[W$S'-X.8.$ '8$ "&AB$ CDE\7A$!'+$%+.R8'-&$ 0'+$ h830-'($@'#924=8-)8$ #-92$/-8$0'+$:.#8.:'+"8-P'($S+.)(.#'$("92$*3+"8-P'+$>2'+":-'$@'-/$ -11O$ 6N-"()$ '8$ "&AB$ CDEEW$I-@'+.$'8$"&AB$CDECW$kA$a"()$'8$"&AB$CDEL7A$g-'&$0-'#'+$O+@'-8$<"+$'#B$f"*8.+'($,3+$I-#-*.#8+"8-=-,-'+3()$,3$=-(0'(B$0-'$#-92B$3("@24()-)$P.($0'+$>3/.+&.*"&-#"8-.($3(0$0'#$`'2"(0&3()#+')-/'#$0'#$5"+,-(./#B$ "&#$)''-)('8$'+<'-#'(A$$a'-8'+2-($-#8$=]+$'-('$-(0-P-03'&&'+'B$,-'&)'+-928'8'$>2'+":-'$'-($e'+#84(0(-#$0'#$%"&&'()"()#*"+,-(./#$"3=$/.&'*3&"+'+$Q@'('$(H8-)A$`-#$d'8,8$*.(,'(8+-'+8'$#-92$0-'$`'8+"9283()$0'+$:+.&-='+"8-P'($a-+*3()$P.($Z%f$3(0$#'-('/$I',':8.+$>+*O$P.+$"&&'/$"3=$0"#$Z'3+.@&"#8./$6g23$'8$"&AB$CDEL7B$g3#"//'(24()'$#-(0$"@'+$"392$=]+$0"#$S"(*+'"#FB$5.&.(FB$3(0$b"//"F5"+,-(./$@'#92+-'@'($6`":"8$'8$"&AB$CDEEW$?-'@&$'8$"&AB$CDELW$Z.2$ '8$ "&AB$ CDEL7A$`'-$ '-('/$*&'-('($ 92-('#-#92'($h830-'(*.&&'*8-P$ 6Ci$S"8-'(8'(7$/-8$ 0'+$!-")(.#'$ '-('#$:'+-2-&4+'($%"&&'()"()#*"+,-(./#$*.((8'$-($J^BE$G$0'+$f4&&'$'-('$T@'+'X:+'##-.($P.($Z%fF'$85A%:*1;*6*8$<'+0'(B$ ,30'/$ ,'-)8'$ #-92$ '-('$ 5.++'&"8-.($ /-8$ 0'/$ O3=8+'8'($ '-('+$ :'+-('3+"&'($ K(P"#-.($ 3(0$ 0'/$O3=8+'8'($P.($?c/:2*(.8'(/'8"#8"#'($6o3$'8$"&AB$CDED7A$O392$@'-/$-11O$,'-)8'$#-92$-($'-('+$h830-'$/-8$iL$f4&&'($ '-('$ T@'+'X:+'##-.($ P.($ Z%f$ -($ C^B^$G$ 3(0$ P.($ >+*O$ -($ CDBJ$G$ 0'+$ f4&&'A$ Q-('$ )&'-92,'-8-)'$T@'+'X:+'##-.($ P.($ Z%f$ 3(0$ >+*O$ *.++'&-'+8'$ /-8$ '-('+$ #92&'928'($ S+.)(.#'$ 3(0$ ,'-)8'$ #-92$ "&#$3("@24()-)'+$ S+.)(.#'="*8.+$ 6:$w$DBDDL7$ 6k"()$ '8$ "&AB$ CDE\7A$ g-'&$ 0'#$ ,<'-8'($>'-&#$ 0'+$ O+@'-8$ <"+B$ 0-'$QX:+'##-.($ P.($ >+*OB$ `B$ 1$ 3(0$ 0-'$ QX:+'##-.($ P.($ Z%fF'$ 58$ 7*8$ ,-./+I+/E*8$ 7*6$ F/+3;*:*(0'($5.&&'*8-P#$,3$3(8'+#392'(A$$

Page 85: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LC""

L"!F @'.$.)/%+08&(+$04+,0E&(.+$(+$0

L"!"!F E&(.+$(+$/%&,&:(+,.)(.:&0"

b4(('+$ 6[EMED[W$ J^B\$G7$ '+*+"(*8'($ @'-/$ P.+&-')'(0'($ 5.&&'*8-P$ EB\F/"&$ 243=-)'+$ "&#$ f+"3'($ 6\JMED[W$\CBJ$G7A$`+-0)'<"8'+$'8$"&A$#"2'($-($-2+'/$5.&&'*8-P$'-('($T@'+&'@'(#P.+8'-&$=]+$f+"3'($6:$w$DBDL^7B$=]+$0"#$:+.)+'##-.(#=+'-'$T@'+&'@'($*.((8'$0"#$%'#92&'928$(-928$"&#$S+.)(.#'="*8.+$'8"@&-'+8$<'+0'($6`+-0)'<"8'+$'8$"&AB$CDE[7A$K($0-'#'+$O+@'-8$*.((8'$-($`',3)$"3=$0"#$%'#92&'928$<'0'+$2-(#-928&-92$0'#$Yh$(.92$0'#$Sfh$'-($#-)(-=-*"(8'+$_(8'+#92-'0$='#8)'#8'&&8$<'+0'(A$$!"#$/'0-"('$Q+*+"(*3()#"&8'+$@'-$Q+#80-")(.#'$&")$@'-$[L$N"2+'(A$h./-8$3(8'+#92-'0$#-92$0"#$5.&&'*8-P$(-928$P.($0'($O()"@'($-($0'+$?-8'+"83+$6b"82'/"$U$Z"F`"()92"()B$CDEJW$I",3/-&"P"$U$%.+'#B$CDE\W$e.)'&$'8$"&AB$ CDE\7A$!'+$Q-(=&3##$0'#$O&8'+#$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$ "3=$0"#$Yh$3(0$0"#$Sfh$<3+0'$P.($P'+#92-'0'('($ O38.+'($ 3(8'+#3928B$ '#$ *.((8'$ "@'+$ *'-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ ='#8)'#8'&&8$ <'+0'($6`+-0)'<"8'+$ '8$ "&AB$ CDE[W$ S'-X.8.$ '8$ "&AB$ CDE\7A$ O($ 3(#'+'/$5.&&'*8-P$ *.((8'($ <-+$ -($ 0'+$/3&8-P"+-"8'($1.XFI')+'##-.(#"("&c#'$ '-('($ T@'+&'@'(#P.+8'-&$ @'-$ 0'+$ d]()'+'($ S"8-'(8'()+3::'$ 6v$[[$ N"2+'7$ #'2'($6/'0-"('#$ Yhn$ EJB\$P#A$EE$b.("8'W$ ;I$DBJD[W$ :$w$DBDCD7B$ #./-8$ *.((8'$ 0"#$ O&8'+$ "&#$ 3("@24()-)'+$S+.)(.#'="*8.+$ '8"@&-'+8$ <'+0'(A$ !-'#$ &4##8$ #-92$ "/$ '2'#8'($ 0"03+92$ '+*&4+'(B$ 0"##$ 0-'$ d]()'+'$S"8-'(8'()+3::'$<"2+#92'-(&-92$<'(-)'+$5./.+@-0-848'($"3=<'-#8$3(0$-(8'(#-P'+'$>2'+":-'"(#48,'$/H)&-92$#-(0$"&#$@'-$4&8'+'($S"8-'(8'(A$K/$;-(@&-9*$"3=$0"#$Sfh$,'-)8'$#-92$*'-('$h-)(-=-*"(,A$$K($ VVBE$G$ 0'+$ f4&&'$ 3(#'+'#$ 5.&&'*8-P#$ <3+0'$ '-($ O0'(.*"+,-(./$ 0-")(.#8-,-'+8B$ '-($ f"&&$ ,'-)8'$ '-($:":-&&4+F/3,-(H#'#$12.&"()-.*"+,-(./B$<"#$/-8$ 0'($Q+)'@(-##'($ "(0'+'+$ h830-'($]@'+'-(#8-//8$ 6?-/$U$S"+*B$CDD\W$b3+"*"/-$'8$"&AB$CDEE7A$$K/$;-(@&-9*$ "3=$ 0"#$%+"0-()$ 0'+$%"&&'()"()#*"+,-(./'$ -#8$ '-('$ _(8'+#92'-03()$ -($ -(8+"2':"8-#92'$ 3(0$'X8+"2':"8-#92'$ 6:11O$ 3(0$ 011O7$ 111#$ (.8<'(0-)A$ %'/4R$ 0'+$ a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iJ$G7B$(3+$=](=$0'+$f4&&'$<"+'($)38$0-=='+'(,-'+8$6iBL$G7A$_(8'+$0'($'X8+"2':"8-#92'($%"&&'()"()#*"+,-(./'($<"+'($/'2+$"&#$0-'$;4&=8'$)'+-()$@-#$3(0-=='+'(,-'+8$6JCBC$G7B$<42+'(0$(3+$LVBE$G$'-('($)38'($.0'+$/4R-)'($!-=='+'(,-'+3()#)+"0$,'-)8'(A$`'-$S"8-'(8'(B$0'+'($>3/.+'$2-#8.&.)-#92$"&#$%E$.0'+$%C$'-()'8'-&8$<3+0'(B$*.((8'$'-($0.::'&8$#.$2.2'#$/'0-"('#$ YP'+"&&$ h3+P-P"&$ 6E[$P#A$i$b.("8'7$ ("92)'<-'#'($ <'+0'($ "&#$ @'-$ S"8-'(8'($ /-8$ %LF$ 3(0$%\F>3/.+'(A$!-'#'+$g3#"//'(2"()$,'-)8'$#-92$-($0'+$3(-P"+-"8'($1.XFI')+'##-.(#"("&c#'$(-928$#-)(-=-*"(8$6;In$ DB^DLW$ :$w$DBE\C7A$ K($ 0'+$ /3&8-P"+-"8'($ O("&c#'$ *.((8'$ 0"#$ %+"0-()$ -($ `',3)$ "3=$ 0"#$ Yh$ "&#$3("@24()-)'+$ f"*8.+$ ,3+$ I-#-*.#8+"8-=-,-'+3()$ '8"@&-'+8$ <'+0'($ 6;I$DB\CVW$ :$w$DBDE[7A$ f]+$ 0"#$:+.)+'##-.(#=+'-'$T@'+&'@'($*.((8'$*'-($Q-(=&3##$0'#$%+"0-()#$='#8)'#8'&&8$<'+0'(A$$

Page 86: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LF""

L"!"AF 15<;,';:&'.)&(.;$0"

`'-$J[B[$G$0'+$S"8-'(8'($0'#$P.+&-')'(0'($5.&&'*8-P#$<3+0'$'-($-(8+"2':"8-#92'#B$@'-$LL$G$'-($:'+-2-&4+'#$3(0$#92&-'R&-92$@'-$0'($+'#8&-92'($EDB\$G$'-($0-#8"&'#$%"&&'()"()#*"+,-(./$0-")(.#8-,-'+8A$`-#$P.+$'-(-)'($N"2+'($2"88'$'-($%+.R8'-&$0'+$111#$#'-('($_+#:+3()$:'+-2-&4+$6JDF^D$G7B$)'=.&)8$P.($-(8+"2':"8-#92'($69"A$CD$G7$3(0$0-#8"&'($69"A$CD$G7$5"+,-(./'($652"($'8$"&AB$CDECW$b-2"&"92'$'8$"&AB$CDED7A$O&&'+0-()#$-#8$@'*"((8B$0"##$0-'$K(,-0'(,$0'#$-(8+"2':"8-#92'($%"&&'()"()#*"+,-(./#$-($0'($<'#8&-92'($?4(0'+($"(#8'-)8$3(0$,3)&'-92$0-'$K(,-0'(,$0'#$'X8+"2':"8-#92'($"@=4&&8$6O&d-==+c$'8$"&AB$CDDVW$S"8'&B$CDDE7A$CDDV$P'+H=='(8&-928'($S"+*$'8$"&A$'-('$O+@'-8B$@'-$0'+$LVBV$G$0'+$h830-'(:"8-'(8'($6iJMCEL7$"($'-('/$-11O$'+*+"(*8$<"+'(B$EiBL$G$6LVMCEL7$"($'-('/$ 'X8+"2':"8-#92'($ 111A$ K($ 0-'#'$ h830-'$ <3+0'($ "392$ S"8-'(8'($ /-8$ '-('/$ %"&&'(@&"#'(*"+,-(./$6^CMCELW$ LLBi$G7$ .0'+$ '-('/$ 5"+,-(./$ 0'+$ e"8'+#92'($ O/:3&&'$ 6E^MCELW$ i$G7$ '-()'#92&.##'(A$ g3$@'+]9*#-928-)'($-#8B$0"##$-($0'+$h830-'$(.92$("92$0'+$[A$O3=&")'$0'+$_K11F5&"##-=-*"8-.($'-()'8'-&8$<3+0'B$#./-8$ <3+0'($ 0-#8"&'$ 3(0$ :'+;%;32+*$ JJJ6$ -8<*+$ 7*+$ ?+-II*$ 0*`<+5%*I5<;6A%*$ %"&&'()"()#*"+,-(./'4$,3#"//'()'="##8$ 6S"+*$ '8$ "&AB$ CDDV7A$ g<'-$ O38.+'($ @'#924=8-)8'($ #-92$ @-#2'+$ /-8$ 0'/$ Q-(=&3##$ 0'+$>3/.+&.*"&-#"8-.($"3=$0"#$Yh$3(0$0"#$SfhA$̀ +-0)'<"8'+$'8$"&A$*.((8'($0-'$>3/.+&.*"&-#"8-.($(-928$"&#$f"*8.+$,3+$I-#-*.#8+"8-=-,-'+3()$ -/$;-(@&-9*$"3=$Yh$3(0$Sfh$'8"@&-'+'($ 6`+-0)'<"8'+$ '8$ "&AB$ CDE[7A$S'-X.8.$'8$ "&A$#8'&&8'($ -($ 0'+$ 3(-P"+-"8'($ O("&c#'$ '-('($ Q-(=&3##$ 0'+$ >3/.+&.*"&-#"8-.($ 6011On$ JBL$b.("8'$P#A$-11On$EDBC$b.("8'W$:$w$DBDL[7$"3=$0"#$Yh$='#8A$K($0'+$/3&8-P"+-"8'($1.XFI')+'##-.($,'-)8'$#-92$0'+$_(8'+#92-'0$(-928$/'2+$#-)(-=-*"(8$6S'-X.8.$'8$"&AB$CDE\7A$K/$P.+&-')'(0'($5.&&'*8-P$,'-)8'($#-92$#.<.2&$=]+$0"#$Yh$"&#$"392$=]+$0"#$Sfh$*'-('$#-)(-=-*"(8'($_(8'+#92-'0'$-/$;-(@&-9*$"3=$0-'$?.*"&-#"8-.(A$$`'-$ `'8+"9283()$ 0'#$ >3/.+#8"0-3/#$ @'-$ Q+#80-")(.#'$ 0-=='+-'+8'($ 0-'$ Q+)'@(-##'$ "@24()-)$ P.($ 0'+$?.*"&-#"8-.($ 0'#$ S+-/4+83/.+#A$ h.$ @'="(0'($ #-92$ LiBL$G$ 0'+$ -(8+"2':"8-#92$ &.*"&-#-'+8'($ 111#$ @'-$Q+#80-")(.#'$@'+'-8#$-($'-('/$/'8"#8"#-'+8'($h8"0-3/B$@'-$0'($5&"8#*-(F>3/.+'($<"+'($'#$L\BL$GA$5'-('#$0'+$ 0-#8"&$ &.*"&-#-'+8'($ %"&&'()"()#*"+,-(./'$ ,'-)8'$ @'-$ Q+#80-")(.#'$ b'8"#8"#'(B$ ,3$ 0-'#'/$ g'-8:3(*8$@'="(0'($#-92$,<'-$f4&&'$-($'-('/$&.*"&-#-'+8'($6EiBC$G7$3(0$('3($<'-8'+'$f4&&'$6iEBi$G7$-($'-('/$+'#'*8"@&'($h8"0-3/A$h./-8$&4##8$#-92$='#82"&8'(B$0"##$0-'$:'+-2-&4+'($3(0$0-#8"&'($111#$.=8$-($'-('/$=+]2'+'($h8"0-3/$0-")(.#8-,-'+8$<'+0'(B$"&#$0-'$-(8+"2':"8-#92$&.*"&-#-'+8'($12.&"()-.*"+,-(./'A$12.&'#8"#'#c/:8./'$8+'8'($"3=)+3(0$0'+$?.*"&-#"8-.($@'-$'X8+"2':"8-#92'($3(0$0-#8"&'($111#$-($'-('/$+'&"8-P$=+]2'($5+"(*2'-8#P'+&"3=$"3=B$=]+$0"#$-11O$-#8$0-'$Q(8<-9*&3()$'-('#$K*8'+3#$0")')'($(-928$8c:-#92A$!-'$>3/.+'$0-'#'+$?.*"&-#"8-.($@&'-@'($.=8$#'2+$&"()'$g'-8$*&-(-#92$#83//$6Z"*''@$'8$"&AB$EVV[7A$̀ '-$0'+$-#.&-'+8'($̀ '8+"9283()$0'+$:'+-2-&4+'($%"&&'()"()#*"+,-(./'$@'-/$P.+&-')'(0'($5.&&'*8-P$=4&&8$"3=B$0"##$#-92$]@'+$0-'$;4&=8'$0'+$S"8-'(8'($6J^BE$G7$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$@'+'-8#$-/$h8"0-3/$Ke$("92$`-#/382F1.+&'88'$@'="(0B$#./-8$-($'-('/$&.*"&$#'2+$<'-8$=.+8)'#92+-88'('($h8"0-3/A$QP'(83'&&$&4##8$#-92$0-'#'$O@<'-923()$P.($0'+$?-8'+"83+$-/$h-(('$'-('#$g'(8+3/#@-"#$ '+*&4+'(B$ 0"$ /"($ 0"P.($ "3#)'2'($ *"((B$ 0"##$ "($ '-('/$ ]@'++')-.("&'($ 3(-P'+#-84+'($5+'@#,'(8+3/$0'+$O(8'-&$"($*./:&-,-'+8'+'($3(0$<'-8'+$=.+8)'#92+-88'('($f4&&'($2H2'+$-#8A$$Q-(-)'$ O38.+'($ '8"@&-'+8'($ 0"#$ Q+*+"(*3()##8"0-3/$ @'-$ Q+#80-")(.#'$ "&#$ )''-)('8'($ f"*8.+$ ,3+$I-#-*.#8+"8-=-,-'+3()$6`+-0)'<"8'+$'8$"&AB$CDE[W$S'-X.8.$'8$"&AB$CDE\7A$̀ +-0)'<"8'+$'8$"&A$3(8'+8'-&8'($-2+$5.&&'*8-P$-($ ,<'-$ %+3::'(A$ !-'$ S"8-'(8'($ 0'+$ '-('($ %+3::'$ @'="(0'($ #-92$ -($ '-('/$ &.*"&$ =.+8)'#92+-88'('($>3/.+#8"0-3/B$@'-$0'($"(0'+'($S"8-'(8'($2"88'$0'+$>3/.+$@'+'-8#$b'8"#8"#'($"3#)'@-&0'8A$!"#$/'8"#8"#-'+8'$h8"0-3/$,'-)8'$#-92$#.<.2&$=]+$0"#$YhB$"&#$"392$=]+$0"#$Sfh$"&#$(')"8-P'+$S+.)(.#'="*8.+$-($0'+$/3&8-P"+-"8'($1.XFI')+'##-.($ 6`+-0)'<"8'+$ '8$ "&AB$ CDE[7A$ K($ 0'+$ P.+&-')'(0'($ O+@'-8$ <3+0'$ 0-'#'&@'$ _(8'+8'-&3()$"()'<"(08A$K($0'+$3(-P"+-"8'($1.XFI')+'##-.($*.((8'($#.<.2&$@',])&-92$0'#$Yh$"&#$"392$0'#$Sfh$Z"928'-&'$@'-$/'8"#8"#-'+8'+$Q+*+"(*3()$='#8)'#8'&&8$<'+0'($6Yhn$;I$DB\\VW$:$w$DBDDEW$Sfhn$;I$DBJEiW$:$w$DBDCV7A$K($0'+$ /3&8-P"+-"8'($ O("&c#'$ *.((8'$ -/$ ;-(@&-9*$ "3=$ 0"#$ Yh$ 0"#$ >3/.+#8"0-3/$ "&#$ 3("@24()-)'+$S+.)(.#'="*8.+$'8"@&-'+8$<'+0'($6;I$DBJ\^W$:$w$DBD\C7A$$!-'$>3/.+-(=-&8+"8-.(#8-'='$6>Fh8"0-3/$("92$>ZbF5&"##-=-*"8-.(7$<3+0'$P.($,<'-$O38.+'($"&#$:+.)(.#8-#92$+'&'P"(8$@'+-928'8$6b3+"*"/-$'8$"&AB$CDEEW$h"X'("$'8$"&AB$CDED7A$K($0'+$3(-P"+-"8'($1.XFI')+'##-.($/-8$0'/$Yh$"&#$Q(0:3(*8$,'-)8'$#-92$ -($0'+$P.+&-')'(0'($O+@'-8$0-'$>3/.+-(=-&8+"8-.(#8-'='$ 6;I$DBJ^JW$:$w$DBDCL7$ "&#$#-)(-=-*"(8'+$S+.)(.#':"+"/'8'+A$K/$/3&8-P"+-"8'($b.0'&&$*.((8'$'@'(="&&#$'-($T@'+&'@'(#P.+8'-&$)'#'2'($<'+0'($6;I$DBJE[W$:$w$DBDL^W$>E$l$>C$P#A$>L$l$>\7A$f]+$0"#$:+.)+'##-.(#=+'-'$T@'+&'@'($,'-)8'$#-92$*'-('$h-)(-=-*"(,A$

$

Page 87: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LJ""

L"!"DF B.).:;C&:(;,+$0$

Q-(-)'$h830-'($*.((8'($@'+'-8#$,'-)'(B$0"##$T@'+)'<-928$/-8$'-('/$'+2H28'($I-#-*.$'-(2'+)'28$"($'-('/$%"&&'()"()#*"+,-(./$,3$'+*+"(*'($6Y2$'8$"&AB$CDDJW$a'&,'&$'8$"&AB$CDD^7A$Q-($`bK$S$LD$*)M/y$<"+$-($'-('+$_(8'+#3923()$P.($%+"-(")'$'8$"&A$/-8$'-('/$EBJF="92'($I-#-*.$=]+$0-'$Q(8<-9*&3()$'-('#$111#$"##.,--'+8B$P'+)&-92'($/-8$ 0'($S"8-'(8'(B$ 0'+'($`bK$3(8'+$ CJ$*)M/y$ &")$ 6%+"-()'$ '8$ "&AB$ CDDV7A$ `'8+"928'8$/"($ 0"#$P.+&-')'(0'$5.&&'*8-PB$#.$2"88'($E^$G$0'+$S"8-'(8'($'-('($`bK$]@'+$LD$*)M/yA$Z"92$O()"@'($0'#$I.@'+8$5.92$K(#8-838#$#-(0$-($!'38#92&"(0$0'+,'-8$CJ$G$0'+$Q+<"92#'('($]@'+)'<-928-)A$h./-8$#-(0$-/$P.+&-')'(0'($5.&&'*8-P$ #.)"+$<'(-)'+$S"8-'(8'($ "0-:H#$ "&#$ 03+92#92(-88&-92$ -($ 0'+$ %'#"/8@'PH&*'+3()A$!-'#$ &4##8$ #-92$"&&'+0-()#$/H)&-92'+<'-#'$03+92$'-('$'P'(83'&&$"3=8+'8'(0'$>3/.+*"92'X-'$3(0$'-('$0"/-8$'-(2'+)'2'(0'$e'+=4&#923()$0'+$Q+)'@(-##'$'+*&4+'(A$!-'$>2'.+-'$'-('#$'+2H28'($I-#-*.#$@'-$O0-:.#-8"#$ &-'R$#-92$ -($0'+$P.+&-')'(0'($O+@'-8$(-928$@'#848-)'(A$$!-'$Q+*+"(*3()$"($!-"@'8'#$/'&&-83#$)-&8$"&#$<'-8'+'+$I-#-*.="*8.+$=]+$0"#$111$6a'&,'&$'8$"&AB$CDD^7A$!'/$%'#3(02'-8#@'+-928$"3#$0'/$N"2+$CDE[$0'+$!'38#92'($!-"@'8'#$%'#'&&#92"=8$,3=.&)'$#-(0$-($!'38#92&"(0$^$F$i$G$0'+$ '+<"92#'('($`'PH&*'+3()$ "($>c:FKKF!-"@'8'#$ '+*+"(*8$ 6!"(('$U$g-')&'+B$ CDE[7A$ K($ 3(#'+'+$h830-'()+3::'$<"+$@'-$E[$G$0'+$S"8-'(8'($0-'$!-")(.#'$'-('#$!-"@'8'#$/'&&-83#$>c:$KK$@'*"((8A$K/$e'+)&'-92$,3+$ Z.+/"&@'PH&*'+3()$ ,'-)8$ #-92$ #./-8$ '-('$ e'+0.::&3()$ 0'+$ S+4P"&'(,$ -($ 0'+$ h830-'(*.2.+8'A$ !-'$Q+*+"(*3()$"($>c:FKKF!-"@'8'#$*"(($#./-8$"&#$/H)&-92'+$I-#-*.="*8.+$"()'#'2'($<'+0'(A$K($'-('+$h830-'$/-8$[DVL$S"8-'(8'($ <"+$ 0-'$ Q+*+"(*3()$ "($ >c:FKKF!-"@'8'#$ (3+$ =]+$ <'-@&-92'$ h830-'(8'-&('2/'+$ /-8$ '-('/$'+2H28'($I-#-*.$ =]+$0-'$Q+*+"(*3()$"($'-('/$%"&&'()"()#*"+,-(./$"##.,--'+8B$ =]+$b4(('+$*.((8'$0-'#'+$g3#"//'(2"()$(-928$)','-)8$<'+0'($6;3"()$'8$"&AB$CDE[7A$!")')'($<"+'($-($0'+$P.+&-')'(0'($O+@'-8$CL$G$0'+$b4(('+$"($'-('/$>c:FKKF!-"@'8'#$'+*+"(*8B$@'-$0'($f+"3'($,'-)8'$#-92$/-8$[B^$G$'-('$S+4P"&'(,$<-'$-($0'+$%'#"/8@'PH&*'+3()A$$a'&,'&$ '8$ "&A$ *.((8'($ -($ -2+'/$ 5.&&'*8-P$ P.($ EDi\$S"8-'(8'($ /-8$ '-('+$ Q+*+"(*3()$ "($ '-('/$%"&&'()"()#*"+,-(./$ '-('$ '+2H28'$ S+4P"&'(,$ =]+$ #.<.2&$ bA$ 1+.2($ "&#$ "392$ 1.&-8-#$ 3&9'+.#"$ ='#8#8'&&'($6a'&,'&$'8$"&AB$CDD^7A$K($'-('+$b'8""("&c#'$<3+0'$ -($0'+$Z.+/"&@'PH&*'+3()$=]+$0'($bA$1+.2($P.($'-('+$S+4P"&'(,$P.($DBLC$G$6LCCMEDDDDD7$@'+-928'8B$=]+$0-'$1.&-8-#$3&9'+.#"$@'&-'=$#-'$#-92$"3=$DBJ$G$6JDJMEDDDDD7$6b.&.0'9*c$'8$"&AB$CDEC7A$e'+)&-92'($/-8$0-'#'($Q+)'@(-##'($&4##8$#-92$-($0'+$P.+&-')'(0'($O+@'-8$'-('$'+2H28'$Q+*+"(*3()#243=-)*'-8$"($1Q!#$='#8#8'&&'(A$`'-$0'+$K(8'+:+'8"8-.($0-'#'+$Q+)'@(-##'$#'-$"@'+$"3=$0-'$)'+-()'($f"&&,"2&'($2-()'<-'#'(A$$Q-('$K(='*8-.($"($'-('+$92+.(-#92'($;':"8-8-#$`F$.0'+$;':"8-8-#$1FK(='*8-.($'+2H28$'@'(="&&#$0"#$I-#-*.B$"($'-('/$%"&&'()"()#*"+,-(./$,3$'+*+"(*'(A$f]+$0"#$'X8+"2':"8-#92'$111$*.((8'$@-#&"()$*'-('$O##.,-"8-.($/-8$'-('+$Q+*+"(*3()$"($;':"8-8-#$`$.0'+$;':"8-8-#$1$='#8)'#8'&&8$<'+0'($6Q&Fh'+")$'8$"&AB$CDDVW$?''$'8$"&AB$CDEJW$ h2"-@$ '8$ "&AB$ CDDJ7A$ Q#$ ,'-)8$ #-92$ "&&'+0-()#$ -($ 0'+$ ?-8'+"83+$ '-($ 0'38&-92'+$ _(8'+#92-'0$ ,<-#92'($"#-"8-#92'($3(0$<'#8&-92'($h830-'(A$h.$<"+$@'-$"#-"8-#92'($111F5.&&'*8-P'($'-('$0'38&-92$'+2H28'$S+4P"&'(,$"($;':"8-8-#$`FK(='*8-.('($='#8,3#8'&&'($6?''$'8$"&AB$CDEJW$?-$'8$"&AB$CDEC7B$<.2-()')'($-($,<'-$"/'+-*"(-#92'($h830-'($'-('$'+2H28'$;43=-)*'-8$"($;':"8-8-#$1FK(='*8-.('($"3=8+"8$6Q&Fh'+")$'8$"&AB$CDDVW$h2"-@$'8$"&AB$CDDJ7A$!-'#'+$ _(8'+#92-'0$ ,<-#92'($ "/'+-*"(-#92'($ 3(0$ "#-"8-#92'($ h830-'($ *"(($ 'P'(83'&&$ /-8$ 0'+$ '+2H28'($K(,-0'(,$"($;':"8-8-#$`B$@''-(=&3##8$P.($_/<'&8="*8.+'($3(0$?'@'(#<'-#'$-($0'($"#-"8-#92'($?4(0'+($'+*&4+8$<'+0'(A$K($0'($<'#8&-92'($?4(0'+($8+-88$'-('$K(='*8-.($/-8$;':"8-8-#$1$243=-)'+$"3=$"&#$'-('$Q+*+"(*3()$"($;':"8-8-#$̀ $6?-$'8$"&AB$CDEC7A$h./-8$-#8$2-'+$'P'(83'&&$'-('$_(8'+#92'-03()$,<-#92'($"#-"8-#92'($3(0$<'#8&-92'($?4(0'+($(.8<'(0-)A$K($0'+$P.+&-')'(0'($O+@'-8$<"+$@'-$EBV$G$0'+$S"8-'(8'($0'#$5.&&'*8-P#$'-('$;':"8-8-#$`$@'*"((8B$'-($S"8-'(8$6DBV$G7$<"+$"($'-('+$;':"8-8-#$1$'+*+"(*8A$P8$7*+$0a<-7;*$G-+$?*6-87%*;<$T+15A%6*8*+$;8$)*-<6A%35874$1*;6*8$b=^$G$0'+$`'PH&*'+3()$b"+*'+$=]+$'-('$"@)'&"3='('$;':"8-8-#$1Fe-+3#FK(='*8-.($"3=B$JBE$G$2"88'($'-('$K(='*8-.($/-8$0'/$;':"8-8-#$`Fe-+3#$03+92&"3='($6S.'82*.Fb3&&'+$'8$"&AB$CDEL7A$e'+)&'-928$/"($0-'#'$g"2&'($/-8$0'($!"8'($0'+$P.+&-')'(0'($O+@'-8B$#.$#8'&&8$/"($='#8B$0"##$0-'$Q+*+"(*3()#243=-)*'-8'($(.92$ 3(8'+$ 0'+$ !3+92#92(-88#@'PH&*'+3()$ &-')'(A$ K($ 0'+$ P.+&-')'(0'($ O+@'-8$ *.((8'$ #./-8$ *'-($g3#"//'(2"()$ ,<-#92'($ 0'+$ Q+*+"(*3()$ "($ '-('+$ e-+3#2':"8-8-#$ 3(0$ 0'+$ Q+*+"(*3()$ "($ '-('/$92.&"()-.,'&&3&4+'($5"+,-(./$='#8)'#8'&&8$<'+0'(A$$

Page 88: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LL""

O392$0'+$%'(3##$P.($Z-*.8-($3(0$O&*.2.&$@')](#8-)8$0-'$Q(8#8'23()$'-('#$12.&"()-.*"+,-(./#$6%+"-()'$'8$"&AB$CDDVW$a3$'8$"&AB$CDDV7A$!-'$g"2&'($,3/$Z-*.8-(F$3(0$"392$O&*.2.&"@3#3#$@'-/$P.+&-')'(0'($5.&&'*8-P$&"##'($'-('$e'+,'++3()$P'+/38'(A$̀ '-$0+'-$0'+$S"8-'(8'($6CBiL$G7$@'#8"(0$'-($@'*"((8'+$Z-*.8-("@3#3#A$Z"92$O3##")'$0'#$!+.)'($3(0$h3928@'+-928#$0'+$`3(0'#+')-'+3()$&-')8$0'+$O(8'-&$0'+$I"392'+$-($0'+$`'PH&*'+3()$@'-$9"A$LD$G$6`3(0'#+')-'+3()B$CDEL7A$12+.(-#92'+$O&*.2.&"@3#3#$<"+$@'-$P-'+$S"8-'(8'($@'*"((8$6LB^^$G7A$%'/4R$0'+$!Q%OFh830-'$0'#$I.@'+8F5.92FK(#8-838#$ &-')8$03+92#92(-88&-92$@'-$C^$G$0'+$`'PH&*'+3()$'-($I-#-*.*.(#3/$P.+$6?"()'$U$I.@'+8F5.92FK(#8-838B$CDEE7$A$!-'$#8"+*'$O@<'-923()$0'+$!"8'($0'#$5.&&'*8-P#$*"(($/"($<./H)&-92$-/$I"2/'($'-('#$h.9-"&F`-"#$'+*&4+'(A$

$

L"!"HF GY<>%:$;(+$K05$40Z+,$<+(&)(&).+,5$60$

O3=)+3(0$0'+$3("3==4&&-)'($5&-(-*$<-+0$0"#$%"&&'()"()#*"+,-(./$.=8$'+#8$-($'-('/$=.+8)'#92+-88'('($h8"0-3/$0-")(.#8-,-'+8B$ /'-#8$ 2"8$ 0'+$ >3/.+$ ,3/$ g'-8:3(*8$ 0'+$ Q+#80-")(.#'$ #92.($ ?c/:2*(.8'(F$ 3(0M.0'+$f'+(/'8"#8"#'($"3#)'@-&0'8A$K($0'+$P.+&-')'(0'($O+@'-8$,'-)8'($,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$\^BC$G$0'+$S"8-'(8'($?c/:2*(.8'(/'8"#8"#'($3(0$LL$G$0'+$S"8-'(8'($f'+(/'8"#8"#'(B$@'-$E^BV$G$0'+$S"8-'(8'($2"88'$0'+$>3/.+$#.<.2&$?c/:2*(.8'(F$"&#$"392$f'+(/'8"#8"#'($"3#)'@-&0'8A$`'-$"&&'($S"8-'(8'(B$0-'$"($'-('/$011O$ '+*+"(*8$ <"+'(B$ <"+$ (.92$ *'-('$ f'+(/'8"#8"#-'+3()$ '-()'8+'8'(A$ !"#$ %"&&'()"()#*"+,-(./$/'8"#8"#-'+8$ =+]2$ &c/:2.)'(B$ @'-$ Q+#8P.+#8'&&3()$ ,'-)'($ 3()'=42+$ 0-'$ ;4&=8'$ "&&'+$ S"8-'(8'($?c/:2*(.8'(/'8"#8"#'($652"($'8$"&AB$CDECW$b3+"*"/-$'8$"&AB$CDEE7A$Q-('$f'+(/'8"#8"#-'+3()$0'#$111#$-#8$(-928$ 0-'$ I')'&$ 3(0$ 8+-88$ /'-#8$ -($ =.+8)'#92+-88'('($ Q+*+"(*3()##8"0-'($ "3=A$ O/$ 243=-)#8'($ *.//'($b'8"#8"#'($-($0'+$?'@'+$P.+B$)'=.&)8$P.($S'+-8.('"&FB$?3()'(F$3(0$5(.92'(Fb'8"#8"#'($6Q9*/"(($'8$"&AB$CDEEW$Y*3#"*"$'8$"&AB$CDD[7A$K/$P.+&-')'(0'($5.&&'*8-P$,'-)8'$#-92$'-('$42(&-92'$e'+8'-&3()$0'+$?.*"&-#"8-.($0'+$b'8"#8"#'($6?'@'+n$CEMLJW$S'+-8.('3/n$iMLJW$?3()'n$JMLJ7A$_(8'+#3928$<3+0'$"392B$.@$>3/.+'$-($'-('/$(-'0+-)'+'($>Fh8"0-3/$#'&8'('+$f'+(/'8"#8"#'($'(8<-9*'&8'($"&#$>3/.+'$-($'-('/$2H2'+'($>Fh8"0-3/A$!-'#$&-'R$#-92$"($3(#'+'/$5.&&'*8-P$(-928$@'#848-)'($6#-'2'$>"@'&&'$CD$3(0$>"@'&&'$CE7A$$$K($ '-('/$ *"("0-#92'($ 5.&&'*8-P$ /-8$ ED[$S"8-'(8'($ <"+$ @'+'-8#$ 0'+$ b'8"#8"#-'+3()##8"83#$ "&#$ (')"8-P'+$S+.)(.#'="*8.+$ @',])&-92$ 0'#$ YP'+"&&$ h3+P-P"&#$ @'#92+-'@'($ <.+0'($ 6S'-X.8.$ '8$ "&AB$ CDE\7A$ K($ 0'+$P.+&-')'(0'($O+@'-8$*.((8'$'-('$b'8"#8"#-'+3()$6bFh8"0-3/B$#-'2'$>ZbF5&"##-=-*"8-.(7$-($0'+$3(-P"+-"8'($1.XFI')+'##-.($/-8$ '-('/$ (')"8-P'($ Q-(=&3##$ "3=$ 0"#$YP'+"&&$ h3+P-P"&$ 6:$w$DBDD\W$;I$DBJ7$ 3(0$ "3=$ 0"#$:+.)+'##-.(#=+'-'$ T@'+&'@'($ 6;I$DBCJ^W$ :$v$DBDDE7$ -($ g3#"//'(2"()$ )'@+"928$ <'+0'(A$ O392$ -($ 0'+$/3&8-P"+-"8'($O("&c#'$,'-)8'$#-92$0'+$_(8'+#92-'0$-($`',3)$"3=$0"#$Yh$6;I$DBJ[\W$:$w$DBD\C7$3(0$"3=$0"#$Sfh$6;I$DBDV^W$:$v$DBDDE7$#-)(-=-*"(8A$$

Page 89: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LR""

L"!"LF G&2;,[+,(+0$

!-'$?"@.+<'+8'$<3+0'($,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$'+2.@'(A$`'-$0'+$Q+2'@3()$0'#$1OEVFV$3(0$0'#$1QOFa'+8'#$<3+0'($ -($ '-('/$ ,<'-8'($`'+'92(3()##92+-88$ 0-'$ S"8-'(8'($ "3#)'#92&.##'(B$ 0'+'($`-&-+3@-($/'2+$"&#$0"#$EBJF="92'$0'#$I'='+'(,<'+8'#$@'8+3)B$0"$'#$0"(($,3$'-('+$e'+=4&#923()$0-'#'+$>3/.+/"+*'+$*.//'($*"(($6h92&-'/"($'8$"&AB$CDDL7A$Y2('$0'($O3##92&3##$P.($Ci$S"8-'(8'($"3=)+3(0$0'#$̀ -&-+3@-(Fa'+8'#$,'-)8'($="#8$iD$G$0'+$S"8-'(8'($0'#$5.&&'*8-P#$'-('($'+2H28'($1OEVFVFa'+8A$a3+0'($0-'#'$S"8-'(8'($(-928$@'+]9*#-928-)8$ <"+$ 0'+$ 1OEVFVFa'+8$ (.92$ @'-$ 9"A$^J$G$ ]@'+$ 0'+$Z.+/A$!"#$O3=8+'8'($ P.($ 1OEVFV$ -#8$"@24()-)$ P.($ 0'+$ >+4)'+#92"=8$ 0'#$ ?'<-#FO(8-)'(#A$ Q#$ -#8$ ,3$ @'"928'(B$ 0"##$ ^$G$ 0'+$ `'PH&*'+3()$ 0"#$?'<-#FO(8-)'($(-928$8+")'($3(0$1OEVFV$#./-8$(-928$)'/'##'($<'+0'($*"(($6Z'2&#$'8$"&AB$CDD\7A$`'-$i$0'+$ED[$S"8-'(8'($ 6^B[$G7$0'#$5.&&'*8-P#$<"+$*'-($1OEVFVFa'+8$@'*"((8B$'P'(83'&&$2"(0'&8$'#$#-92$@'-$0-'#'($S"8-'(8'($3/$?'<-#FO(8-)'($(')"8-P'$S"8-'(8'(A$`'8+"928'8$/"($0'($1QOFa'+8B$#.$,'-)8$#-92$'-('$Q+2H23()$@'-$@'-0'($%+3::'($6/-8$3(0$.2('$O3##92&3##$@'-$'+2H28'/$`-&-+3@-(7$@'-$'-('/$e-'+8'&$0'+$S"8-'(8'(A$$!-'#$0'9*8$#-92$-($'8<"$/-8$0'($O()"@'($-($0'+$?-8'+"83+$6123()$'8$"&AB$CDEEW$h"X'("$'8$"&AB$CDED7A$Q-('$5.++'&"8-.($,<-#92'($ 0'+$ Q+2H23()$ 0'#$ 1QOF$ 3(0$ 0'#$ 1OEVFVFa'+8'#$ &-'R$ #-92$ @'-/$ P.+&-')'(0'($5.&&'*8-P$ (-928$='#8#8'&&'(A$K($'-('+$h830-'$/-8$EVC$S"8-'(8'($<3+0'$)','-)8B$0"##$'-('$Q+2H23()$@'-0'+$a'+8'$6Z.+/<'+8'n$1OEVFV$U$L^$_M&W$ 1QO$U$\B[$ ()M/&7$/-8$ '-('/$ P'+/'2+8'($O3=8+'8'($ P.($ ?'@'+/'8"#8"#'($ '-(2'+)'28$6Z'2&#$'8$"&AB$CDD\7A$K/$P.+&-')'(0'($5.&&'*8-P$,'-)8'$#-92$@'-$="#8$0'+$;4&=8'$0'+$S"8-'(8'(B$@'-$0'('($@'-0'$b"+*'+$]@'+$0-'$Z.+/$'+2H28$<"+'($6\^BE$G7$'-('$b'8"#8"#-'+3()$-($0-'$?'@'+A$!")')'($*"/$'#$@'-$0'($S"8-'(8'(B$0'+'($>3/.+/"+*'+$3(8'+2"&@$0'+$%+'(,<'+8'$&")'($(3+$@'-$CCBC$G$,3$'-('+$?'@'+/'8"#8"#-'+3()A$K($'-('/$5.&&'*8-P$/-8$EDE$S"8-'(8'($*"/$'#$@'-$0'('(B$0'+'($:+4.:'+"8-P'+$1OEVFVFa'+8$]@'+$0-'$Z.+/$'+2H28$<"+B$ P'+/'2+8$ ,3$I',-0-P'($ 6123()$ '8$ "&AB$ CDDV7A$!-'#$ &-'R$ #-92$ -($ 0'+$ P.+&-')'(0'($O+@'-8$ (-928$@'#848-)'(A$`'-$[$P.($CE$S"8-'(8'($6CiB[$G7$/-8$'-('/$1OEVFVFa'+8$U$L^$_M&$3(0$@'-$CC$P.($iJ$S"8-'(8'($6CJBV$G7$/-8$'-('/$]@'+$0-'$Z.+/$'+2H28'($1OEVFV$*"/$'#$,3$'-('/$I',-0-PA$`'+'-8#$-($/'2+'+'($h830-'($<3+0'($1OEVFV$3(0$1QO$"&#$"04j3"8'$S+.)(.#'="*8.+'($-/$*3+"8-P'($O(#"8,$@'#92+-'@'($6N-"()$'8$"&AB$CDEEW$I-@'+.$'8$"&AB$CDECW$>A$>A$a"()$'8$"&AB$CDEL7A$K($3(#'+'/$5.&&'*8-P$&")$1OEVFV$(3+$@'-$CEB\$G$0'+$S"8-'(8'($@'-$a'+8'($U$L^$_M&B$ #.0"##$ '-('$_(8'+8'-&3()$ -($%+3::'($ "(2"(0$0-'#'#$%+'(,<'+8'#$(-928$ "&#$ #-((P.&&$'+"928'8$<3+0'A$Q-($1OEVFV$938F.==$P.($EDDD$_M&$,'-)8'$#-92$@'+'-8#$=]+$0"#$S"(*+'"#*"+,-(./$"&#$)''-)('8$,3+$ :'+-.:'+"8-P'($ I-#-*.'-(#9248,3()$ 6f'++.('$ '8$ "&AB$ CDD[7$ 3(0$ '+<-'#$ #-92$ "392$ =]+$ 0"#$%"&&'()"()#*"+,-(./$"&#$ -0'"&'+$>+'((<'+8A$K($0'+$3(-P"+-"8'($O("&c#'$*.((8'($#-)(-=-*"(8'$_(8'+#92-'0'$,<-#92'($0'($@'-0'($%+3::'($ -/$;-(@&-9*$"3=$Yh$3(0$Sfh$'+,-'&8$<'+0'($6:$w$DBDDE$ -($@'-0'($f4&&'(7A$a3+0'($ d'0.92$0-'$S"8-'(8'($"3#)'#92&.##'(B$0'+'($`-&-+3@-($x$EBJF/"&$I'='+'(,<'+8$<"+B$'+)"@$#-92$(3+$(.92$ =]+$ 0"#$ Yh$ '-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ 6:$w$DBDDE7$ 6#-'2'$ >"@'&&'$ L\$ 3(0$ >"@'&&'$ LJ7A$ K($ 0'+$/3&8-P"+-"8'($O("&c#'$*.((8'$(3+$ -/$;-(@&-9*$"3=$0"#$Sfh$'-($ #-)(-=-*"(8'+$_(8'+#92-'0$)'#'2'($<'+0'($6;I$DBL[VW$:$w$DBDEL7A$h./-8$*H((8'$'-($1OEVFVFa'+8$/-8$'-('/$938F.==$P.($EDDD$_M&$"&#$)''-)('8'+$f"*8.+$,3+$I-#-*.#8+"8-=-,-'+3()$0-'('(A$$_/$ '-('($ K(=.+/"8-.(#P'+&3#8$ 03+92$ 0-'$ Q-(8'-&3()$ '-('+$ *.(8-(3-'+&-92'($ e"+-"@&'$ -($ %+3::'($ ,3$P'+/'-0'(B$ <3+0'($ "&&'$ *.(8-(3-'+&-92'($ e"+-"@&'($ 6?"@.+:"+"/'8'+7$ ("92$ 0'+$ >+"(#=.+/"8-.($ -($ 0'($("8]+&-92'($?.)"+-82/3#$'+('38$-($0"#$1.XFI')+'##-.(#/.0'&&$'-()'=])8A$$f]+$ 0'($ &.)$z1OEVFV{$ '+)"@'($ #-92$ -($ 0'+$ 3(-P"+-"8'($ O("&c#'$ #.<.2&$ -($ `',3)$ "3=$ 0"#$Yh$ 6;I$EBCJCW$:$v$DBDDE7$ "&#$ "392$ -($ `',3)$ "3=$ 0"#$ Sfh$ 6;I$EBCCEW$ :$w$DBDDJ7$ #-)(-=-*"(8'$ Q+)'@(-##'A$ K($ '-('/$/3&8-P"+-"8'($1.XFb.0'&&$/-8$0'/$Q(0:3(*8$Yh$,'-)8'$#-92$&.)$z1OEVFV{$"&#$#-)(-=-*"(8'+$S+.)(.#'="*8.+$6;I$EBLVDW$ :$v$DBDDE7B$ -($ `',3)$ "3=$ 0"#$ Sfh$<"+'($ #.<.2&$ 1OEVFV$ 6;I$DBL[VW$ :$w$DBDEL7$ "&#$ "392$ 0'+$&.)$z1OEVFV{$6;I$EBCDCW$:$w$DBDLD7$#8"8-#8-#92$#-)(-=-*"(8A$$p2(&-92'$Q+)'@(-##'$'+)"@$"392$0-'$̀ '8+"9283()$0'#$>3/.+/"+*'+#$1QOA$K($0'+$3(-P"+-"8'($O("&c#'$,'-)8'($#-92$#-)(-=-*"(8'$_(8'+#92-'0'$#.<.2&$ =]+$0"#$Yh$6;I$DB\JiW$:$w$DBDDE7$"&#$"392$=]+$0"#$Sfh$6;I$DB\VLW$:$w$DBDDE7A$O392$2-'+$<3+0'($-($'-('/$,<'-8'($h92+-88$"&&'$S"8-'(8'($"3#)'#92&.##'(B$0'+'($`-&-+3@-(Fa'+8$)+HR'+$"&#$EBJF/"&$ I'='+'(,<'+8$ <"+A$ Q#$ ,'-)8'$ #-92$ '-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ -/$ YP'+"&&$ h3+P-P"&$6Ei$P#A$JBJ$b.("8'W$ :$v$DBDDE7B$(-928$ "@'+$ =]+$0"#$Sfh$ 6VBJ$P#A$L$b.("8'W$:$w$DBEE\7A$ K($0'+$/3&8-P"+-"8'($1.XFI')+'##-.(#"("&c#'$ '+<-'#$ #-92$ 0'+$ >3/.+/"+*'+$ 1QO$ (-928$ "&#$ #-)(-=-*"(8'+$ f"*8.+$ ,3+$I-#-*.#8+"8-=-,-'+3()A$$

Page 90: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

LM""

K($'-('+$d":"(-#92'($h830-'$*.((8'$'-($1IS$U$DBJ$/)M0&$"&#$:.#-8-P'+$S+.)(.#'="*8.+$'8"@&-'+8$<'+0'($6k.2$'8$"&AB$CDE^7A$K($0'+$P.+&-')'(0'($O+@'-8$<3+0'($'-($938F.==$P.($E$/)M0&$P'+<'(0'8$6?"@.++'='+'(,<'+87A$K($0'+$ 3(-P"+-"8'($ O("&c#'$ ,'-)8'($ #-92$ <'0'+$ -/$ ;-(@&-9*$ "3=$ 0"#$ Yh$ (.92$ "3=$ 0"#$ Sfh$ #-)(-=-*"(8'$_(8'+#92-'0'A$K/$/3&8-P"+-"8'($b.0'&&$#8'&&8'$#-92$1IS$v$E$/)M0&$"&#$3("@24()-)'+$:.#-8-P'+$S+.)(.#'="*8.+$-($;-(@&-9*$ "3=$ 0"#$Sfh$2'+"3#$ 6;I$DBCV[W$ :$w$DBDL[7A$Q-(-)'$O38.+'($ '/:="2&'($ 0-'$O(<'(03()$ '-('#$938F.==#$ P.($ J$/)M0&$ 6>"("*"$ '8$ "&AB$ CDDiW$_'(.$ '8$ "&AB$ CDDD7A$b-8$ 0-'#'+$b'82.0'$ &-'R$ #-92$ "($ 3(#'+'/$5.&&'*8-P$*'-('$h-)(-=-*"(,$-($0'+$3(-P"+-"8'($I')+'##-.(#"("&c#'$<'0'+$-($`',3)$"3=$0"#$Yh$(.92$"3=$0"#$Sfh$'++'-92'(A$!'+$&.)$z1IS{$'+<-'#$#-92$-($0'+$/3&8-P"+-"8'($O("&c#'$-($`',3)$"3=$0"#$Sfh$"&#$)''-)('8'+$f"*8.+$,3+$I-#-*.#8+"8-=-,-'+3()$6;I$DBJVVW$:$w$DBDLC7B$(-928$d'0.92$-/$;-(@&-9*$"3=$0"#$YhA$$Q-('$O(4/-'$8+-88$243=-)$@'-$"&&'($O+8'($P.($>3/.+'+*+"(*3()'($"3=B$#.$*.((8'$"392$@'-/$P.+&-')'(0'($5.&&'*8-P$ @'-$ ="#8$ 0'+$;4&=8'$ 0'+$S"8-'(8'($ '-('$;@F5.(,'(8+"8-.($v$EL$)M0&$ )'/'##'($<'+0'(A$ K($ '-('+$)+.R'($@+-8-#92'($h830-'$2"88'$0"#$e.+&-')'($'-('+$O(4/-'$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$'-('($(')"8-P'($Q-(=&3##$"3=$0"#$Yh$3(0$0"#$Sfh$6`+-0)'<"8'+$'8$"&AB$CDE[7A$!-'#$*.((8'$P.($S'-X.8.$'8$"&A$(-928$@'#848-)8$<'+0'($6S'-X.8.$'8$"&AB$CDE\7A$K/$P.+&-')'(0'($5.&&'*8-P$*.((8'$'-($;4/.)&.@-($v$EL$)M0&$#.<.2&$-($0'+$3(-F$ "&#$ "392$ -($0'+$/3&8-P"+-"8'($O("&c#'$ "&#$(')"8-P'+$S+.)(.#'="*8.+$ =]+$0"#$YP'+"&&$ h3+P-P"&$ @'#848-)8$<'+0'($63(-P"+-"8n$i$P#A$EV$b.("8'W$;I$EBV[LW$:$w$DBDD\W$/3&8-P"+-"8n$;I$EBi^W$:$w$DBD\[7B$(-928$"@'+$=]+$0"#$:+.)+'##-.(#=+'-'$T@'+&'@'($6;I$EBLCCW$:$w$DBLLV7A$O392$0'+$&.)$z;@{$,'-)8'$#-92$-/$;-(@&-9*$"3=$0"#$Yh$"&#$3("@24()-)'+$f"*8.+$,3+$I-#-*.#8+"8-=-,-'+3()$6;I$DBDL\W$:$w$DBDL\7A$$h.<.2&$'-('$Q+2H23()$0'#$`-&-+3@-(Fa'+8'#$"&#$"392$'-('$Q+2H23()$0'+$?'3*.,c8'($,'-)8'$#-92$-($0'+$h830-'$P.($ `+-0)'<"8'+$ '8$ "&A$ "&#$ "04j3"8'+$ f"*8.+$ ,3+$ I-#-*.#8+"8-=-,-'+3()$ 6:$w$DBDi7A$ K($ 0-'#'+$ O+@'-8$ <3+0'$"&&'+0-()#$'-($h-)(-=-*"(,(-P'"3$P.($:$v$DBE$P'+<'(0'8$6`+-0)'<"8'+$'8$"&AB$CDE[7A$_(8'+$0'+$O(("2/'$0-'#'#$h-)(-=-*"(,(-P'"3#$*.((8'$-($0'+$P.+&-')'(0'($O+@'-8$'-('$?'3*.,c8'("(,"2&$v$EE$%M&$-($0'+$/3&8-P"+-"8'($O("&c#'$ -($ `',3)$ "3=$ 0"#$ Yh$ "&#$ :.#-8-P'+$ S+.)(.#'="*8.+$ '8"@&-'+8$ <'+0'($ 6;I$DBJCVW$ :$w$DBDi7A$ $ Q-($`-&-+3@-(Fa'+8$v$E$/)M0&$ ,'-)8'$ #-92$ -($ 0'+$/3&8-P"+-"8'($O("&c#'$ -/$;-(@&-9*$ "3=$ 0-'$ Sfh$ "&#$ :.#-8-P'+$S+.)(.#'="*8.+$6;I$DBL[VW$:$w$DBDEE7A$

$

L"!"MF 1%+,&>.+0

L"!"M"!F @5,&(.*+01%+,&>.+0$

e.+"3##'8,3()$=]+$'-('$*3+"8-P'$>2'+":-'$-#8$0-'$&.*"&'$`')+'(,3()$0'#$>3/.+#B$'#$#.&&8'$"&#.$-($0'+$I')'&$*'-('$b'8"#8"#-'+3()$ P.+&-')'(A$!"$ 0-'$!-")(.#'$ 0'+$ Q+*+"(*3()$ 243=-)$ '+#8$ -($ '-('/$ =.+8)'#92+-88'('($h8"0-3/$='#8)'#8'&&8$<-+0$6I-,P-$U$%.+'#B$CDEL7B$-#8$0'/'(8#:+'92'(0$0-'$O(,"2&$0'+$S"8-'(8'(B$0-'$#-92$'-('+$*3+"8-P'($ Y:'+"8-.($ 3(8'+,-'2'($ *H(('(B$ @')+'(,8A$ a-'$ @'+'-8#$ '+<42(8$ <'+0'($ <'-8'+$ 0-#8"&$ )'&')'('$%"&&'()"()#*"+,-(./'$/'-#8$-($=+]2'+'($h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a'@'+$'8$"&A$:.#83&-'+8'($0'($Z38,'($'-('+$h8")-()F?":"+.#*.:-'$@'-/$%"&&'()"()#*"+,-(./A$ K($ -2+'+$h830-'$<"+'($0-'$:'+-2-&4+'($%"&&'()"()#*"+,-(./'$ P.($ J[$S"8-'(8'($ 03+92$ @-&0)'@'(0'$ e'+="2+'($ "&#$ +'#'*8"@'&$ '-()'#83=8$ <.+0'(A$K(8+".:'+"8-P$ ,'-)8'$ #-92$ d'0.92$ @'-$ E\$ 6CJ$G7$ S"8-'(8'($ '-('$ ,3$ =.+8)'#92+-88'('$ Q+*+"(*3()A$ Q-('$:+4.:'+"8-P'$?":"+.#*.:-'$*H((8'$@'-$EML$0'+$S"8-'(8'($'-('$?":"+.8./-'$P'+2-(0'+($6a'@'+$'8$"&AB$CDDC7A$O392$ "/$ P.+&-')'(0'($ S"8-'(8'()38$ <3+0'$ :+-/4+$ @'-$ J\$S"8-'(8'($ 0-'$ !3+92=]2+3()$ '-('+$ *3+"8-P'($Y:'+"8-.($)':&"(8A$!-'#'$/3##8'$"&&'+0-()#$@'-$E[B[$G$0'+$S"8-'(8'($-(8+".:'+"8-P$"&#$'X:&.+"8-P'$?":"+.8./-'$@'-$ ,3$ <'-8$ =.+8)'#92+-88'('+$ Q+*+"(*3()$ "@)'@+.92'($<'+0'(A$ K($ 0'+$5":&"(Fb'-'+FO("&c#'$ ,'-)8'$ #-92$-(('+2"&@$0'+$S"8-'(8'()+3::'B$0-'$*3+"8-P$82'+":-'+8$<3+0'B$'+<"+83()#)'/4R$'-($#-)(-=-*"(8$&4()'+'#$YP'+"&&$h3+P-P"&$P.($EV$b.("8'($6:$w$DBDDE7A$$

Page 91: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RT""

K($0'+$P.+&-')'(0'($+'8+.#:'*8-P'($O("&c#'$*.((8'($ -(#)'#"/8$[[B^$G$0'+$S"8-'(8'($ID$+'#',-'+8$<'+0'(A$!-'#'$Q+)'@(-##'$#-(0$P'+)&'-92@"+$/-8$0'($O()"@'($"(0'+'+$h830-'(B$@'-$0'('($'-('$IDFI'#'*8-.($-($+3(0$^J$G$0'+$f4&&'$/H)&-92$<"+$6%3)&-'&/-$'8$"&AB$CDDVW$?-$'8$"&AB$CDE\W$b3+"*"/-$'8$"&AB$CDEE7A$`'8+"928'8'$/"($0-'$'-(,'&('($?.*"&-#"8-.('($-#.&-'+8B$#.$=-'&$"3=B$0"##$-/$P.+&-')'(0'($5.&&'*8-P$(3+$\[$G$0'+$S"8-'(8'(B$0'+'($111$ :'+-2-&4+$ &.*"&-#-'+8$ <"+B$ IDF+'#',-'+8$ <'+0'($ *.((8'A$b3+"*"/-$ '8$ "&A$ *.((8'($ @'-$ 0'($ :11O#$ @'-$0'38&-92$)+HR'+'($f"&&,"2&'($6($w$JD7$-($^\$G$0'+$f4&&'$(')"8-P'$I'#'*8-.(#+4(0'+$'++'-92'($6b3+"*"/-$'8$"&AB$ CDEE7A$ O392$ @'-$ '-('/$ )+.R'($ >'-&$ 0'+$ S"8-'(8'($ /-8$ '-('/$ -(8+"2':"8-#92$ .0'+$ 'X8+"2':"8-#92$&.*"&-#-'+8'($%"&&'()"()#*"+,-(./$ *.((8'$ '-('$IDFI'#'*8-.($ '++'-928$<'+0'($ 6-11On$[C$GW$ 011On$iD$G7$6b3+"*"/-$'8$"&AB$CDEE7A$%'&"()$'-('$Q(8='+(3()$0'#$%"&&'()"()#*"+,-(./#$-/$)'#3(0'($%'<'@'B$2"88'$0-'#$'-('$#-)(-=-*"(8'$O3#<-+*3()$"3=$0"#$T@'+&'@'($6?3.$'8$"&AB$CDE\W$b3+"*"/-$'8$"&AB$CDEE7A$K($0'+$P.+&-')'(0'($O+@'-8$ *.((8'$ -($ 0'+$ 5":&"(Fb'-'+FO("&c#'$ *'-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ 2-(#-928&-92$ 0'#$ T@'+&'@'(#$='#8)'#8'&&8$<'+0'($6/'0-"('$T@'+&'@'(#,'-8'(n$ID$w$EVBJ$b.("8'W$IE$w$E^$b.("8'W$:$w$DBiJ7A$$[CBC$G$0'+$*3+"8-P$82'+":-'+8'($S"8-'(8'($0'#$P.+&-')'(0'($5.&&'*8-P#$'+&-88'($'-($I',-0-PA$!-'#$@'8+"=$^E$G$0'+$ S"8-'(8'(B$ @'-$ 0'('($ '-('$ IDFI'#'*8-.($ 0'#$ >3/.+#$ /H)&-92$ <"+B$ 0")')'($ "@'+$ (3+$ JD$G$ 0'+$IEF+'#',-'+8'($S"8-'(8'(A$g30'/$@'8+3)$0"#$/'0-"('$*+"(*2'-8#=+'-'$K(8'+P"&&$("92$IDFI'#'*8-.($^$b.("8'B$("92$IEFI'#'*8-.($0")')'($CD$b.("8'A$̀ '-$=](=$0'+$S"8-'(8'($6E^BV$G7$<3+0'$0"#$I',-0-P$03+92$'-('$'+('38'$Y:'+"8-.($82'+":-'+8B$,<'-$0"P.($'(8<-9*'&8'($'-($,<'-8'#$I',-0-PA$CD$S"8-'(8'($'+2-'&8'($("92$0'/$O3=8+'8'($'-('#$I',-0-P#$'-('$:"&&-"8-P'$12'/.82'+":-'A$K($'-('/$42(&-92$)+.R'($5.&&'*8-P$6($w$\D7$*.((8'$@'-$^D$G$0'+$ S"8-'(8'($ '-('$ IDFI'#'*8-.($ '++'-928$ <'+0'(B$ -/$ %')'(#"8,$ ,3$ 3(#'+'+$ O+@'-8$ ,'-)8'$ #-92$ -($ 0'+$3(-P"+-"8'($1.XFI')+'##-.($ '-($ #-)(-=-*"(8$ &4()'+'#$/'0-"('#$Yh$@'-$ 0-'#'($S"8-'(8'($ 6LE$P#A$ED$b.("8'W$:$v$DBDDE7A$K($0'+$/3&8-P"+-"8'($O("&c#'$'+<-'#$#-92$0-'#'+$_(8'+#92-'0$"&#$(-928$#-)(-=-*"(8A$̀ '-$[i$G$6C[MLi7$0'#$ '@'($ '+<42(8'($5.&&'*8-P#$ 8+"8$ ("92$ '-('/$/'0-"('($ *+"(*2'-8#=+'-'($ K(8'+P"&&$ P.($ CE$b.("8'($ '-($I',-0-P$"3=B$0"#$-($,<'-$f4&&'($'+('38$.:'+"8-P$82'+":-'+8$<3+0'$6h"X'("$'8$"&AB$CDED7A$$!-'#'$ Q+)'@(-##'B$ 0-'$ 0'($ Q+<"+83()'($ '2'+$ (-928$ '(8#:+'92'(B$ *H((8'($ #-92$ @'-#:-'&#<'-#'$ 03+92$ 0-'$>"8#"92'$'+*&4+'($&"##'(B$0"##$@'-$0'/$P.+&-')'(0'($5.&&'*8-P$(3+$ED$G$0'+$IDF+'#',-'+8'($S"8-'(8'($'-('$"0d3P"(8'$>2'+":-'$ '+2-'&8'(B$ 0")')'($ "@'+$ JD$G$ 0'+$IEF+'#',-'+8'(A$ e.+$ 0'/$;-(8'+)+3(0$ 0'+$ @-#$ 0"8.$3(,3+'-92'(0'($QP-0'(,$=]+$0-'$Q=='*8-P-848$'-('+$"0d3P"(8'($>2'+":-'$&4##8$#-92$0-'#'$;c:.82'#'$"&&'+0-()#$#92<'+&-92$03+92$2-#8.+-#92'$e'+)&'-92'$#8]8,'(A$_(#'+'#$a-##'(#$("92$@'&')'($@-#$0"8.$(3+$0-'$!"8'($0'+$`K?1OSFh830-'$0'($Q=='*8$'-('+$"0d3P"(8'($12'/.82'+":-'$@'-$S"8-'(8'($/-8$'-('/$111$6S+-/+.#'$'8$"&AB$CDE^7A$!-'$>2'#'B$0"##$-/$P.+&-')'(0'($5.&&'*8-P$'2'+$d]()'+'$S"8-'(8'($IEF+'#',-'+8$<.+0'($<"+'($3(0$#-92$#.$0"#$@'##'+'$Y389./'$@'-$0-'#'+$S"8-'(8'()+3::'$'+*&4+'($&4##8B$*.((8'$(-928$)'2"&8'($<'+0'(A$!"#$O&8'+$0'+$IEF+'#',-'+8'($S"8-'(8'($@'8+3)$-/$P.+&-')'(0'($5.&&'*8-P$-/$b'0-"($[J$N"2+'B$@'-$0'($IDF+'#',-'+8'($S"8-'(8'($@'8+3)$0'+$b'0-"($[\BJ$N"2+'A$Q#$,'-)8'$#-92$"&#.$*'-($0'38&-92'+$_(8'+#92-'0A$`'8+"928'8'$/"($0"#$>Fh8"0-3/$#.$=-'&$"3=B$0"##$#-92$@'-$0'($IDF+'#',-'+8'($S"8-'(8'($^[B^G$-($'-('/$(-'0+-)'+'($>Fh8"0-3/$6>E$.0'+$>C7$@'="(0'(B$@'-$0'($IEF+'#',-'+8'($<"+'($'#$(3+$[\BLGA$O392$2-'+$<]+0'$/"($'-($@'##'+'#$Y389./'$=]+$0-'$S"8-'(8'($'+<"+8'(B$0'+'($>3/.+$ #-92$ -($'-('/$(-'0+-)'+'($>Fh8"0-3/$@'=-(0'8B$<"#$ #-92$"(2"(0$3(#'+'+$!"8'($d'0.92$(-928$@'#848-)'($&-'RA$$>+.8,$0'+$2.2'($:.#8.:'+"8-P'($I',-0-PFI"8'($#.&&8'B$<'(($/H)&-92B$'-('$I'#'*8-.($0'#$>3/.+#$"()'#8+'@8$<'+0'(B$0"$0-'#'$0-'$'-(,-)'$bH)&-92*'-8$0'+$*3+"8-P'($>2'+":-'$0"+#8'&&8A$K/$P.+&-')'(0'($5.&&'*8-P$<-'#'($0-'$.:'+-'+8'($S"8-'(8'($ 6($w$\J7$ 8+.8,$0'#$243=-)'($3(0$ =+]2'($O3=8+'8'(#$P.($I',-0-P'($'-($ #-)(-=-*"(8$&4()'+'#$YP'+"&&$h3+P-P"&$"3=$"&#$0-'$%+3::'$6($w$[D7B$@'-$0'+$(3+$(.92$'-('$:"&&-"8-P'$>2'+":-'$/H)&-92$<"+$6EV$P#A$i$b.("8'W$ :$w$DBDDE7A$p2(&-92'$O()"@'($ =-(0'($ #-92$ "392$ -($ 0'+$ ?-8'+"83+A$5.((8'$ '-('$ *3+"8-P'$>2'+":-'$ 0'#$ >3/.+#$ 03+92)'=]2+8$ <'+0'(B$ #.$ &")'($ 0-'$ /'0-"('($ T@'+&'@'(#,'-8'($ ,<-#92'($CDF\D$b.("8'($ 6%3)&-'&/-$ '8$ "&AB$ CDDVW$ b3+"*"/-$ '8$ "&AB$ CDEEW$ h"X'("$ '8$ "&AB$ CDED7A$ `'="(0$ #-92$ 0"#$%"&&'()"()#*"+,-(./$@'+'-8#$-($'-('/$,3$=.+8)'#92+-88'('($h8"0-3/$=]+$'-('$*3+"8-P'$Y:'+"8-.(B$#.$@'8+3)$0-'$?'@'(#'+<"+83()$0'+$S"8-'(8'($/'-#8$<'(-)'+$"&#$'-($N"2+$6Q9*/"(($'8$"&AB$CDEEW$;3))'88$'8$"&AB$CDE\W$h"X'("$'8$"&AB$CDED7A$

$

Page 92: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

R!""

L"!"M"AF E&''.&(.*+01%+,&>.+0"

`'-$'-('/$%+.R8'-&$0'+$"($'-('/$111$'+*+"(*8'($S"8-'(8'($'+=.&)8$0-'$Q+#80-")(.#'$-($'-('/$=]+$'-('$*3+"8-P'$Y:'+"8-.($,3$=.+8)'#92+-88'('($h8"0-3/B$#.0"##$(3+$(.92$'-('$>2'+":-'$/-8$'-('/$:"&&-"8-P'($O(#"8,$#-((P.&&$-#8A$K($0'+$P.+&-')'(0'($O+@'-8$@'="(0'($#-92$\^BC$G$0'+$S"8-'(8'($,3/$g'-8:3(*8$0'+$Q+#80-")(.#'$-($'-('/$:"&&-"8-P'($ Q+*+"(*3()##8"0-3/A$ `'-$ 0+'-$S"8-'(8'($ *"/$ '#$ 03+92$ 0-'$ :"&&-"8-P'$ 12'/.82'+":-'$ ,3$ '-('/$I')+'##B$#.0"##$#-'$#-92$0"(($'-('+$*3+"8-P'($Y:'+"8-.($3(8'+,-'2'($*.((8'(A$O3#$0-'#'+$%+3::'$<3+0'$'-($S"8-'(8$/-8$0'+$5./@-("8-.($%'/9-8"@-($3(0$1-#:&"8-(B$'-('+$/-8$'-('+$S2.8.82'+":-'$3(0$'-('+$03+92$'-('$12'/.'/@.&-#"8-.($ @'2"(0'&8A$ `'-$ #-'@'($S"8-'(8'(B$ 0-'$ #-92$ 3(8'+$ *3+"8-P'/$ O(#"8,$ '-('+$ Y:'+"8-.($3(8'+,.)'(B$ /3##8'$ 0-'#'$ @'-$ ,3$ =.+8)'#92+-88'('+$ Q+*+"(*3()$ "&#$ 'X:&.+"8-P'$ ?":"+.8./-'$ "@)'@+.92'($<'+0'(A$g30'/$8+"8$@'-$[CBC$G$0'+$*3+"8-P$82'+":-'+8'($S"8-'(8'($'-($I',-0-P$"3=B$P.($0'('($0"(($EV$(3+$(.92$-($:"&&-"8-P'+$O@#-928$82'+":-'+8$<'+0'($*.((8'(A$K(#)'#"/8$'+2-'&8'($"&#.$^[$S"8-'(8'($0'#$5.&&'*8-P#$'-('$EA$:"&&-"8-P'$>2'+":-'B$<.@'-$@'-$'-('/$0"#$>2'+":-'#92'/"$(-928$'+3-'+8$<'+0'($*.((8'A$$T@'+$ &"()'$ g'-8$ )"&8$ 0-'$ b.(.82'+":-'$ /-8$ %'/9-8"@-($ -($ 0'+$ >2'+":-'$ 0'#$ =.+8)'#92+-88'('($%"&&'()"()#*"+,-(./#$ "&#$ h8"(0"+0B$ .2('$ 0"##$ 0-'$ a-+*#"/*'-8$ -($ '-('+$ S2"#'FKKKFh830-'$ ("92)'<-'#'($<.+0'($<4+'A$ K($'-('+$CDD[$P'+H=='(8&-928'($S2"#'FKKFh830-'B$ -($0'+'($g3)'$\D$S"8-'(8'($/-8$%'/9-8"@-($82'+":-'+8$ <.+0'($ <"+'(B$ @'8+3)$ 0"#$ /'0-"('$ YP'+"&&$ h3+P-P"&$ ^B[$b.("8'$ 6Y*3#"*"$ '8$ "&AB$ CDD[7A$ h'-8$e'+H=='(8&-923()$ 0'+$ _5FO`1FDCFh830-'$ )-&8$ 0-'$ 5./@-("8-.($ P.($ %'/9-8"@-($ 3(0$ 1-#:&"8-($ "&#$h8"(0"+082'+":-'A$ K($ 0-'#'+$ h830-'$ <3+0'($ \ED$S"8-'(8'($ '-()'#92&.##'(B$ 0-'$ +"(0./-#-'+8$ '(8<'0'+$ /-8$%'/9-8"@-($.0'+$/-8$%'/9-8"@-($-($5./@-("8-.($/-8$1-#:&"8-($@'2"(0'&8$<3+0'(A$f]+$0-'$S"8-'(8'()+3::'B$0-'$ /-8$ 0'+$ 5./@-("8-.(#82'+":-'$ @'2"(0'&8$ <3+0'B$ '+)"@$ #-92$ #.<.2&$ '-($ #-)(-=-*"(8$ &4()'+'#$ Yh$6EEB^$b.("8'$P#A$iBE$b.("8'W$:$v$DBDDE7B$"&#$"392$'-($#-)(-=-*"(8$&4()'+'#$Sfh$6i$b.("8'$P#A$J$b.("8'7$-/$e'+)&'-92$,3$0'+$%+3::'B$0-'$%'/9-8"@-($"&#$b.(.82'+":-'$'+2-'&8A$!-'$>.X-,-848$0'+$@'-0'($>2'+":-'+')-/'$<"+$ P'+)&'-92@"+B$ /-8$ O3#("2/'$ '-('+$ '+2H28'($ Z'-)3()$ ,3+$ Z'38+.:'(-'$ @'-$ 0'($ /-8$ 0'+$5./@-("8-.(#82'+":-'$@'2"(0'&8'($S"8-'(8'(A$!-'$O(,"2&$0'+$/-8$0'+$Z'38+.:'(-'$"##.,--'+8'($K(='*8-.('($<"+$"@'+$)&'-92P'+8'-&8$]@'+$0-'$@'-0'($%+3::'($6e"&&'$'8$"&AB$CDED7A$Y@<.2&$(3($0-'$5./@-("8-.(#82'+":-'$/-8$%'/9-8"@-($3(0$1-#:&"8-($"&#$h8"(0"+082'+":-'$0'#$=.+8)'#92+-88'('($12.&"()-.*"+,-(./#$)-&8B$,'-)'($#-92$@'-$ 0'+$O(<'(03()$ '-('+$5./@-("8-.($ "3#$%'/9-8"@-($ 3(0$YX"&-:&"8-($ 42(&-92'$Q+)'@(-##'$ -/$Yh$@'-$0'38&-92$)'+-()'+'+$>.X-,-848$6f-8'(-$'8$"&AB$CDE\7$K($'-('+$b'8""("&c#'$<3+0'($-(#)'#"/8$E\^D$S"8-'(8'($/-8$'-('/$=.+8)'#92+-88'('($111$'-()'#92&.##'(B$0-'$'(8<'0'+$/-8$0'+$5./@-("8-.($%'/9-8"@-(M1-#:&"8-($.0'+$%'/9-8"@-(MYX"&-:&"8-($ @'2"(0'&8$ <.+0'($ <"+'(A$ Q#$ '+)"@$ #-92$ '-($ &4()'+'#$ Yh$ =]+$ 0-'$ /-8$%'/9-8"@-(M1-#:&"8-($ @'2"(0'&8'$ S"8-'(8'()+3::'$ 6EEB^$b.("8'$P#A$VBJ$b.("8'7B$ "&&'+0-()#$ @'-$ '+2H28'+$;':"8.F$3(0$;4/"8.8.X-,-848$6f-8'(-$'8$"&AB$CDE\7A$K/$I"2/'($0'+$`KZ%YFh830-'$<3+0'($EJD$S"8-'(8'($/-8$0'+$!-")(.#'$'-('#$=.+8)'#92+-88'('($%"&&'()"()#*"+,-(./#$"($Ei$P'+#92-'0'('($5&-(-*'($-($f+"(*+'-92$3(0$!'38#92&"(0$ +'*+38-'+8A$ ^\$S"8-'(8'($ <3+0'($ /-8$ 0'+$ 5./@-("8-.($ "3#$ %'/9-8"@-($ 3(0$ YX"&-:&"8-($82'+":-'+8B$ ^[$S"8-'(8'($ '+2-'&8'($ ,3#48,&-92$ 1'83X-/"@A$ Q(82-'&8$ 0-'$ >2'+":-'$ ,3#48,&-92$ 0'($ O(8-*H+:'+$1'83X-/"@$'+)"@$#-92$)')'(]@'+$0'+$5.(8+.&&)+3::'$,<"+$'-($&4()'+'#$Sfh$6[BE$b.("8'$P#A$JBJ$b.("8'7B$0"#$/'0-"('$ Yh$ ,'-)8'$ #-92$ "&&'+0-()#$ P'+*]+,8$ 6EE$b.("8'$P#A$ECB\$b.("8'7A$ !'/'(8#:+'92'(0$ #.&&8'$ 0-'$5./@-("8-.($"3#$%'/9-8"@-($3(0$'-('/$S&"8-(0'+-P"8$("92$0'+,'-8-)'/$5'((8(-##8"(0$0-'$h8"(0"+082'+":-'$@&'-@'($6b"&*"$'8$"&AB$CDE\7A$$

Page 93: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

R<""

K($0'+$P.+&-')'(0'($O+@'-8$'+2-'&8'($E\BJ$G$0'+$S"8-'(8'($'-('$"&&'-(-)'$Q+#8&-(-'(82'+":-'$/-8$%'/9-8"@-(B$LJBJ$G$ '+2-'&8'($ '-('$ 5./@-("8-.(#82'+":-'$ /-8$ '-('/$ S&"8-(0'+-P"8$ 61-#:&"8-($ .0'+$ YX"&-:&"8-(7A$ !-'$T@'+&'@'(#3(8'+#92-'0'$ ,'-)8'($ #-92$ -($ 0'+$ 5":&"(Fb'-'+FO("&c#'$ (-928$ #-)(-=-*"(8$ 6%'/9-8"@-($ /.(.n$V$b.("8'$P#A$%'/9-8"@-($l$S&"8-(0'+-P"8n$ [$b.("8'W$ :$w$DB\EV7$ 3(0$ *.((8'($ #./-8$ 0-'$ O()"@'($ -($ 0'+$?-8'+"83+$ (-928$ @'#848-)'(A$ O392$ @'-$ 0'/$ e'+)&'-92$ 0'+$ %+3::'($ %'/9-8"@-($l$1-#:&"8-($ 6ECM^[W$EJBi$G7$P#A$%'/9-8"@-($l$YX"&-:&"8-($6EJM^[W$EVB^$G7$'+)"@'($#-92$,<"+$_(8'+#92-'0'$-/$YhB$0-'#'$<"+'($"@'+$ (-928$ #-)(-=-*"(8$ 6ELBJ$b.("8'$P#A$[$b.("8'7A$Q-($<'-8'+'#$ :"&&-"8-P'#$>2'+":-'*.(,':8B$ 0"#$@'-$ '-('+$+'&"8-P$)+.R'($S"8-'(8'()+3::'$ 6iM^[W$EDBJ$G7$"()'<"(08$<3+0'B$<"+$0-'$#'&'*8-P'$ -(8'+('$I"0-.82'+":-'A$_(8'+$0-'#'+$>2'+":-'$'+)"@$#-92$@'-$0'($S"8-'(8'($0'#$5.&&'*8-P#$'-($/'0-"('#$Yh$P.($CC$b.("8'(A$a3+0'$0")')'($'-('$"3##92&-'R&-92$S2.8.0c("/-#92'$>2'+":-'$"()'<"(08B$@'8+3)$0"#$/'0-"('$YP'+"&&$h3+P-P"&$(3+$V$b.("8'A$ !-'#'+$ _(8'+#92-'0$ ,'-)8'$ #-92$ -($ 0'+$ 5":&"(Fb'-'+FO("&c#'$ #-)(-=-*"(8$ 6:$w$DBDDJ7A$ b'2+'+'$O38.+'($:.#83&-'+8'($'-('$e'+&4()'+3()$0'#$Yh$03+92$0-'$O(<'(03()$'-('+$S!>$6?'))'88$'8$"&AB$CDECW$Y+8('+$'8$"&AB$EVVi7A$!-'#'$>2'#'$*.((8'$"($3(#'+'/$5.&&'*8-P$(-928$@'*+4=8-)8$<'+0'(A$O392$-/$e'+)&'-92$/-8$'-('+$%'/9-8"@-($ '(82"&8'(0'($ 12'/.82'+":-'$ 6%'/9-8"@-($ /.(.$}$1-#:&"8-(MYX"&-:&"8-(7$ '+@+"928'$ 0-'$>2'+":-'$/-8$'-('+$hKI>$'-('($#-)(-=-*"(8'($T@'+&'@'(#P.+8'-&$6CC$b.("8'$P#A$^$b.("8'W$:$w$DBDEi7A$a3+0'$-($0'/$b.0'&&$#8"88$0'+$hKI>$0'+$Q-(=&3##$'-('+$:2.8.0c("/-#92'($>2'+":-'$"3=$0"#$Yh$]@'+:+]=8B$'+)"@$#-92$*'-($#-)(-=-*"(8'+$_(8'+#92-'0A$K($'-('+$O+@'-8$P.($;3))'88$'8$"&A$#92-'($'-('$JFf_F@"#-'+8'$>2'+":-'$'-('$42(&-92'$Q=='*8-P-848$ "3=,3<'-#'($<-'$'-($%'/9-8"@-(F@"#-'+8'#$>2'+":-'#92'/"$ 6;3))'88$ '8$ "&AB$ CDE\7A$ K($3(#'+'+$O+@'-8$<3+0'($(3+$0+'-$S"8-'(8'($/-8$'-('+$JFf_F'(82"&8'(0'($>2'+":-'$@'2"(0'&8B$-(#.='+($&4##8$#-92$@',])&-92$0-'#'+$f+")'#8'&&3()$*'-('$O3##")'$8+'=='(A$$`'-$J^BV$G$0'+$S"8-'(8'($<3+0'$"3=)+3(0$'-('#$='2&'(0'($O(#:+'92'(#$"3=$0-'$Q+#8&-(-'(82'+":-'$3(0M.0'+$"3=)+3(0$0'+$Z'@'(<-+*3()'($'-('$g<'-8&-(-'(82'+":-'$03+92)'=]2+8A$%-&8$("92$0'+$_5FO`1FDCFh830-'$0-'$5./@-("8-.($P.($%'/9-8"@-($3(0$1-#:&"8-($"&#$>2'+":-'Fh8"(0"+0$=]+$0-'$Q+#8&-(-'(82'+":-'B$)-@8$'#$*'-('($h8"(0"+0F>2'+":-'"(#"8,$ =]+$ 0-'$ g<'-8&-(-'(82'+":-'A$ !-'#$ ,'-)8$ #-92$ "392$ "($ 0'($ Q+)'@(-##'($ 0'+$P.+&-')'(0'($ O+@'-8A$ Q#$ <3+0'($ -(#)'#"/8$ EJ$ P'+#92-'0'('$ >2'+":-'"(#48,'$ "()'<'(0'8$ 6#-'2'$ \AEA^AL7A$O3=)+3(0$ 0'+$ 0"+"3#$ +'#3&8-'+'(0'($ )'+-()'($ O3##")'*+"=8$ <3+0'($ (3+$ 0"#$ Yh$ 0'+$ P-'+$ "/$ 243=-)#8'($"()'<"(08'($>2'+":-'($@'+'92('8A$!-'#'$<"+'($'-('$̀ '2"(0&3()$/-8$'(8<'0'+$%'/9-8"@-($"&#$b.(.82'+":-'$6EiBC$G7$.0'+$-($0'+$5./@-("8-.($/-8$'-('/$S&"8-(0'+-P"8$61-#:&"8-($.0'+$YX"&-:&"8-(W$CJ$G7B$0-'$O(<'(03()$'-('+$hKI>$6V$G7$.0'+$0-'$̀ '2"(0&3()$/-8$0'/$fY?fKIKFh92'/"$6JFf_$l$f.&-(#43+'$l$K+-(.8'9"(W$EEB\$G7A$!"#$/'0-"('$Yh$@'8+3)$\DBJB$CiB$LV$3(0$i$b.("8'A$K($0'+$5":&"(Fb'-'+FO("&c#'$,'-)8'$#-92$(3+$,<-#92'($0'+$S"8-'(8'()+3::'B$@'-$0'+$0-'$5./@-("8-.($%'/9-8"@-($l$S&"8-(0'+-P"8$"()'<"(08$<.+0'($<"+B$3(0$d'('+B$0-'$/-8$ 0'/$fY?fKIKFh92'/"$@'2"(0'&8$<.+0'($<"+B$ '-($ #-)(-=-*"(8'+$_(8'+#92-'0$ 6:$w$DBDD\7A$`'-$0'+$K(8'+:+'8"8-.($0'+$Q+)'@(-##'$#'-$"&&'+0-()#$0"+"3=$2-()'<-'#'(B$0"##$'#$#-92$3/$#'2+$*&'-('$f"&&,"2&'($2"(0'&8$3(0$#-92$#./-8$(3+$@'0-()8$'-('$O3##")'$]@'+$0-'$Q=='*8-P-848$0'+$>2'+":-'*.(,':8'$8+'=='($&4##8A$$K($ '-('+$ =+"(,H#-#92'($ b3&8-9'(8'+Fh830-'B$ 0-'$ [DL$ /-8$ 0'+$ 5./@-("8-.($ %'/9-8"@-($l$S&"8-(0'+-P"8$@'2"(0'&8'$S"8-'(8'($'-(#92&.##B$'+2-'&8'($LCBJ$G$0'+$S"8-'(8'($'-('$#'9.(0F&-('F>2'+":-'A$_()'=42+$EML$0'+$S"8-'(8'($'+2-'&8$0-'$5./@-("8-.($P.($JFf_B$f.&-(#43+'$3(0$K+-(.8'9"(B$d'<'-&#$9"A$CD$G$<3+0'($/-8$JFf_$-($5./@-("8-.($/-8$'(8<'0'+$1-#:&"8-($.0'+$1":'9-8"@-($@'2"(0'&8B$0'+$I'#8$'+2-'&8$'-('$5./@-("8-.($"3#$JFf_$3(0$YX"&-:&"8-($69"A$ED$G7B$h3(-8-(-@$6J$G7$.0'+$"(0'+'($>2'+":-'($6EEB^$G7A$Z"92$'-('/$/'0-"('($f.&&.<F3:$P.($C[B\$b.("8'($@'8+3)$0"#$/'0-"('$Yh$[B^$b.("8'B$0"#$Sfh$LBC$b.("8'A$Q#$,'-)8'$#-92$*'-($#-)(-=-*"(8'+$_(8'+#92-'0$-($Yh$3(0$Sfh$-/$;-(@&-9*$"3=$0-'$O(<'(03()$P.($JFf_$"&&'-('$.0'+$ -($'-('+$5./@-("8-.(#82'+":-'$6`+-'"3$'8$"&AB$CDEJ7A$K($'-('/$*&'-('($"/'+-*"(-#92'($5.&&'*8-P$P.($J[$S"8-'(8'(B$0-'$,3/$ %+.R8'-&$ "($ '-('/$ -(8+"2':"8-#92'($ %"&&'()"()#*"+,-(./$ '+*+"(*8$ <"+'(B$ '+2-'&8'($ 0-'$ /'-#8'($S"8-'(8'($ =.&)'(0'$ 12'/.82'+":'38-*"$ "&#$ g<'-8&-(-'(82'+":-'n$ %'/9-8"@-($ -($ 5./@-("8-.($ /-8$ '-('/$S&"8-(0'+-P"8$ 6CD$G7B$ %'/9-8"@-($ -($ 5./@-("8-.($ /-8$ JFf_$ 6CiB[$G7$ .0'+$ '-('$f&3.+.:c+-/-0-(F5./@-("8-.($6L^BJ$G7A$Q#$'+)"@$#-92$'-($/'0-"('#$Yh$P.($ELBi$b.("8'($3(0$'-($/'0-"('#$Sfh$ P.($ CB^$b.("8'(A$ O392$ 2-'+$ ,'-)8'$ #-92$ *'-($ #-)(-=-*"(8'+$ _(8'+#92-'0$ ,<-#92'($ 0'($ '-(,'&('($>2'+":-'"(#48,'($ 6I.)'+#$ '8$ "&AB$ CDE\7A$ f.+("+.$ '8$ "&A$ *.((8'($ 0-'#$ @'#848-)'(B$ '#$ ,'-)8'$ #-92$ 2-'+$ 3(8'+$O(<'(03()$'-('+$5./@-("8-.(#@'2"(0&3()$'-('$"&&'+0-()#$(-928$#-)(-=-*"(8'$>'(0'(,$,3$'-('/$@'##'+'($Y389./'$ -/$ ;-(@&-9*$ "3=$ 0-'$ 5+"(*2'-8#*.(8+.&&'$ 3(0$ 0"#$ SfhA$ _(8'+$ `'2"(0&3()$ /-8$ '-('+$5./@-("8-.(#82'+":-'$'+)"@$#-92$'-($&4()'+'#$YP'+"&&$h3+P-P"&$6^BE$P#A$J$b.("8'W$:$w$DBDD[7A$!-'#'#$Q+)'@(-#$,'-)8'$ #-92$ #8"8-#8-#92$ #-)(-=-*"(8$ 6f.+("+.$ '8$ "&AB$ CDEJ7A$ K/$ P.+&-')'(0'($ 5.&&'*8-P$ '+)"@$ #-92$ 3(8'+$g<'-8&-(-'(82'+":-'$ '-($/'0-"('#$ YP'+"&&$ h3+P-P"&$ P.($ CE$b.("8'($ 3(0$ '-($ Sfh$ P.($ i$b.("8'(B$ #./-8$<'-8"3#$&4()'+$"&#$-($0'($.A)A$h830-'(A$!-'$_+#"92'($2-'+=]+$@&'-@'($,3$0-#*38-'+'(A$`'-$3(#'+'/$5.&&'*8-P$<3+0'($,3/$>'-&$<'-8"3#$<'(-)'+$"))+'##-P'$>2'+":-'($<-'$0-'$"&&'-(-)'$`'2"(0&3()$/-8$%'/9-8"@-($.0'+$'-('+$hKI>$03+92)'=]2+8A$!-'$O(<'(03()$'-('+$>2'+":-'B$0-'$JFf&3.+.3+"9-&$@'-(2"&8'8B$3(0$-($0'+$?-8'+"83+$

Page 94: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

R?""

="#8$ "&#$ h8"(0"+0$@'-$!3+92=]2+3()$'-('+$g<'-8&-(-'(82'+":-'$ )-&8B$ '+=.&)8'$ @'-$ 3(#'+'/$5.&&'*8-P$(3+$@'-$EEB\$G$0'+$S"8-'(8'(A$a3+0'($-($0'+$P.+&-')'(0'($O+@'-8$(3+$0"#$Yh$3(0$0-'$Sfh$0'+$S"8-'(8'($@'8+"928'8B$0-'$/-8$JFf_$6"&&'-($.0'+$"&#$>'-&$'-('+$5./@-("8-.(#82'+":-'7$@'2"(0'&8$<3+0'(B$'+)"@$#-92$'-($/'0-"('#$YP'+"&&$h3+P-P"&$P.($EJ$b.("8'($3(0$'-($/'0-"('#$:+.)+'##-.(#=+'-'#$P.($\$b.("8'(B$#./-8$#92.($0'38&-92$*]+,'+A$!-'$_+#"92'$=]+$0-'#'#$Q+)'@(-#$@&'-@8$,3$0-#*38-'+'(A$Q-('$e'+=4&#923()$0-'#'+$+'8+.#:'*8-P'($!"8'($03+92$'-('($h'&'98-.(F`-"#$-#8$(-928$"3#,3#92&-'R'(A$$`'-$C^B[$G$0'+$S"8-'(8'($0'#$P.+&-')'(0'($5.&&'*8-P#B$0-'$#-92$-/$:"&&-"8-P'($5+"(*2'-8##8"0-3/$@'="(0'(B$<3+0'$'-('$!+-88&-(-'(82'+":-'$03+92)'=]2+8A$!"#$/'0-"('$Yh$@'8+3)$C[$b.("8'B$0"#$Sfh$V$b.("8'B$#.0"##$#-92$ 2-'+$ *'-($ _(8'+#92-'0$ -/$ e'+)&'-92$ ,3+$ S+.)(.#'$ @'-$ g<'-8&-(-'(82'+":-'$ ='#8#8'&&'($ &4##8A$ _(#'+'($I'92'+92'($,3=.&)'$)-@8$'#$=]+$0-'$!+-88&-(-'(82'+":-'$<'0'+$"3##")'*+4=8-)'$h830-'($(.92$Q/:='2&3()'(A$K($'-('/$-8"&-'(-#92'($5.&&'*8-P$/-8$E^\$S"8-'(8'(B$0-'$@'+'-8#$'-('$g<'-8&-(-'(82'+":-'$'+2"&8'($2"88'(B$<3+0'$@'-$ \CBJ$G$ 0'+$ S"8-'(8'($ 6^\ME^\7$ '-('$!+-88&-(-'(82'+":-'$ 03+92)'=]2+8A$ !-'$/'-#8'($ P.($ -2('($ 6E\$G7$'+2-'&8'($ '-($ S&"8-(0'+-P"8$ -($ 5./@-("8-.($ /-8$ %'/9-8"@-($ .0'+$ JFf_A$ ED$G$ '+2-'&8'($ K+-(.8'9"($ -($5./@-("8-.($/-8$'(8<'0'+$JFf_$.0'+$1":'9-8"@-(B$[$G$<3+0'($/-8$JFf_$.0'+$1":'9-8"@-($@'2"(0'&8A$Q#$*.((8'$ -/$ e'+)&'-92$ ,3+$ Q+#8&-(-'(82'+":-'$ *'-($ @'0'38'(0'+$ _(8'+#92-'0$ -/$ ;-(@&-9*$ "3=$ 0"#$ YP'+"&&$h3+P-P"&$3(0$0-'$O(#:+'92+"8'$='#8)'#8'&&8$<'+0'($6f.+("+.$'8$"&AB$CDEJ7A$$K($0'+$P.+&-')'(0'($O+@'-8$<3+0'$-/$I"2/'($0'+$!+-88&-(-'(82'+":-'$@'-$CLBi$G$0'+$S"8-'(8'($'-('$>2'+":-'$/-8$%'/9-8"@-($03+92)'=]2+8A$EV$G$0'+$S"8-'(8'($'+2-'&8'($0-'$5./@-("8-.($%'/9-8"@-($l$YX"&-:&"8-(A$N'<'-&#$VBJ$G$0'+$S"8-'(8'($<3+0'($/-8$YX"&-:&"8-(B$JFf_$.0'+$JFf_$-($5./@-("8-.($/-8$%'/9-8"@-($3(0$`'#8+"2&3()$@'2"(0'&8A$!-'$+'#8&-92'($>2'+":-'#92'/"8"$<3+0'($d'<'-&#$(3+$@'-$'-('/$S"8-'(8'($03+92)'=]2+8B$#.0"##$#-'$2-'+$"3=)+3(0$0'+$)'+-()'($f"&&,"2&$*'-('$<'-8'+'$Q+<42(3()$=-(0'(A$O392$'-('$_(8'+#3923()$0'+$T@'+&'@'(#,'-8'($'+#92-'($"3=)+3(0$0'#$*&'-('($5.&&'*8-P#$(-928$#-((P.&&A$$EiB\$G$0'+$S"8-'(8'($0'#$5.&&'*8-P#$'+2-'&8'($'-('$e-'+8&-(-'(82'+":-'B$^BV$G$'-('$f](=8&-(-'(82'+":-'B$LBV$G$'-('$h'92#8&-(-'(82'+":-'B$CB[$G$'-('$h-'@8&-(-'(82'+":-'$3(0$#92&-'R&-92$'-($S"8-'(8$'-('$O928&-(-'(82'+":-'A$!"$ /'-#8$ P'+#92-'0'('$ >2'+":-'#92'/"8"$ "()'<'(0'8$ <.+0'($ <"+'(B$ <3+0'$ "3=$ 0-'$ O3#<'+83()$ 0'+$T@'+&'@'(#,'-8'($P'+,-928'8A$$K(#)'#"/8$,'-)8$#-92$"@'+B$0"##$("92$'-('/$e'+#")'($0'+$>2'+":-'$/-8$%'/9-8"@-($-($5./@-("8-.($/-8$'-('/$S&"8-(0'+-P"8$@-#$d'8,8$*'-($'-(2'-8&-92'#B$'=='*8-P'#$>2'+":-'#92'/"$@'*"((8$-#8A$!+-()'(0$#-(0$2-'+$<'-8'+'$h830-'($@',])&-92$0'+$:"&&-"8-P'($>2'+":-'$0'#$%"&&'()"()#*"+,-(./#$'+=.+0'+&-92A$$!'#$ a'-8'+'($ &4##8$ #-92$ "3#$ 3(#'+'($ !"8'($ =.&)'+(B$ 0"##B$ 8+.8,$ 8'-&#$ ='2&'(0'+$ S2"#'FKKKFQP-0'(,B$ 0-'$`'2"(0&3()$ "($ '-('/$ 2.92#:',-"&-#-'+8'($ g'(8+3/$ -(0-P-03"&-#-'+8'+$ 3(0$ /3&8-/.0"&'+$ 6hKI>B$ S!>7$ ,3$'+=.&)'($#92'-(8B$"&#$0-'#$-(('+2"&@$"(0'+'+$e'+#.+)3()##8+3*83+'($/H)&-92$-#8A$$

" $

Page 95: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RC""

L"AF 7O>,+)).;$0*;$0I9ZK!"#$%"&'$()*0"

!"$ 0-'$ :"&&-"8-P'$ >2'+":-'$ 0'#$ %"&&'()"()#*"+,-(./#$ /-8$ '-('+$ #92&'928'($ S+.)(.#'$ '-(2'+)'28B$ -#8$ 0-'$_(8'+#3923()$0'#$>3/.+#$"3=$/.&'*3&"+@-.&.)-#92'+$Q@'('$3(@'0-()8$'+=.+0'+&-92B$3/$('3'B$,-'&)'+-928'8'$>2'+":-'/H)&-92*'-8'($ ,3$ '8"@&-'+'(A$ Q+#8$ -($ 0'($ &'8,8'($ N"2+'($ )'&"()8'$ 0-'$ :'+-('3+"&'$ K(P"#-.($ @'-/$%"&&'()"()#*"+,-(./$ -($0'($f.*3#$0'+$ "*83'&&'($f.+#923()$ 6#-'2'$2-'+,3$EAC7A$h'-8$e'+H=='(8&-923()$0'+$Q+)'@(-##'$P.($`.'9*/"(($'8$"&A$)-&8$0-'$>2'.+-'$]@'+2.&8B$0"##$0-'$>3/.+,'&&'($-/$I"2/'($0'+$SZK$0'($a')$0'#$*&'-(#8'($a-0'+#8"(0'#$<42&'(A$K($0-'#'+$h830-'$*.((8'$7*.$,?@B$*;8*$*8<6A%*;7*87*$D/33*$E*;$7*+$K(P"#-.($ 0'+$ >3/.+,'&&'($ ,3)'#92+-'@'($ <'+0'($ 6`.9*/"($ '8$ "&AB$ EVV\7A$ !-'#'$ h830-'$ &-'='+8'$ 0'($'(8#92'-0'(0'($;-(<'-#B$0"##$'#$#-92$@'-$0'+$SZK$3/$'-('$"*8-P'$K(8'+"*8-.($,<-#92'($Z'+P$3(0$>3/.+,'&&'$2"(0'&8A$a'-8'+'$h830-'($=.&)8'(B$-($0'('($'-('$P'+#84+*8'$QX:+'##-.($P.($Z%f$3(0$#'-('/$I',':8.+$>+*O$"($:"(*+'"8-#92'($>3/.+,'&&'($"&#$"392$"($12.&"()-.,c8'($("92)'<-'#'($<'+0'($*.((8'$6`":"8$'8$"&AB$CDEEW$%-)&-.,,-$'8$"&AB$CDD\7A$!3+92$0-'$h8-/3&-$92.&-('+)'+$Z'+P'($*.//8$'#$,3$'-('+$K(03*8-.($P.($Z%f$ 60"$S'(2"$`'+,")2-$'8$"&AB$EVVL7B$0-'#'+$<-'0'+3/$-(03,-'+8$"*8-P$0"#$a"92#83/$P.($92.&-('+)'($Z'+P'(="#'+($6;"c"*"<"$ '8$ "&AB$ CDE^7A$Q#$2"(0'&8$ #-92$ "&#.$(-928$3/$'-('($a')$0'#$ )'+-()#8'($a-0'+#8"(0'#B$ #.(0'+($P-'&/'2+$3/$'-('($"*8-P'($1+.##8"&*$,<-#92'($Z'+P'($3(0$>3/.+,'&&'(A$$h.$<"+$'-('$<'-8'+'$f+")'#8'&&3()$0-'#'+$O+@'-8B$.@$"($0'/$5.&&'*8-P$'-('$P'+/'2+8'$QX:+'##-.($P.($Z%fF'$3(0$#'-('($I',':8.+'($>+*OB$`$.0'+$1$("92)'<-'#'($<'+0'($*.((8'A$K/$P.+&-')'(0'($5.&&'*8-P$*.((8'($P.($ JD$G$ 0'+$ ED[$S"8-'(8'($>-##3'$b-9+.$O++"c#$ "()'='+8-)8$<'+0'($ 3(0$ #./-8$ "3=$ 0-'$QX:+'##-.($ P.($Z%fF'$ 3(0$:"(>+*$3(8'+#3928$<'+0'(A$ JCBi$G$0'+$>3/.+:+.@'($2"88'($ -2+'($_+#:+3()$ -(8+"2':"8-#92B$CiBL$G$:'+-2-&4+$3(0$EiB^$G$0-#8"&A$O($3(#'+'/$5.&&'*8-P$*.((8'$*'-('$QX:+'##-.($P.($Z%fF'$/7*+$I58,+N$("92)'<-'#'($<'+0'(A$!-'#'$Q+)'@(-##'$3(8'+#92'-0'($#-92$2-'+/-8$#-)(-=-*"(8$P.($0'($@-#2'+-)'($O()"@'($-($ 0'+$ ?-8'+"83+$ ,3$ 0-'#'/$ >2'/"A$ K($ '-('/$ 92-('#-#92'($ 5.&&'*8-P$ /-8$ iL$ "($ -(8+"2':"8-#92'/$ 111$'+*+"(*8'($S"8-'(8'($*.((8'$@'-$C^B^$G$0'+$>3/.+:+.@'($ 6CLMiL7$'-('$T@'+'X:+'##-.($P.($Z%fF'=$E*;$CDBJ$G$6E^MiL7$'-('$T@'+'X:+'##-.($P.($>+*O$='#8)'#8'&&8$<'+0'(A$`'-$EJB[$G$6ELMiL7$<"+'($@'-0'$b"+*'+$]@'+'X:+-/-'+8A$`'-$0'($)38$0-=='+'(,-'+8'($%"&&'()"()#*"+,-(./'($="(0$#-92$'-('$#-)(-=-*"(8$2H2'+'$O(,"2&$"($T@'+'X:+'##-.($P.($Z%fF'$CI$w$DBDC\7A$!-'$f4&&'B$@'-$0'('($:.#8.:'+"8-P$'-('$:'+-('3+"&'$K(P"#-.($0'#$>3/.+#$='#8)'#8'&&8$<'+0'($*.((8'B$,'-)8'($-($'-('+$#-)(-=-*"(8$'+2H28'($O(,"2&$'-('$T@'+'X:+'##-.($P.($>+*O$6:$w$DBDDL7A$O&&'+0-()#$2"88'$0-'$T@'+'X:+'##-.($P.($Z%fF'$.0'+$>+*O$"&&'-('$<-0'+$Q+<"+8'($*'-('($#-)(-=-*"(8'($Q-(=&3##$"3=$0"#$YP'+"&&$h3+P-P"&$0'+$S"8-'(8'(A$a"+'($ d'0.92$@'-0'$b"+*'+$]@'+'X:+-/-'+8B$*.((8'$'-($#-)(-=-*"(8'+$Q-(=&3##$"3=$0"#$Yh$='#8)'#8'&&8$<'+0'($6k"()$'8$"&AB$CDE\7A$K($'-('+$"(0'+'($O+@'-8$<3+0'$0-'$QX:+'##-.($P.($Z%fF'$58$*;8*.$#'2+$*&'-('($5.&&'*8-P$P.($Ci$S"8-'(8'($/-8$ '-('/$:'+-2-&4+$&.*"&-#-'+8'($12.&"()-.*"+,-(./$3(8'+#3928A$̀ '-$]@'+$0'+$;4&=8'$0'+$S"8-'(8'($6E[MCiW$J^BE$G7$,'-)8'$#-92$@'-$0'($ -//3(2-#8.92'/-#92'($ f4+@3()'($ '-('$ T@'+'X:+'##-.($ P.($ Z%fF'($ !-'#'$ T@'+'X:+'##-.($ <"+$#-)(-=-*"(8$ 2H2'+$ -($ 0'+$ S"8-'(8'()+3::'B$ @'-$ 0'+$ "392$ ?c/:2*(.8'(/'8"#8"#'($ ("92)'<-'#'($ <'+0'($*.((8'(A$Q-('$T@'+'X:+'##-.($,'-)8'$#-92$"392$P'+/'2+8$@'-$0'($>3/.+:+.@'(B$@'-$0'('($:.#8.:'+"8-P$'-('$:'+-('3+"&'$K(P"#-.($("92)'<-'#'($<'+0'($*.((8'$6iiBV$G$P#A$\CBE$G7$6o3$'8$"&AB$CDED7A$K($'-('+$d":"(-#92'($h830-'$ /-8$ EEC$ "($ 0-#8"&'/$ %"&&'()"()#*"+,-(./$ '+*+"(*8'($ S"8-'(8'($ *.((8'$ @'-$ JJ$G$ 0'+$ S"8-'(8'($6[CMEEC7$ '-('$ 2.2'$ QX:+'##-.($ P.($ Z%fF'$ 85A%:*1;*6'($ <'+0'(B$ @'-$ 0'($ +'#8&-92'($ \J$G$ 6JDMEEC7$,3/-(0'#8$ '-('$ )'+-()'A$ ;-'+$ ,'-)8'$ #-92$ "&&'+0-()#$ *'-($ #-)(-=-*"(8'+$ g3#"//'(2"()$ ,<-#92'($ 0'+$Z%fF'FQX:+'##-.($ 3(0$ '-('+$ :'+-('3+"&'($ K(P"#-.($ .0'+$ 0'/$ ?c/:2*(.8'(#8"83#A$ O392$ '-($g3#"//'(2"()$/-8$O&8'+B$%'#92&'928B$>3/.+&.*"&-#"8-.(B$!-=='+'(,-'+3()$.0'+$0'/$>3/.+#8"0-3/$("92$_K11$*.((8'$(-928$("92)'<-'#'($<'+0'($6_+"@'$'8$"&AB$CDE[7A$

" $

Page 96: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RF""

Q#$ @&'-@8$ ,3$ 0-#*38-'+'(B$ "3#$ <'&92'/$%+3(0$ #-92$ 3(#'+$5.&&'*8-P$ -($ 0-'#'/$ f"&&'$ #.$ 0'38&-92$ P.($ 0'($Q+)'@(-##'($ 0'+$ ?-8'+"83+$ 3(8'+#92'-0'8A$ Q-($ /'82.0-#92'#$ S+.@&'/$ -#8$ @'-$ f4+@3()'($ P.($S.#-8-PF5.(8+.&&'($ 6)'#3(0'$ :"(*+'"8-#92'$ K(#'&,'&&'($ =]+$Z%fF'$ -87$ 8/+.53*6$O*E*88;*+*8:*1'@'$ =]+$:"(>+*7$ "3#,3#92&-'R'(A$ _(#'+'#$ a-##'(#$ ("92$ <3+0'$ 0-'#'$ f+")'#8'&&3()$ @-#$ d'8,8$ (3+$ "($ "#-"8-#92'($5.&&'*8-P'($3(8'+#3928A$!-'$Q+)'@(-##'$0'+$P.+&-')'(0'($O+@'-8$&"##'($'-('($@'0'38'(0'($_(8'+#92-'0$-($0'+$>3/.+@-.&.)-'$0'+$%"&&'()"()#*"+,-(./'$P.($5"3*"#-'+($3(0$O#-"8'($P'+/38'(A$a'-8'+'$h830-'($F$PA"A$-/$'3+.:4-#92'($I"3/$F$#-(0$=.&)&-92$3(@'0-()8$(.8<'(0-)B$3/$'-('$)',-'&8'+'$>2'+":-'$,3$'+/H)&-92'(A$!-'#$-#8$@'#.(0'+#$P.+$0'/$;-(8'+)+3(0B$0"##$>+*FK(2-@-8.+'($@'+'-8#$-/$I"2/'($P.($*&-(-#92'($h830-'($=]+$0-'$`'2"(0&3()$P.($#.&-0'($>3/.+'($,3/$Q-(#"8,$*.//'($P.($)+.R'+$*&-(-#92'+$I'&'P"(,B$0"$@'-$='2&'(0'+$T@'+'X:+'##-.($ 0'#$ :2"+/"*.&.)-#92'($ >"+)'8#$ 03+92"3#$ "392$ '-($ e'+&3#8$ 0'+$ a-+*#"/*'-8$ 0'+$,-'&)'+-928'8'($>2'+":-'$/H)&-92$#92'-(8A$

Page 97: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RJ""

MF W5)&<<+$C&))5$60

"

K(#)'#"/8$<3+0'($ED[$S"8-'(8'($-($0-'#'$+'8+.#:'*8-P'$h830-'$'-()'#92&.##'(B$0-'$#-92$,<-#92'($CDD[$3(0$CDEC$<')'($'-('#$>3/.+#$0'#$@-&-4+'($>+"*8#$"/$5&-(-*3/$0'+$_(-P'+#-848$b](92'($1"/:3#$%+.R2"0'+($P.+#8'&&8'(A$ `'-$ "&&'($ S"8-'(8'($ &")$ '-($ 2-#8.:"82.&.)-#92$ )'#-92'+8'#$ 12.&"()-.*"+,-(./$ P.+A$ !-'#'#$&.*"&-#-'+8'$#-92$@'-$J[B[$G$0'+$f4&&'$-(8+"2':"8-#92B$@'-$LL$G$:'+-2-&4+$3(0$@'-$EDB\$G$0'+$f4&&'$0-#8"&A$\CBJ$G$0'+$%"&&'()"()#*"+,-(./'$@'="(0'($#-92$-($'-('/$+'#'*8"@&'($h8"0-3/B$C\BJ$G$<"+'($&.*"&$=.+8)'#92+-88'($3(0$LL$G$@'+'-8#$/'8"#8"#-'+8A$g3/$g'-8:3(*8$0'#$Q(0'#$0'+$!"8'('+2'@3()$ 6EJADLACDE[7$<"+'($@'+'-8#$^[B\$G$ 0'+$ S"8-'(8'($ P'+#8.+@'(B$ \B^$G$<"+'($ (.92$ "/$ ?'@'(B$ @'-$ 0'($ +'#8&-92'($ *.((8'$ *'-('$<'-8'+'$K(=.+/"8-.($]@'+$0'($5+"(*2'-8#P'+&"3=$'+2.@'($<'+0'(A$!"#$/'0-"('$Yh$@'8+3)$EJ$b.("8'B$0"#$/'0-"('$Sfh$^$b.("8'A$$K($'-('/$'+#8'($h92+-88$<3+0'($P'+#92-'0'('$*&-(-#92'$S"+"/'8'+$0'#$5.&&'*8-P#$':-0'/-.&.)-#92$"3#)'<'+8'8A$!-'#$ <"+'($ 3A"A$ O&8'+B$ %'#92&'928B$ >3/.+#8"0-3/$ @'-$ Q+#80-")(.#'B$ %+"0-()B$ P'+#92-'0'('$ '8<"-)'$I-#-*.="*8.+'($ 6!-"@'8'#$ /'&&-83#$ >c:$ K$l$KKB$ 1Q!#B$ ;':"8-8-0'(B$ O&*.2.&F$ 3(0$ Z-*.8-("@3#3#7$ 3(0$P'+#92-'0'('$?"@.+:"+"/'8'+$,3/$g'-8:3(*8$0'+$Q+#80-")(.#'A$$`'-$\CBJ$G$0'+$S"8-'(8'($*.((8'$:+-/4+$'-('$*3+"8-P'$>2'+":-'$-/$I"2/'($'-('+$Y:'+"8-.($03+92)'=]2+8$<'+0'(B$ -(#)'#"/8$'+2-'&8'($^CB^$G$0'#$5.&&'*8-P#$'-('$:"&&-"8-P'$>2'+":-'B$<.@'-$0-'#$(3+$@'-$[\B\$G$0'+$S"8-'(8'($0-'$:+-/4+$"()'<"(08'$>2'+":-'$<"+A$!-'$:"&&-"8-P'$Q+#8&-(-'(82'+":-'$'(82-'&8$@'-$0'+$;4&=8'$0'+$f4&&'$ 6JEBL$G7$ %'/9-8"@-(B$ #.<.2&$ "&#$ b.(.F$ "&#$ "392$ "&#$ 5./@-("8-.(#82'+":-'$ /-8$ 1-#:&"8-($ .0'+$YX"&-:&"8-(A$ J^BV$G$ 0'+$ S"8-'(8'(B$ 0-'$ #-92$ -/$ :"&&-"8-P'($ Q+*+"(*3()##8"0-3/$ @'="(0'(B$ '+2-'&8'($ '-('$g<'-8&-(-'(82'+":-'B$"392$2-'+$@"#-'+8'$0-'$>2'+":-'$@'-$'-('/$%+.R8'-&$6\JBC$G7$"3=$%'/9-8"@-(A$K(#)'#"/8$<3+0'($@'-$'-(-)'($S"8-'(8'($0'#$5.&&'*8-P#$@-#$,3$#-'@'($:"&&-"8-P'$>2'+":-'"(#48,'$"()'<"(08B$'-($S"8-'(8$'+2-'&8$'-('$O928&-(-'(82'+":-'A$a3+0'$@'-$0'($S"8-'(8'($'-('$Y:'+"8-.($-($*3+"8-P'+$O@#-928$03+92)'=]2+8B$,'-)8'$ #-92$ '-($ #8"8-#8-#92$ #-)(-=-*"(8$ &4()'+'#$ YP'+"&&$ h3+P-P"&$ P.($ EV$b.("8'($ -/$ e'+)&'-92$ ,3+$S"8-'(8'()+3::'B$0-'$(-928$*3+"8-P$82'+":-'+8$<'+0'($*.((8'$6Yhn$V$b.("8'7A$$Q-('$ ,'(8+"&'$ O3=)"@'$ 0-'#'+$ O+@'-8$ <"+$ 0-'$ Q8"@&-'+3()$ #8"8-#8-#92$ #-)(-=-*"(8'+$ f"*8.+'($ ,3+$I-#-*.#8+"8-=-,-'+3()A$K($0'+$3(-P"+-"8'($O("&c#'$'+)"@'($#-92$-/$;-(@&-9*$"3=$0"#$Yh$#-)(-=-*"(8'$Q+)'@(-##'$=]+$1OEVFVB$1QOB$;4/.)&.@-(B$ 0-'$>3/.+)+HR'$ 6>Fh8"0-3/$("92$>Zb7$ 3(0$0"#$>3/.+#8"0-3/$ 6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+87A$K($0'+$/3&8-P"+-"8'($1.XFI')+'##-.(#"("&c#'$'+<-'#'($#-92$'-($d]()'+'#$O&8'+$6v$[[$N"2+'7B$'-($)38$.0'+$/4R-)$0-=='+'(,-'+8'#$5"+,-(./$6%E$l$%C7B$'-($(-'0+-)'+'#$>Fh8"0-3/$6>E$l$>C7B$'-('$ ?'3*.,c8'(,"2&$v$EE$ %M&B$ '-($ &.*"&$ =.+8)'#92+-88'('#$ >3/.+#8"0-3/$ 6&.*"&$=.+8)'#92+-88'($P#A$/'8"#8"#-'+87$3(0$0'+$&.)$z;@{$"&#$3("@24()-)'B$:.#-8-P'$S+.)(.#'="*8.+'($-/$;-(@&-9*$"3=$0"#$YhA$Z')"8-P'$S+.)(.#'="*8.+'($<"+'($'-($(-'0+-)'+$;4/.)&.@-(Fa'+8$6v$EL$)M0&7$3(0$0'+$&.)$z1OEVFV{A$K($0'+$3(-P"+-"8'($1.XFI')+'##-.(#"("&c#'$/-8$0'/$Q(0:3(*8$Sfh$'+)"@'($#-92$=]+$0"#$>3/.+#8"0-3/B$'-('$'8<"-)'$b'8"#8"#-'+3()B$1OEVFV$3(0$1QO$#-)(-=-*"(8'$Q+)'@(-##'A$Z"92$!3+92=]2+3()$0'+$/3&8-P"+-"8'($O("&c#'$*.((8'($'-('$(-928$'-()'8+'8'('$f'+(/'8"#8"#-'+3()B$`-&-+3@-($v$E$/)M0&B$1IS$v$E$)M0&B$&.)$z1IS{B$1OEVFV$v$EDDD$_M/&$"&#$:.#-8-P'$S+.)(.#':"+"/'8'+$='#8)'&')8$<'+0'(A$?.)$z1OEVFV{$*.((8'$"&#$(')"8-P'+$f"*8.+$,3+$I-#-*.#8+"8-=-,-'+3()$-($;-(@&-9*$"3=$0"#$Sfh$='#8)'&')8$<'+0'(A$$!"$0"#$92.&"()-.,'&&3&4+'$5"+,-(./$'-('$#'2+$#92&'928'$S+.)(.#'$"3=<'-#8B$-#8$0"#$e'+#84(0(-#$0'#$>3/.+#$"3=$/.&'*3&"+@-.&.)-#92'+$Q@'('$(H8-)B$3/$('3'B$,-'&)'+-928'8'$>2'+":-'($'8"@&-'+'($,3$*H(('(A$h./-8$<"+$'#$g-'&$0-'#'+$O+@'-8B$'-('$'P'(83'&&'$P'+/'2+8'$QX:+'##-.($P.($Z%f$3(0$:"(>+*$("92,3<'-#'($3(0$'-('($g3#"//'(2"()$/-8$0'/$Yh$.0'+$0'/$Sfh$,3$3(8'+#392'(A$K/$P.+&-')'(0'($5.&&'*8-P$*.((8'($P.($JD$G$0'+$>3/.+:+.@'($>-##3'$b-9+.$O++"c#$"()'='+8-)8$3(0$#./-8$"3=$'-('$QX:+'##-.($P.($:"(>+*$3(0$Z%f$3(8'+#3928$<'+0'(A$O($3(#'+'/$5.&&'*8-P$*.((8'$-/$%')'(#"8,$,3+$?-8'+"83+$6_+"@'$'8$"&AB$CDE[W$o3$'8$"&AB$CDEDW$k"()$'8$"&AB$CDE\7$*'-('$QX:+'##-.($P.($:"(>+*$3(0$Z%f$("92)'<-'#'($<'+0'(A$g3$@'"928'($-#8B$0"##$'#$ #-92$ @'-$ '+<42(8'($ h830-'($ "3##92&-'R&-92$ 3/$ "#-"8-#92'$ 5.&&'*8-P'$ 2"(0'&8A$ Q#$ &4##8$ #-92$ "&#.$ 0-'$e'+/383()$"(#8'&&'(B$0"##$#-92$0"#$"#-"8-#92'$3(0$0"#$<'#8'3+.:4-#92'M"/'+-*"(-#92'$%"&&'()"()#*"+,-(./$2-(#-928&-92$0'+$>3/.+@-.&.)-'$0'38&-92$3(8'+#92'-0'(B$#.0"##$2-'+$<'-8'+'$_(8'+#3923()'($(.8<'(0-)$#-(0B$3/$ 0-'$ ,3)+3(0'&-')'(0'($ b'92"(-#/'($ 0-'#'+$ _(8'+#92-'0'$ ,3$ 0'=-(-'+'($ 3(0$ '8<"-)'$ 82'+":'38-#92'$5.(#'j3'(,'($,3$,-'2'(A$$

Page 98: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RL""

_F G.(+,&(5,*+,-+./%$.)0"

V&I$>>1Xc"S+c"b-&.9c"S+"m+c"'("-&+"Y<TTMZ+"V7G-%8'."$%"7$-*%3.$.c"(1'-(4'%("-%7"6-&&$-($3%"3>"893&-%*$38-18$%34-`"!MMTK<TTM+"`26$%)o)Y3/-62.'-.62$>)*GY?CZc"C<CTKC<J<+""

V&('01).'c"N+"[+c"@'(1$80c"m+"D+c"'("-&+"Y<T!FZ+"/'3*1-69$8"G-1$-($3%"3>"$%(1-9'6-($8"893&-%*$38-18$%34-c"'O(1-9'6-($8"893&-%*$38-18$%34-c"-%7"9'6-(38'&&)&-1"8-18$%34-"$%"(9'"5%$('7"N(-('.+"d92Q)g'.>)*@Y?Zc"'T!<TFLC+"73$`!T+!?L!lI3)1%-&+63%'+T!<TFLC"

V%7'1.'%c"m+"A+c"r"E931*'$1..3%c"N+"N+"Y<T!<Z+"/'%'($8"613>$&$%*"3>"$%(1-9'6-($8"893&-%*$38-18$%34-+"S&66)gF#')Y3/-62.'-.62$>)?WY?Zc"<JJK<L<+"73$`!T+!TMLlS]/+TBT!?'?<R?F<?8L'"

V%7'1.'%c"m+"=+c"N31'%.'%c"N+"S+c"'("-&+"Y!MRMZ+"=-%734$.'7"(1$-&"3>"'%73.836$8"'%73613.(9'.$."G'1.)."36'1-($G'"BX6-.."$%"4-&$*%-%("3B.(1)8($G'"I-)%7$8'+"Y&->)N@YRZc"!!?<K!!?F+""

V%7'1.3%c"P+",+c"=$8'c"S+"W+c"'("-&+"Y<TTCZ+"[&)3137'3OX*&)83.'"@#E"$4-*$%*"$%"(9'"'G-&)-($3%"3>"*-&&B&-77'1"8-18$%34-"-%7"893&-%*$38-18$%34-+"o)Y3/-62#'-./-)Q&6(>)WY!Zc"MTKML+""

V1'G-&3c"m+"P+c"r"b)c"N+"W+"Y<TTJZ+"H')13(1369$%".$*%-&$%*`"4-%X"'O8$($%*".)161$.'.u"S.$$)K2$)9#D.)Q0#>)MNY!?Zc"!F<?K!F?L+"73$`!T+!TTLl.TTT!RKTTJKJT!TK!"

V)4a&&'1c"/+c"V).(c"/+c"'("-&+"Y<T!CZ+"C&3$.)b.#1.)!'3-28#.`"/'31*"E9$'4'"_'1&-*+"VX-&-c"/+"#+c"b9''&'1c"E+"S+c"'("-&+"Y<TT!Z+"Q%"G$(13"731.-&"133("*-%*&$-"-%7"9)4-%"613.(-('"8'&&"&$%'"

$%('1-8($3%`"1'7'>$%$%*"6'1$%')1-&"$%G-.$3%"$%"613.(-('"8-%8'1+"d62/-3-.>)AXY?Zc"<!?K<<?+""A-6-(c"V+"V+c"W3.('(('1c"/+c"'("-&+"Y<T!!Z+"@'1$%')1-&"$%G-.$3%"-%7"-..38$-('7"6-$%"$%"6-%81'-($8"8-%8'1+"

J3-)b.[)S3'0.6>)**Y!TZc"JMFKLTL+"73$`!T+!T?Rl%18?!?!"A-1&3\c"V+",+c"/-18'-c"/+c"'("-&+"Y<T!?Z+"N(-*$%*"&-6-13.836X">31"9$&-1"893&-%*$38-18$%34-"$%"!TT"

6-($'%(.+"93'(.'".0:/)!601)Q&6(>)NXWYLZc"MR?KMRR+"73$`!T+!TTLl.TTC<?KT!?K!!TCK?"A-(.-0$.c"m+"/+"Y!MRFZ+"H'1G'."-%7"%')13(136$8"8-18$%34-.+"!'')g-2$)b1#'2$)936E'(2$>)XAYC"@("!Zc"C<JK

C<L+""A'80'1c"E+c"D'9%'1c"[+c"'("-&+"Y<TT?Z+"N)1*$8-&"(1'-(4'%(">31"9$&-1"893&-%*$38-18$%34-"Y;&-(.0$%v."()431Z+"

c.'-63$"$)S1#6>)*?WY!!Zc"M<RKM?F+"73$`!T+!TFFl.K<TT?KCCRTT"A'%Km3.'>c"#+c"/)(91$'c";+"V+c"'("-&+"Y<T!FZ+"Nb]/"NTRTM`"V"@9-.'"QQ"Q%('1*13)6"E1$-&"3>"V7I)G-%("

P-6'8$(-B$%'"-%7"/'48$(-B$%'"[3&&3\'7"BX"=-7$3(9'1-6X"-%7"P3%8)11'%("P-6'8$(-B$%'"$%"#O(1-9'6-($8"P93&-%*$38-18$%34-"-%7"/-&&B&-77'1"P-18$%34-+"o)S$#')g'02$>)NNY<CZc"<J!LK<J<<+"73$`!T+!<TTlI83+<T!C+JT+<<!M"

A'1*w)$.(c"V+c"/&-)4-%%c"W+c"'("-&+"Y<TTJZ+"@1$4-1X".8&'13.$%*"893&-%*$($."8-%"61'.'%("\$(9"-8)('"&$G'1">-$&)1'`"='631("3>"(\3"8-.'.+"o)h.F3-2$>)AAYFZc"!TTFK!TTR+"73$`!T+!T!JlI+I9'6+<TTJ+T!+T??"

A$.4)(9c"W+c"H-0-89'c"=+c"'("-&+"Y!MM<Z+"S-%-*'4'%(".(1-('*$'."$%"1'.'8($3%">31"9$&-1"893&-%*$38-18$%34-+"!'')Q&6(>)?*GY!Zc"?!K?R+""

A&'89-82c"A+c";34)(-c"S+c"'("-&+"Y<T!!Z+"P&$%$8-&"7$-*%3.$."-%7".(-*$%*"3>"893&-%*$38-18$%34-+"J3-)b.[)Y3/-62.'-.62$)h.F3-2$>)WYMZc"F!<KF<<+"73$`!T+!T?Rl%1*-.(13+<T!!+!?!"

A3804-%c",+"#+c"A)89&'1c"S+c"'("-&+"Y!MMCZ+"Q%('1-8($3%"3>"6-%81'-($8"7)8(-&"8-18$%34-"\$(9"%'1G'."&'-7."(3"%'1G'"7-4-*'+"Y3/-62.'-.62$2(E>)*@VY!Zc"<!MK<?T+""

A3'80c"N+c"b$((\'1c"P+c"'("-&+"Y<T!?Z+"PX(30'1-($%"!MK>1-*4'%(."YPp[=V"<!K!Z"-."-"%3G'&".'1)4"B$34-10'1">31"1'.63%.'"-%7".)1G$G-&"$%"6-($'%(."\$(9"-7G-%8'7"6-%81'-($8"8-%8'1+"L6)o)S3'0.6>)*@WYRZc"!JRCK!JMC+"73$`!T+!T?RlBI8+<T!?+!FR"

A1$7*'\-('1c"m+c"D36'.c"V+c"'("-&+"Y<T!JZ+"@13*%3.($8">-8(31.">31"613*1'..$3%K>1''"-%7"3G'1-&&".)1G$G-&"$%"-7G-%8'7"B$&$-1X"(1-8("8-%8'1+"!'')g'02$>)?VY!Zc"!?CK!CT+"73$`!T+!TM?l-%%3%8l47GCR?"

A1$'-)c"A+c",-9-%c"D+c"'("-&+"Y<T!FZ+"N'83%7K&$%'"89'43(9'1-6X">31"-7G-%8'7"B$&$-1X"(1-8("8-%8'1"->('1">-$&)1'"3>"(9'"*'48$(-B$%'K6&-($%)4"834B$%-($3%`"V"&-1*'"4)&($8'%('1".()7X"BX"(9'"V..38$-($3%"7'."/-.(13K#%('13&3*)'."]%83&3*)'.+"S3'0.6>)*?*Y!RZc"?<MTK?<ML+"73$`!T+!TT<l8%81+<MCL!"

Aa9&c"V+"Y<T!CZ+"N@NN"<<`"#$%>a91)%*"$%"7$'"437'1%'",-('%-%-&X.'c"!C+"!&D$3(.>)Kf'01.'+""A)%7'.1'*$'1)%*+"Y<T!?Z+",13*'%K)%7"N)89(B'1$89(+"N(-%7`"S-$"<T!?+"""='(1$'G'7">134"

9((6`ll\\\+B)%7'.*'.)%79'$(.4$%$.('1$)4+7'l>$&'-74$%l,-('$'%lFx@)B&$0-($3%'%l,13*'%x)%7xN)89(lA13.89)'1'%lAS/x,13*'%Kx)%7xN)89(B'1$89(x<T!?xb#Ax/'.-4(+67>"

Page 99: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RR""

P-1('1c"A+",+c";-&(.894$7(c"P+c"'("-&+"Y!MMJZ+"N'&'8($G'"-8($G-($3%"3>"H[K0-66-"A"BX"%'1G'"*13\(9">-8(31"(913)*9"(9'"%')13(1369$%"1'8'6(31"6LF+"Q0#.'0.>)?V?YF<J!Zc"FC<KFCF+""

P9-$(''1-0$Ic"=+c"p-%*c"m+",+c"'("-&+"Y<T!?Z+"=$.0">-8(31.">31"$%(1-9'6-($8"893&-%*$38-18$%34-`"-..38$-($3%"B'(\''%"4'(>314$%").'"-%7"1'7)8'7"8-%8'1"1$.0+"h.F3-2$2(E>)GVY<Zc"JCRKJFF+"73$`!T+!TT<l9'6+<JTM<"

P9-&-.-%$c"H+c"A-&)X)(c"V+c"'("-&+"Y<TTTZ+"P93&-%*$38-18$%34-"$%"6-($'%(."\$(9"61$4-1X".8&'13.$%*"893&-%*$($.`"-"4)&($8'%('1"8-.'K83%(13&".()7X+"h.F3-2$2(E>)N*Y!Zc"LK!!+"73$`!T+!TT<l9'6+F!T?!T!T?"

P9-64-%c"S+"W+c"N-%7-%-X-0'c"H+"N+c"'("-&+"Y<T!!Z+"P$18)&-($%*"Pp[=V"<!K!"$."-"N6'8$>$8",$-*%3.($8"-%7"@13*%3.($8"A$34-10'1"$%"A$&$-1X"E1-8("P-%8'1+"o)S$#'),RF)h.F3-2$>)*Y!Zc"JK!<+"73$`!T+!T!Jl.TML?KJRR?Y!!ZJT!!TK<"

P9)%*c"m+"p+c"W3%*c"N+"S+c"'("-&+"Y<TTMZ+"E9'"'O61'..$3%"3>"693.693KV;Ec"693.693K4E]=c"-%7"@E#H"$%"'O(1-9'6-($8"893&-%*$38-18$%34-+"S$#')S3'0.6)b./>)*GY<Zc"JJTKJJL+"73$`!T+!!FRl!TLRKTC?<+881KTRK!TRC"

P9)%*c"S+"m+c"D''c";+"m+c"'("-&+"Y<T!!Z+"@1'36'1-($G'"N'1)4"PV"!MKM"D'G'&"-."-"@1'7$8($G'"[-8(31">31"='8)11'%8'"->('1"P)1-($G'"='.'8($3%"$%"A$&$-1X"E1-8("P-%8'1+"!''3$/)2D)Q&6(#03$)g'02$2(E>)*WYJZc"!JF!K!JFJ+"73$`!T+!<CFl.!TC?CKT!TK!F<MKL"

P&-'..'%c"S+"S+c"_&'**--1c"[+"@+c"'("-&+"Y<TTMZ+"W$*9"&$>'($4'"1$.0"3>"8-%8'1"$%"61$4-1X".8&'13.$%*"893&-%*$($.+"o)h.F3-2$>)G@Y!Zc"!FRK!JC+"73$`!T+!T!JlI+I9'6+<TTR+TR+T!?"

P1)G'$&9$'1c"m+"Y!R?FZ+"S-&-7$'."7'."%'1>.+"!'3-28#.)d3-12$2(#q&.)%&)S26F)h&83#'>)?'%).%'=)o)L3#$$#.6.>)d36#/>)d36->)?c"?K<!+""

7-"@'%9-"A'12-*9$c"S+c"P336'1c"m+c"'("-&+"Y!MM?Z+"P93&$%'1*$8"1'*)&-($3%"3>"B1-$%K7'1$G'7"%')13(1369$8">-8(31"YA,H[Z"-%7"%'1G'"*13\(9">-8(31"YH/[Z"B)("%3("%')13(1369$%K?"YHEK?Z"4=HV"&'G'&."$%"(9'"7'G'&36$%*"1-("9$6638-46).+"o2&6'3$)2D)J.&62/0#.'0.>)*NYMZc"?R!RK?R<J+""

,-$c"W+c"D$c"=+c"'("-&+"Y<TTLZ+"#%9-%8'7".)1G$G-&"$%"6'1$%')1-&"$%G-.$3%"3>"6-%81'-($8"8-%8'1`"-%"$%"G$(13"-6613-89+"h&8)d3-12$>)NWY<Zc"<MMK?TL+"73$`!T+!T!JlI+9)46-(9+<TTJ+TR+TT<"

,-%8X*$'1c"W+"Y<TT?Z+"7$#'#/01.)h.F3-2$2(#.+)Y6&'%$3(.'>)C#3('2/-#:)&'%)I1.63F#.)1.F3-2"#$#56.6),6:63':&'(.'_)8#-)?GV)I3".$$.'`"N61$%*'1K_'1&-*+"

,-%%'c"E+c"r"U$'*&'1c"=+"Y<T!JZ+",$-B'('."B'$";$%7'1%")%7"m)*'%7&$89'%+"C.&-/01.6)Y./&'%1.#-/".6#01-c"MJ+""

,-1\$.9"S)1-7c"N+c";$4c"b+"=+c"'("-&+"Y<T!<Z+"#>>$8-8X"3>"%'3-7I)G-%("89'431-7$-($3%c">3&&3\'7"BX"&$G'1"(1-%.6&-%(-($3%c">31"6'1$9$&-1"893&-%*$38-18$%34-"-("!<"5N"8'%('1.+"Y3/-62.'-.62$2(E>)*ANY!Zc"RRKMR"'R?h"w)$2"'!C+"73$`!T+!TF?lI+*-.(13+<T!<+TC+TTR"

,'[1'$(-.c"S+"[+c"S8e)$&&'%c"@+"N+c"'("-&+"Y<TT!Z+"V"%3G'&"6LFHE=".$*%-&$%*"6-(9\-X"61343('.".)1G$G-&c"%3("7'-(9c"3>"$44)%36)1$>$'7"%'3831($8-&".)B6&-('"%')13%.+"o)J.&62/0#>)?*Y!CZc"F!<!KF!<M+""

,']&$G'$1-c"S+"D+c"P)%%$%*9-4c"N+"P+c"'("-&+"Y<TTLZ+"P93&-%*$38-18$%34-`"(9$1(XK3%'KX'-1"'O6'1$'%8'"\$(9"FJC"6-($'%(."-("-".$%*&'"$%.($()($3%+"!'')Q&6(>)?AGYFZc"LFFKLJ<+"73$`!T+!TMLlT!+.&-+TTTT<F!?JJ+J<J?<+7?"

,']&$G'$1-c"S+"D+c"N89)&$80c"=+",+c"'("-&+"Y<T!!Z+"H'\".(-*$%*".X.('4"-%7"-"1'*$.(1X">31"6'1$9$&-1"893&-%*$38-18$%34-+"h.F3-2$2(E>)GNYCZc"!?J?K!?L!+"73$`!T+!TT<l9'6+<C<<L"

,3%-73%c"_+c"A-&B$c"S+c"'("-&+"Y<T!TZ+"S'(>314$%"-%7"1'7)8'7"1$.0"3>"9'6-(38'&&)&-1"8-18$%34-"$%"7$-B'($8"6-($'%(."\$(9"8913%$8"&$G'1"7$.'-.'+"9#[.6)U'->)N@YFZc"LFTKLFR+"73$`!T+!!!!lI+!CLRK?<?!+<T!T+T<<<?+O"

#80'&c"[+c"r"N894$7c"=+"S+"Y<TTLZ+"P9'43(9'1-6X"$%"-7G-%8'7"B$&$-1X"(1-8("8-18$%34-`"-"633&'7"-%-&X.$."3>"8&$%$8-&"(1$-&.+"L6)o)S3'0.6>)XMYJZc"RMJKMT<+"73$`!T+!T?Rl.I+BI8+JJT?JCR"

#804-%%c";+"=+c"@-('&c",+";+c"'("-&+"Y<T!!Z+"P9'43(9'1-6X"3)(834'.">31"(9'"(1'-(4'%("3>")%1'.'8(-B&'"$%(1-9'6-($8"-%7"9$&-1"893&-%*$38-18$%34-`"-"1'(13.6'8($G'"-%-&X.$.+"Y3/-62#'-./-)S3'0.6)b./>)AYFKJZc"!FFK!JT+""

#$.'%9-)'1c"#+"V+c"E9'1-..'c"@+c"'("-&+"Y<TTMZ+"H'\"1'.63%.'"'G-&)-($3%"81$('1$-"$%".3&$7"()43)1.`"1'G$.'7"=#PQNE"*)$7'&$%'"YG'1.$3%"!+!Z+",&6)o)S3'0.6>)AGY<Zc"<<RK<CL+"73$`!T+!T!JlI+'I8-+<TTR+!T+T<J"

#&KN'1-*c"W+"A+c"#%*'&.c"#+"V+c"'("-&+"Y<TTMZ+"=$.0"3>"9'6-(3B$&$-1X"-%7"6-%81'-($8"8-%8'1."->('1"9'6-($($."P"G$1)."$%>'8($3%`"V"636)&-($3%KB-.'7".()7X"3>"5+N+"G'('1-%.+"h.F3-2$2(E>)AXY!Zc"!!JK!<?+"73$`!T+!TT<l9'6+<<JTJ"

Page 100: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

RM""

#%73c"Q+c"/3%'%c"S+c"'("-&+"Y<TTRZ+"Q%(1-9'6-($8"893&-%*$38-18$%34-`"1$.$%*">1'w)'%8Xc"$4613G'7".)1G$G-&c"-%7"7'('14$%-%(."3>"3)(834'"->('1"1'.'8($3%+"!'')Q&6(>)?AWY!Zc"RCKMJ+"73$`!T+!TMLlNDV+TBT!?'?!R!LJ8C7?"

#1$89.'%c"=+c"m'6.'%c"@+c"'("-&+"Y<TTMZ+"Q%8$7'%8'"-%7"613*%3.$."3>"893&-%*$38-18$%34-"$%",-%$.9"6-($'%(."\$(9"-%7"\$(93)("$%>&-44-(31X"B3\'&"7$.'-.'`"-"%-($3%-&"83931(".()7Xc"!MLRK<TT?+",&6)o),F#%.8#2$>)?AYMZc"F!?KF<T+"73$`!T+!TTLl.!TJFCKTTMKM?JFKC"

#1%.(c"@+"Y!MTFZ+"^B'1"7-."b-89.()4")%7"7$'"_'1B1'$()%*"Bn.-1($*'1"/'.89\)&.('"$%.B'.3%7'1'"7'.";1'B.'."$%"7'%"DX469B-9%'%"7'1"H'1G'%+"L.#-6)d3-12$)!'3-+""

#G'19-1(c"m+"#+c"r"=)9&c"P+"#+"Y<TTMZ+"A)17'%"3>"7$*'.($G'"7$.'-.'."$%"(9'"5%$('7"N(-('."@-1("QQQ`"D$G'1c"B$&$-1X"(1-8(c"-%7"6-%81'-.+"Y3/-62.'-.62$2(E>)*NMYCZc"!!?CK!!CC+"73$`!T+!TF?lI+*-.(13+<TTM+T<+T?R"

[-1*'.c"]+c"[)0.c",+c"'("-&+"Y<T!!Z+"VmPP"L(9"'7$($3%"3>"EHS".(-*$%*"-88)1-('&X"7$.81$4$%-('."3)(834'."3>"6-($'%(."\$(9"1'.'8(-B&'"$%(1-9'6-($8"893&-%*$38-18$%34-+"S3'0.6>)**VY!TZc"<!LTK<!LL+"73$`!T+!TT<l8%81+<FL!<"

['113%'c"P+"=+c"[$%0'&.('$%c",+"S+c"'("-&+"Y<TTJZ+"@'1$36'1-($G'"PV!MKM"&'G'&."8-%"61'7$8(".(-*'"-%7".)1G$G-&"$%"6-($'%(."\$(9"1'.'8(-B&'"6-%81'-($8"-7'%38-18$%34-+"o)S$#')g'02$>)?AY!RZc"<RMLK<MT<+"73$`!T+!<TTlI83+<TTF+TF+?M?C"

[$('%$c"[+c"H*)X'%c"E+c"'("-&+"Y<T!CZ+"P$.6&-($%l*'48$(-B$%'"31"3O-&$6&-($%l*'48$(-B$%'"$%"(9'"(1'-(4'%("3>"-7G-%8'7"B$&$-1X"(1-8("8-%8'1`"-".X.('4-($8"1'G$'\+"S3'0.6)K.%>)NYJZc"!FT<K!F!!+"73$`!T+!TT<l8-4C+<MM"

[31%-13c"D+c"_$G-&7$c"P+c"'("-&+"Y<T!FZ+"N'83%7K&$%'"89'43(9'1-6X"$%"-7G-%8'7"B$&$-1X"8-%8'1"613*1'..'7"(3">$1.(K&$%'"6&-($%)4K*'48$(-B$%'"834B$%-($3%`"-"4)&($8'%('1".)1G'X"-%7"633&'7"-%-&X.$."\$(9"6)B&$.9'7"7-(-+"o),RF)S$#')S3'0.6)b./>)NAc"!FJ+"73$`!T+!!RJl.!?TCJKT!FKT<JLKO"

/-((3c"S+c"A1-*-22$c"S+"P+c"'("-&+"Y<T!TZ+"P93&-%*$38-18$%34-`")67-('"-%7">)()1'"6'1.6'8($G'.+"C#()9#[.6)C#/>)A?YCZc"<F?K<JT+"73$`!T+!T!JlI+7&7+<TTM+!<+TTR"

/93)1$c"p+"V+c"S$-%c"Q+c"'("-&+"Y<T!FZ+"P-%8'1"1'G$'\`"P93&-%*$38-18$%34-+"o)S360#'2(>)*Ac"!+"73$`!T+C!T?l!CLLK?!J?+!F!MCT"

/$*&$322$c"V+c"V&6$%$c"/+c"'("-&+"Y<TTCZ+"H'1G'"*13\(9">-8(31"437)&-('."(9'"613&$>'1-($G'"8-6-8$(X"3>"(9'"$%(1-9'6-($8"B$&$-1X"'6$(9'&$)4"$%"'O6'1$4'%(-&"893&'.(-.$.+"Y3/-62.'-.62$2(E>)*?VYCZc"!!MRK!<TM+""

/1-$%*'c"S+"m+c"b'.(c"m+c"'("-&+"Y<TTMZ+"E9'"-%('8'7'%(."3>"B$&$-1X"8-%8'1`"-"61$4-1X"8-1'"8-.'K83%(13&".()7X"$%"(9'"5%$('7";$%*734+"L6)o)S3'0.6>)*@@Y!Zc"!LRK!RT+"73$`!T+!T?Rl.I+BI8+JJTCLJF"

/)*&$'&4$c"V+c"=)22'%'%('c"V+c"'("-&+"Y<TTMZ+"Q%(1-9'6-($8"893&-%*$38-18$%34-`"613*%3.($8">-8(31."->('1".)1*$8-&"1'.'8($3%+"`26$%)o)Q&6(>)NNYJZc"!<CLK!<FC+"73$`!T+!TTLl.TT<JRKTTMKMMLTKT"

W-%c"P+c"D'%*c"m+c"'("-&+"Y<TTCZ+"PX8&33OX*'%-.'K<"61343('."9)4-%"893&-%*$38-18$%34-"*13\(9`"'G$7'%8'">31"8X8&33OX*'%-.'K<K$%7'6'%7'%("4'89-%$.4"$%"8'&'83O$BK4'7$-('7"$%7)8($3%"3>"6<!\->!l8$6!"-%7"6<L0$6!"-%7"8'&&"8X8&'"-11'.(+"S3'0.6)b./>)MAYCZc"!?JMK!?LJ+""

W-X-0-\-c"p+c"N-0$(-%$c";+c"'("-&+"Y<T!LZ+"H'1G'"/13\(9"[-8(31"@1343('."/-.(1$8"E)431$*'%'.$."(913)*9"VB'11-%("P93&$%'1*$8"N$*%-&$%*+"S3'0.6)S.$$>)N*Y!Zc"<!K?C+"73$`!T+!T!JlI+88'&&+<T!J+!!+TTF"

W'13&7c"/+"Y<T!<Z+"U''.6.)K.%#4#'+).#'.)[26$./&'(/26#.'-#.6-.)C36/-.$$&'(_)&'-.6)L.6f0:/#01-#(&'()%./)Y.(.'/-3'%/:3-3$2(./)Df6)%#.)564-$#01.)d6fD&'(_)8#-)USC)*@PQ01$f//.$)#8)I.R-)&'%)Q-#01H26-[.64.#01'#/`"#$*'%G'1&+"

W3>>4-%%c"=+"E+c"@-613((0-c"@+"S+c"'("-&+"Y<T!<Z+"E1-%.-1('1$-&"9'6-($8"X((1$)4KMT"1-7$3'4B3&$2-($3%"$%"6-($'%(."\$(9")%1'.'8(-B&'"$%(1-9'6-($8"893&-%*$38-18$%34-`">-8(31."-..38$-('7"\$(9"613&3%*'7".)1G$G-&+"S36%#2[3/0)U'-.6[.'-)b3%#2$>)NGY!Zc"!TFK!!J+"73$`!T+!TTLl.TT<LTKT!!KT!C<KO"

W3%*c"S+"m+c"P9'3%c"p+";+c"'("-&+"Y<T!CZ+"D3%*K('14"3)(834'"3>"693(37X%-4$8"(9'1-6X"\$(9".X.('4$8"89'43(9'1-6X"8346-1'7"(3"693(37X%-4$8"(9'1-6X"-&3%'"$%"6-($'%(."\$(9"-7G-%8'7"9$&-1"893&-%*$38-18$%34-+"Y&-)9#[.6>)WY?Zc"?!RK?<?+"73$`!T+FTTMl*%&+<T!C+R+?+?!R"

W31*-%c"V+"S+c"V4$1c"#+c"'("-&+"Y<T!<Z+"V7I)G-%("(9'1-6X"$%"(9'"(1'-(4'%("3>"B$&$-1X"(1-8("8-%8'1`"-".X.('4-($8"1'G$'\"-%7"4'(-K-%-&X.$.+"o)S$#')g'02$>)N@Y!JZc"!M?CK!MCT+"73$`!T+!<TTlI83+<T!!+CT+F?R!"

Page 101: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

MT""

W)-$c"m+"@+c",$%*c"m+c"'("-&+"Y<T!CZ+"Q%>&-44-(31X"B3\'&"7$.'-.'"-%7"1$.0"3>"893&-%*$38-18$%34-`"'G$7'%8'">134"-"4'(-K-%-&X.$."3>"636)&-($3%KB-.'7".()7$'.+"!/#3')d30)o)S3'0.6)d6.[>)*GYRZc"?CLLK?CR<+""

W)-%*c"#+"m+c"r"='$89-17(c"D+"[+"Y<TT!Z+"H')13(1369$%.`"13&'."$%"%')13%-&"7'G'&364'%("-%7">)%8($3%+"!''&)b.[)J.&62/0#>)?Ac"JLLKL?J+"73$`!T+!!CJl-%%)1'G+%')13+<C+!+JLL"

W)-%*c"D+c"P9'%c"b+c"'("-&+"Y<T!CZ+"N'1)4"Pp[=V"<!K!"$%"A$&$-1X"E1-8("P-%8'1.`"V"='&$-B&'"A$34-10'1">31"/-&&B&-77'1"P-18$%34-"-%7"Q%(1-9'6-($8"P93&-%*$38-18$%34-+"C#()C#/)Q0#+"73$`!T+!TTLl.!TJ<TKT!CK?CL<KT"

W)-%*c"p+"m+c"E9"b)c"V+c"'("-&+"Y<T!JZ+"Q%('1-8($G'"13&'"3>"7$-B'('."4'&&$()."-%7">'4-&'".'O"$%"(9'"1$.0"3>"893&-%*$38-18$%34-`"V"636)&-($3%KB-.'7"%'.('7"8-.'K83%(13&".()7X+"g'02-36(.-+"73$`!T+!RJ?<l3%83(-1*'(+!C<FC"

W)**'((c"S+"E+c"@-..-%(c"W+c"'("-&+"Y<T!CZ+"])(834'"-%7"6-(('1%."3>"8-1'"$%"-7G-%8'7"B$&$-1X"(1-8("8-18$%34-"YVAPZ`"'O6'1$'%8'">134"(\3"('1($-1X"$%.($()($3%."$%"(9'"5%$('7";$%*734+"I&826#>)*@@Y<Zc"<!MK<<C+"73$`!T+!LTTl!CM!+!JC<!"

Q%8'c"V+"E+c"p$&7$2c";+c"'("-&+"Y<T!CZ+"=3&'."3>".'1)4"-%7"B$&$-1X"P#Vc"PV!MKMc"_#/[=?c"-%7"EVP"$%"7$>>'1'%($-($%*"B'(\''%"4-&$*%-%("-%7"B'%$*%"B$&$-1X"3B.(1)8($3%.+"I&6:)o)Y3/-62.'-.62$>)?GY<Zc"!J<K!JM+"73$`!T+F!F<l(I*+<T!C+JTFJ"

m-$%c"=+c"[$.89'1c"N+c"'("-&+"Y<T!TZ+"E9'").'"3>"PX(30'1-($%"!M"YP;!MZ"$44)%39$.(389'4$.(1X"$%"&'.$3%."3>"(9'"6-%81'-.c"*-.(13$%('.($%-&"(1-8(c"-%7"&$G'1+"!FF$)U88&'21#/-201.8)K2$)K26F12$>)*WY!Zc"MK!F+"73$`!T+!TMLl@VQ+TBT!?'?!R!-7?J'-"

m-1%-*$%c"b+"=+c"r"N93)6c"S+"Y<TTCZ+"N)1*$8-&"4-%-*'4'%("3>"893&-%*$38-18$%34-+"Q.8#')9#[.6)C#/>)?AY<Zc"!RMK!MM+"73$`!T+!TFFl.K<TTCKR<RRMF"

m$-%*c"b+c"U'%*c"U+"P+c"'("-&+"Y<T!!Z+"V"613*%3.($8".831$%*".X.('4"B-.'7"3%"8&$%$8-&">'-()1'."3>"$%(1-9'6-($8"893&-%*$38-18$%34-`"(9'"[)7-%".831'+"!'')g'02$>)??YLZc"!JCCK!JF<+"73$`!T+!TM?l-%%3%8l47wJFT"

ma(('c"W+c"r"E-%%-6>'&c"V+"Y<T!JZ+"E)431"*1-7$%*"3>"(9'"9'6-(3B$&$-1X".X.('4+"C.6)d3-12$2(.>)NVYCZc"<MMK?T?+"73$`!T+!TTLl.TT<M<KT!JKT!LJKJ"

;-'\6$(33%c"H+c";-'\6$(33%c"N+"m+c"'("-&+"Y<TTRZ+"]6$.(93189$."G$G'11$%$`"(9'"8-18$%3*'%$8"9)4-%"&$G'1">&)0'+"`26$%)o)Y3/-62.'-.62$>)*AYFZc"JJJKJLC+""

;9-7'1$c"N+"V+c"r"N)..4-%c"H+"D+"Y<T!FZ+"N81''%$%*">31"4-&$*%-%8X"$%"61$4-1X".8&'13.$%*"893&-%*$($."Y@NPZ+"S&66)Y3/-62.'-.62$)b.F>)*VYCZc"!L+"73$`!T+!TTLl.!!RMCKT!FKTC?RKT"

;9-%c"N+"V+c",-G$7.3%c"A+"=+c"'("-&+"Y<TT<Z+"/)$7'&$%'.">31"(9'"7$-*%3.$."-%7"(1'-(4'%("3>"893&-%*$38-18$%34-`"83%.'%.)."738)4'%(+"Y&->)G*)Q&FF$)Mc"_Q!KM+""

;9-%c"N+"V+c",-G$7.3%c"A+"=+c"'("-&+"Y<T!<Z+"/)$7'&$%'.">31"(9'"7$-*%3.$."-%7"(1'-(4'%("3>"893&-%*$38-18$%34-`"-%")67-('+"Y&->)M*Y!<Zc"!JFLK!JJM+"73$`!T+!!?Jl*)(I%&K<T!!K?T!LCR"

;9-%c"N+"V+c"E934-.c"W+"P+c"'("-&+"Y<TTFZ+"P93&-%*$38-18$%34-+"93'0.->)NMMYMCM?Zc"!?T?K!?!C+"73$`!T+!T!Jl.T!CTKJL?JYTFZJLF?TKL"

;9-%c"N+"V+c"E934-.c"W+"P+c"'("-&+"Y<TTFZ+"6F?"S)(-($3%."$%"9)4-%"893&-%*$38-18$%34-`"-"1'G$'\+"9#[.6)U'->)?GYCZc"LTCKL!J+"73$`!T+!!!!lI+!CLRK?<?!+<TTF+T!!TJ+O"

;$4c"S+"m+c"S$(89'&&c",+"/+c"'("-&+"Y<TTTZ+"A$&$-1X"7$&-(-($3%`"7$>>'1'%($-($3%"3>"B'%$*%">134"4-&$*%-%("8-).'.KKG-&)'"3>"-77$%*"83%G'%($3%-&"S="$4-*$%*"(3"S="893&-%*$36-%81'-(3*1-69X+"b3%#2$2(E>)?*AY!Zc"!L?K!R!+"73$`!T+!!CRl1-7$3&3*X+<!C+!+1TTI-?F!L?"

;&-(.0$%c"/+"Y!MJFZ+"V7'%38-18$%34-"3>"(9'"9'6-($8"7)8("-("$(."B$>)18-($3%"\$(9$%"(9'"631(-"9'6-($.+"V%")%).)-&"()431"\$(9"7$.($%8($G'"8&$%$8-&"-%7"6-(93&3*$8-&">'-()1'.+"+"!8)o)K.%>)NWc"<C!K<FJ+""

;3%73c"N+c"E-0-7-c"E+c"'("-&+"Y<TTRZ+"/)$7'&$%'.">31"(9'"4-%-*'4'%("3>"B$&$-1X"(1-8("-%7"-46)&&-1X"8-18$%34-.`".)1*$8-&"(1'-(4'%(+"o)h.F3-2"#$#36E)d3'06.3-)Q&6(>)*GY!Zc"C!KFC+"73$`!T+!TTLl.TTF?CKTTLK!<LMKF"

;336c"Q+"Y<T!?Z+"Y3/-62.'-.62$2(#.)028F30-)+)3$$./)Df6)7$#'#:)&'%)d63R#/`"E9$'4'+";)B$80-c"N+c";)9%'&c"[+c"'("-&+"Y<TT!Z+";K1-."4)(-($3%."$%"(9'"B$&'"3>"6-($'%(."\$(9"61$4-1X".8&'13.$%*"

893&-%*$($.+"Y&->)AWY?Zc"CT?KCTR+"";)B3c"N+c";$%3.9$(-c"W+c"'("-&+"Y!MMFZ+"W'6-(3&$(9$-.$."-..38$-('7"\$(9"893&-%*$38-18$%34-+"`26$%)o)Q&6(>)

*XYCZc"J?LKJC!+""D-%*'c"P+c"r"=3B'1(K;389KQ%.($()(+"Y<T!!Z+"C3-.')&'%)O3:-.'+),6(."'#//.)%.6)Q-&%#.r)Y./&'%1.#-)#')

C.&-/01$3'%)3:-&.$$)?@@Xr`"=3B'1(K;389KQ%.(+"

Page 102: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

M!""

D'-&c"/+c"P3461$73c",+c"'("-&+"Y<T!CZ+"A,H[K$%7)8'7"&38-&"613('$%".X%(9'.$."-%7".X%-6($8"6&-.($8$(X+"J.&62F1368302$2(E>)VM)d-)Sc"J?MKJFJ+"73$`!T+!T!JlI+%')1369-14+<T!?+TC+TTF"

D''c"A+"N+c"@-10c"#+"P+c"'("-&+"Y<T!FZ+"W'6-($($."A"G$1)."$%>'8($3%c"7$-B'('."4'&&$().c"-%7"(9'$1".X%'1*$.4">31"893&-%*$38-18$%34-"7'G'&364'%(`"-"8-.'K83%(13&".()7X"$%";31'-+"`26$%)o)Y3/-62.'-.62$>)?*Y<Zc"FT<KF!T+"73$`!T+?LCRl\I*+G<!+$<+FT<"

D''c"S+"N+c"W.)c"P+"P+c"'("-&+"Y<T!!Z+"EX6'"<"7$-B'('."$%81'-.'."-%7"4'(>314$%"1'7)8'."(3(-&c"83&31'8(-&c"&$G'1"-%7"6-%81'-($8"8-%8'1"$%8$7'%8'."$%"E-$\-%'.'`"-"1'61'.'%(-($G'"636)&-($3%"613.6'8($G'"83931(".()7X"3>"RTTcTTT"$%7$G$7)-&.+"LKS)S3'0.6>)**c"<T+"73$`!T+!!RJl!CL!K<CTLK!!K<T"

D'**'((c"P+"D+c"/313.6'c"#+"P+c"'("-&+"Y<T!<Z+"@93(37X%-4$8"(9'1-6X">31")%1'.'8(-B&'"893&-%*$38-18$%34-`"-"8346-1-($G'"'>>'8($G'%'..".X.('4-($8"1'G$'\"-%7"4'(-K-%-&X.'.+"d12-2%#3('2/#/)d12-2%E')I1.6>)XY?Zc"!RMK!MF+"73$`!T+!T!JlI+6767(+<T!<+T?+TT<"

D$c"S+c"D$c"m+c"'("-&+"Y<T!<Z+"W'6-($($."A"G$1)."$%>'8($3%"$%81'-.'."(9'"1$.0"3>"893&-%*$38-18$%34-`"-"4'(-K-%-&X.$."-%7".X.('4-($8"1'G$'\+"o)Y3/-62.'-.62$)h.F3-2$>)?VY!TZc"!FJ!K!FJR+"73$`!T+!!!!lI+!CCTK!LCJ+<T!<+TL<TL+O"

D$c"E+c"e$%c"D+"o+c"'("-&+"Y<T!CZ+"N(-*$%*c"613*%3.($8">-8(31."-%7"-7I)G-%("(9'1-6X"3>"$%(1-9'6-($8"893&-%*$38-18$%34-"->('1"8)1-($G'"1'.'8($3%+"9#[.6)U'->)NAYJZc"MF?KMJT+"73$`!T+!!!!l&$G+!<?JC"

D$'B$*c"P+c"VX-&-c"/+c"'("-&+"Y<TTMZ+"@'1$%')1-&"$%G-.$3%"$%"8-%8'1`"-"1'G$'\"3>"(9'"&$('1-()1'+"S3'0.6>)**GY!FZc"??LMK??M!+"73$`!T+!TT<l8%81+<C?MJ"

D$'B&c"[+c",'4$1c"Q+"#+c"'("-&+"Y<T!?Z+"E9'".'G'1$(X"3>"%')1-&"$%G-.$3%"$."-..38$-('7"\$(9".931('%'7".)1G$G-&"$%"83&3%"8-%8'1+"S$#')S3'0.6)b./>)*XY!Zc"FTKJ!+"73$`!T+!!FRl!TLRKTC?<+881K!<K<?M<"

D$'.'1c"S+"m+c"A-11Xc"S+";+c"'("-&+"Y!MMRZ+"N)1*$8-&"4-%-*'4'%("3>"$%(1-9'6-($8"893&-%*$38-18$%34-`"-"?!KX'-1"'O6'1$'%8'+"o)h.F3-2"#$#36E)d3'06.3-)Q&6(>)GY!Zc"C!KCL+""

D$4c"m+"W+c"r"@-10c"P+";+"Y<TTCZ+"@-(93&3*X"3>"893&-%*$38-18$%34-+"!"%28)U83(#'(>)?XYFZc"FCTKFCL+"73$`!T+!TTLl.TT<J!KTTCKT!RLK<"

D)4-89$c"[+c"D3"='c"/+c"'("-&+"Y<T!CZ+"S'-.)1'4'%("3>".'1)4"8-18$%3'4B1X3%$8"-%($*'%c"8-1B39X71-('"-%($*'%"!MKMc"8X(30'1-($%K!M">1-*4'%("-%7"4-(1$O"4'(-&&3613('$%-.'KL">31"7'('8($%*"893&-%*$38-18$%34-`"-"61'&$4$%-1X"8-.'K83%(13&".()7X+"!'-#03'0.6)b./>)NAY!!Zc"JJJ?KJJJL+""

D)3c"o+c"p)-%c"D+c"'("-&+"Y<T!CZ+"N)1G$G-&"3)(834'."-%7"613*%3.($8">-8(31."3>".)1*$8-&"(9'1-6X">31"-&&"63('%($-&&X"1'.'8(-B&'"$%(1-9'6-($8"893&-%*$38-18$%34-`"-"&-1*'".$%*&'K8'%('1"83931(".()7X+"o)Y3/-62#'-./-)Q&6(>)*WY?Zc"FJ<KFL<+"73$`!T+!TTLl.!!JTFKT!?K<CCLK?"

='>8?#%T":M"UMT"VW=,')'T"NM"NMT",5"'-M"<XYZ[GM"O,)9,7"),3#--('"8-17$34X38X('"613&$>'1-($3%"-%7"9'-1("1'*'%'1-($3%+"C.[.$2F8.'-3$)0.$$>)NAYCZc"?RLK?MM+""

S-&9$c"W+c"r"/31'.c"/+"m+"Y<TTJZ+"='G$'\"-1($8&'`"(9'"437'1%"7$-*%3.$."-%7"(9'1-6X"3>"893&-%*$38-18$%34-+"!$#8.'-36E)d1368302$2(E)a)I1.63F.&-#0/>)?NYMZc"!<RLK!<MJ+"73$`!T+!!!!lI+!?JFK<T?J+<TTJ+T<MTT+O"

S-&0-c",+c"P'1G'1-c"@+c"'("-&+"Y<T!CZ+"/'48$(-B$%'"-%7"3O-&$6&-($%"\$(9"31"\$(93)("8'()O$4-B"$%"-7G-%8'7"B$&$-1XK(1-8("8-%8'1"YAQH/]Z`"-"1-%734$.'7c"36'%K&-B'&c"%3%K8346-1-($G'"69-.'"<"(1$-&+"93'0.-)g'02$>)*GYRZc"R!MKR<R+"73$`!T+!T!Jl.!CLTK<TCFY!CZLT<!<KR"

S-189'.$c"[+c"@$'43%($c"D+c"'("-&+"Y<TTRZ+"E9'"89'430$%'"1'8'6(31"Po?P=!"$."$%G3&G'7"$%"(9'"%')1-&"(136$.4"-%7"4-&$*%-%("B'9-G$31"3>"6-%81'-($8"7)8(-&"-7'%38-18$%34-+"S3'0.6)b./>)MWY<!Zc"MTJTKMTJM+"73$`!T+!!FRlTTTRKFCL<+8-%KTRK!R!T"

S-189'.$c"[+c"@$'43%($c"D+c"'("-&+"Y<T!TZ+"S3&'8)&-1"4'89-%$.4."3>"6'1$%')1-&"$%G-.$3%c"-">31*3(('%"6-(9\-X"3>"7$..'4$%-($3%"-%7"4'(-.(-.$.+"SE-2:#'.)Y62H-1)O30-26)b.[>)?*Y!Zc"LLKR<+"73$`!T+!T!JlI+8X(3*>1+<TTM+!!+TT!"

S-11'&&$c",+c"P-1).3c"N+c"'("-&+"Y<TTMZ+"PV!MKM".'1)4"&'G'&."$%"3B.(1)8($G'"I-)%7$8'`"8&$%$8-&"G-&)'"$%"B'%$*%"-%7"4-&$*%-%("83%7$($3%.+"I1.)!8.6#03')o2&6'3$)2D)Q&6(.6E>)*XWY?Zc"???K??M+"73$`9((6`ll7O+73$+31*l!T+!T!JlI+-4I.)1*+<TTR+!<+T?!"

S-(9'4-c"_+"A+c"r"H-KA-%*89-%*c";+"Y<T!FZ+"P)11'%("$%.$*9(."3%"893&-%*$38-18$%34-"1'.'-189`"-"B1$'>"1'G$'\+"!/#3')d30)o)S3'0.6)d6.[>)*MYCZc"!?TLK!?!?+""

S'X'1c"P+"/+c"@'%%c"Q+c"'("-&+"Y<TTTZ+"D$G'1"(1-%.6&-%(-($3%">31"893&-%*$38-18$%34-`"1'.)&(."$%"<TL"6-($'%(.+"I63'/F$3'-3-#2'>)MXYRZc"!J??K!J?L+""

S$9-&-89'c"[+c"E-%(-)c"S+c"'("-&+"Y<T!TZ+"N)1G$G-&"-%7"w)-&$(X"3>"&$>'"3>"893&-%*$38-18$%34-"6-($'%(.`"-"613.6'8($G'".()7X"3G'1"-"C"X'-1"6'1$37+"o)Y3/-62#'-./-#')9#[.6)C#/>)*XY?Zc"<RFK<MT+""

Page 103: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

M<""

S3&&c"=+c"[1-%0'c"b+"b+c"'("-&+"Y!MR<Z+"E9'"8-(-&3*"3>"9)4-%"8X(30'1-($%.`"6-(('1%."3>"'O61'..$3%"$%"%314-&"'6$(9'&$-c"()431."-%7"8)&()1'7"8'&&.+"S.$$>)N*Y!Zc"!!K<C+""

S3&37'80Xc"H+"V+c"N33%c"Q+"N+c"'("-&+"Y<T!<Z+"Q%81'-.$%*"$%8$7'%8'"-%7"61'G-&'%8'"3>"(9'"$%>&-44-(31X"B3\'&"7$.'-.'."\$(9"($4'c"B-.'7"3%".X.('4-($8"1'G$'\+"Y3/-62.'-.62$2(E>)*A?Y!Zc"CJKFC+'C<h"w)$2"'?T+"73$`!T+!TF?lI+*-.(13+<T!!+!T+TT!"

S)1-0-4$c"N+c"VI$0$c"E+c"'("-&+"Y<T!CZ+"[-8(31."->>'8($%*".)1G$G-&"->('1"1'.'8($3%"3>"$%(1-9'6-($8"893&-%*$38-18$%34-+"Q&6()I2%3E>)AAY!TZc"!RCLK!RFC+"73$`!T+!TTLl.TTFMFKT!?KTR<FKM"

S)1-0-4$c"p+c"5'4)1-c";+c"'("-&+"Y<T!!Z+"@13*%3.($8">-8(31."->('1".)1*$8-&"1'.'8($3%">31"$%(1-9'6-($8c"9$&-1c"-%7"7$.(-&"893&-%*$38-18$%34-+"!'')Q&6()g'02$>)*WY?Zc"JF!KJFR+"73$`!T+!<CFl.!TC?CKT!TK!?<FKC"

H-0-*391$c"E+c"V.-%3c"E+c"'("-&+"Y<TT?Z+"V**1'..$G'".)1*$8-&"1'.'8($3%">31"9$&-1K$%G-.$G'"-%7"6'1$69'1-&"$%(1-9'6-($8"893&-%*$38-18$%34-+"`26$%)o)Q&6(>)?VY?Zc"<RMK<M?+"73$`!T+!TTLl.TT<JRKTT<KJJMJKL"

H-0''Bc"V+c"@$((c"W+"V+c"'("-&+"Y!MMJZ+"P93&-%*$38-18$%34-+"V".6'8(1)4"3>"$%(1-9'6-($8c"6'1$9$&-1c"-%7"7$.(-&"()431.+"!'')Q&6(>)??AYCZc"CJ?KCL?h"7$.8)..$3%"CL?KCJF+""

H-(9-%c"W+c"V&3$-c"E+"V+c"'("-&+"Y<TTMZ+"V"61363.'7".(-*$%*".X.('4">31"$%(1-9'6-($8"893&-%*$38-18$%34-+"!'')Q&6()g'02$>)*MY!Zc"!CK<<+"73$`!T+!<CFl.!TC?CKTTRKT!RTK2"

H'9&.c"]+c"/1'*31c"S+c"'("-&+"Y<TTCZ+"N'1)4"-%7"B$&'"4-10'1.">31"893&-%*$38-18$%34-+"Q.8#')9#[.6)C#/>)?AY<Zc"!?MK!FC+"73$`!T+!TFFl.K<TTCKR<RRM!"

H')4-%%c"#+"Y!RJ<Z+"N'8)%7:1'"P-%813$7$%>$&(1-($3%"7'."H'1G)."4'%(-&$."B'$"'$%'4"[-&&"G3%"D$66'%8-%813$7+"!601#[)Df6)F3-12$2(#/01.)!'3-28#.)&'%)d1E/#2$2(#.)&'%)Df6):$#'#/01.)K.%#0#'>)?AY!K<Zc"<T!K<T<+""

H39c"N+"m+c"A-'c"m+"N+c"'("-&+"Y<T!?Z+"#O61'..$3%"3>"%'1G'"*13\(9">-8(31"-%7"9'4'"3OX*'%-.'K!"61'7$8("6331".)1G$G-&"3>"B1'-.("8-18$%34-"6-($'%(.+"LKS)S3'0.6>)*Nc"F!J+"73$`!T+!!RJl!CL!K<CTLK!?KF!J"

H2'-03c"5+"P+c"/)$88$-17$c"S+"#+c"'("-&+"Y<TT<Z+"P]oK<"$%9$B$(."[-.K4'7$-('7"-636(3.$."$%"893&-%*$38-18$%34-"8'&&.+"h.F3-2$2(E>)NGY?Zc"FF<KFFM+"73$`!T+!TF?lI9'6+<TT<+?!LLC"

]9c"N+"b+c"p33%c"p+"N+c"'("-&+"Y<TTFZ+"#>>'8(."3>"'O8'.."\'$*9("3%"8-%8'1"$%8$7'%8'."7'6'%7$%*"3%"8-%8'1".$('."-%7"9$.(3&3*$8">$%7$%*."-43%*"4'%`";31'-"H-($3%-&"W'-&(9"Q%.)1-%8'"P31631-($3%"N()7X+"o)S$#')g'02$>)?NY<!Zc"CLC<KCLFC+"73$`!T+!<TTlI83+<TTF+!!+L<J"

]0-B-X-.9$c"E+c"p-4-43(3c"m+c"'("-&+"Y<TT!Z+"V"%'\".(-*$%*".X.('4">31"4-..K>314$%*"$%(1-9'6-($8"893&-%*$38-18$%34-`"-%-&X.$."3>"61'36'1-($G'"-%7"63.(36'1-($G'"G-1$-B&'.+"S3'0.6>)X?YMZc"<?LCK<?R?+""

]0).-0-c"E+c"Q.9$$c"W+c"'("-&+"Y<TTJZ+"@9-.'"QQ".()7X"3>".$%*&'K-*'%("*'48$(-B$%'"$%"6-($'%(."\$(9"-7G-%8'7"B$&$-1X"(1-8("8-%8'1+"S3'0.6)S1.82-1.6)d1368302$>)GVYFZc"JCLKJF?+"73$`!T+!TTLl.TT<RTKTTFKTTMFK?"

]1(%'1c"S+"V+c"D$'B'(1)(9c"m+c"'("-&+"Y!MMRZ+"@93(37X%-4$8"(9'1-6X"3>"%3%1'.'8(-B&'"893&-%*$38-18$%34-+"Y3/-62.'-.62$2(E>)**AY?Zc"F?JKFC<+""

@-10c"Q+c"D''c"m+"D+c"'("-&+"Y<TTMZ+"@13*%3.($8">-8(31."-%7"61'7$8($G'"437'&"$%"6-($'%(."\$(9"-7G-%8'7"B$&$-1X"(1-8("-7'%38-18$%34-"1'8'$G$%*">$1.(K&$%'"6-&&$-($G'"89'43(9'1-6X+"S3'0.6>)**GY!RZc"C!CRKC!FF+"73$`!T+!TT<l8%81+<CCL<"

@-('&c"E+"Y<TT!Z+"Q%81'-.$%*"$%8$7'%8'"-%7"431(-&$(X"3>"61$4-1X"$%(1-9'6-($8"893&-%*$38-18$%34-"$%"(9'"5%$('7"N(-('.+"h.F3-2$2(E>)NNYJZc"!?F?K!?FL+"73$`!T+!TF?lI9'6+<TT!+<FTRL"

@-('&c"E+"Y<TTJZ+"P93&-%*$38-18$%34-+"J3-)S$#')d630-)Y3/-62.'-.62$)h.F3-2$>)NY!Zc"??KC<+"73$`!T+!T?Rl%86*-.(9'6T?RM"

@'$O3(3c"=+",+c"='%3)>c",+c"'("-&+"Y<T!CZ+"V"636)&-($3%"B-.'7"-%-&X.$."3>"613*%3.($8">-8(31."$%"-7G-%8'7"B$&$-1X"(1-8("8-%8'1+"o)Y3/-62#'-./-)g'02$>)GYJZc"C<RKC?<+"73$`!T+?MLRlI+$..%+<TLRKJRM!+<T!C+TR!"

@3'.89&c"#+"S+c"@3&&9'$4'1c"S+"m+c"'("-&+"Y<T!TZ+"@'1$%')1-&"$%G-.$3%`"8311'&-($3%"\$(9"-**1'..$G'"69'%3(X6'"-%7"$%7'6'%7'%("613*%3.($8"G-1$-B&'"$%"B3(9"83&3%"-%7"1'8()4"8-%8'1+"o)S$#')g'02$>)?WY<!Zc"'?FRK?JTh"-)(931"1'6&X"'?J!K?F<+"73$`!T+!<TTlI83+<TTM+<L+?FR!"

@3'(903KS)&&'1c"P+c"U$44'14-%%c"=+c"'("-&+"Y<T!?Z+"#6$7'4$3&3*X"3>"9'6-($($."Vc"Ac"-%7"P"-43%*"-7)&(."$%"/'14-%X`"1'.)&(."3>"(9'"/'14-%"W'-&(9"Q%('1G$'\"-%7"#O-4$%-($3%"N)1G'X">31"V7)&(."

Page 104: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

M?""

Y,#/N!Z+"L&'%./(./&'%1.#-/"$3--)Y./&'%1.#-/D26/01&'()Y./&'%1.#-//01&-4>)GMYFKJZc"LTLKL!F+"73$`!T+!TTLl.TT!T?KT!?K!JL?KO"

@1$413.'c"m+"H+c"[3Oc"=+c"'("-&+"Y<T!LZ+"V7I)G-%("8-6'8$(-B$%'">31"B$&$-1X"(1-8("8-%8'1`"E9'"AQDPV@"1-%734$2'7".()7X+"o2&6'3$)2D)S$#'#03$)g'02$2(E>)NGY!Fx.)66&Zc"CTTJKCTTJ+"73$`!T+!<TTlmP]+<T!L+?F+!Fx.)66&+CTTJ"

=-2)4$&-G-c"H+c"r"/31'.c"/+"m+"Y<T!CZ+"P93&-%*$38-18$%34-+"93'0.->)NWNYMM?FZc"<!JRK<!LM+"73$`!T+!T!Jl.T!CTKJL?JY!?ZJ!MT?KT"

='$89-17(c"D+"[+"Y<TTJZ+"H')13(1369$%K1'*)&-('7".$*%-&&$%*"6-(9\-X.+"d1#$2/)I63'/)b)Q20)92'%)L)L#2$)Q0#>)NM*Y!CL?Zc"!FCFK!FJC+"73$`!T+!TMRl1.(B+<TTJ+!RMC"

=$B'13c",+c"@$%%-c"V+",+c"'("-&+"Y<T!<Z+"N)1*$8-&"V6613-89">31"D3%*K('14"N)1G$G-&"3>"@-($'%(."b$(9"Q%(1-9'6-($8"P93&-%*$38-18$%34-`"V"S)&($K$%.($()($3%-&"V%-&X.$."3>"C?C"@-($'%(.+"!601)Q&6(>)*AVY!<Zc"!!TLK!!!?+"73$`!T+!TT!l-189.)1*+<T!<+!MJ<"

=$2G$c"N+c"r"/31'.c"/+"m+"Y<T!?Z+"@-(93*'%'.$.c"7$-*%3.$.c"-%7"4-%-*'4'%("3>"893&-%*$38-18$%34-+"Y3/-62.'-.62$2(E>)*AGYJZc"!<!FK!<<M+"73$`!T+!TF?lI+*-.(13+<T!?+!T+T!?"

=3*'1.c"m+"#+c"D-\c"D+c"'("-&+"Y<T!CZ+"N'83%7K&$%'".X.('4$8"(1'-(4'%(">31"-7G-%8'7"893&-%*$38-18$%34-+"o)Y3/-62#'-./-)g'02$>)GYJZc"CTRKC!?+"73$`!T+?MLRlI+$..%+<TLRKJRM!+<T!C+TL<"

=3..c"m+"N+c"b-%*c";+c"'("-&+"Y<T!CZ+"H'\"13)('."(3"(-1*'('7"(9'1-6X"3>"$%(1-9'6-($8"893&-%*$38-18$%34-."1'G'-&'7"BX"%'O(K*'%'1-($3%".'w)'%8$%*+"g'02$2(#/->)*XY?Zc"<?FK<C<+"73$`!T+!J?Cl(9'3%83&3*$.(+<T!?KT?F<"

N-O'%-c"V+c"P9)-c"E+"P+c"'("-&+"Y<T!TZ+"P&$%$836-(93&3*$8"-%7"(1'-(4'%(K1'&-('7">-8(31."$%>&)'%8$%*"1'8)11'%8'"-%7".)1G$G-&"->('1"9'6-($8"1'.'8($3%"3>"$%(1-9'6-($8"893&-%*$38-18$%34-`"-"!MKX'-1"'O6'1$'%8'">134"-%"'.(-B&$.9'7"V).(1-&$-%"9'6-(3B$&$-1X")%$(+"o)Y3/-62#'-./-)Q&6(>)*AYLZc"!!<RK!!?R+"73$`!T+!TTLl.!!JTFKT!TK!<T?K!"

N89&$'4-%c"S+"/+c"W3c"W+"N+c"'("-&+"Y<TT?Z+"5($&$(X"3>"()431"4-10'1."$%"7'('14$%$%*"1'.'8(-B$&$(X"3>"6-%81'-($8"8-%8'1+"!601)Q&6(>)*NWYMZc"MF!KMFFh"7$.8)..$3%"MFFKMFJ+"73$`!T+!TT!l-189.)1*+!?R+M+MF!"

N''93>'1c",+c";-469)'.c"P+c"'("-&+"Y<T!<Z+"='.'8($3%"3>";&-(.0$%"()431.+"S1#6&6(>)WNY?Zc"<<!K<<R+"73$`!T+!TTLl.TT!TCKT!!K<!LLKJ"

N'1->$%$c"[+"S+c"N-89.c",+c"'("-&+"Y<TT!Z+"D38-($3%c"%3(".(-*$%*c"3>"893&-%*$38-18$%34-"7'('14$%'."(9'"13&'">31"-7I)G-%("89'431-7$-($3%"(9'1-6X+"!8)Q&6(>)MVYMZc"R?MKRC?h"7$.8)..$3%"RC?KR?C+""

N9-$Bc"p+"W+c",-G$&-c"m+"V+c"'("-&+"Y<TTCZ+"=$.$%*"$%8$7'%8'"3>"$%(1-9'6-($8"893&-%*$38-18$%34-"$%"(9'"5%$('7"N(-('.`"-"(1)'"$%81'-.'y"o)h.F3-2$>)A@Y?Zc"CL<KCLL+"73$`!T+!T!JlI+I9'6+<TT?+!!+T?T"

N9-$Bc"p+"W+c"#&KN'1-*c"W+"A+c"'("-&+"Y<TTFZ+"=$.0">-8(31."3>"$%(1-9'6-($8"893&-%*$38-18$%34-"$%"(9'"5%$('7"N(-('.`"-"8-.'K83%(13&".()7X+"Y3/-62.'-.62$2(E>)*?WY?Zc"J<TKJ<J+""

N9'%c"[+"U+c"U9-%*c"A+"p+c"'("-&+"Y<T!TZ+"P)11'%("1'.'-189"$%"6'1$%')1-&"$%G-.$3%"3>"893&-%*$38-18$%34-+"o),RF)S$#')S3'0.6)b./>)?Xc"<C+"73$`!T+!!RJl!LFJKMMJJK<MK<C"

N9$%c"W+"=+c"D''c"P+"5+c"'("-&+"Y!MMJZ+"W'6-($($."A"-%7"P"G$1).c"P&3%3189$.".$%'%.$.">31"(9'"1$.0"3>"&$G'1"8-%8'1`"-"8-.'K83%(13&".()7X"$%"@).-%c";31'-+"U'-)o),F#%.8#2$>)?GYFZc"M??KMCT+""

N9$1-$c";+c"#B-(-c"E+c"'("-&+"Y<TTRZ+"@'1$%')1-&"$%G-.$3%"$."-"613*%3.($8">-8(31"$%"$%(1-9'6-($8"893&-%*$38-18$%34-+"`26$%)o)Q&6(>)N?Y!!Zc"<?MFK<CT<+"73$`!T+!TTLl.TT<JRKTTRKML<JK<"

N$-c",+c"W3.9$7-c"p+c"'("-&+"Y<T!?Z+"Q%('*1-($G'"43&'8)&-1"-%-&X.$."3>"$%(1-9'6-($8"893&-%*$38-18$%34-"1'G'-&."<"8&-..'."(9-("9-G'"7$>>'1'%("3)(834'.+"Y3/-62.'-.62$2(E>)*AAYCZc"R<MKRCT+"73$`!T+!TF?lI+*-.(13+<T!?+T!+TT!"

N($%(2$%*c"N+c"W'$%'4-%%c"_+c"'("-&+"Y<TTMZ+"E9'"(1'-(4'%("3>"83&31'8(-&"8-18$%34-"\$(9"43%38&3%-&"-%($B37$'.`"(9'"$4631(-%8'"3>";=VN"4)(-($3%"-%-&X.$."-%7"#/[=".(-().+"C-/01)!64-."$)U'->)*@MY!<Zc"<T<K<TJ+"73$`!T+?<?Rl-12('B&+<TTM+T<T<"

N)-1'2KS)%32c"S+"V+c"['1%-%7'2KV*)$&-1c"m+"D+c"'("-&+"Y<T!?Z+"=$.0">-8(31."-%7"8&-..$>$8-($3%."3>"9$&-1"893&-%*$38-18$%34-+"`26$%)o)Y3/-62#'-./-)g'02$>)GYLZc"!?<K!?R+"73$`!T+C<F!l\I*3+GF+$L+!?<"

N)*-\-1-c"W+c"p-.3.9$4-c"S+c"'("-&+"Y!MMRZ+"='&-($3%.9$6"B'(\''%"$%('1&')0$%KJ"-%7"613&$>'1-($3%"-%7"7$>>'1'%($-($3%"$%"893&-%*$38-18$%34-+"h#/-2F3-12$2(E>)NNY<Zc"!CFK!F?+""

N)1c"S+",+c"Q%c"W+c"'("-&+"Y<T!CZ+",'>$%$%*"(9'"A'%'>$("3>"V7I)G-%("E9'1-6X"[3&&3\$%*"='.'8($3%">31"Q%(1-9'6-($8"P93&-%*$38-18$%34-+"!'')Q&6()g'02$+"73$`!T+!<CFl.!TC?CKT!CKC<LFKC"

Page 105: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

MC""

E-0-7-c"S+c"S-.)7-c"H+c"'("-&+"Y!MMFZ+"S'-.)1'4'%("3>"8X(30'1-($%"!M">1-*4'%(."-."-"4-10'1"3>"&)%*"8-%8'1"BX"Pp[=V"<!K!"'%2X4'"$44)%3-..-X+"L6)o)S3'0.6>)V*Y!Zc"!JTK!JF+""

E-0-7-c"E+c"V4-%3c"W+c"'("-&+"Y<TT<Z+"Q."63.(36'1-($G'"-7I)G-%("89'43(9'1-6X").'>)&">31"*-&&B&-77'1"8-18$%34-y"V"69-.'"QQQ"4)&($8'%('1"613.6'8($G'"1-%734$2'7"83%(13&&'7"(1$-&"$%"6-($'%(."\$(9"1'.'8('7"6-%81'-($83B$&$-1X"8-18$%34-+"S3'0.6>)XGYRZc"!JRFK!JMF+"73$`!T+!TT<l8%81+!TR?!"

E-%-0-c"E+c"Q0'7-c"S+c"'("-&+"Y<TTRZ+"@13*%3.($8">-8(31."$%"I-6-%'.'"6-($'%(."\$(9"-7G-%8'7"6-%81'-($8"8-%8'1"(1'-('7"\$(9".$%*&'K-*'%("*'48$(-B$%'"-.">$1.(K&$%'"(9'1-6X+"oF')o)S$#')g'02$>)NWY!!Zc"LFFKLJ!+"73$`!T+!TM?lII83l9X%TMR"

E-%%-6>'&c"V+c",$'%'.c"W+K@+c"'("-&+"Y<T!<Z+"Q%7$0-($3%'%"2)1"D'B'1B$36.$'+"C-/01)!64-."$)U'->)*@Xc"CLL"K"CR?+"73$`!T+?<?Rl-12('B&+<T!<+TCLL"

EX.3%c"/+"D+c"r"#&KN'1-*c"W+"A+"Y<T!!Z+"=$.0">-8(31.">31"893&-%*$38-18$%34-+"h.F3-2$2(E>)GAY!Zc"!L?K!RC+"73$`!T+!TT<l9'6+<C?F!"

5'%$.9$c"E+c"p-4-2-0$c"]+c"'("-&+"Y<TTRZ+"N'1)4"8X(30'1-($%"!M">1-*4'%("YPp[=V<!K!Z"-."-"613*%3.($8">-8(31"$%"$%(1-9'6-($8"893&-%*$38-18$%34-+"!'')Q&6()g'02$>)*GY<Zc"FR?KFRM+"73$`!T+!<CFl.!TC?CKTTLKMJFTKX"

5'%3c"W+c"]0-7-c"N+c"'("-&+"Y<TTTZ+"@13*%3.($8">-8(31."$%"6-($'%(."\$(9"4'(-.(-($8"6-%81'-($8"-7'%38-18$%34-"1'8'$G$%*".X.('4$8"89'43(9'1-6X+"g'02$2(E>)GXYCZc"<MJK?T!+"73$`!<!RJ"

51-B'c";+c"S)1-0-4$c"p+c"'("-&+"Y<T!JZ+"H'1G'"/13\(9"[-8(31"#O61'..$3%"Q."H3("V..38$-('7"\$(9"@'1$%')1-&"Q%G-.$3%"$%"#O(1-9'6-($8"P93&-%*$38-18$%34-+"C#()C#/)Q0#>)M*Y?Zc"LLCKLRC+"73$`!T+!TTLl.!TJ<TKT!FK?MF?KM"

_-&&'c"m+c"b-.-%c"W+c"'("-&+"Y<T!TZ+"P$.6&-($%"6&)."*'48$(-B$%'"G'1.)."*'48$(-B$%'">31"B$&$-1X"(1-8("8-%8'1+"J),'($)o)K.%>)NM?Y!CZc"!<L?K!<R!+"73$`!T+!TFJlH#mS3-TMTRL<!"

_-%"P)(.'4c"#+c"_'1G'%%'c"b+"D+c"'("-&+"Y<TTMZ+"@9-.'"QQQ"(1$-&"3>"B'G-8$2)4-B"$%"834B$%-($3%"\$(9"*'48$(-B$%'"-%7"'1&3($%$B"$%"6-($'%(."\$(9"4'(-.(-($8"6-%81'-($8"8-%8'1+"o)S$#')g'02$>)?VY!?Zc"<<?!K<<?L+"73$`!T+!<TTlI83+<TTR+<T+T<?R"

_3*'&c"V+c"b'*'c"W+c"'("-&+"Y<T!CZ+"E9'"7$-*%3.$."-%7"(1'-(4'%("3>"893&-%*$38-18$%34-+"C-/01)!64-."$)U'->)***YCCZc"LCRKLFC+"73$`!T+?<?Rl-12('B&+<T!C+TLCR"

b-%*c"E+"E+c"P-3c"e+"W+c"'("-&+"Y<T!?Z+"A'8&$%"!"7'>$8$'%8X"8311'&-('7"\$(9"&X469"%37'"4'(-.(-.$.c"61'7$8(."-"7$.($%8("3)(834'"$%"$%(1-9'6-($8"-%7"'O(1-9'6-($8"893&-%*$38-18$%34-+"d92Q)g'.>)WY!!Zc"'RT?!L+"73$`!T+!?L!lI3)1%-&+63%'+TTRT?!L"

b-%*c"p+c"D$c"m+c"'("-&+"Y<T!?Z+"@13*%3.($8"%343*1-4">31"$%(1-9'6-($8"893&-%*$38-18$%34-"->('1"6-1($-&"9'6-('8(34X+"o)S$#')g'02$>)N*YMZc"!!RRK!!MF+"73$`!T+!<TTlI83+<T!<+C!+FMRC"

b'B'1c"N+"S+c",'S-(('3c"=+"@+c"'("-&+"Y<TT<Z+"N(-*$%*"&-6-13.836X"$%"6-($'%(."\$(9"'O(1-9'6-($8"B$&$-1X"8-18$%34-+"V%-&X.$."3>"!TT"6-($'%(.+"!'')Q&6(>)?NGY?Zc"?M<K?MM+""

b'&.89c"5+c"r",'&&'1c"E+"Y<T!TZ+"9.16"&01)h#/-2$2(#.`"#&.'G$'1c"51B-%r[$.89'1_'1&-*+"b'&2'&c"E+"S+c"/1-)B-17c"A+"Q+c"'("-&+"Y<TTLZ+"=$.0">-8(31.">31"$%(1-9'6-($8"-%7"'O(1-9'6-($8"

893&-%*$38-18$%34-"$%"(9'"5%$('7"N(-('.`"-"636)&-($3%KB-.'7"8-.'K83%(13&".()7X+"S$#')Y3/-62.'-.62$)h.F3-2$>)GY!TZc"!<<!K!<<R+"73$`!T+!T!JlI+8*9+<TTL+TF+T<T"

b'&2'&c"E+"S+c"/1-)B-17c"A+"Q+c"'("-&+"Y<T!!Z+"S'(-B3&$8".X%7134'"$%81'-.'."(9'"1$.0"3>"61$4-1X"&$G'1"8-%8'1"$%"(9'"5%$('7"N(-('.`"-".()7X"$%"(9'"N##=KS'7$8-1'"7-(-B-.'+"h.F3-2$2(E>)GAY<Zc"CJ?KCL!+"73$`!T+!TT<l9'6+<C?ML"

b$(('0$%7c"P+c"r"]B'1.894$7c"A+"Y<T!TZ+"EHSK;&-..$>$0-($3%"4-&$*%'1"E)431'%"<T!T+"C.6)d3-12$2(.>)N*YFZc"???K??R+""

b)c"P+c"D-$c"P+"[+c"'("-&+"Y<TT!Z+"H'1G'"*13\(9">-8(31"-8($G-('."6'1.$.('%("=-6!".$*%-&$%*"$%"'%73.34'.+"o)J.&62/0#>)?*Y!FZc"FCTJKFC!J+""

b)c"E+"E+c"D'GXc"S+c"'("-&+"Y<TTMZ+"A$&$-1X"$%(1-'6$(9'&$-&"%'36&-.$-"$%"6-($'%(."\$(93)("8913%$8"B$&$-1X"7$.'-.'`"-%-&X.$."3>"&$G'1"'O6&-%(."\$(9"-&8393&$8"8$1193.$.c"9'6-($($."P"$%>'8($3%c"-%7"%3%8$1193($8"&$G'1"7$.'-.'.+"S3'0.6>)**GY!MZc"CFJCKCFLF+"73$`!T+!TT<l8%81+<CCL!"

o)c"D+"A+c"D$)c"P+c"'("-&+"Y<T!TZ+"H'1G'"*13\(9">-8(31KB'(-"'O61'..$3%"$."-..38$-('7"\$(9"&X469"%37'"4'(-.(-.$."-%7"%'1G'"$%>$&(1-($3%"$%"9)4-%"9$&-1"893&-%*$38-18$%34-+"`26$%)o)Q&6(>)NAYFZc"!T?MK!TCF+"73$`!T+!TTLl.TT<JRKT!TKTC!LKC"

p-4-.-0$c"N+"Y<TT?Z+"Q%(1-9'6-($8"893&-%*$38-18$%34-`"4-813.836$8"(X6'"-%7".(-*'"8&-..$>$8-($3%+"o)h.F3-2"#$#36E)d3'06.3-)Q&6(>)*@YCZc"<RRK<M!+"73$`!T+!TTLl.TTF?CKTT<KTL?<KR"

Page 106: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

MF""

p-%*c"o+"e+c"o)c"p+"[+c"'("-&+"Y<T!CZ+"P&$%$8-&".$*%$>$8-%8'"3>"%'1G'"*13\(9">-8(31"-%7"(13634X3.$%K1'8'6(31K0$%-.'".$*%-&$%*"6-(9\-X"$%"$%(1-9'6-($8"893&-%*$38-18$%34-+"`26$%)o)Y3/-62.'-.62$>)?@Y!CZc"CTLJKCTRC+"73$`!T+?LCRl\I*+G<T+$!C+CTLJ"

p-%*c"U+c"U9-%*c"o+c"'("-&+"Y<T!FZ+"S'(>314$%"73'."%3("$4613G'".)1G$G-&"3>"893&-%*$38-18$%34-"6-($'%(."\$(9"7$-B'('.+"h.F3-2$2(E+"73$`!T+!TT<l9'6+<LR<!"

p39c"E+c"N'3c"N+c"'("-&+"Y<T!LZ+"V"H3G'&"A$34-10'1KA-.'7"@1'36'1-($G'"@13*%3.($8"/1-7$%*"NX.('4">31"@1'7$8($%*"N)1G$G-&"V>('1"N)1*'1X">31"Q%(1-9'6-($8"P93&-%*$38-18$%34-+"!'')Q&6()g'02$+"73$`!T+!<CFl.!TC?CKT!JKFLTRK2"

p3.9$7-c"E+c"S-(.)43(3c"E+c"'("-&+"Y<TT<Z+"@13*%3.($8">-8(31."->('1"6-%81'-(37)37'%'8(34X"\$(9"'O('%7'7"&X469-7'%'8(34X">31"7$.(-&"B$&'"7)8("8-%8'1+"!601)Q&6(>)*NVY!Zc"JMKL?+""

U-B13%c"V+c"#7\-17.c"=+"m+c"'("-&+"Y<T!?Z+"E9'"89-&&'%*'"3>"893&-%*$38-18$%34-`"7$..'8($%*"(9'"43&'8)&-1"4'89-%$.4."3>"-%"$%.$7$3)."8-%8'1+"C#/)K2%.$)K.01>)MY<Zc"<R!K<M<+"73$`!T+!<C<l744+T!TFJ!"

U'%*c"o+c"r"E-3c"W+"Y<T!FZ+",$-*%3.($8"-%7"613*%3.($8".'1)4"4-10'1"3>"893&-%*$38-18$%34-"Y='G$'\Z+"g'02$)9.-->)XY!Zc"?KR+"73$`!T+?RM<l3&+<T!C+<JMJ"

U93)c"U+"W+c"U9-%*c"m+",+c"'("-&+"Y<T!FZ+",$-4'('1"3>"$%G3&G'7"%'1G'."$."-"G-&)-B&'"613*%3.($8">-8(31">31"*-.(1$8"8-%8'1+"h#/-2$)h#/-2F3-12$c"!!JTM+"73$`!T+!CJLTl99K!!KJTM"

U9)c"p+c"D$c"p+c"'("-&+"Y<T!?Z+",'6'%7'%8'"1'8'6(31"5HPF,"4'7$-('."%'1G'"*13\(9">-8(31"7'6&'($3%K$%7)8'7"%')13B&-.(34-"1'*1'..$3%+"o)S$#')U'[./->)*?NYLZc"<M?FK<MCL+"73$`!T+!!L<lI8$JFMRR"

U9)c"U+c"[1$'..c"W+c"'("-&+"Y!MMMZ+"H'1G'"*13\(9">-8(31"'O61'..$3%"8311'&-('."\$(9"6'1$%')1-&"$%G-.$3%"-%7"6-$%"$%"9)4-%"6-%81'-($8"8-%8'1+"o)S$#')g'02$>)*VYRZc"<C!MK<C<R+""

U$'*&'1c"V+c"D-%*'c"N+c"'("-&+"Y<TTLZ+"^B'1&'B'%.2'$(-%-&X.'`"#$*'%.89->('%")%7";-6&-%KS'$'1"S'(937'+"CK`PC.&-/01.)K.%#4#'#/01.)`201.'/016#D->)*N?YN"T!Zc"'?JK'?R+""

U\$'%'1c"Q+c"A&'((%'1c"S+c"'("-&+"Y<T!!Z+"E'$&"!F"7'1"N'1$'"2)1"A'\'1()%*"\$..'%.89->(&$89'1"@)B&$0-($3%'%+"C-/01)s64-."$>)*@Wc"!J?K!JM+""

Page 107: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

MJ""

`F 8&$:)&65$60"

b'-($@'#.(0'+'+$!"(*$)-&8$/'-('/$`'8+'3'+$;'++($!+A$/'0A$`'('0-*8$a'#8:2"&'($6b'0-,-(-#92'$5&-(-*$KKKB$5&-(-*3/$0'+$_(-P'+#-848$b](92'($!$%+.R2"0'+(7$=]+$#'-('$43R'+#8$'()")-'+8'B$"3#0"3'+(0'$3(0$*./:'8'(8'$`'+"83()A$T@'+$0-'$)'#"/8'$!"3'+$0'+$O+@'-8$<"+$'+$'+#8'+$O(#:+'92:"+8('+$=]+$S+.@&'/'$3(0$f+")'($d'0'+$O+8$3(0$3(8'+#8]8,8'$/-92$/-8$#'-('+$f"92*'((8(-#$#8'8#$3(P'+,])&-92A$h'-($2'+P.++")'(0'+$Q-(#"8,$<"+$=]+$0"#$%'&-()'($0-'#'+$O+@'-8$P.($)+.R'+$`'0'383()A$

b'-('($!"(*$/H928'$-92$"392$;'++($S+.='##.+$!+A$/'0A$h8'="($`H9*$6Y@'+"+,8$b'0-,-(-#92'$5&-(-*$KKKB$5&-(-*3/$0'+$_(-P'+#-848$b](92'($!$%+.R2"0'+(7$=]+$0-'$`'+'-8#8'&&3()$0'#$>2'/"#$3(0$#'-('$=+'3(0&-92'$3(0$*./:'8'(8'$_(8'+#8]8,3()$ "3##:+'92'(A$O392$ '+$<"+$@'-$ "3=*.//'(0'($f+")'(MS+.@&'/'($ -//'+$'++'-92@"+$3(0$#8'8#$]@'+"3#$2-&=#@'+'-8A$$

e-'&'($ 2'+,&-92'($ !"(*$ "392$ "($ !+A$ /'0A$ h8'=='($ Y+/"((#$ 6S"82.&.)-#92'#$ K(#8-838$ 0'+$ _(-P'+#-848$b](92'(7$=]+$0-'$̀ '+'-8#8'&&3()$0'+$%'<'@':+.@'($0'#$5.&&'*8-P#B$0-'$2-#8.:"82.&.)-#92'($_(8'+#3923()'(B$#'-('$ _(8'+#8]8,3()$ @'-$ 0'+$ O(=.+0'+3()$ 'X8'+('+$ >3/.+:+.@'($ 3(0$ PA"A$ =]+$ #'-('$ %'03&0$ @'-$ 0'+$`'"(8<.+83()$/'-('+$,"2&+'-92'($f+")'(A$

`'#.(0'+'($ !"(*$ /H928'$ -92$ "392$ f+"3$ b"+)"+'82'$ a.'9*'&$ 6b#17$ =]+$ -2+'$ ]@'+"3#$ *./:'8'(8'$_(8'+#8]8,3()$-($"&&'($#8"8-#8-#92'($f+")'#8'&&3()'($"3##:+'92'(A$K2+$Q-(#"8,$3(0$-2+'$`'+"83()$<"+'($=]+$0"#$%'&-()'($0-'#'+$O+@'-8$3(P'+,-928@"+A$

b'-($!"(*$)-&8$"392$;'++($!+A$/'0A$h'@"#8-"($a-(*&'+$=]+$#'-('$)'03&0-)'$3(0$*./:'8'(8'$_(8'+#8]8,3()$@'-$0'+$f.+/"8-'+3()$0'+$O+@'-8A$

$

Page 108: Prognostische Faktoren bei Patienten mit Gallengangskarzinomen … · 2018. 12. 5. · Aus der Medizinischen Klinik und Poliklinik III der Ludwig-Maximilians-Universität München

ML""

aF 3$%&$60"

9((6`ll\\\+3%03&3*$.89'KB$&7*'B)%*+71*+7'l4'7$-l738)4'%(lFFRTl0$(('&(-.89'%0-1('K1'8$.(+67>"